

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22809 A2

- (51) International Patent Classification⁷: C12N 15/00 (74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (21) International Application Number: PCT/US01/29229
- (22) International Filing Date:
17 September 2001 (17.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/233,035 15 September 2000 (15.09.2000) US
60/263,657 23 January 2001 (23.01.2001) US
60/291,726 17 May 2001 (17.05.2001) US
60/300,210 22 June 2001 (22.06.2001) US
- (81) Designated States (*national*): AI, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GH, GM, HN, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, HU, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): COLLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): BAUER, Stefan [DE/DE]; Waisenhausstrasse 13, 80637 Munchen (DE); LIPFORD, Grayson [US/US]; Innere Wiener Strasse 7A, 81667 Munchen (DE); WAGNER, Hermann [DE/DE]; Kaagangerstrasse 36, 82279 Eching (DE).
- Published:**
without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/22809 A2

(54) Title: PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG BASED IMMUNO AGONIST/ANTAGONIST

(57) Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8.

- 1 -

**PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED
IMMUNO-AGONIST/ANTAGONIST**

Related Applications

5 This invention claims benefit of U.S. Provisional Application 60/233,035, filed September 15, 2000; U.S. Provisional Application 60/263,657, filed January 23, 2001; U.S. Provisional Application 60/291,726, filed May 17, 2001; and U.S. Provisional Application 60/300,210, filed June 22, 2001.

10 **Field of the Invention**

The invention pertains to signal transduction by immunostimulatory nucleic acids.

Background of the Invention

15 Bacterial DNA is a potent immunomodulatory substance. Yamamoto S et al., *Microbiol Immunol* 36:983-997 (1992). It has been hypothesized to be a pathogen-derived ligand recognized by an unidentified pathogen recognition receptor that initiates a host of innate and adaptive immune responses. Wagner H, *Adv Immunol* 73:329-368 (1999). CpG motif-containing oligodeoxynucleotides (CpG ODN) can mimic the biology of bacterial DNA. Krieg AM et al., *Nature* 374:546-549 (1995). CpG ODN and DNA vectors have
20 recently been shown to be of clinical value due to immunostimulatory, hematopoietic and adjuvant qualities.

 The adaptive immune system appeared approximately 450 million years ago when a transposon that carried the forerunners of the recombinase activating genes, RAG-1 and RAG-2, was inserted into the germ line of early jawed vertebrates. Agarwal A. et al., *Nature*
25 394:744 (1998). The ability to mount an adaptive immune response allowed organisms to remember the pathogens that they had already encountered, and natural selection made the adaptive immune response a virtually universal characteristic of vertebrates. However, this did not lead to discarding the previous form of host defense, the innate immune system. Indeed, this earlier form of host defense has been coopted to serve a second function,
30 stimulating and orienting the primary adaptive immune response by controlling the expression of costimulatory molecules.

- 2 -

It had been surmised for a decade that cells of the innate immune system bear receptors for conserved molecular patterns associated with microbial pathogens. According to this model, when the protein antigens derived from pathogens are processed and presented as peptides that serve as the stimulus for specific T cell receptors, pattern recognition receptors (PRRs) on the antigen-presenting cells also induce the synthesis of costimulatory molecules, cytokines, and chemokines. These activated antigen-presenting cells serve to attract and activate the antigen-specific T cells that are essential to all adaptive immune responses. Janeway CAJ, *Cold Spring Harbor Symp Quant Biol* 54:1 (1989); Fearon DT et al., *Science* 272:50 (1996); and Medzhitov R et al., *Cell* 91:295 (1997). It was known that the substances that can induce costimulation include bacterial lipopolysaccharide (LPS), synthetic double-stranded RNA, glycans, and mannans. Furthermore, experimental evidence indicated that the processed antigen ligand for the T cell had to be on the same cell as the costimulatory molecule. This is obviously of crucial importance for maintaining self-tolerance; bystander presentation of costimulatory molecules would mean that tolerance would be lost whenever an infection occurred.

To validate this model, it was necessary to identify receptors for microbial patterns that, upon binding pathogen ligands, initiate signaling cascades leading to the production of costimulatory molecules and cytokines. Molecules such as mannose binding protein (MBP) do not qualify for this role, because they activate proteolytic cascades or promote phagocytosis but are not known to induce costimulation. The break-through came with the identification of a human homologue of *Drosophila* Toll initially cloned as a cDNA and later named hTLR4 (for human Toll-like receptor). Medzhitov R et al., *Nature* 388:394 (1997); Rock FL et al., *Proc Natl Acad Sci USA* 95:588 (1998); Chaudhary PM et al., *Blood* 91:4020-4027 (1998).

Toll-like receptors (TLRs) are a family of germline-encoded transmembrane proteins that facilitate pathogen recognition and activation of the innate immune system. Hoffmann JA et al., *Science* 284, 1313-1318 (1999); Rock FL et al., *Proc Natl Acad Sci USA* 95:588-593 (1998). TLRs engage conserved pathogen-derived ligands and subsequently activate the TLR/IL-1R signal transduction pathway to induce a variety of effector genes. Medzhitov R et al., *Mol Cell* 2:253-258 (1998); Muzio M et al., *J Exp Med* 187:2097-2101 (1998).

So far, ten different mammalian TLRs have been described. Rock FL et al., *Proc Natl*

- 3 -

Acad Sci USA 95:588-593 (1998); Chaudhary PM et al., *Blood* 91:4020-4027 (1998); Takeuchi O et al., *Gene* 231:59-65 (1999); Aderem A. et al., *Nature* 406:782-7 (2000). So far, genetic data suggest that the TLRs have unique functions and are not redundant. Ligands for and the function of most of these TLRs, aside from TLR2 and TLR4, remain to be elucidated.

It turns out that an LPS-binding and signaling receptor complex is assembled when hTLR4 interacts with LPS bound to CD14, a peripheral membrane protein held to the cell surface by a glycosyl-phosphoinositol tail. The presence of LPS binding protein (LBP) further increases signaling. The hTLR4 protein has a leucine-rich repeat sequence in its extracellular domain that interacts with CD14 complexed with LPS. TLR4 then transduces the LPS signal across the membrane because destructive mutation of this gene lead to an LPS-unresponsive state in mice, which are also deficient in the clearance of Gram-negative bacteria. Poltorak A et al., *Science* 282:2085 (1998); Qureshi ST et al., *J Exp Med* 189:615-625 (1999); Eden CS et al., *J Immunol* 140:180 (1988). It has since become apparent that humans, like flies, have numerous Toll-like receptors (TLRs).

TLR4 and other TLRs have a cytoplasmic Toll/IL-1 receptor (TIR) homology domain. This domain communicates with a similar domain on an adapter protein (MyD88) that interacts with TLR4 by means of a like:like interaction of TIR domains. The next interaction is between the adapter and a kinase, through their respective "death domains." The kinase in turn interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I κ B and its dissociation from NF- κ B. The first kinase is a mitogen-activated kinase kinase kinase (MAPKKK) known as NIK, for NF- κ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I κ B kinase α (IKK α) and I κ B kinase β (IKK β), that together form a heterodimer of IKK α :IKK β , which phosphorylates I κ B. NF- κ B translocates to the nucleus to activate genes with κ B binding sites in their promoters and enhancers such as the genes encoding interleukin-1 β (IL-1 β), IL-6, IL-8, the p40 protein of IL-12, and the costimulatory molecules CD80 and CD86.

The types of cells that respond to CpG DNA - B cells, dendritic cells (DCs) and macrophages - are also stimulated by other pathogen-derived pattern-recognition factors, such

- 4 -

as LPS. In general, the PRRs of the innate immune system are situated on the cell surface, where they are probably best able to detect microbes. Although cell-surface proteins that bind DNA are well described, and have been proposed to mediate immune activation by CpG motif (Liang H et al., *J Clin Invest* 98:1119-1129 (1998)), this binding is sequence-
5 independent and does not bring about cell activation. Krieg AM et al., *Nature* 374:546-549 (1995); Yamamoto T et al., *Microbiol Immunol* 38:831-836 (1994); Häcker H et al., *EMBO J* 17:6230-6240 (1998). Because CpG ODNs that have been immobilized to prevent cell uptake are nonstimulatory (Krieg AM et al., *Nature* 374:546-549 (1995); Manzel L et al., *Antisense Nucleic Acid Drug Dev* 9:459-464 (1999)), it appears that CpG ODN probably
10 work by binding to an intracellular receptor. In support of this hypothesis, drugs such as chloroquine, which interfere with the endosomal acidification/processing of ODNs, specifically block the immune stimulatory effects of CpG DNA. Häcker H et al., *EMBO J* 17:6230-6240 (1998); Macfarlane DE et al., *J Immunol* 160:1122-1131 (1998); Yi AK et al., *J Immunol* 160:4755-4761 (1998). It has been proposed that an endosomal step is required
15 for the CpG-induced signal transduction pathways. Häcker H et al., *EMBO J* 17:6230-6240 (1998); Yi AK et al., *J Immunol* 160:4755-4761 (1998). How the information contained in unmethylated CpG-motifs of bacterial DNA trigger changes in gene expression has not previously been discovered.

Since the receptor for bacterial DNA has been unknown, development of screening for
20 optimal CpG motifs through direct binding analysis has been limited. An additional complication appears to be species-specific selectivity for CpG sequence, i.e., an optimal sequence for one species may not be optimal for another.

Summary of the Invention

25 Nucleic acids encoding three Toll-like receptors, Toll-like receptor 7 (TLR7), TLR8, and TLR9 of the mouse have now been identified, isolated, cloned and sequenced by the inventors. The invention in general provides isolated nucleic acid molecules encoding TLRs and isolated fragments of those nucleic acid molecules; isolated TLR polypeptides and isolated fragments of those polypeptides; expression vectors containing the foregoing nucleic
30 acid molecules; host cells having the foregoing expression vectors; fusion proteins including the TLR polypeptides and fragments thereof; and screening methods useful for identifying,

- 5 -

comparing, and optimizing agents which interact with these TLRs, particularly agents that alter the expression of and signaling associated with these TLR molecules. In preferred embodiments the screening methods are high throughput screening methods.

The invention in some aspects arises from the surprising discovery that TLR9 is involved in immunostimulatory nucleic acid (ISNA)-induced immunostimulation. The invention also stems in part from the surprising discovery that TLR9 transduces immune activating signals in response to ISNA in a manner that is both sequence-specific and species-specific.

In a first aspect the invention provides isolated nucleic acid molecules which encode full-length murine TLR9. According to this aspect of the invention, isolated nucleic acid molecules are provided which are selected from the group consisting of (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:1, and which code for a murine TLR9 having an amino acid sequence set forth as SEQ ID NO:3; (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code; and (c) complements of (a) or (b). In a certain embodiment, the isolated nucleic acid molecule codes for SEQ ID NO:3, where SEQ ID NO:3 represents the deduced amino acid sequence of full-length murine TLR9. In some embodiments the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2, where these correspond to full-length cDNA and the open reading frame for murine TLR9, respectively.

The term "stringent conditions" as used herein refers to combined conditions based on parameters including salt, temperature, organic solvents, and optionally other factors with which the practitioner skilled in the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% bovine serum albumin, 2.5mM NaH₂PO₄ (pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulfate; and EDTA is ethylenediaminetetraacetic

- 6 -

acid. After hybridization, the membrane upon which the DNA is transferred is washed with 2 x SSC at room temperature and then with 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C. There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of alleles of murine TLR nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

The invention in a second aspect provides isolated TLR9 polypeptides or fragments thereof. The isolated TLR9 polypeptides or fragments thereof include at least one amino acid of a murine TLR9 selected from the group consisting of amino acids 2, 3, 4, 6, 7, 18, 19, 22, 38, 44, 55, 58, 61, 62, 63, 65, 67, 71, 80, 84, 87, 88, 91, 101, 106, 109, 117, 122, 123, 134, 136, 140, 143, 146, 147, 157, 160, 161, 167, 168, 171, 185, 186, 188, 189, 191, 199, 213, 217, 220, 227, 231, 236, 245, 266, 269, 270, 271, 272, 273, 274, 278, 281, 285, 297, 298, 301, 305, 308, 311, 322, 323, 325, 326, 328, 332, 335, 346, 348, 353, 355, 358, 361, 362, 365, 367, 370, 372, 380, 381, 382, 386, 389, 392, 394, 397, 409, 412, 413, 415, 416, 419, 430, 432, 434, 435, 438, 439, 443, 444, 446, 447, 448, 450, 451, 452, 454, 455, 459, 460, 463, 465, 466, 468, 469, 470, 472, 473, 474, 475, 478, 488, 489, 494, 495, 498, 503, 508, 510, 523, 531, 539, 540, 543, 547, 549, 561, 563, 565, 576, 577, 579, 580, 587, 590, 591, 594, 595, 597, 599, 601, 603, 610, 611, 613, 616, 619, 632, 633, 640, 643, 645, 648, 650, 657, 658, 660, 667, 670, 672, 675, 679, 689, 697, 700, 703, 705, 706, 711, 715, 716, 718, 720, 723, 724, 726, 729, 731, 735, 737, 743, 749, 750, 751, 752, 754, 755, 759, 760, 772, 774, 780, 781, 786, 787, 788, 800, 814, 821, 829, 831, 832, 835, 844, 857, 858, 859, 862, 864, 865, 866, 879, 893, 894, 898, 902, 910, 917, and 927 of SEQ ID NO:3, wherein the TLR9 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR9 polypeptide or fragment thereof except for the at least one amino acid of murine TLR9. The TLR9 polypeptide or fragment thereof in certain embodiments according to this aspect of the invention further includes at least one amino acid of murine TLR9 selected from the group consisting of amino acids 949, 972, 975, 976, 994, 997, 1000, 1003, 1004, 1010,

- 7 -

1011, 1018, 1023, and 1027 of SEQ ID NO:3. Thus specifically excluded from this aspect of the invention are TLR9 fragments restricted to the C-terminal 95 amino acids and fragments thereof.

5 In certain embodiments the TLR9 polypeptide and fragments thereof according to this aspect of the invention exclude those TLR9 polypeptides and fragments thereof which differ from human TLR9 and fragments thereof only by one or more conservative amino acid substitutions at particular sites noted above. As is well known in the art, a "conservative amino acid substitution" refers to an amino acid substitution which generally does not alter the relative charge or size characteristics of the polypeptide in which the amino acid
10 substitution is made. Conservative substitutions of amino acids typically include substitutions made amongst amino acids within the following groups: methionine (M), isoleucine (I), leucine (L), valine (V); phenylalanine (F), tyrosine (Y), tryptophan (W); lysine (K), arginine (R), histidine (H); alanine (A), glycine (G); serine (S), threonine (T); glutamine (Q), asparagine (N); and glutamic acid (E), aspartic acid (D).

15 According to this and other aspects of the invention, with reference to TLR "polypeptides and fragments thereof," "fragments thereof" refers to polypeptide fragments having stretches of contiguous amino acid residues that are at least about 8 amino acids long. Generally the fragments are at least about 10 amino acids long; more generally at least 12 amino acids long; often at least about 14 amino acids long; more often at least about 16
20 amino acids long; typically at least 18 amino acids long; more typically at least 20 amino acids long; usually at least 22 amino acids long; and more usually at least 24 amino acids long. Certain preferred embodiments include larger fragments that are, for example, at least about 30 amino acids long, at least about 40 amino acids long, at least about 50 amino acids long, at least about 100 amino acids long, at least about 200 amino acids long, and so on, up
25 to and including fragments that are a single amino acid shorter than full-length TLR polypeptide.

In certain embodiments, the human TLR9 has an amino acid sequence set forth as SEQ ID NO:6.

In preferred embodiments, the isolated TLR9 polypeptides or fragments thereof
30 include an amino acid sequence selected from the group consisting of SEQ ID NO:3 and fragments of SEQ ID NO:3. In some embodiments according to this aspect of the invention,

- 8 -

the isolated TLR9 polypeptides or fragments thereof include combinations of the foregoing human and murine TLR9 polypeptides.

In certain preferred embodiments the isolated TLR9 polypeptide or fragment thereof is an extracytoplasmic domain (also referred to herein as extracellular domain) of TLR9, or a portion thereof. As described in greater detail further herein, TLR7, TLR8, and TLR9 have certain structural and functional domains. Structural domains of these TLRs include but are not limited to an extracytoplasmic domain, a transmembrane domain, and a cytoplasmic domain. The extracytoplasmic domain extends into the lumen of endosomal/lysosomal vesicles. The cytoplasmic domain includes a Toll/interleukin-1 receptor-like domain (also referred to as Toll/IL-1R domain, TIR homology domain, or TIR domain). In murine TLR9 the extracytoplasmic, transmembrane, and cytoplasmic domains correspond to amino acids 1 to about 819, about 820 to about 837, and about 838 to about 1032, respectively.

As mentioned above, it has been discovered according to the invention that TLR9 is involved in immune activation induced by certain nucleic acid molecules referred to in the art as immunostimulatory nucleic acids (ISNAs), including CpG nucleic acids. It is believed by the inventors that binding of ISNA to TLR9 leads to signal transduction involving the TIR domain of TLR9. Thus in certain embodiments according to this aspect of the invention, the isolated TLR9 polypeptide or fragment thereof selectively binds to an ISNA, including an ISNA that is a CpG nucleic acid.

Also included according to this aspect of the invention are isolated TLR9 polypeptides or fragments thereof which are portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids such as CpG nucleic acids. In certain embodiments such portions include an MBD motif set forth as any one of SEQ ID NOs: 126, 127, 210, and 211. In certain embodiments portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids include a CXXC motif set forth as any one of SEQ ID NOs: 196, 197, and 198.

According to a third aspect of the invention, isolated nucleic acid molecules are provided which encode the foregoing isolated TLR9 polypeptides or fragments thereof. The isolated nucleic acid molecules according to this aspect of the invention specifically exclude certain expressed sequence tags (ESTs) identified by the following GenBank accession numbers: AA162495, AA197442, AA273731, AA794083, AA915125, AA968074,

- 9 -

AI428529, AI451215, AI463056, AI893951, AV142833, AV326033, AV353853,
AW048117, AW048548, AW215685, AW549817, BB179985, BB215203, BB283380,
BB285606, BB312895, BB497196, BB622397, BF016670, BF150116, BF161011,
BF300296, BF385702, BF539367, BF784415, BG863184, BG922959, BG967012,
5 BG974917, BI105291, BI153921, BI651868, BI653892, and W76964.

In a fourth aspect the invention provides isolated nucleic acid molecules which encode full-length murine TLR7. According to this aspect of the invention, isolated nucleic acid molecules are provided which are selected from the group consisting of (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a
10 nucleotide sequence set forth as SEQ ID NO:173, and which code for a murine TLR7 having an amino acid sequence set forth as SEQ ID NO:175; (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code; and (c) complements of (a) or (b). In a certain embodiment, the isolated nucleic acid molecule codes for SEQ ID NO:175, where SEQ ID NO:175 represents the deduced amino
15 acid sequence of full-length murine TLR7. In some embodiments the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:173 or SEQ ID NO:174, where these correspond to full-length cDNA and the open reading frame for murine TLR7, respectively.

The invention in a fifth aspect provides isolated TLR7 polypeptides or fragments
20 thereof. The isolated TLR7 polypeptides or fragments thereof include at least one amino acid of a murine TLR7 selected from the group consisting of amino acids 4, 8, 15, 16, 18, 21, 23, 24, 25, 27, 37, 39, 40, 41, 42, 44, 45, 61, 79, 83, 86, 89, 92, 96, 103, 109, 111, 113, 119, 121, 127, 128, 131, 145, 148, 151, 164, 172, 176, 190, 202, 203, 204, 205, 222, 225, 226, 228, 236, 238, 243, 250, 253, 266, 268, 271, 274, 282, 283, 287, 288, 308, 313, 314, 315, 325,
25 328, 331, 332, 341, 343, 344, 347, 351, 357, 360, 361, 362, 363, 364, 365, 366, 370, 371, 377, 378, 387, 388, 389, 392, 397, 398, 413, 415, 416, 419, 421, 422, 425, 437, 438, 440, 446, 449, 453, 454, 455, 456, 462, 470, 482, 486, 487, 488, 490, 491, 493, 494, 503, 505, 509, 511, 529, 531, 539, 540, 543, 559, 567, 568, 574, 583, 595, 597, 598, 600, 611, 613, 620, 624, 638, 645, 646, 651, 652, 655, 660, 664, 665, 668, 669, 672, 692, 694, 695, 698,
30 701, 704, 714, 720, 724, 727, 728, 733, 738, 745, 748, 755, 762, 777, 780, 789, 803, 846, 850, 851, 860, 864, 868, 873, 875, 884, 886, 888, 889, 890, 902, 903, 911, 960, 967, 970,

- 10 -

980, 996, 1010, 1018, 1035, and 1045 of SEQ ID NO:175, wherein the TLR7 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR7 polypeptide or fragment thereof except for the at least one amino acid of murine TLR7.

5 In certain embodiments the TLR7 polypeptide and fragments thereof according to this aspect of the invention exclude those TLR7 polypeptides and fragments thereof which differ from human TLR7 and fragments thereof only by one or more conservative amino acid substitutions at particular sites noted above.

In certain embodiments, the human TLR7 has an amino acid sequence set forth as SEQ ID NO:170.

10 In preferred embodiments, the isolated TLR7 polypeptides or fragments thereof include an amino acid sequence selected from the group consisting of SEQ ID NO:175 and fragments of SEQ ID NO:175. In some embodiments according to this aspect of the invention, the isolated TLR7 polypeptides or fragments thereof include combinations of the foregoing human and murine TLR7 polypeptides.

15 In certain preferred embodiments the isolated TLR7 polypeptide or fragment thereof is an extracytoplasmic domain of TLR7, or a portion thereof. In certain embodiments according to this aspect of the invention, the isolated TLR7 polypeptide or fragment thereof selectively binds to an ISNA, including an ISNA that is a CpG nucleic acid. Also included according to this aspect of the invention are isolated TLR7 polypeptides or fragments thereof which are
20 portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids such as CpG nucleic acids. In certain embodiments such portions include an MBD motif set forth as any one of SEQ ID NOs: 203, 204, 212, and 213.

In certain embodiments portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids include a CXXC motif set forth as any one of
25 SEQ ID NOs: 196, 199, and 200.

According to a sixth aspect of the invention, isolated nucleic acid molecules are provided which encode the foregoing isolated TLR7 polypeptides or fragments thereof. The isolated nucleic acid molecules according to this aspect of the invention specifically exclude certain ESTs identified by the following GenBank accession numbers: AA176010,
30 AA210352, AA241310, AA266000, AA266744, AA276879, AA288480, AA871870, AI119722, AI449297, AI466859, AI604175, AV322307, BB033376, BB116163, BB210788,

- 11 -

BB464985, BB466708, BB636153, BF101884, BF124798, BF143871, BG067922, BG080980, BG082140, BG871070, BG964747, BG976560, BI150306, BI411471, and C87987.

In a seventh aspect the invention provides isolated nucleic acid molecules which
5 encode full-length murine TLR8. According to this aspect of the invention, isolated nucleic acid molecules are provided which are selected from the group consisting of (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:190, and which code for a murine TLR8 having an amino acid sequence set forth as SEQ ID NO:192; (b) nucleic acid molecules that differ
10 from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code; and (c) complements of (a) or (b). In a certain embodiment, the isolated nucleic acid molecule codes for SEQ ID NO:192, where SEQ ID NO:192 represents the deduced amino acid sequence of full-length murine TLR8. In some embodiments the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:190 or SEQ ID NO:191, where
15 these correspond to full-length cDNA and the open reading frame for murine TLR8, respectively.

The invention in an eighth aspect provides isolated TLR8 polypeptides or fragments thereof. The isolated TLR8 polypeptides or fragments thereof include at least one amino acid of a murine TLR8 selected from the group consisting of amino acids 5, 6, 9, 10, 14, 15, 18,
20 21, 22, 23, 24, 25, 26, 27, 28, 30, 39, 40, 41, 43, 44, 50, 51, 53, 55, 61, 67, 68, 74, 80, 85, 93, 98, 99, 100, 104, 105, 106, 107, 110, 114, 117, 119, 121, 124, 125, 134, 135, 138, 145, 155, 156, 157, 160, 161, 162, 163, 164, 166, 169, 170, 174, 180, 182, 183, 186, 187, 191, 193, 194, 196, 197, 199, 200, 207, 209, 210, 227, 228, 230, 231, 233, 234, 241, 256, 263, 266, 267, 268, 269, 272, 274, 275, 276, 280, 285, 296, 298, 299, 300, 303, 305, 306, 307, 310,
25 312, 320, 330, 333, 335, 343, 344, 345, 346, 347, 349, 351, 356, 362, 365, 366, 375, 378, 379, 380, 381, 383, 384, 386, 387, 392, 402, 403, 408, 414, 416, 417, 422, 426, 427, 428, 429, 430, 431, 433, 437, 438, 439, 440, 441, 444, 445, 449, 456, 461, 463, 471, 483, 486, 489, 490, 494, 495, 496, 505, 507, 509, 512, 513, 519, 520, 523, 537, 538, 539, 541, 542, 543, 545, 554, 556, 560, 567, 569, 574, 575, 578, 586, 592, 593, 594, 595, 597, 599, 602,
30 613, 617, 618, 620, 621, 623, 628, 630, 633, 639, 641, 643, 644, 648, 655, 658, 661, 663, 664, 666, 668, 677, 680, 682, 687, 688, 690, 692, 695, 696, 697, 700, 702, 703, 706, 714,

- 12 -

715, 726, 727, 728, 730, 736, 738, 739, 741, 746, 748, 751, 752, 754, 757, 764, 766, 772, 776, 778, 781, 784, 785, 788, 791, 795, 796, 801, 802, 806, 809, 817, 820, 821, 825, 828, 829, 831, 839, 852, 853, 855, 858, 863, 864, 900, 903, 911, 918, 934, 977, 997, 1003, 1008, 1010, 1022, 1023, 1024, 1026, and 1030 of SEQ ID NO:192, wherein the TLR8 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR8 polypeptide or fragment thereof except for the at least one amino acid of murine TLR8.

In certain embodiments the TLR8 polypeptide and fragments thereof according to this aspect of the invention exclude those TLR8 polypeptides and fragments thereof which differ from human TLR8 and fragments thereof only by one or more conservative amino acid substitutions at particular sites noted above.

In certain embodiments, the human TLR8 has an amino acid sequence set forth as SEQ ID NO:184.

In preferred embodiments, the isolated TLR8 polypeptides or fragments thereof include an amino acid sequence selected from the group consisting of SEQ ID NO:192 and fragments of SEQ ID NO:192. In some embodiments according to this aspect of the invention, the isolated TLR8 polypeptides or fragments thereof include combinations of the foregoing human and murine TLR8 polypeptides.

In certain preferred embodiments the isolated TLR8 polypeptide or fragment thereof is an extracytoplasmic domain of TLR8, or a portion thereof. In certain embodiments according to this aspect of the invention, the isolated TLR8 polypeptide or fragment thereof selectively binds to an ISNA, including an ISNA that is a CpG nucleic acid. Also included according to this aspect of the invention are isolated TLR8 polypeptides or fragments thereof which are portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids such as CpG nucleic acids. In certain embodiments such portions include an MBD motif set forth as any one of SEQ ID NOs: 205, 206, 214, and 215.

In certain embodiments portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids include a CXXC motif set forth as any one of SEQ ID NOs: 196, 201, and 202.

According to a ninth aspect of the invention, isolated nucleic acid molecules are provided which encode the foregoing isolated TLR8 polypeptides or fragments thereof. The isolated nucleic acid molecules according to this aspect of the invention specifically exclude

- 13 -

certain ESTs identified by the following GenBank accession numbers: AA116795, AA268605, AA920337, AI529457, AI849892, AV097766, AV117427, AV164719, AV169968, AW551677, BB143750, BB214171, BB243478, BB244318, BB254686, BB256660, BB258368, BB278984, BB291470, BB292008, BB364655, BB373674, 5 BB428800, BB439876, BB444812, BB445724, BB465766, BB470182, BB535086, BB573907, BB573981, BB607650, BF135656, BF722808, BG299237, BG918020, BG919592, and W39977.

In a further aspect, the invention provides TLR expression vectors comprising the foregoing isolated nucleic acid molecules operably linked to a promoter. Thus in certain 10 embodiments pertaining to TLR9, the expression vector includes an isolated nucleic acid molecule according to the first aspect or the third aspect of the invention, operably linked to a promoter. In other embodiments, relating to TLR7, the expression vector includes an isolated nucleic acid molecule according to the fourth aspect or the sixth aspect of the invention, operably linked to a promoter. In yet other embodiments, relating to TLR8, the expression 15 vector includes an isolated nucleic acid molecule according to the seventh aspect or the ninth aspect of the invention, operably linked to a promoter.

The expression vectors according to this aspect of the invention are designed and constructed so that when they are introduced into a cell, under proper conditions they direct expression of the gene product encoded by the incorporated isolated nucleic acid molecule. 20 For example, the promoter can be constitutively active or it can be inducible or repressible upon interaction with a suitable inducer or repressor compound.

According to another aspect, host cells are provided that include a TLR expression vector of the invention. While any suitable method can be used, an expression vector typically is introduced into a cell by transfection or transformation. The host cells 25 transformed or transfected with the TLR expression vectors are in some embodiments co-transformed or co-transfected with another expression vector useful for the expression of another polypeptide. Alternatively, a host cell can be transformed or transfected with an expression vector capable of directing expression of a TLR polypeptide or fragment thereof of the invention and (i) at least one additional TLR polypeptide or fragment thereof, or (ii) at 30 least one non-TLR polypeptide or fragment thereof. In certain preferred embodiments, the host cell includes separate expression vectors for any combination of TLR7, TLR8, and

- 14 -

TLR9. In some embodiments, a co-transformed or co-transfected expression vector may be useful for detection or regulation of TLR expression or TLR-related signaling. Specifically, in certain preferred embodiments the host cell includes an expression vector providing a reporter construct capable of interacting with a TIR domain.

5 In another aspect, the invention provides agents which selectively bind the isolated TLR polypeptides and fragments thereof of the invention. In certain embodiments the agent does not bind a human TLR polypeptide or fragment thereof, wherein the human TLR is selected from human TLR7, TLR8, and TLR9. In certain embodiments the agent is a polypeptide, preferably one selected from the group consisting of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab')₂ antibody fragments, Fv antibody
10 fragments, antibody fragments including a CDR3 region, and fusion proteins and other polypeptides including any such antibodies or antibody fragments.

Also provided are agents which selectively bind the foregoing isolated nucleic acid molecules, preferably antisense nucleic acid molecules which selectively bind to any of the
15 foregoing isolated nucleic acid molecules encoding a TLR polypeptide or fragment thereof. In some embodiments the agent is an isolated nucleic acid molecule which hybridizes under stringent conditions to an isolated nucleic acid molecule provided according to any of the first, third, fourth, fifth, sixth, and eighth aspects of the invention. In certain preferred embodiments the agent is an isolated nucleic acid molecule having a nucleotide sequence
20 which is complementary to an isolated nucleic acid molecule provided according to any of the first, third, fourth, fifth, sixth, and eighth aspects of the invention.

In still other aspects of the invention, methods for inhibiting TLR expression and TLR signaling in a cell are provided. The methods include contacting the cell with an amount of an agent effective to inhibit TLR expression and TLR signaling in the cell, wherein the TLR
25 is selected from the group consisting of TLR7, TLR8, and TLR9. In some embodiments the agent brought into contact with the cell is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab')₂ antibody fragments, Fv antibody fragments, antibody fragments including a CDR3 region, and fusion proteins and other polypeptides that include any such antibodies or antibody fragments. In some
30 embodiments the cell is contacted with an antisense nucleic acid specific for the TLR, in an amount effective to inhibit TLR expression in the cell. In some embodiments the cell is

- 15 -

contacted with an agent such as a cytokine or small molecule, in an amount effective to inhibit TLR expression in the cell.

In yet another aspect the invention provides a method for identifying nucleic acid molecules which interact with a TLR polypeptide or a fragment thereof. The method involves contacting a TLR polypeptide selected from the group consisting of TLR7, TLR8, TLR9, and nucleic acid-binding fragments thereof with a test nucleic acid molecule; and measuring an interaction of the test nucleic acid molecule with the TLR polypeptide or fragment thereof. Nucleic acid-binding fragments of TLRs preferably include the extracytoplasmic domain or subportions thereof, such as those which include at least an MBD motif, a CXXC motif, or both an MBD motif and a CXXC motif.

In this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is TLR7. Likewise in this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is TLR8. Also in this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is TLR9.

In this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is expressed in a cell. The cell expressing the TLR polypeptide or fragment thereof may naturally express the TLR polypeptide or fragment thereof, or it may be a host cell as provided by other aspects of the instant invention.

In this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is an isolated TLR polypeptide or fragment thereof. In certain preferred embodiments the isolated TLR polypeptide or fragment thereof is immobilized on a solid support, for example a multiwell plate, a slide, a BIAcore chip, a bead, a column, and the like. The immobilization can be accomplished by any chemical or physical method suitable for the purpose of the assay to be performed according to the method of the invention.

In certain embodiments the TLR polypeptide or fragment thereof is fused with an Fc fragment of an antibody. The Fc fragment portion of such a fusion molecule may be useful,

- 16 -

for example, for attaching the TLR polypeptide or fragment thereof to a substrate, or for providing a target for detecting the presence of the TLR polypeptide or fragment thereof. The Fc fragment can be selected from any suitable vertebrate species and will typically, but not necessarily, be derived from an antibody belonging to the IgG class of antibodies. For
5 example, the Fc can be a human or a murine Fc γ . In certain embodiments the TLR polypeptide or fragment thereof is fused with an Fc fragment of an antibody with a specific cleavage site at or near the junction between the TLR polypeptide or fragment thereof and the Fc fragment. In one preferred embodiment the cleavage site is a thrombin protease recognition site. In a preferred embodiment the TLR polypeptide or fragment thereof fused
10 with the Fc fragment includes a TLR extracytoplasmic domain.

In certain embodiments the interaction involving the TLR polypeptide or fragment thereof and the test nucleic acid molecule is binding between the TLR polypeptide or fragment thereof and the test nucleic acid molecule.

In certain embodiments according to this aspect of the invention, the measuring is
15 accomplished by a method selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), biomolecular interaction assay (BIA), electromobility shift assay (EMSA), radioimmunoassay (RIA), polyacrylamide gel electrophoresis (PAGE), and Western blotting.

In certain embodiments the measuring is accomplished by a method comprising
20 measuring a response mediated by a TLR signal transduction pathway. For example, the response mediated by a TLR signal transduction pathway can be selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine. In certain preferred embodiments the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and
25 TNF-luc. In certain preferred embodiments the secreted cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.

In another embodiment the method according to this aspect of the invention can be used to determine if the test nucleic acid molecule is an immunostimulatory nucleic acid. The method involves the additional steps of comparing (a) the response mediated by a TLR signal
30 transduction pathway as measured in the presence of the test nucleic acid molecule with (b) a response mediated by a TLR signal transduction pathway as measured in the absence of the

- 17 -

test nucleic acid molecule; and determining the test nucleic acid molecule is an immunostimulatory nucleic acid when (a) exceeds (b).

In yet another embodiment the method according to this aspect of the invention can be used to determine if the response to the test nucleic acid molecule is stronger or weaker than a response to a reference nucleic acid molecule. The method involves the additional steps of comparing the response to a reference response when the TLR polypeptide is independently contacted with a reference nucleic acid molecule; and determining if the response is stronger or weaker than the reference response. In this embodiment the test nucleic acid molecule and the reference nucleic acid molecule are not able to compete or interact. For example, the reference response can be a parallel control or a historical control.

In another embodiment the method involves the additional steps of comparing the response to a reference response when the TLR polypeptide is concurrently contacted with a reference nucleic acid molecule; and determining if the response is stronger or weaker than the reference response. In this embodiment the test nucleic acid molecule and the reference nucleic acid molecule are potentially able to compete or interact since they are both present, for example, in a single reaction.

In another aspect the invention provides a screening method for identifying an immunostimulatory nucleic acid. The method according to this aspect involves contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test nucleic acid molecule; detecting presence or absence of a response mediated by a TLR signal transduction pathway in the presence of the test nucleic acid molecule arising as a result of an interaction between the functional TLR and the test nucleic acid molecule; and determining the test nucleic acid molecule is an ISNA when the presence of a response mediated by the TLR signal transduction pathway is detected. A functional TLR refers to a TLR polypeptide or fragment thereof that can bind with a ligand and as a consequence of the binding engage at least one step or additional polypeptide in a TLR signal transduction pathway.

In one embodiment the method according to this aspect of the invention includes the further step of comparing (a) the response mediated by the TLR signal transduction pathway arising as a result of an interaction between the functional TLR and the test nucleic acid molecule with (b) a response arising as a result of an interaction between the functional TLR and a reference ISNA. In this and other screening assays of the instant invention, in preferred

- 18 -

embodiments the screening method is performed on a plurality of test nucleic acids. In certain preferred embodiments the response mediated by the TLR signal transduction pathway is measured quantitatively, and the response mediated by the TLR signal transduction pathway associated with each of the plurality of test nucleic acid molecules is compared with a response arising as a result of an interaction between the functional TLR and a reference ISNA.

In certain preferred embodiments a subset of the plurality of test nucleic acid molecules is selected based on the ability of the subset to produce a specific response mediated by the TLR signal transduction pathway. For example, the specific response can be induction of a specific cytokine or panel of cytokines, e.g., Th1 cytokines, or, alternatively, inhibition of a specific cytokine or panel of cytokines, e.g., Th2 cytokines. The specific response can be induction, or, alternatively, inhibition of a specific class or subclass of antibody or panel of classes or subclasses of antibodies, e.g., Th1-associated antibodies or Th2-associated antibodies. The specific response in some embodiments can be activation or inhibition of certain types of immune cells, e.g., B cells, dendritic cells (DCs), and natural killer (NK) cells. In some embodiments the specific response can be induction or inhibition of proliferation of certain types of immune cells, e.g., B cells, T cells, NK cells, dendritic cells, monocytes/macrophages. The subset of the plurality of test nucleic acids is therefore selected on the basis of the common association between the test nucleic acids of the subset and the particular type of response mediated by the TLR signal transduction pathway. The particular type of response mediated by the TLR signal transduction pathway is typically, but not necessarily, an immune cell response.

In certain embodiments the response mediated by a TLR signal transduction pathway is selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine. In certain preferred embodiments the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc. In certain preferred embodiments the cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.

In certain preferred embodiments the reference ISNA is a CpG nucleic acid.

In certain preferred embodiments the test nucleic acid molecule is a CpG nucleic acid. According to this and other aspects of the invention involving functional TLR in a

- 19 -

screening assay, in some embodiments the functional TLR is expressed in a cell. In some
embodiments the functional TLR is naturally expressed by the cell. In certain preferred
embodiments the cell is an isolated mammalian cell that naturally expresses the functional
TLR. Whether the cell expresses the TLR naturally or the cell expresses the TLR because an
5 expression vector having an isolated nucleic acid molecule encoding the TLR operatively
linked to a promoter has been introduced into the cell, in some embodiments the cell further
includes an expression vector comprising an isolated nucleic acid which encodes a reporter
construct selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc,
and TNF-luc, operatively linked to a promoter.

10 Also according to this and other aspects of the invention involving functional TLR in
a screening assay, in certain embodiments the functional TLR is part of a cell-free system.

Also according to this and other aspects of the invention involving functional TLR in
a screening assay, in certain embodiments the functional TLR is part of a complex with
another TLR. In certain preferred embodiments the complex is a complex of TLR9 and
15 TLR7. In certain preferred embodiments the complex is a complex of TLR9 and TLR8.

Also according to this and other aspects of the invention involving functional TLR in
a screening assay, in certain embodiments the functional TLR is part of a complex with a
non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B,
and functional homologues and derivatives thereof.

20 Further according to this and other aspects of the invention involving functional
TLR in a screening assay, in certain embodiments the response mediated by a TLR signal
transduction pathway is selected from the group consisting of induction of a gene under
control of NF- κ B promoter and secretion of a cytokine.

Also according to this and other aspects of the invention involving functional
25 TLR in a screening assay, in certain embodiments the gene under control of NF- κ B promoter
is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and
TNF-luc.

Also according to this and other aspects of the invention involving functional
TLR in a screening assay, in certain embodiments wherein the cytokine is selected from the
30 group consisting of IL-8, TNF- α , and IL-12 p40.

In a further aspect, the invention provides a screening method for comparing TLR

- 20 -

signaling activity of a test compound with an ISNA. The method entails contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a reference ISNA and detecting a reference response mediated by a TLR signal transduction pathway; contacting a functional TLR selected from the group consisting of TLR7, TLR8,
5 and TLR9 with a test compound and detecting a test response mediated by a TLR signal transduction pathway; and comparing the test response with the reference response to compare the TLR signaling activity of the test compound with the ISNA.

In certain embodiments according to this aspect of the invention, the reference ISNA is a CpG nucleic acid.

10 In certain embodiments according to this aspect of the invention, the test compound is a polypeptide. In certain embodiments the test compound is part of a combinatorial library of compounds.

In certain embodiments the functional TLR is contacted with the reference ISNA and the test compound independently. Accordingly, in certain embodiments the screening method
15 is a method for identifying an ISNA mimic, and the test compound is determined to be an ISNA mimic when the test response is similar to the reference response obtained with the reference ISNA. A test response is similar to the reference response when the test and reference responses are qualitatively alike, even if not quantitatively alike. Thus, for example, the test and reference responses are considered alike when both responses include
20 induction of a Th1-like immune response. The test response can be quantitatively less than, about the same as, or greater than the reference response.

In certain other embodiments the functional TLR is contacted with the reference ISNA and the test compound concurrently to produce a test-reference response mediated by a TLR signal transduction pathway, wherein the test-reference response may be compared to the
25 reference response. In certain preferred embodiments the screening method is a method for identifying an ISNA agonist, wherein the test compound is an ISNA agonist when the test-reference response is greater than the reference response. In certain preferred embodiments the screening method is a method for identifying an ISNA antagonist, wherein the test compound is an ISNA antagonist when the test-reference response is less than the reference
30 response.

In a further aspect the invention provides a screening method for identifying species

- 21 -

specificity of an ISNA. The method according to this aspect of the invention involves contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a first species with a test ISNA; contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a second species with the test ISNA; measuring a response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA; and comparing (a) the response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA with (b) the response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA. In preferred embodiments the TLR of the first species corresponds to the TLR of the second species, e.g., the TLR of the first species is human TLR9 and the TLR of the second species is murine TLR9. In certain embodiments the functional TLR may be expressed in a cell, part of cell-free system, or part of a complex with another TLR or with a non-TLR protein, as previously described.

In yet another aspect the invention provides a method for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with TLR9 signaling activity. The method according to this aspect of the invention involves providing a cell comprising a TLR9 polypeptide or fragment thereof as provided in the second aspect of the invention; contacting the cell with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of TLR9 signaling activity; and determining a second amount of TLR9 signaling activity as a measure of the effect of the pharmacological agent on the TLR9 signaling activity, wherein a second amount of TLR9 signaling activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces TLR9 signaling activity and wherein a second amount of TLR9 signaling activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases TLR9 signaling activity.

These and other aspects of the invention are described in greater detail below.

- 22 -

Brief Description of the Figures

FIG. 1 is two paired bar graphs showing (A) the induction of NF- κ B and (B) the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

5 FIG. 2 is a bar graph showing the induction of NF- κ B produced by 293 fibroblast cells transfected with murine TLR9 in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS, and medium.

FIG. 3 is a series of gel images depicting the results of reverse transcriptase-polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

FIG. 4 is a graph showing the degree of induction of NF- κ B-luc by various stimuli in stably transfected 293-hTLR9 cells.

15 FIG. 5 is a graph showing the degree of induction of NF- κ B-luc by various stimuli in stably transfected 293-mTLR9 cells.

FIG. 6 is an image of a Coomassie-stained polyacrylamide gel depicting the presence of soluble hTLR9 in the supernatants of yeast cells transfected with hTLR9, either induced (lane 1) or not induced (lane 2).

20 FIG. 7 is a graph showing proliferation of human B cells in response to various stimuli, including *Escherichia coli* (*E. coli*) DNA, DNase-digested *E. coli* DNA, CpG-ODN, GpC-ODN, and LPS.

FIG. 8 is two paired bar graphs showing induction of (top) IL-8 and (bottom) TNF in plasmacytoid dendritic cells (CD123+ DC) and monocyte-derived dendritic cells (MDDC) in response to various stimuli, including *E. coli* DNA, DNase-digested *E. coli* DNA, CpG-ODN, GpC-ODN, and LPS.

FIG. 9 is a series of images of stained gels showing results of semi-quantitative RT-PCR comparing relative levels of human TLR9, TLR2, and TLR4 mRNA expression in human peripheral blood cells: MDDC (lane 1), purified CD14+ monocytes (lane 2), B cells (lane 3), CD123+ DC (lane 4), CD4+ T cells (lane 5), and CD8+ T cells (lane 6). GAPDH is a control for equalizing amounts of cDNA.

- 23 -

FIG. 10 is a pair of graphs showing amounts of IL-12 induced in (A) human peripheral blood mononuclear cells (PBMC) and (B) murine splenocytes in response to shown concentrations of various ODN, including ODN 2006 (filled circles), 2006-GC (open circles), 1668 (filled triangles), and 1668-GC (open triangles).

FIG. 11 is a quartet of graphs depicting responsiveness of 293 cells transfected with hTLR9 (left panels) or mTLR9 (right panels) upon stimulation with shown concentrations of various ODN, including ODN 2006 (filled circles), 2006-GC (open circles), 1668 (filled triangles), and 1668-GC (open triangles). Responses are shown in terms of induction of NF- κ B-luc (upper panels) and IL-8 (lower panels).

FIG. 12 is a bar graph depicting the dose-response of 293-hTLR9 cells to *E. coli* DNA (black bars) and to DNase-digested *E. coli* DNA (gray bars).

FIG. 13 is a pair of graphs showing the responsiveness of (A) 293-hTLR9 and (B) 293-mTLR9 cells to shown concentrations of phosphodiester versions of ODN 2006 (filled circles), 2006-GC (open circles), 1668 (filled triangles), and 1668-GC (open triangles).

Fig. 14 is a pair of graphs showing the responsiveness of 293-hTLR9 and 293-mTLR9 cells to shown concentrations of ODN 5002 (filled circles) and ODN 5007 (open circles).

FIG. 15 is a bar graph showing the response of 293 cells transfected with mTLR9 to CpG-ODN 1668 is inhibited in a dose-dependent manner by co-exposure to non-CpG-ODN PZ2.

FIG. 16 is a bar graph showing the response of 293-hTLR9 cells to CpG-ODN (black bars) or to TNF (gray bars) in the presence of shown amounts of blocking non-CpG-ODN.

FIG. 17 is a bar graph showing blockade of response of 293-hTLR9 cells to CpG-ODN, but not to IL-1 or TNF, in the presence of Bafilomycin A (gray bars). Control treatment with dimethyl sulfoxide (DMSO) is shown in black bars.

FIG. 18 is a graph showing the effect of varying concentrations of dominant negative human MyD88 on the induction of NF- κ B in 293-hTLR9 cells stimulated with CpG-ODN (open circles), TNF- α (filled circles), or control (filled triangles).

FIG. 19 is a series of three Western blot images showing the response of various polyclonal antibodies to purified hTLR9-FLAG and mTLR9-FLAG: upper panel, anti-human and anti-mouse intracellular; middle, anti-mouse extracellular; and lower, anti-human extracellular. Arrows indicate position of TLR9 in each blot.

- 24 -

FIG. 20 is a bar graph depicting the responsiveness of native form hTLR9 and hTLR9 variant form hTLR9-CXXCm to various stimuli at different concentrations.

FIG. 21 is a bar graph depicting the responsiveness of native form mTLR9 and mTLR9 variant form mTLR9-CXXCm to various stimuli at different concentrations.

5 FIG. 22 is a bar graph showing the responsiveness of native form mTLR9, mTLR9 variant form mTLR9-Phmut, and mTLR9 variant form mTLR9-MBDmut to various stimuli at different concentrations.

FIG. 23 is a bar graph showing the responsiveness of native form hTLR9, hTLR9 variant form hTLR9-PHmut, and hTLR9 variant form hTLR9-MBDmut to various stimuli at
10 different concentrations.

FIG. 24 is a bar graph showing the responsiveness of native form mTLR9 and mTLR9 variant form mTLR9-TIRh to various stimuli at different concentrations.

FIG. 25 is a bar graph showing the responsiveness of native form hTLR9 and hTLR9 variant form hTLR9-TIRm to various stimuli at different concentrations.

15 FIG. 26 is a series of linear maps representing various features of human TLR7, TLR8, and TLR9 polypeptides.

FIG. 27 is an image of a silver stained polyacrylamide gel and schematic representation of a fusion protein in which the extracellular domain of human TLR9 (hTLR9) is fused to a human IgG1 Fc domain (hIgG-Fc) with a thrombin protease recognition site
20 interposed. From left to right, the gel was loaded with (1) supernatant of transfectants; (2) lysates of transfectants, treated with thrombin; (3) untreated lysates of transfectants; (4) molecular weight markers; (5) supernatant of mock transfectants; (6) lysates of mock transfectants, treated with thrombin; and (7) untreated lysates of mock transfectants. Soluble hTLR9 and Fc are the products released from intact hTLR9-IgG-Fc following thrombin
25 treatment. Molecular weights are indicated along the right side of the silver stain gel image.

Brief Description of Selected Sequences

SEQ ID NO:1 is the nucleotide sequence encoding a cDNA for murine TLR9.

SEQ ID NO:2 is the nucleotide sequence encoding the coding region of murine TLR9.

30 SEQ ID NO:3 is the amino acid sequence of a murine TLR9 encoded by SEQ ID NO:1.

- 25 -

SEQ ID NO:173 is the nucleotide sequence encoding a cDNA for murine TLR7.

SEQ ID NO:174 is the nucleotide sequence encoding the coding region of murine TLR7.

SEQ ID NO:175 is the amino acid sequence of a murine TLR7 encoded by SEQ ID NO:173.

SEQ ID NO:190 is the nucleotide sequence encoding a cDNA for murine TLR8.

SEQ ID NO:191 is the nucleotide sequence encoding the coding region of murine TLR8.

SEQ ID NO:192 is the amino acid sequence of a murine TLR8 encoded by SEQ ID NO:190.

Detailed Description of the Invention

The present invention in one aspect involves the identification of cDNAs encoding mouse TLR9, referred to herein as murine TLR9 and, equivalently, mTLR9. The nucleotide sequence of the cDNA for murine TLR9 is presented as SEQ ID NO:1, the coding region of the cDNA for murine TLR9 is presented as SEQ ID NO:2, and the amino acid sequence of the murine TLR9 is presented as SEQ ID NO:3. The closely related human TLR9 (equivalently, hTLR9) was deposited in GenBank under accession numbers AF245704 and NM_017742.

The nucleotide sequence of the cDNA for murine TLR9 presented as SEQ ID NO:1 is 3200 nucleotides long and includes the open reading frame (ORF, bases 40-3135) presented as SEQ ID NO:2 which spans 3096 nucleotides (excluding the stop codon). The amino acid sequence of the murine TLR9 presented as SEQ ID NO:3 is 1032 amino acids (aa) long, and it is believed to include an extracellular domain (aa 1-819), a transmembrane domain (aa 820-837), and an intracellular domain (aa 838-1032).

The amino acid sequence of human TLR9 (SEQ ID NO:6) and the amino acid sequence of the murine TLR9 (SEQ ID NO:3) are thus both 1032 amino acids long. Comparison of the aligned amino acid sequences for the murine and the human TLR9 molecules reveals a single base insertion at aa 435 of the murine TLR9 and a single base deletion at aa 860 of the human TLR9. (See Table 4 below.)

Whereas much of the polypeptide presented herein is identical to human TLR9,

- 26 -

murine TLR9 has several single amino acid differences. These differences in amino acids are specifically amino acids 2, 3, 4, 6, 7, 18, 19, 22, 38, 44, 55, 58, 61, 62, 63, 65, 67, 71, 80, 84, 87, 88, 91, 101, 106, 109, 117, 122, 123, 134, 136, 140, 143, 146, 147, 157, 160, 161, 167, 168, 171, 185, 186, 188, 189, 191, 199, 213, 217, 220, 227, 231, 236, 245, 266, 269, 270, 271, 272, 273, 274, 278, 281, 285, 297, 298, 301, 305, 308, 311, 322, 323, 325, 326, 328, 332, 335, 346, 348, 353, 355, 358, 361, 362, 365, 367, 370, 372, 380, 381, 382, 386, 389, 392, 394, 397, 409, 412, 413, 415, 416, 419, 430, 432, 434, 435, 438, 439, 443, 444, 446, 447, 448, 450, 451, 452, 454, 455, 459, 460, 463, 465, 466, 468, 469, 470, 472, 473, 474, 475, 478, 488, 489, 494, 495, 498, 503, 508, 510, 523, 531, 539, 540, 543, 547, 549, 561, 563, 565, 576, 577, 579, 580, 587, 590, 591, 594, 595, 597, 599, 601, 603, 610, 611, 613, 616, 619, 632, 633, 640, 643, 645, 648, 650, 657, 658, 660, 667, 670, 672, 675, 679, 689, 697, 700, 703, 705, 706, 711, 715, 716, 718, 720, 723, 724, 726, 729, 731, 735, 737, 743, 749, 750, 751, 752, 754, 755, 759, 760, 772, 774, 780, 781, 786, 787, 788, 800, 814, 821, 829, 831, 832, 835, 844, 857, 858, 859, 862, 864, 865, 866, 879, 893, 894, 898, 902, 910, 917, 927, 949, 972, 975, 976, 994, 997, 1000, 1003, 1004, 1010, 1011, 1018, 1023, and 1027 of SEQ ID NO:3

In some forms the mouse protein mTLR9 contains a signal sequence at the N-terminus (amino acids 1-26) which allows transport to the endoplasmic reticulum and subsequently to the cell surface or intracellular compartments. A transmembrane region (amino acids 820-837) anchors the protein to the cell membrane. The cytoplasmic tail contains a Toll/IL-1 receptor (TIR) homology domain which is believed to function in signaling upon ligand binding. Leucine-rich-repeats (LRR) can be found in the extracellular region (a common feature of TLRs) and may be involved in ligand binding or dimerization of the molecule.

Both mouse and human TLR9 have an N-terminal extension of approximately 180 amino acids compared to other TLRs. An insertion also occurs at amino acids 253-268, which is not found in TLRs 1-6 but is present in human TLR7 and human TLR8. (See **Figure 26.**) This insert has two CXXC motifs which participate in forming a CXXC domain. The CXXC domain resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g., methyl-CpG binding protein-1 (MBD-1). Fujita N et al., *Mol Cell Biol* 20:5107-5118 (2000). Both human and mouse TLR9 CXXC domains occur at aa 253-268:

- 27 -

CXXC motif:	GNCXXCXXXXXXXXCXXC	SEQ ID NO:196
Human TLR9:	GNCRRCDHAPNPCMEC	SEQ ID NO:197
Murine TLR9:	GNCRRCDHAPNPCMIC	SEQ ID NO:198

5

An additional motif involved in CpG binding is the MBD motif, also found in MBD-1, listed below as SEQ ID NO:125. Fujita, N et al., *Mol Cell Biol* 20:5107-18 (2000); Ohki I et al., *EMBO J* 18:6653-6661 (1999). Amino acids 524-554 of hTLR9 and aa 525-555 of mTLR9 correspond to the MBD motif of MBD-1 as shown:

10

MBD motif:

MBD-1	R-XXXXXXXX-R-X-D-X-Y-XXXXXXXXXX-R-S-XXXXXX-Y	SEQ ID NO:125
hTLR9	Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXXX-R-L-XXXXXX-Y	SEQ ID NO:126
mTLR9	Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXXX-Q-L-XXXXXX-Y	SEQ ID NO:127

15

hTLR9	Q-VLDLSRN-K-L-D-L-Y-HEHSFTELP-R-L-EALDLS-Y	SEQ ID NO:210
mTLR9	Q-VLDLSHN-K-L-D-L-Y-HWKSFSLELP-Q-L-QALDLS-Y	SEQ ID NO:211

20

Although the signaling functions of MBD-1 and TLR9 are quite different, the core D-X-Y is involved in CpG binding and is conserved. The C-terminal octamer S-XXXXXX-Y of the MBD motif may not be involved in binding and the S is not conserved by TLR9. The other mismatches are highly conserved or moderately conserved; example R to K or R to Q. These changes could explain MBD-1 as a methyl-CpG binder and TLR9 as a non-methyl-CpG binder. The differences between mouse and human TLR9 may explain inter-species differences in CpG-motif sequence selectivity. See Figure 14 for inter-species sequence selectivity.

25

30

As discussed in Example 11 below and shown in Figures 22 and 23, the D-X-Y core of this MBD motif occurs as D-L-Y in both mTLR9 (aa 535-537) and hTLR9 (aa 534-536). Substitution of A for D and A for Y in the D-X-Y core, resulting in A-L-A in place of D-L-Y, destroys receptor activity for mTLR9 and hTLR9 alike.

The invention involves in one aspect murine TLR9 nucleic acids and polypeptides, as

- 28 -

well as therapeutics relating thereto. The invention also embraces isolated functionally equivalent variants, useful analogs and fragments of the foregoing nucleic acids and polypeptides; complements of the foregoing nucleic acids; and molecules which selectively bind the foregoing nucleic acids and polypeptides.

5 The murine TLR9 nucleic acids and polypeptides of the invention are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA
10 techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which PCR primer sequences have been disclosed is considered isolated, but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may
15 comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its
20 native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other
25 substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless
30 isolated in that it has been separated from the substances with which it may be associated in living systems, i.e., isolated from other proteins.

- 29 -

As used herein a murine TLR9 nucleic acid refers to an isolated nucleic acid molecule which codes for a murine TLR9 polypeptide. Such nucleic acid molecules code for murine TLR9 polypeptides which include the sequence of SEQ ID NO:3 and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:1, SEQ ID NO:2, and
5 nucleotide sequences which differ from the sequences of SEQ ID NO:1 and SEQ ID NO:2 in codon sequence due to the degeneracy of the genetic code. The murine TLR9 nucleic acids of the invention also include alleles of the foregoing nucleic acids, as well as fragments of the foregoing nucleic acids. Such fragments can be used, for example, as probes in hybridization assays and as primers in a polymerase chain reaction. Preferred murine TLR9 nucleic acids
10 include the nucleic acid sequence of SEQ ID NO:1 and SEQ ID NO:2. Complements of the foregoing nucleic acids also are embraced by the invention.

As used herein a murine TLR9 nucleic acid or murine TLR9 polypeptide also embraces homologues and alleles of murine TLR9. In general homologues and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to
15 the sequences of specified nucleic acids and polypeptides, respectively. Thus homologues and alleles of murine TLR9 typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to the sequences of murine TLR9 nucleic acids and TLR9 polypeptides, respectively. In some instances homologues and alleles will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances will
20 share at least 60% nucleotide identity and/or at least 75% amino acid identity. Preferably the homologues and alleles will share at least 80% nucleotide identity and/or at least 90% amino acid identity, and more preferably will share at least 90% nucleotide identity and/or at least 95% amino acid identity. Most preferably the homologues and alleles will share at least 95% nucleotide identity and/or at least 99% amino acid identity. The homology can be calculated
25 using various publicly available software tools developed by the National Center for Biotechnology Information (NCBI, Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available from the NCBI at <http://www.ncbi.nlm.nih.gov>, used with default settings. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic
30 analysis can be obtained, for example, using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also

- 30 -

are embraced by the invention.

Alleles of the murine TLR9 nucleic acids of the invention can be identified by conventional techniques. For example, alleles of murine TLR9 can be isolated by hybridizing a probe which includes at least a fragment of SEQ ID NO:1 or SEQ ID NO:2 under stringent conditions with a cDNA library and selecting positive clones. Thus, an aspect of the invention is those nucleic acid sequences which code for murine TLR9 polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:1 or SEQ ID NO:2 under stringent conditions.

In screening for murine TLR nucleic acids, a Southern blot may be performed using the foregoing stringent conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. Corresponding non-radioactive methods are also well known in the art and can be used to similar effect.

The murine TLR nucleic acids of the invention also include degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons AGC, AGT, and TCA, TCC, TCG and TCT. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating murine TLR polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). As is well known by those of ordinary skill in the art, other specific amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code. The above-noted codon degeneracy notwithstanding, it is well appreciated by those skilled in the art that there are certain codon usage preferences in specific host organisms, such that in practice it may be preferred to select or to avoid certain degenerate codons in a particular host.

- 31 -

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. The modified nucleic acid molecules according to this aspect of the invention exclude fully native human TLR9 nucleic acid molecules (GenBank Accession No. AF245704 (SEQ ID NO:4) or GenBank Accession No. NM_017442 (SEQ ID NO:5)). In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as signaling activity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated fragments of SEQ ID NO:1 and SEQ ID NO:2. The fragments can be used as probes in Southern blot assays to identify such nucleic acids, or

- 32 -

they can be used in amplification assays such as those employing PCR. Smaller fragments are those comprising 12, 13, 14, 15, 16, 17, 18, 20, 22, 25, 30, 40, 50, or 75 nucleotides, and every integer therebetween, and are useful, e.g., as primers for nucleic acid amplification procedures. As known to those skilled in the art, larger probes such as 200, 250, 300, 400 or
5 more nucleotides are preferred for certain uses such as Southern blots, while smaller fragments will be preferred for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments. Likewise, fragments can be employed to produce non-fused fragments of the murine TLR9 polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and the
10 like. The foregoing nucleic acid fragments further can be used as antisense molecules to inhibit the expression of murine TLR9 nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

The invention also includes functionally equivalent variants of the murine TLR9, which include variant nucleic acids and polypeptides which retain one or more of the
15 functional properties of the murine TLR9. Preferably such variants include the murine-specific N-terminal domain (e.g., amino acids 1-819 or amino acids 1-837 of SEQ ID NO:3). For example, variants include a fusion protein which includes the extracellular and transmembrane domains of the murine TLR9 (i.e., amino acids 1-837) which retains the ability to interact with extracellular molecules in a manner similar to intact murine TLR9.
20 Alternative variants include, for example, a fusion protein which includes the cytoplasmic domain of murine TLR9 (i.e., amino acids 838-1032) which retains the ability to interact with intracellular molecules in a manner similar to intact murine TLR9. Still other functionally equivalent variants include truncations, deletions, point mutations, or additions of amino acids to the sequence of SEQ ID NO:3 which retain functions of SEQ ID NO:3. For example,
25 the FLAG peptide sequence (DYKDDDDK) can be added at the N-terminal end, or green fluorescent protein (GFP) can be added at the C-terminal end. All such addition variant polypeptides are preferably made by translation of modified nucleic acids based on SEQ ID NO:1 or SEQ ID NO:2 with corresponding appropriate coding nucleic acid sequence appended thereto with maintenance of the proper reading frame.

30 Functionally equivalent variants also include a murine TLR9 which has had a portion (e.g., of the N-terminus) removed or replaced by a similar domain from another TLR (e.g., a

- 33 -

“domain-swapping” variant). Examples of such domain-swapping variants include at least two types: those involving swapping a TLR9 domain from one species with a TLR9 domain from another species, and those involving swapping a TLR domain from TLR9 with a TLR domain from another TLR. In certain preferred embodiments the swapping involves

5 corresponding domains between the different TLR molecules. It is believed that certain such domain-swapping variants are not functionally equivalent in a literal sense, insofar as they can function in a manner superior to either or both intact parent TLR molecules from which a particular domain-swapping variant derives. For example, the TLR/IL-1R signaling mediated by human TLR9 could be limited, not by the capacity of its extracellular domain to interact

10 with CpG ODN, but rather by the capacity of its cytoplasmic domain to engage the TLR/IL-1R signaling pathway. In such a circumstance, it could be advantageous to substitute a more potent cytoplasmic domain from a TLR9 from another species. Such a domain-swapping variant, e.g., chimeric hTLR9/mTLR9, could be used in screening assays for CpG immuno-agonist/antagonists to increase the sensitivity of the assay, without changing the species

15 specificity.

Other functionally equivalent variants will be known to one of ordinary skill in the art, as will be methods for preparing such variants. The activity of a functionally equivalent variant can be determined using the methods provided herein, and in references that have described assays using other TLRs and TLRs of other species. Such variants are useful, *inter*

20 *alia*, for evaluating bioavailability of drugs, in assays for identification of compounds which bind to and/or regulate the signaling function of the murine TLR9, and for determining the portions of the murine TLR9 which are required for signaling activity.

Variants which are non-functional also can be prepared as described above. Such variants are useful, for example, as negative controls in experiments testing TLR9 signaling

25 activity. Examples of non-functional variants include those incorporating a mutation of proline at aa 915 to histidine (P915H) which renders both mTLR9 and hTLR9 nonfunctional with respect to signaling. Further examples of non-functional variants include those incorporating a mutation of the D-X-Y core of the MBD motif to A-L-A, as discussed above, to render both mTLR9 and hTLR9 nonfunctional with respect to CpG DNA binding.

30 A murine TLR9 nucleic acid, in one embodiment, is operably linked to a gene expression sequence which can direct the expression of the murine TLR9 nucleic acid within

- 34 -

a eukaryotic or prokaryotic cell. A "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably linked.

With respect to murine TLR9 nucleic acid, the "gene expression sequence" is any regulatory
5 nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the murine TLR9 nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian
10 promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPR^T), adenosine deaminase, pyruvate kinase, β -actin promoter, and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus (e.g., SV40), papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus (RSV), cytomegalovirus (CMV), the long terminal repeats (LTR) of Moloney murine
15 leukemia virus and other retroviruses, and the thymidine kinase (TK) promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein (MT) promoter is induced to promote transcription and
20 translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the
25 like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined murine TLR9 nucleic acid. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

Generally a nucleic acid coding sequence and a gene expression sequence are said to
30 be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the nucleic acid coding sequence under the influence or

- 35 -

control of the gene expression sequence. Thus the murine TLR9 nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the murine TLR9 coding sequence under the influence or control of the gene expression sequence. If it is desired that the murine TLR9 sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the murine TLR9 sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the murine TLR9 sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a murine TLR9 nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that murine TLR9 nucleic acid sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The murine TLR9 nucleic acid molecules and the murine TLR9 polypeptides (including the murine TLR9 inhibitors described below) of the invention can be delivered to the eukaryotic or prokaryotic cell alone or in association with a vector. In its broadest sense, a "vector" is any vehicle capable of facilitating: (1) delivery of a nucleic acid or polypeptide to a target cell, (2) uptake of a nucleic acid or polypeptide by a target cell, or (3) expression of a nucleic acid molecule or polypeptide in a target cell. In this particular setting, a "vector" is any vehicle capable of facilitating: (1) delivery of a murine TLR9 nucleic acid or polypeptide to a target cell, (2) uptake of a murine TLR9 nucleic acid or polypeptide by a target cell, or (3) expression of a murine TLR9 nucleic acid molecule or polypeptide in a target cell.

Preferably, the vectors transport the murine TLR9 nucleic acid or polypeptide into the target cell with reduced degradation relative to the extent of degradation that would result in the absence of the vector. Optionally, a "targeting ligand" can be attached to the vector to selectively deliver the vector to a cell which expresses on its surface the cognate receptor (e.g., a receptor, an antigen recognized by an antibody) for the targeting ligand. In this manner, the vector (containing a murine TLR9 nucleic acid or a murine TLR9 polypeptide) can be selectively delivered to a specific cell. In general, the vectors useful in the invention are divided into two classes: biological vectors and chemical/physical vectors. Biological

- 36 -

vectors are more useful for delivery/uptake of murine TLR9 nucleic acids to/by a target cell. Chemical/physical vectors are more useful for delivery/uptake of murine TLR9 nucleic acids or murine TLR9 proteins to/by a target cell.

Biological vectors include, but are not limited to, plasmids, phagemids, viruses, other
5 vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the nucleic acid sequences of the invention, and free nucleic acid fragments which can be linked to the nucleic acid sequences of the invention. Viral vectors are a preferred type of biological vector and include, but are not limited to, nucleic acid sequences from the following viruses: retroviruses, such as Moloney murine leukemia virus; Harvey
10 murine sarcoma virus; murine mammary tumor virus; Rous sarcoma virus; adenovirus; adeno-associated virus; SV40-type viruses; polyoma viruses; poxviruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; and polio virus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-
15 essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered
20 retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target
25 cells with viral particles) are provided in Kriegler, M., *"Gene Transfer and Expression, A Laboratory Manual,"* W.H. Freeman Co., New York (1990) and Murray, E.J., ed., *"Methods in Molecular Biology,"* vol. 7, Humana Press, Inc., Clifton, New Jersey (1991):

Another preferred virus for certain applications is the adeno-associated virus (AAV), a double-stranded DNA virus. The AAV can be engineered to be replication-deficient and is
30 capable of infecting a wide range of cell types and species. It further has advantages, such as heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages; and

- 37 -

lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the AAV can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type AAV infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the AAV genomic integration is a relatively stable event. The AAV can also function in an extrachromosomal fashion.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a murine TLR9 polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human CMV enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nucleic Acids Res* 18:5322 (1990)), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol Cell Biol* 16:4710-4716 (1996)). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for F1 and E3 proteins (*J Clin Invest* 90:626-630 (1992)).

In addition to the biological vectors, chemical/physical vectors may be used to deliver a nucleic acid or polypeptide to a target cell and facilitate uptake thereby. As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived

- 38 -

from bacteriological or viral sources, capable of delivering an isolated nucleic acid or polypeptide to a cell. As used herein with respect to a murine TLR9 nucleic acid or polypeptide, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the isolated murine
5 TLR9 nucleic acid or polypeptide to a cell.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vesicles which are useful as a delivery vector *in*
10 *vivo* or *in vitro*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2 - 4.0 μm can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley et al., *Trends Biochem Sci* 6:77 (1981)). In order for a liposome to be an efficient nucleic acid transfer vector, one or more of the following characteristics should be
15 present: (1) encapsulation of the nucleic acid of interest at high efficiency with retention of biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue by coupling the liposome to a
20 specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to a particular cell will depend on the particular cell or tissue type. Additionally when the vector encapsulates a nucleic acid, the vector may be coupled to a nuclear targeting peptide, which will direct the murine TLR9 nucleic acid to the nucleus of the host cell.

25 Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleoyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications.

30 Other exemplary compositions that can be used to facilitate uptake by a target cell of nucleic acids in general, and nucleic acids encoding the murine TLR9 in particular, include

- 39 -

calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a murine TLR9 nucleic acid into a preselected location within a target cell chromosome).

5 The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the murine TLR9
10 cDNA sequences in expression vectors to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., 293 fibroblast cells (ATCC, CRL-1573), MonoMac-6, THP-1, U927, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, pig, goat, primate, rodent, guinea pig, etc. They may be of a wide variety of tissue
15 types, and include primary cells and cell lines. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also provides isolated murine TLR9 polypeptides which include the amino acid sequences of SEQ ID NO:3 and fragments thereof, encoded by the murine TLR9 nucleic acids described above. Murine TLR9 polypeptides also embrace alleles, functionally
20 equivalent variants and analogs (those non-allelic polypeptides which vary in amino acid sequence from the disclosed murine TLR9 polypeptides by 1, 2, 3, 4, 5, or more amino acids) provided that such polypeptides retain TLR9 activity. Non-functional variants also are embraced by the invention; these are useful as antagonists of TLR9 signaling function, as negative controls in assays, and the like. Such alleles, variants, analogs and fragments are
25 useful, for example, alone or as fusion proteins for a variety of purposes including as a component of assays.

Fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the intact polypeptide, in particular as a receptor of various molecules. Accordingly, fragments of a TLR9 polypeptide preferably are those fragments which retain a
30 distinct functional capability of the TLR9 polypeptide, in particular as a receptor of various molecules. Of particular interest are fragments that bind to ISNAs, including, for example,

- 40 -

fragments that bind CpG nucleic acids. Other functional capabilities which can be retained in a fragment of a polypeptide include signal transduction (e.g., TLR/IL-1R signaling by murine TLR9), interaction with antibodies and interaction with other polypeptides (such as would be found in a protein complex). Those skilled in the art are well versed in methods that can be applied for selecting fragments which retain a functional capability of the murine TLR9. Confirmation of the functional capability of the fragment can be carried out by synthesis of the fragment and testing of the capability according to standard methods. For example, to test the signaling activity of a murine TLR9 fragment, one inserts or expresses the fragment in a cell in which signaling can be measured. Such methods, which are standard in the art, are described further herein.

The invention embraces variants of the murine TLR9 polypeptides described above. As used herein, a "variant" of a polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a polypeptide. Accordingly, a "variant" of a murine TLR9 polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a murine TLR9 polypeptide. Modifications which create a murine TLR9 variant can be made to a murine TLR9 polypeptide for a variety of reasons, including 1) to reduce or eliminate an activity of a murine TLR9 polypeptide, such as signaling; 2) to enhance a property of a murine TLR9 polypeptide, such as signaling, binding affinity for nucleic acid ligand or other ligand molecule, protein stability in an expression system, or the stability of protein-protein binding; 3) to provide a novel activity or property to a murine TLR9 polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety, e.g., luciferase, FLAG peptide, GFP; 4) to establish that an amino acid substitution does or does not affect molecular signaling activity; or 5) reduce immunogenicity of a murine TLR9 polypeptide. Modifications to a murine TLR9 polypeptide are typically made to the nucleic acid which encodes the murine TLR9 polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety (for example, biotin, fluorophore, radioisotope, enzyme, or peptide), addition of a fatty acid, and the like.

Modifications also embrace fusion proteins comprising all or part of the murine TLR9

- 41 -

amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant murine TLR9 according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87 (1997), whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a murine TLR9 polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants include murine TLR9 polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a murine TLR9 polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a murine TLR9 polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with a desired property. Further mutations can be made to variants (or to non-variant murine TLR9 polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a murine TLR9 gene or cDNA clone to enhance expression of the polypeptide.

The activity of variants of murine TLR9 polypeptides can be tested by cloning the gene encoding the variant murine TLR9 polypeptide into a prokaryotic or eukaryotic (e.g., mammalian) expression vector, introducing the vector into an appropriate host cell,

- 42 -

expressing the variant murine TLR9 polypeptide, and testing for a functional capability of the murine TLR9 polypeptides as disclosed herein. For example, the variant murine TLR9 polypeptide can be tested for ability to provide signaling, as set forth below in the examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in murine TLR9 polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the murine TLR9 polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the polypeptide in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the murine TLR9 polypeptides include conservative amino acid substitutions of SEQ ID NO:3. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Conservative amino acid substitutions in the amino acid sequence of murine TLR9 polypeptide to produce functionally equivalent variants of murine TLR9 typically are made by alteration of the nucleic acid sequence encoding murine TLR9 polypeptides (e.g., SEQ ID NO:1 and SEQ ID NO:2). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc Natl Acad Sci USA* 82:488-492 (1985)), or by chemical synthesis of a gene encoding a murine TLR9 polypeptide. The activity of functionally equivalent fragments of murine TLR9 polypeptides can be tested by cloning the gene encoding the altered murine TLR9 polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered murine TLR9 polypeptide, and testing for the ability of the

- 43 -

murine TLR9 polypeptide to mediate a signaling event. Peptides which are chemically synthesized can be tested directly for function.

A variety of methodologies well known to the skilled practitioner can be utilized to obtain isolated murine TLR9 polypeptide molecules. The polypeptide may be purified from
5 cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to
10 produce polypeptide. Those skilled in the art also can readily follow known methods for isolating murine TLR9 polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention as described herein has a number of uses, some of which are described
15 elsewhere herein. For example, the invention permits isolation of the murine TLR9 polypeptide molecules by, e.g., expression of a recombinant nucleic acid to produce large quantities of polypeptide which may be isolated using standard protocols. As another example, the isolation of the murine TLR9 gene makes it possible for murine TLR9 to be used in methods for assaying molecular interactions involving TLR9.

20 As discussed further in the Examples below, it has been discovered according to one aspect of the invention that responsiveness to ISNA can be reconstituted in ISNA-unresponsive cells by introducing into ISNA-unresponsive cells an expression vector that directs the expression of murine TLR9 (and certain homologues and variants thereof). Cells so reconstituted also exhibit responses to substances other than phosphorothioate ISNA, e.g.,
25 *E. coli* DNA, phosphodiester CpG-ODN, and even methylated CpG-ODN.

Also as discussed further in the Examples below, it has been discovered according to certain aspects of the instant invention that TLR9 not only confers upon cells the ability to signal in response to binding ISNA, but also confers both sequence specificity and species
30 specificity to such signaling responses. Thus murine TLR9 signaling in response to CpG-ODN 1668, reportedly an optimal murine ISNA, was found to be significantly stronger than the corresponding murine TLR9 signaling response to CpG-ODN 2006, reportedly an optimal

- 44 -

human ISNA. The converse was also found to be true, i.e., human TLR9 signaling in response to CpG-ODN 2006 was found to be significantly stronger than the corresponding human TLR9 signaling response to CpG-ODN 1668. Furthermore, it has been discovered according to the instant invention that certain types of cells preferentially express TLR9. For example, TLR9 is strongly expressed in B cells and plasmacytoid dendritic cells (CD123+ DC), but only weakly by T cells, monocyte-derived dendritic cells (MDDC), and CD14+ monocytes. In contrast, TLR2 and TLR4 are strongly expressed by MDDC and CD14+ monocytes, but relatively weakly by B cells, CD123+ DC, and T cells.

The invention also embraces agents which bind selectively to the murine TLR9 nucleic acid molecules or polypeptides as well as agents which bind to variants and fragments of the polypeptides and nucleic acids as described herein. The agents include polypeptides which bind to murine TLR9, and antisense nucleic acids, both of which are described in greater detail below. The agents can inhibit or increase murine TLR9-mediated signaling activity (antagonists and agonists, respectively).

Some of the agents are inhibitors. A murine TLR9 inhibitor is an agent that inhibits murine TLR9-mediated signaling across a cell membrane.

As used herein "TLR9 signaling" refers to an ability of a TLR9 polypeptide to activate the TLR/IL-1R (TIR) signaling pathway, also referred to herein as the TLR signal transduction pathway. Without meaning to be held to any particular theory, it is believed that the TLR/IL-1R signaling pathway involves signaling via the molecules myeloid differentiation marker 88 (MyD88) and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), leading to activation of kinases of the I κ B kinase complex and the c-jun NH₂-terminal kinases (e.g., JNK 1/2). Häcker H et al., *J Exp Med* 192:595-600 (2000). A molecule which inhibits TLR9 activity (an antagonist) is one which inhibits TLR9-mediated activation of the TLR/IL-1R signaling pathway, and a molecule which increases TLR9 signaling (an agonist) is one which increases TLR9-mediated activation of the TLR/IL-1R signaling pathway. Changes in TLR9 activity can be measured by assays such as those disclosed herein, including expression of genes under control of κ B-sensitive promoters and enhancers. Such naturally occurring genes include the genes encoding IL-1 β , IL-6, IL-8, the p40 subunit of interleukin 12 (IL-12p40), and the costimulatory molecules CD80 and CD86. Other genes can be placed under the control of such regulatory elements (see below) and thus

- 45 -

serve to report the level of TLR9 signaling. Additional nucleotide sequence can be added to SEQ ID NO:1 or SEQ ID NO:2, preferably to the 5' or the 3' end of SEQ ID NO:2, to yield a nucleotide sequence encoding a chimeric polypeptide that includes a detectable or reporter moiety, e.g., FLAG, luciferase (luc), green fluorescent protein (GFP) and others known by those skilled in the art. These are discussed in greater detail in the Examples below.

In one embodiment the murine TLR9 inhibitor is an antisense oligonucleotide that selectively binds to a murine TLR9 nucleic acid molecule, to reduce the expression of murine TLR9 (or TLR9 of another species) in a cell. This is desirable in virtually any medical condition wherein a reduction of TLR9 signaling activity is desirable.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions.

Based upon SEQ ID NO:1 and SEQ ID NO:2, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides. Wagner RW et al., *Nat Biotechnol* 14:840-844 (1996). Most preferably, the antisense oligonucleotides comprise

- 46 -

a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol Neurobiol* 14(5):439-457 (1994)) and at which polypeptides are not expected to bind. Thus, the present invention also provides for antisense oligonucleotides which are complementary to allelic or homologous cDNAs and genomic DNAs corresponding to murine TLR9 nucleic acid containing SEQ ID NO:1 or SEQ ID NO:2.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art-recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a

- 47 -

covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding murine TLR9 polypeptides, together with pharmaceutically acceptable carriers.

Agents which bind murine TLR9 also include binding peptides and other molecules which bind to the murine TLR9 polypeptide and complexes containing the murine TLR9 polypeptide. When the binding molecules are inhibitors, the molecules bind to and inhibit the activity of murine TLR9. When the binding molecules are activators, the molecules bind to and increase the activity of murine TLR9. To determine whether a murine TLR9 binding agent binds to murine TLR9 any known binding assay may be employed. For example, the binding agent may be immobilized on a surface and then contacted with a labeled murine TLR9 polypeptide. The amount of murine TLR9 which interacts with the murine TLR9 binding agent or the amount which does not bind to the murine TLR9 binding agent may then be quantitated to determine whether the murine TLR9 binding agent binds to murine TLR9.

The murine TLR9 binding agents include molecules of numerous size and type that bind selectively or preferentially to murine TLR9 polypeptides, and complexes of both murine TLR9 polypeptides and their binding partners. These molecules may be derived from a variety of sources. For example, murine TLR9 binding agents can be provided by screening degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using, e.g., m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array.

- 48 -

One then can select phage-bearing inserts which bind to the murine TLR9 polypeptide. This process can be repeated through several cycles of reselction of phage that bind to the murine TLR9 polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the murine TLR9 polypeptide can be determined. One can repeat the procedure using a biased library containing inscrtis containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the murine TLR9 polypeptides. Thus, the murine TLR9 polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the murine TLR9 polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of murine TLR9 and for other purposes that will be apparent to those of ordinary skill in the art.

The invention also embraces agents which bind selectively to certain regulatory sequences associated with the murine TLR9 nucleic acid molecules described herein. The agents include polypeptides which bind to transcription and translation regulatory sequences of murine TLR9, and antisense nucleic acids, both of which are described in greater detail below. The agents can inhibit or increase murine TLR9 expression, as well as signaling activity (antagonists and agonists, respectively). Agents which bind selectively to regulatory sequences associated with the murine TLR9 nucleic acid molecules can be identified using methods familiar to those of skill in the art. For example, a promoter region including at least 100, 200, 300, 400, 500, or more nucleotides upstream (5') of the coding region of murine TLR9 can be identified by isolating, from appropriate genomic DNA, such nucleotide sequences using the sequences of SEQ ID NO:1 or SEQ ID NO:2 as primers or as probes, and then inserting the promoter region DNA into an appropriate expression vector so as to control the expression of TLR9 or some other reporter gene, introducing the TLR9 promoter vector into an appropriate host cell, and screening for TLR9 or reporter expression by those cells following their incubation in the prescnce and absence of various test agents. A reporter gene other than TLR9 can include, for example, an enzyme, a cytokine, a cell surface antigen,

- 49 -

luciferase, chloramphenicol acetyl transferase (CAT), etc. An agent that inhibits expression of TLR9 or the reporter under the control of the TLR9 promoter is classified as a TLR9 expression inhibitor. Conversely, an agent that augments expression of TLR9 or reporter under the control of the TLR9 promoter is classified as a TLR9 expression enhancer. It was discovered according to the instant invention, for example, that the cytokine IL-4 inhibits the expression of TLR9. In this manner it is possible to identify agents that can be administered in conjunction with ISNA, for example by local administration, to enhance response to the ISNA. Such an enhancing effect might be desirable, for example, in the setting of immunization or vaccination. Conversely, it is possible to identify agents that can be administered in conjunction with a ISNA, for example by local administration, to inhibit response to the ISNA. Such an inhibiting response might be desirable, for example, in the setting of gene replacement therapy.

Therefore the invention generally provides efficient methods of identifying pharmacological agents or lead compounds for agents useful in the treatment of conditions associated with TLR9 activity and the compounds and agents so identified. Generally, the screening methods involve assaying for compounds which inhibit or enhance signaling through murine TLR9. Such methods are adaptable to automated, high throughput screening of compounds. Examples of such high throughput screening methods are described in U.S. patents 6,103,479; 6,051,380; 6,051,373; 5,998,152; 5,876,946; 5,708,158; 5,443,791; 5,429,921; and 5,143,854.

A variety of assays for pharmacological agents are provided, including labeled *in vitro* protein binding assays, signaling assays using detectable molecules, etc. For example, protein binding screens are used to rapidly examine the binding of candidate pharmacological agents to a murine TLR9. The candidate pharmacological agents can be derived from, for example, combinatorial peptide or nucleic acid libraries. Convenient reagents for such assays are known in the art. An exemplary cell-based assay of signaling involves contacting a cell having a murine TLR9 with a candidate pharmacological agent under conditions whereby the induction of a detectable molecule can occur. Specific conditions are well known in the art and are described, for example, in Häcker H et al., *J Exp Med* 192:595-600 (2000), and references cited therein. A reduced degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological

- 50 -

agent reduces the signaling activity of murine TLR9. An increased degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent increases the signaling activity of murine TLR9.

Murine TLR9 used in the methods of the invention can be added to an assay mixture
5 as an isolated polypeptide (where binding of a candidate pharmaceutical agent is to be measured) or as a cell or other membrane-encapsulated space which includes a murine TLR9 polypeptide. In the latter assay configuration, the cell or other membrane-encapsulated space can contain the murine TLR9 as a polypeptide or as a nucleic acid (e.g., a cell transfected with an expression vector containing a murine TLR9). In the assays described herein, the
10 murine TLR9 polypeptide can be produced recombinantly, isolated from biological extracts, or synthesized *in vitro*. Murine TLR9 polypeptides encompass chimeric proteins comprising a fusion of a murine TLR9 polypeptide with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, enhancing signaling capability, facilitating detection, or enhancing stability of the murine TLR9 polypeptide under assay conditions. A
15 polypeptide fused to a murine TLR9 polypeptide or fragment thereof may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The assay mixture also comprises a candidate pharmacological agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a
20 different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate pharmaceutical agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight
25 of more than 50 yet less than about 2500. Polymeric candidate agents can have higher molecular weights, e.g., oligonucleotides in the range of about 2500 to about 12,500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides, and may include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of
30 the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more

- 51 -

of the above-identified functional groups. Candidate agents also can be biomolecules such as nucleic acids, peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified
5 nucleic acids having non-natural bonds or subunits are also contemplated.

Candidate agents are obtained from a wide variety of sources, including libraries of natural, synthetic, or semisynthetic compounds, or any combination thereof. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides,
10 synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further, known pharmacological agents may be subjected
15 to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc., to produce structural analogs of the agents.

Therefore, a source of candidate agents are libraries of molecules based on known TLR9 ligands, e.g., CpG oligonucleotides shown herein to interact with TLR9, in which the structure of the ligand is changed at one or more positions of the molecule to contain more or
20 fewer chemical moieties or different chemical moieties. The structural changes made to the molecules in creating the libraries of analog inhibitors can be directed, random, or a combination of both directed and random substitutions and/or additions. One of ordinary skill in the art in the preparation of combinatorial libraries can readily prepare such libraries based on existing TLR9 ligands.

25 A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease
30 inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby,

- 52 -

but for the presence of the candidate pharmacological agent, the murine TLR9 mediates TLR/IL-1R signaling. For determining the binding of a candidate pharmaceutical agent to a murine TLR9, the mixture is incubated under conditions which permit binding. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 1 minute and 10 hours.

After incubation, the level of signaling or the level of specific binding between the murine TLR9 polypeptide and the candidate pharmaceutical agent is detected by any convenient method available to the user. For cell-free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. For example, separation can be accomplished in solution, or, conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximize signal-to-noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as measurement of an induced polypeptide within, on the surface of, or secreted by the cell. Examples of detection methods useful in such cell-based assays include fluorescence-activated cell sorting (FACS) analysis, bioluminescence, fluorescence, enzyme-linked

- 53 -

immunosorbent assay (ELISA), reverse transcriptase-polymerase chain reaction (RT-PCR), and the like.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly
5 detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc., or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The murine TLR9 binding agent may also be an antibody or a functionally active
10 antibody fragment. Antibodies are well known to those of ordinary skill in the science of immunology. As used herein, the term "antibody" means not only intact antibody molecules but also fragments of antibody molecules retaining specific target binding ability. Such fragments are also well known in the art and are regularly employed both *in vitro* and *in vivo*. In particular, as used herein, the term "antibody" means not only intact immunoglobulin
15 molecules but also the well-known active fragments $F(ab')_2$ and Fab. $F(ab')_2$ and Fab fragments which lack the Fc fragment of intact antibody clear more rapidly from the circulation and may have less non-specific tissue binding than an intact antibody (Wahl RL et al., *J Nucl Med* 24:316-325 (1983)).

Monoclonal antibodies may be made by any of the methods known in the art utilizing
20 murine TLR9, or a fragment thereof, as an immunogen. Alternatively the antibody may be a polyclonal antibody specific for murine TLR9 which inhibits murine TLR9 activity. The preparation and use of polyclonal antibodies are also known to one of ordinary skill in the art.

Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in
25 general, Clark, W.R. (1986) *The Experimental Foundations of Modern Immunology*, Wiley & Sons, Inc., New York; Roitt, I. (1991) *Essential Immunology*, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated
30 an $F(ab')_2$ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been

- 54 -

produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

The sequences of the antigen-binding Fab' portion of the anti-murine TLR9 monoclonal antibodies identified as being useful according to the invention in the assays provided above, as well as the relevant FR and CDR regions, can be determined using amino acid sequencing methods that are routine in the art. It is well established that non-CDR regions of a mammalian antibody may be replaced with corresponding regions of non-specific or hetero-specific antibodies while retaining the epitope specificity of the original antibody. This technique is useful for the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Techniques to humanize antibodies are particularly useful when non-human animal (e.g., murine) antibodies which inhibit murine TLR9 activity are identified. These non-human animal antibodies can be humanized for use in the treatment of a human subject in the methods according to the invention. Examples of methods for humanizing a murine antibody are provided in U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Other antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂ and Fab fragments of an anti-murine TLR9 monoclonal antibody;

- 55 -

chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR9 antibody have been replaced by homologous human or non-human sequences; chimeric F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR9 antibody have been replaced by homologous human or non-human sequences; and chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences.

According to the invention murine TLR9 inhibitors also include "dominant negative" polypeptides derived from SEQ ID NO:3. A dominant negative polypeptide is an inactive variant of a polypeptide, which, by interacting with the cellular machinery, displaces an active polypeptide from its interaction with the cellular machinery or competes with the active polypeptide, thereby reducing the effect of the active polypeptide. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the receptor. As shown in the Examples below, TLR9 polypeptides which incorporate the substitution of histidine for proline at aa 915 (P915H mutation) are functionally inactive and are dominant negative with respect to the native TLR9 polypeptide.

The end result of the expression of a dominant negative murine TLR9 polypeptide of the invention in a cell is a reduction in TLR9 activity such as signaling through the TIR pathway. One of ordinary skill in the art can assess the potential for a dominant negative variant of a murine TLR9 polypeptide and, using standard mutagenesis techniques, create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of a murine TLR9 polypeptide, one of ordinary skill in the art can modify the sequence of the murine TLR9 polypeptide by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in murine TLR9 activity and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a murine TLR9 polypeptide will be apparent to one of ordinary skill in the art.

- 56 -

Each of the compositions according to this aspect of the invention is useful for a variety of therapeutic and non-therapeutic purposes. For example, the murine TLR9 nucleic acids of the invention are useful as oligonucleotide probes. Such oligonucleotide probes can be used herein to identify genomic or cDNA library clones possessing an identical or
5 substantially similar nucleic acid sequence. A suitable oligonucleotide or set of oligonucleotides, which is capable of hybridizing under stringent hybridization conditions to the desired sequence, a variant or fragment thereof, or an anti-sense complement of such an oligonucleotide or set of oligonucleotides, can be synthesized by means well known in the art (see, for example, *Synthesis and Application of DNA and RNA*, S.A. Narang, ed., 1987,
10 Academic Press, San Diego, CA) and employed as a probe to identify and isolate the desired sequence, variant or fragment thereof by techniques known in the art. Techniques of nucleic acid hybridization and clone identification are disclosed by Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.

15 To facilitate the detection of a desired nucleic acid sequence, or variant or fragment thereof, whether for cloning purposes or for the mere detection of the presence of the sequence, the above-described probes may be labeled with a detectable group. Such a detectable group may be any material having a detectable physical or chemical property. Such materials have been well developed in the field of nucleic acid hybridization and, in
20 general, many labels useful in such methods can be applied to the present invention. Particularly useful are radioactive labels. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life. If single stranded, the oligonucleotide may be radioactively labeled using kinase reactions. Alternatively, oligonucleotides are also useful as nucleic acid hybridization probes when labeled with a non-
25 radioactive marker such as biotin, an enzyme or a fluorescent group. See, for example, Leary JJ et al., *Proc Natl Acad Sci USA* 80:4045 (1983); Renz M et al., *Nucleic Acids Res* 12:3435 (1984); and Renz M, *EMBO J* 6:817 (1983).

Additionally, complements of the murine TLR9 nucleic acids can be useful as antisense oligonucleotides, e.g., by delivering the antisense oligonucleotide to an animal to
30 induce a murine TLR9 "knockout" phenotype. The administration of antisense RNA probes to block gene expression is discussed in Lichtenstein C, *Nature* 333:801-802 (1988).

- 57 -

Alternatively, the murine TLR9 nucleic acid of the invention can be used to prepare a non-human transgenic animal. A "transgenic animal" is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), Harlan (Indianapolis, IN), etc. Transgenic animals having a particular property associated with a particular disease can be used to study the effects of a variety of drugs and treatment methods on the disease, and thus serve as genetic models for the study of a number of human diseases. The invention, therefore, contemplates the use of murine TLR9 knockout and transgenic animals as models for the study of disorders involving TLR9-mediated signaling. A variety of methods known to one of ordinary skill in the art are available for the production of transgenic animals associated with this invention.

Inactivation or replacement of the endogenous TLR9 gene can be achieved by a homologous recombination system using embryonic stem cells. The resultant transgenic non-human mammals having a TLR9^{-/-} knockout phenotype may be made transgenic for the murine TLR9 and used as a model for screening compounds as modulators (agonists or antagonists/inhibitors) of the murine TLR9. In this manner, such therapeutic drugs can be identified.

Additionally, a normal or mutant version of murine TLR9 can be inserted into the germ line to produce transgenic animals which constitutively or inducibly express the normal or mutant form of murine TLR9. These animals are useful in studies to define the role and function of murine TLR9 in cells.

Generally, doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable and in one or several administrations per day. Lower doses will result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of

- 58 -

compound, although fewer doses typically will be given when compounds are prepared as slow release or sustained release medications.

The antagonists, agonists, nucleic acids, and polypeptides of murine TLR9 useful according to the invention may be combined, optionally, with a pharmaceutically acceptable carrier. Thus the invention also provides pharmaceutical compositions and a method for preparing the pharmaceutical compositions which contain compositions of this aspect of the invention. The pharmaceutical compositions include any one or combination of the antagonists, agonists, nucleic acids and polypeptides of murine TLR9 useful according to the invention and, optionally, a pharmaceutically acceptable carrier. Each pharmaceutical composition is prepared by selecting an antagonist, agonist, nucleic acid or polypeptide of murine TLR9 useful according to the invention, as well as any combination thereof, and, optionally, combining it with a pharmaceutically acceptable carrier.

The term "pharmaceutically acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including, without limitation: acetic acid in a salt; citric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as benzalkonium chloride, chlorobutanol, parabens, and thimerosal.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically acceptable amounts and in pharmaceutically acceptable compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic,

- 59 -

sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

A variety of administration routes are available. The particular mode selected will
5 depend, of course, upon the particular compound selected, the severity of the condition being treated, and the dosage required for therapeutic efficacy. The methods of the invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral,
10 rectal, topical, nasal, intradermal, or parenteral routes. The term "parenteral" includes, without limitation, subcutaneous, transdermal, intravenous, intra-arterial, intrathecal, intramuscular, intraperitoneal, mucosal (apart from gastrointestinal mucosa), pulmonary, intralesional, and infusion.

The pharmaceutical compositions may conveniently be presented in unit dosage form
15 and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

20 Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile
25 aqueous preparation of the antagonists, agonists, nucleic acids, or polypeptides of murine TLR9, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example,
30 as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition,

- 60 -

sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intrathecal, intramuscular, etc.

5 administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

Other delivery systems can include time-release, delayed release or sustained release delivery systems such as the biological/chemical vectors is discussed above. Such systems can avoid repeated administrations of the active compound, increasing convenience to the
10 subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary
15 skill in the art and include some of the release systems described above.

In another aspect the invention involves the identification of cDNAs encoding mouse TLR7 and mouse TLR8, referred to herein as murine TLR7 and murine TLR8 and, equivalently, mTLR7 and mTLR8, respectively. The nucleotide sequence of the cDNA for murine TLR7 is presented as SEQ ID NO:173, the coding region of the cDNA for murine
20 TLR7 is presented as SEQ ID NO:174, and the amino acid sequence of the murine TLR7 is presented as SEQ ID NO:175. The closely related human TLR7 (equivalently, hTLR7) was previously deposited in GenBank under accession numbers AF245702 and AF240467. The nucleotide sequence of the cDNA for murine TLR7 presented as SEQ ID NO:173 is 3357 nucleotides long and includes the ORF spanning bases 117-3266, presented as SEQ ID
25 NO:174, which spans 3150 nucleotides (excluding the stop codon). The amino acid sequence of the murine TLR7 presented as SEQ ID NO:175 is 1050 amino acids long.

The nucleotide sequence of the cDNA for murine TLR8 is presented as SEQ ID NO:190, the coding region of the cDNA for murine TLR8 is presented as SEQ ID NO:191, and the amino acid sequence of the murine TLR8 is presented as SEQ ID NO:192. The
30 closely related human TLR8 (equivalently, hTLR8) was previously deposited in GenBank under accession numbers AF245703 and AF246971.

- 61 -

Like both human and murine TLR9, human TLR7 and human TLR8 each contains one CXXC motif and one MBD motif. The hTLR7 CXXC motif contains amino acids 258-273, and the hTLR8 CXXC motif contains amino acids 255-270.

5

CXXC motif:	GNCXXCXXXXXXXXCXXC	SEQ ID NO:196
hTLR9:	GNCRRCDHAPNPCMEC	SEQ ID NO:197
mTLR9:	GNCRRCDHAPNPCMIC	SEQ ID NO:198
hTLR7:	GNCPRCYNAPFPCAPC	SEQ ID NO:199
10 mTLR7:	GNCPRCYNVPYPCTPC	SEQ ID NO:200
hTLR8:	GNCPRCFNAPFPCVPC	SEQ ID NO:201
mTLR8:	GNCPRCYNAPFPCTPC	SEQ ID NO:202

Also like human and murine TLR9, human TLR7 and TLR8 also have a single MBD motif. The the hTLR7 MBD motif spans amino acids 545-575, and the hTLR8 MBD motif amino acids spans 533-563.

15

MBD motif

MBD-1	R-XXXXXXX-R-X-D-X-Y-XXXXXXXXXX-R-S-XXXXXX-Y	SEQ ID NO:125
20 hTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXXX-R-L-XXXXXX-Y	SEQ ID NO:126
mTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXXX-Q-L-XXXXXX-Y	SEQ ID NO:127
hTLR7	R-XXXXXXX-R-X-D-X-L-XXXXXXXXXX-K-L-XXXXXX-S	SEQ ID NO:203
mTLR7	R-XXXXXXX-R-X-D-X-L-XXXXXXXXXX-S-L-XXXXXX-S	SEQ ID NO:204
hTLR8	K-XXXXXXX-R-X-D-X-D-XXXXXXXXXX-D-L-XXXXXX-Y	SEQ ID NO:205
25 mTLR8	K-XXXXXXX-R-X-D-X-D-XXXXXXXXXX-D-L-XXXXXX-H	SEQ ID NO:206
hTLR7	R-YLDFSNN-R-L-D-L-L-HSTAFEEELH-K-L-EVLDIS-S	SEQ ID NO:212
mTLR7	R-YLDFSNN-R-L-D-L-L-YSTAFEEELQ-S-L-EVLDSL-S	SEQ ID NO:213
30 hTLR8	K-YLDLTNN-R-L-D-F-D-NASALTELS-D-L-EVLDSL-Y	SEQ ID NO:214
mTLR8	K-YLDLTNN-R-L-D-F-D-DNNAPSDLH-D-L-EVLDSL-H	SEQ ID NO:215

- 62 -

The core D-X-Y in the MBD motif is involved in CpG binding of the MBD-1 protein and is conserved in TLR9 but only partially conserved in TLR8 and TLR7 (Y to D or L). The other mismatches are highly or moderately conserved; example R to K, Q, or D. These changes could explain MBD-1 as a methyl-CpG binder and TLR9 as a binder for CpG-DNA. The modification in the core sequence (D-X-Y) in hTLR7 (D-X-L) and TLR8 (D-X-D) is likely a structural basis for the recognition of different nucleic acid motifs. Combined with the presence of a CXXC domain TLR7 and TLR8 appear certainly to be nucleic acid binding receptors relevant to the innate immune system and thus clinical value.

The invention involves in one aspect murine TLR7 and murine TLR8 nucleic acids and polypeptides, as well as therapeutics relating thereto. The invention also embraces isolated functionally equivalent variants, useful analogs and fragments of the foregoing murine TLR7 and murine TLR8 nucleic acids and polypeptides; complements of the foregoing murine TLR7 and murine TLR8 nucleic acids; and molecules which selectively bind the foregoing murine TLR7 and murine TLR8 nucleic acids and polypeptides.

The murine TLR7 and murine TLR8 nucleic acids and polypeptides of the invention are isolated. The term "isolated," with respect to murine TLR7 and murine TLR8 nucleic acids and polypeptides, has the same meaning as used elsewhere herein.

As used herein a murine TLR7 nucleic acid refers to an isolated nucleic acid molecule which codes for a murine TLR7 polypeptide. Such nucleic acid molecules code for murine TLR7 polypeptides which include the sequence of SEQ ID NO:175 and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:173, SEQ ID NO:174, and nucleotide sequences which differ from the sequences of SEQ ID NO:173 and SEQ ID NO:174 in codon sequence due to the degeneracy of the genetic code.

Also as used herein a murine TLR8 nucleic acid refers to an isolated nucleic acid molecule which codes for a murine TLR8 polypeptide. Such nucleic acid molecules code for murine TLR8 polypeptides which include the sequences of SEQ ID NO:193, and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:190, SEQ ID NO:191, and nucleotide sequences which differ from the sequences of SEQ ID NO:190 and SEQ ID NO:191 in codon sequence due to the degeneracy of the genetic code.

The murine TLR7 and murine TLR8 nucleic acids of the invention also include alleles

- 63 -

as well as fragments of the foregoing nucleic acids. Such fragments can be used, for example, as probes in hybridization assays and as primers in a polymerase chain reaction. Preferred murine TLR7 nucleic acids include the nucleic acid sequence of SEQ ID NO:173 and SEQ ID NO:174. Preferred murine TLR8 nucleic acids include the nucleic acid sequence of SEQ ID NO:190 and SEQ ID NO:191. Complements of the foregoing nucleic acids also are embraced by the invention.

As used herein a murine TLR7 nucleic acid or murine TLR7 polypeptide also embraces homologues and alleles of murine TLR7. Likewise, as used herein a murine TLR8 nucleic acid or murine TLR8 polypeptide also embraces homologues and alleles of murine TLR8. Homologues and alleles of murine TLR7 and murine TLR8 comply with the degrees of nucleotide and amino acid identity as previously set forth herein in reference to homologues and alleles of murine TLR9.

Alleles of the murine TLR7 and murine TLR8 nucleic acids of the invention can be identified by conventional techniques. For example, alleles of murine TLR7 can be isolated by hybridizing a probe which includes at least a fragment of SEQ ID NO:173 or SEQ ID NO:174 under stringent conditions with a cDNA library and selecting positive clones. Thus, an aspect of the invention is those nucleic acid sequences which code for murine TLR7 polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:173 or SEQ ID NO:174 under stringent conditions. Likewise, an aspect of the invention is those nucleic acid sequences which code for murine TLR8 polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:190 or SEQ ID NO:191 under stringent conditions. Stringent conditions in this context has the same meaning as described elsewhere herein, including the use of a suitable hybridization buffer and a temperature of about 65°C.

In screening for murine TLR7 or murine TLR8 nucleic acids, a Southern blot may be performed using the stringent conditions previously described herein, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. Corresponding non-radioactive methods are also well known in the art and can be used to similar effect.

The murine TLR7 and murine TLR8 nucleic acids of the invention also include degenerate nucleic acids which include alternative codons to those present in the native materials, as previously described herein.

- 64 -

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. The modified nucleic acid molecules according to this aspect of the invention exclude fully native human TLR7 (SEQ ID NO:168, 5 SEQ ID NO:169, GenBank Accession No. AF245702, and GenBank Accession No. AF240467) and fully native human TLR8 nucleic acid molecules (SEQ ID NO:182, SEQ ID NO:183, GenBank Accession No. AF245703, and GenBank Accession No. AF246971). In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or 10 the polypeptides, such as signaling activity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so 15 that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

The invention also provides isolated fragments of nucleotide sequences for murine TLR7 (SEQ ID NO:173 and SEQ ID NO:174) and for murine TLR8 (SEQ ID NO:190 and SEQ ID NO:191). The fragments can be used as probes in Southern blot assays to identify 20 such nucleic acids, or can be used in amplification assays such as those employing PCR. Smaller fragments are those comprising 12, 13, 14, 15, 16, 17, 18, 20, 22, 25, 30, 40, 50, or 75 nucleotides, and every integer therebetween, and are useful, e.g., as primers for nucleic acid amplification procedures. As known to those skilled in the art, larger probes such as 200, 250, 300, 400 or more nucleotides are preferred for certain uses such as Southern blots, 25 while smaller fragments will be preferred for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments. Likewise, fragments can be employed to produce non-fused fragments of the murine TLR7 and murine TLR8 polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and the like. The foregoing nucleic acid fragments further can 30 be used as antisense molecules to inhibit the expression of murine TLR7 and murine TLR8 nucleic acids and polypeptides.

- 65 -

The invention also includes functionally equivalent variants of the murine TLR7 and murine TLR8, which include variant nucleic acids and polypeptides which retain one or more of the functional properties of the murine TLR7 and murine TLR8. Preferably such variants include the murine-specific N-terminal domain.

5 Functionally equivalent variants also include a murine TLR7 or murine TLR8 which has had a portion (e.g., of the N-terminus) removed or replaced by a similar domain from another TLR (e.g., a "domain-swapping" variant). Examples of such domain-swapping variants include those involving swapping a TLR7 domain from another species and swapping a TLR domain from another TLR.

10 Other functionally equivalent variants will be known to one of ordinary skill in the art, as will be methods for preparing such variants. The activity of a functionally equivalent variant can be determined using the methods provided herein, and in references that have described assays using other TLRs and TLRs of other species. Such variants are useful, *inter alia*, for evaluating bioavailability of drugs, in assays for identification of compounds which
15 bind to and/or regulate the signaling function of the murine TLR7 and murine TLR8, and for determining the portions of the murine TLR7 and murine TLR8 which are required for signaling activity.

 Variants which are non-functional also can be prepared as described above. Such variants are useful, for example, as negative controls in experiments testing TLR7 and TLR8
20 signaling activity. Examples of non-functional variants include those incorporating a truncation or mutation of amino acids deemed critical to ligand binding or signaling activity.

 In certain embodiments a murine TLR7 or murine TLR8 nucleic acid is operably linked to a gene expression sequence which can direct the expression of the murine TLR7 or murine TLR8 nucleic acid within a eukaryotic or prokaryotic cell. The terms "gene
25 expression sequence" and "operably linked" are as previously described herein.

 The murine TLR7 and murine TLR8 nucleic acid molecules and the murine TLR7 and murine TLR8 polypeptides of the invention can be delivered to a eukaryotic or prokaryotic cell alone or in association with a vector. As applied to murine TLR7 and murine TLR8 nucleic acid molecules, a "vector" is any vehicle capable of facilitating: (1) delivery of a
30 murine TLR7 or murine TLR8 nucleic acid or polypeptide to a target cell, (2) uptake of a murine TLR7 or murine TLR8 nucleic acid or polypeptide by a target cell, or (3) expression

- 66 -

of a murine TLR7 or murine TLR8 nucleic acid molecule or polypeptide in a target cell.

In addition to the biological vectors, chemical/physical vectors may be used to deliver a murine TLR7 or murine TLR8 nucleic acid or polypeptide to a target cell and facilitate uptake thereby. As used herein with respect to a murine TLR7 or murine TLR8 nucleic acid
5 or polypeptide, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the isolated murine TLR7 or murine TLR8 nucleic acid or polypeptide to a cell.

Other exemplary compositions that can be used to facilitate uptake by a target cell of the murine TLR7 or murine TLR8 nucleic acids include calcium phosphate and other
10 chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a murine TLR7 or murine TLR8 nucleic acid into a preselected location within a target cell chromosome).

It will also be recognized that the invention embraces the use of the murine TLR7 and murine TLR8 cDNA sequences in expression vectors to transfect host cells and cell lines, be
15 these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., 293 fibroblast cells (ATCC, CRL-1573), MonoMac-6, THP-1, U927, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, pig, goat, primate, rodent, guinea pig, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. The expression vectors require that the
20 pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also provides isolated murine TLR7 and isolated murine TLR8 polypeptides which include the amino acid sequences of SEQ ID NO:175, SEQ ID NO:192, and fragments thereof, encoded by the murine TLR7 and murine TLR8 nucleic acids described above. Murine TLR7 and murine TLR8 polypeptides also embrace alleles,
25 functionally equivalent variants and analogs (those non-allelic polypeptides which vary in amino acid sequence from the disclosed murine TLR7 and murine TLR8 polypeptides by 1, 2, 3, 4, 5, or more amino acids) provided that such polypeptides retain murine TLR7 or murine TLR8 activity. Non-functional variants also are embraced by the invention; these are useful as antagonists of TLR7 and TLR8 signaling function, as negative controls in assays, and the
30 like. Such alleles, variants, analogs and fragments are useful, for example, alone or as fusion proteins for a variety of purposes including as a component of assays.

- 67 -

The invention also embraces variants of the murine TLR7 and murine TLR8 polypeptides described above. Modifications which create a murine TLR7 variant or murine TLR8 variant can be made to a murine TLR7 or murine TLR8 polypeptide for a variety of reasons, including 1) to reduce or eliminate an activity of a murine TLR7 or murine TLR8 polypeptide, such as signaling; 2) to enhance a property of a murine TLR7 or murine TLR8 polypeptide, such as signaling, binding affinity for nucleic acid ligand or other ligand molecule, protein stability in an expression system, or the stability of protein-protein binding; 3) to provide a novel activity or property to a murine TLR7 or murine TLR8 polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety, e.g., luciferase, FLAG peptide, GFP; 4) to establish that an amino acid substitution does or does not affect molecular signaling activity; or 5) reduce immunogenicity. Modifications to a murine TLR7 or murine TLR8 polypeptide are typically made to the nucleic acid which encodes the murine TLR7 or murine TLR8 polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety (for example, biotin, fluorophore, radioisotope, enzyme, or peptide), addition of a fatty acid, and the like.

Modifications also embrace fusion proteins comprising all or part of the murine TLR7 or murine TLR8 amino acid sequence.

Variants include murine TLR7 and murine TLR8 polypeptides which are modified specifically to alter a feature of each polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a murine TLR7 or murine TLR8 polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a murine TLR7 or murine TLR8 polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide. Methods of making mutations of murine TLR7 or murine TLR8 are as

- 68 -

described elsewhere herein with reference to making mutations of murine TLR9.

The activity of variants of murine TLR7 and murine TLR8 polypeptides can be tested by cloning the gene encoding the variant murine TLR7 or murine TLR8 polypeptide into a prokaryotic or eukaryotic (e.g., mammalian) expression vector, introducing the vector into an appropriate host cell, expressing the variant murine TLR7 or murine TLR8 polypeptide, and testing for a functional capability of the murine TLR7 or murine TLR8 polypeptides as disclosed herein.

The skilled artisan will also realize that conservative amino acid substitutions may be made in murine TLR7 and murine TLR8 polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the murine TLR7 and murine TLR8 polypeptides.

A variety of methodologies well known to the skilled practitioner can be utilized to obtain isolated murine TLR7 and murine TLR8 polypeptide molecules, as previously described in reference to murine TLR9 polypeptides.

The invention as described herein has a number of uses, some of which are described elsewhere herein. For example, the invention permits isolation of the murine TLR7 and the murine TLR8 polypeptide molecules by, e.g., expression of a recombinant nucleic acid to produce large quantities of polypeptide which may be isolated using standard protocols. As another example, the isolation of the murine TLR7 gene makes it possible for murine TLR7 to be used in methods for assaying molecular interactions involving TLR7.

The invention also embraces agents which bind selectively to the murine TLR7 or murine TLR8 nucleic acid molecules or polypeptides as well as agents which bind to variants and fragments of the polypeptides and nucleic acids as described herein. The agents include polypeptides which bind to murine TLR7 or murine TLR8, and antisense nucleic acids, both of which are described in greater detail below. Some agents can inhibit or increase murine TLR7-mediated signaling activity (antagonists and agonists, respectively), and some can inhibit or increase murine TLR8-mediated signaling activity.

In one embodiment the murine TLR7 inhibitor is an antisense oligonucleotide that selectively binds to a murine TLR7 nucleic acid molecule, to reduce the expression of murine TLR7 (or TLR7 of another species) in a cell. This is desirable in virtually any medical condition wherein a reduction of TLR7 signaling activity is desirable. Based upon SEQ ID

- 69 -

NO:173 and SEQ ID NO:174, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention.

In one embodiment the murine TLR8 inhibitor is an antisense oligonucleotide that
5 selectively binds to a murine TLR8 nucleic acid molecule, to reduce the expression of murine TLR8 (or TLR8 of another species) in a cell. This is desirable in virtually any medical condition wherein a reduction of TLR8 signaling activity is desirable. Based upon SEQ ID NO:190 and SEQ ID NO:191, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of
10 appropriate antisense molecules for use in accordance with the present invention.

Antisense oligonucleotides for murine TLR7 or murine TLR8 can include "natural" and "modified" oligonucleotides as previously described herein.

Agents which bind murine TLR7 or murine TLR8 also include binding peptides and other molecules which bind to the murine TLR7 or murine TLR8 polypeptide and complexes
15 containing the murine TLR7 or murine TLR8 polypeptide, respectively. When the binding molecules are inhibitors, the molecules bind to and inhibit the activity of murine TLR7 or murine TLR8. When the binding molecules are activators, the molecules bind to and increase the activity of murine TLR7 or murine TLR8. To determine whether a murine TLR7 or murine TLR8 binding agent binds to murine TLR7 or murine TLR8, any known binding
20 assay may be employed. For example, the binding agent may be immobilized on a surface and then contacted with a labeled murine TLR7 or murine TLR8 polypeptide. The amount of murine TLR7 or murine TLR8 which interacts with the murine TLR7 or murine TLR8 binding agent, or the amount which does not bind to the murine TLR7 or murine TLR8 binding agent, may then be quantitated to determine whether the murine TLR7 or murine
25 TLR8 binding agent binds to murine TLR7 or murine TLR8.

The murine TLR7 or murine TLR8 binding agents include molecules of numerous size and type that bind selectively or preferentially to murine TLR7 or murine TLR8 polypeptides, and to complexes involving murine TLR7 or murine TLR8 polypeptides and their binding partners. These molecules may be derived from a variety of sources. For
30 example, murine TLR7 or murine TLR8 binding agents can be provided by screening degenerate peptide libraries which can be readily prepared in solution, in immobilized form or

- 70 -

as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Exemplary methods useful for identifying murine TLR7 and murine TLR8 binding peptides are analogous to those described herein with reference to methods for identifying murine TLR9 binding peptides murine, and thus are not repeated here.

Therefore the invention generally provides efficient methods of identifying pharmacological agents or lead compounds for agents useful in the treatment of conditions associated with TLR7 and TLR8 activity, and the compounds and agents so identified. Generally, the screening methods involve assaying for compounds which inhibit or enhance the expression of or signaling through murine TLR7 or murine TLR8. Such methods are adaptable to automated, high throughput screening of compounds.

A variety of assays for pharmacological agents are provided, including labeled *in vitro* protein binding assays, signaling assays using detectable molecules, etc. For example, protein binding screens are used to rapidly examine the binding of candidate pharmacological agents to a murine TLR7 or murine TLR8. The candidate pharmacological agents can be derived from, for example, combinatorial peptide or nucleic acid libraries. Convenient reagents for such assays are known in the art. An exemplary cell-based assay of signaling involves contacting a cell having a murine TLR7 or murine TLR8 with a candidate pharmacological agent under conditions whereby the induction of a detectable molecule can occur. A reduced degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent reduces the signaling activity of murine TLR7 or murine TLR8. An increased degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent increases the signaling activity of murine TLR7 or murine TLR8.

Murine TLR7 and murine TLR8 used in the methods of the invention can be added to an assay mixture as an isolated polypeptide (where binding of a candidate pharmaceutical agent is to be measured) or as a cell or other membrane-encapsulated space which includes a murine TLR7 or murine TLR8 polypeptide. In the latter assay configuration, the cell or other membrane-encapsulated space can contain the murine TLR7 or murine TLR8 as a

- 71 -

polypeptide or as a nucleic acid (c.g., a cell transfected with an expression vector containing a nucleic acid molecule encoding murine TLR7). In the assays described herein, the murine TLR7 or murine TLR8 polypeptide can be produced recombinantly, isolated from biological extracts, or synthesized *in vitro*. Murine TLR7 or murine TLR8 polypeptides encompass
5 chimeric proteins comprising a fusion of a murine TLR7 or murine TLR8 polypeptide with another polypeptide, c.g., a polypeptide capable of providing or enhancing protein-protein binding, enhancing signaling capability, facilitating detection, or enhancing stability of the murine TLR7 or murine TLR8 polypeptide under assay conditions. A polypeptide fused to a murine TLR7 or murine TLR8 polypeptide or fragment thereof may also provide means of
10 readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The assay mixture also comprises a candidate pharmacological agent, as previously described in reference to murine TLR9. Candidate pharmacologic agents are obtained from a wide variety of sources, including libraries of natural, synthetic, or semisynthetic compounds,
15 or any combination thereof. Presently, natural ligands of murine TLR7 and murine TLR8 are unknown, but they appear not to include CpG-ODN.

A variety of other reagents also can be included in the assay mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent
20 may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the murine TLR7 or murine
25 TLR8 mediates TLR7-mediated or TLR8-mediated signaling, preferably TLR/IL-1R signaling. For determining the binding of a candidate pharmaceutical agent to a murine TLR7 or murine TLR8, the mixture is incubated under conditions which permit binding. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization
30 of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized

- 72 -

to facilitate rapid, high throughput screening, and typically are between 1 minute and 10 hours.

After incubation, the level of signaling or the level of specific binding between the murine TLR7 or murine TLR8 polypeptide and the candidate pharmaceutical agent is detected by any convenient method available to the user, as described elsewhere herein.

The murine TLR7 or murine TLR8 binding agent may also be an antibody or a functionally active antibody fragment. Antibodies, including monoclonal antibodies and antibody fragments, are well known to those of ordinary skill in the science of immunology and are as described elsewhere herein. Monoclonal antibodies may be made by any of the methods known in the art utilizing murine TLR7 or murine TLR8, or a fragment thereof, as an immunogen. Alternatively the antibody may be a polyclonal antibody specific for murine TLR7 or murine TLR8 which inhibits murine TLR7 or murine TLR8 activity. The preparation and use of polyclonal antibodies are also known to one of ordinary skill in the art.

The sequences of the antigen-binding Fab' portion of the anti-murine TLR7 or anti-murine TLR8 monoclonal antibodies identified as being useful according to the invention in the assays provided above, as well as the relevant FR and CDR regions, can be determined using amino acid sequencing methods that are routine in the art. Such sequence information can be used to generate humanized and chimeric antibodies, as well as various fusion proteins and binding fragments, as described elsewhere herein.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for $F(ab')_2$ and Fab fragments of an anti-murine TLR7 or anti-murine TLR8 monoclonal antibody; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR7 or anti-murine TLR8 antibody have been replaced by homologous human or non-human sequences; chimeric $F(ab')_2$ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR7 or anti-murine TLR8 antibody have been replaced by homologous human or non-human sequences; and chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences.

According to the invention murine TLR7 and murine TLR8 inhibitors also include "dominant negative" polypeptides derived from SEQ ID NO:175 or SEQ ID NO:192,

- 73 -

respectively. The end result of the expression of a dominant negative murine TLR7 or dominant negative murine TLR8 polypeptide of the invention in a cell is a reduction in TLR7 or murine TLR8 activity such as signaling through the TIR pathway. One of ordinary skill in the art can assess the potential for a dominant negative variant of a murine TLR7 or dominant negative murine TLR8 polypeptide and, using standard mutagenesis techniques, create one or more dominant negative variant polypeptides.

Each of the compositions according to this aspect of the invention is useful for a variety of therapeutic and non-therapeutic purposes. For example, the murine TLR7 and murine TLR8 nucleic acids of the invention are useful as oligonucleotide probes. Such oligonucleotide probes can be used herein to identify genomic or cDNA library clones possessing an identical or substantially similar nucleic acid sequence. Methods of hybridization, synthesis of probes, and detection are generally as described elsewhere herein.

Additionally, complements of the murine TLR7 and murine TLR8 nucleic acids can be useful as antisense oligonucleotides, e.g., by delivering the antisense oligonucleotide to an animal to induce a murine TLR7 or murine TLR8 "knockout" phenotype.

Alternatively, the murine TLR7 and murine TLR8 nucleic acids of the invention can be used to prepare a non-human transgenic animal. The invention, therefore, contemplates the use of murine TLR7 and murine TLR8 knockout and transgenic animals as models for the study of disorders involving TLR7- and murine TLR8-mediated signaling. A variety of methods known to one of ordinary skill in the art are available for the production of transgenic animals associated with this invention.

Inactivation or replacement of the endogenous TLR7 or TLR8 gene can be achieved by a homologous recombination system using embryonic stem cells. The resultant transgenic non-human mammals having a TLR7^{-/-} or TLR8^{-/-} knockout phenotype may be made transgenic for the murine TLR7 or murine TLR8 and used as a model for screening compounds as modulators (agonists or antagonists/inhibitors) of the murine TLR7 or murine TLR8. In this manner, such therapeutic drugs can be identified.

Additionally, a normal or mutant version of murine TLR7 or murine TLR8 can be inserted into the germ line to produce transgenic animals which constitutively or inducibly express the normal or mutant form of murine TLR7 or murine TLR8. These animals are useful in studies to define the role and function of murine TLR7 or murine TLR8 in cells.

- 74 -

The antagonists, agonists, nucleic acids, and polypeptides of murine TLR7 and murine TLR8 useful according to the invention may be combined, optionally, with a pharmaceutically acceptable carrier. Thus the invention also provides pharmaceutical compositions and a method for preparing the pharmaceutical compositions which contain compositions of this aspect of the invention. The pharmaceutical compositions include one or any combination of the antagonists, agonists, nucleic acids and polypeptides of murine TLR7 and murine TLR8 useful according to the invention and, optionally, a pharmaceutically acceptable carrier. Each pharmaceutical composition is prepared by selecting an antagonist, agonist, nucleic acid or polypeptide of murine TLR7 and murine TLR8 useful according to the invention, as well as any combination thereof, and, optionally, combining it with a pharmaceutically acceptable carrier.

A variety of administration routes are available, as described previously herein. The particular mode selected will depend, of course, upon the particular compound selected, the severity of the condition being treated, and the dosage required for therapeutic efficacy.

Likewise, a variety of formulations are contemplated, including, by analogy those discussed above in reference to murine TLR9, unit dose solids, liquids, extended release formulations, etc.

Screening Assays

In another aspect the invention provides methods for screening candidate compounds that act as ISNA mimics, agonists or antagonists in ISNA-induced immunomodulation via TLR7, TLR8, and TLR9. Preferably the screening method can be adapted to accommodate high throughput screening assays, as can be achieved, for example, through the use of multiwell arrays of samples in conjunction with robotic or automated array handling devices.

Immunostimulatory nucleic acids include but are not limited to CpG nucleic acids.

A "CpG nucleic acid" or a "CpG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine dinucleotide sequence, i.e. "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanine and linked by a phosphate bond) and activates a component of the immune system. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

- 75 -

In one embodiment a CpG nucleic acid is represented by at least the formula:




wherein X_1 and X_2 are nucleotides, N is any nucleotide, and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments X_1 is adenine, guanine, or thymine and/or X_2 is cytosine, adenine, or thymine. In other embodiments X_1 is cytosine and/or X_2 is guanine.

In other embodiments the CpG nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides; N is any nucleotide; and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments, X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA. In some embodiments, X_1X_2 are GpA or GpT and X_3X_4 are TpT. In other embodiments X_1 or X_2 or both are purines and X_3 or X_4 or both are pyrimidines or X_1X_2 are GpA and X_3 or X_4 or both are pyrimidines.

In another embodiment the CpG nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides; N is any nucleotide; and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments, X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA. In some embodiments, X_1X_2 are GpA or GpT and X_3X_4 are TpT. In other embodiments X_1 or X_2 or both are purines and X_3 or X_4 or both are pyrimidines or X_1X_2 are GpA and X_3 or X_4 or both are pyrimidines.

Examples of CpG nucleic acids according to the invention include but are not limited to those listed in Table 1, such as SEQ ID NOs:21-29, 31-42, 44, 46-50, 52-62, 64-75, 77-88, 90-117, 119-124.

- 76 -

Table 1. Exemplary CpG nucleic acids

	AACGTTCT	SEQ ID NO:21
	AAGCGAAATGAAATGACT	SEQ ID NO:22
	ACCATGGACGAACTGTTTCCCCTC	SEQ ID NO:23
5	ACCATGGACGACCTGTTTCCCCTC	SEQ ID NO:24
	ACCATGGACGAGCTGTTTCCCCTC	SEQ ID NO:25
	ACCATGGACGATCTGTTTCCCCTC	SEQ ID NO:26
	ACCATGGACGGTCTGTTTCCCCTC	SEQ ID NO:27
	ACCATGGACGTACTGTTTCCCCTC	SEQ ID NO:28
10	ACCATGGACGTTCTGTTTCCCCTC	SEQ ID NO:29
	AGATTTC TAGGAATCAATC	SEQ ID NO:30
	AGCGGGGGCGAGCGGGGGCG	SEQ ID NO:31
	AGCTATGACGTTCCAAGG	SEQ ID NO:32
	ATCGACTCTCGAGCGTTCTC	SEQ ID NO:33
15	ATGACGTTCTTGACGTT	SEQ ID NO:34
	ATGGAAGGTCCAACGTTCTC	SEQ ID NO:35
	ATGGAAGGTCCAGCGTTCTC	SEQ ID NO:36
	ATGGACTCTCCAGCGTTCTC	SEQ ID NO:37
	ATGGAGGCTCCATCGTTCTC	SEQ ID NO:38
20	CAACGTT	SEQ ID NO:39
	CACGTTGAGGGGCAT	SEQ ID NO:40
	CAGGCATAACGGTTCCGTAG	SEQ ID NO:41
	CCAACGTT	SEQ ID NO:42
	CTCCTAGTGGGGGTGTCTAT	SEQ ID NO:43
25	CTGATTTC CCGAAATGATG	SEQ ID NO:44
	CTGCTGAGACTGGAG	SEQ ID NO:45
	GAGAACGATGGACCTTCCAT	SEQ ID NO:46
	GAGAACGCTCCAGCACTGAT	SEQ ID NO:47
	GAGAACGCTCGACCTTCCAT	SEQ ID NO:48
30	GAGAACGCTCGACCTTCGAT	SEQ ID NO:49
	GAGAACGCTGGACCTTCCAT	SEQ ID NO:50
	GAGCAAGCTGGACCTTCCAT	SEQ ID NO:51
	GATTGCCTGACGTCAGAGAG	SEQ ID NO:52
	GCATGACGTTGAGCT	SEQ ID NO:53
35	GCGGCGGGCGGCGGCGGGC	SEQ ID NO:54
	GCGTGCGTTGTCTGTTCTGTT	SEQ ID NO:55
	GCTAGACGTTAGCGT	SEQ ID NO:56
	GCTAGACGTTAGTGT	SEQ ID NO:57
	GCTAGATGTTAGCGT	SEQ ID NO:58
40	GCTTGATGACTCAGCCGGAA	SEQ ID NO:59
	GGAATGACGTTCCCTGTG	SEQ ID NO:60
	GGGGTCAACGTTGACGGGG	SEQ ID NO:61
	GGGGTCAGTCTTGACGGGG	SEQ ID NO:62
	GTATTTCCAGAAAAGGAAC	SEQ ID NO:63
45	GTCCATTTCCCGTAAATCTT	SEQ ID NO:64
	GTCGCT	SEQ ID NO:65
	GTCGTT	SEQ ID NO:66
	TACCGCGTGGGACCCCTCT	SEQ ID NO:67
	TATGCATATTCTGTAAAGTG	SEQ ID NO:68
50	TCAACGTC	SEQ ID NO:69
	TCAACGTT	SEQ ID NO:70
	TCAAGCTT	SEQ ID NO:71
	TCAGCGCT	SEQ ID NO:72
	TCAGCGTGCGCC	SEQ ID NO:73
55	TCATCGAT	SEQ ID NO:74
	TCCACGACGTTTTCGACGTT	SEQ ID NO:75
	TCCAGGACTTCTCTCAGGTT	SEQ ID NO:76
	TCCATAACGTTCCCTGATGCT	SEQ ID NO:77
	TCCATAGCGTTCTTAGCGTT	SEQ ID NO:78
60	TCCATCAGGTGCCTGATGCT	SEQ ID NO:79
	TCCATGACGTTCTGATGCT	SEQ ID NO:80
	TCCATGACGTTCCCTGATGCT	SEQ ID NO:81

- 77 -

	TCCATGACGTGCCCTGATGCT	SEQ ID NO: 82
	TCCATGACGTTCCCTGACGTT	SEQ ID NO: 83
	TCCATGACGTTCCCTGATGCT	SEQ ID NO: 84
	TCCATGAGCTTCCCTGATGCT	SEQ ID NO: 85
5	TCCATGCCGGTCCCTGATGCT	SEQ ID NO: 86
	TCCATGCCGTGCGTGCGTTTT	SEQ ID NO: 87
	TCCATGCCGTTGCGTTGCGTT	SEQ ID NO: 88
	TCCATGCTGGTCCCTGATGCT	SEQ ID NO: 89
	TCCATGGCGGTCCCTGATGCT	SEQ ID NO: 90
10	TCCATGTGCGATCCCTGATGCT	SEQ ID NO: 91
	TCCATGTGCGTCCTGATGCT	SEQ ID NO: 92
	TCCATGTGCGTCCCTGATGCT	SEQ ID NO: 93
	TCCATGTGCGTCCCTGCTGAT	SEQ ID NO: 94
	TCCATGTGCTCCCTGATGCT	SEQ ID NO: 95
15	TCCATGTGCTTCCCTGATGCT	SEQ ID NO: 96
	TCCATGTGCTTCCCTGTCGTT	SEQ ID NO: 97
	TCCATGTGCTTTTTTGTGCTT	SEQ ID NO: 98
	TCCTGACGTTCCCTGACGTT	SEQ ID NO: 99
	TCCTGTGCTTCCCTGTCGTT	SEQ ID NO: 100
20	TCCTGTGCTTCCCTGTCGTT	SEQ ID NO: 101
	TCCTGTGCTTTTTTGTGCTT	SEQ ID NO: 102
	TCCTTGTGCTTCCCTGTCGTT	SEQ ID NO: 103
	TCGATCGGGCGGGCGGAGC	SEQ ID NO: 104
	TCGTGCTGTCTCCGCTTCTT	SEQ ID NO: 105
25	TCGTGCTGTCTCCGCTTCTTCTTGCC	SEQ ID NO: 106
	TCGTGCTGTCTGCCCTTCTT	SEQ ID NO: 107
	TCGTGCTGTGTTGTCGTTTCTT	SEQ ID NO: 108
	TCGTGCTGCTCGTT	SEQ ID NO: 109
	TCGTGCTTGTGCTTGTGCTT	SEQ ID NO: 110
30	TCGTGCTTGTGCTTTTGTGCTT	SEQ ID NO: 111
	TCGTGCTTTTGTGCTTTTGTGCTT	SEQ ID NO: 112
	TCTCCCAGCGCGCGCCAT	SEQ ID NO: 113
	TCTCCCAGCGGGCGCAT	SEQ ID NO: 114
	TCTCCCAGCGTGCAGCCAT	SEQ ID NO: 115
35	TCTTCGAA	SEQ ID NO: 116
	TGCAGATTGCGCAATCTGCA	SEQ ID NO: 117
	TGCTGCTTTTGTGCTTTTGTGCTT	SEQ ID NO: 118
	TGTCGCT	SEQ ID NO: 119
	TGTCGTT	SEQ ID NO: 120
40	TGTCGTTGTGCTT	SEQ ID NO: 121
	TGTCGTTGTGCTTGTGCTT	SEQ ID NO: 122
	TGTCGTTGTGCTTGTGCTTGTGCTT	SEQ ID NO: 123
	TGTCGTTTGTGCTTGTGCTT	SEQ ID NO: 124


45 Other ISNAs include but are not limited to T-rich nucleic acids, poly G nucleic acids, and nucleic acids having phosphate modified backbones, such as phosphorothioate backbones.

A "T rich nucleic acid" or "T rich immunostimulatory nucleic acid" is a nucleic acid which includes at least one poly T sequence and/or which has a nucleotide composition of
50 greater than 25% T nucleotide residues and which activates a component of the immune system. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'TTTT3'. Preferably the T rich nucleic acid includes more than one poly T sequence. In preferred embodiments the T rich nucleic acid may have 2, 3, 4, etc poly T sequences. One of

- 78 -

the most highly immunostimulatory T rich oligonucleotides discovered according to the invention is a nucleic acid composed entirely of T nucleotide residues. Other T rich nucleic acids have a nucleotide composition of greater than 25% T nucleotide residues, but do not necessarily include a poly T sequence. In these T rich nucleic acids the T nucleotide residues may be separated from one another by other types of nucleotide residues, i.e., G, C, and A. In some embodiments the T rich nucleic acids have a nucleotide composition of greater than 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 99%, T nucleotide residues and every integer % in between. Preferably the T rich nucleic acids have at least one poly T sequence and a nucleotide composition of greater than 25% T nucleotide residues.

In one embodiment the T rich nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In one embodiment $X_1 X_2$ is TT and/or $X_3 X_4$ is TT. In another embodiment $X_1 X_2$ are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and $X_3 X_4$ are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

In some embodiments it is preferred that the T-rich nucleic acid does not contain poly C (CCCC), poly A (AAAA), poly G (GGGG), CpG motifs, or multiple GGs. In other embodiments the T-rich nucleic acid includes these motifs. Thus in some embodiments of the invention the T rich nucleic acids include CpG dinucleotides and in other embodiments the T rich nucleic acids are free of CpG dinucleotides. The CpG dinucleotides may be methylated or unmethylated.

Poly G containing nucleic acids are also immunostimulatory. A variety of references, including Pisetsky and Reich, 1993 *Mol. Biol. Reports*, 18:217-221; Krieger and Herz, 1994, *Ann. Rev. Biochem.*, 63:601-637; Macaya et al., 1993, *PNAS*, 90:3745-3749; Wyatt et al., 1994, *PNAS*, 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, ed. Krieg and Stein, p. 335-352; and Kimura et al., 1994, *J. Biochem.* 116, 991-994 also describe the immunostimulatory properties of poly G nucleic acids.

Poly G nucleic acids preferably are nucleic acids having the following formulas:



- 79 -

wherein X₁, X₂, X₃, and X₄ are nucleotides. In preferred embodiments at least one of X₃ and X₄ are a G. In other embodiments both of X₃ and X₄ are a G. In yet other embodiments the preferred formula is 5' GGGN_NGGG 3', or 5' GGGN_NGGG_NGGG 3' wherein N represents between 0 and 20 nucleotides. In other embodiments the Poly G nucleic acid is free of
5 unmethylated CG dinucleotides. In other embodiments the poly G nucleic acid includes at least one unmethylated CG dinucleotide.

Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Patents Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe
10 immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

The ISNAs may be double-stranded or single-stranded. Generally, double-stranded molecules may be more stable *in vivo*, while single-stranded molecules may have increased
15 activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)) or a modified base. As used herein, the terms refer to oligoribonucleotides as well as
20 oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base-containing polymer. The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other
25 than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide- nucleic acids (which have amino acid
30 backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

- 80 -

The substituted purines and pyrimidines of the ISNAs include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases. Wagner RW et al., *Nat Biotechnol* 14:840-844 (1996). Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

The ISNA is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5' to 3' order from left to right and that "A" denotes adenine, "C" denotes cytosine, "G" denotes guanine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

Immunostimulatory nucleic acid molecules useful according to the invention can be obtained from natural nucleic acid sources (e.g., genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g., produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic acid encompasses both synthetic and isolated nucleic acids.

The term "isolated" as used herein with reference to an ISNA means substantially free of or separated from components which it is normally associated with in nature, e.g., nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids are sufficiently pure and are sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid of the invention may be admixed with a pharmaceutically-acceptable carrier in a pharmaceutical preparation,

- 81 -

the nucleic acid may comprise only a small percentage by weight of the preparation. The nucleic acid is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

The ISNAs can be produced on a large scale in plasmids, (see *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

For use in the instant invention, the ISNAs can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the β -cyanoethyl phosphoramidite method (Beaucage SL and Caruthers MH, *Tetrahedron Let* 22:1859 (1981)); nucleoside H-phosphonate method (Garegg et al., *Tetrahedron Let* 27:4051-4054 (1986); Froehler et al., *Nucl Acid Res* 14:5399-5407 (1986); Garegg et al., *Tetrahedron Let* 27:4055-4058 (1986); Gaffney et al., *Tetrahedron Let* 29:2619-2622 (1988)). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

ISNAs having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Patents Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

The ISNA may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Immunostimulatory nucleic acids can be produced on a large scale in plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

"Palindromic sequence" shall mean an inverted repeat (i.e., a sequence such as ABCDEE'D'C'B'A' in which A and A', B and B', etc., are bases capable of forming the usual Watson-Crick base pairs and which includes at least 6 nucleotides in the palindrome. *In vivo*,

- 82 -

such sequences may form double-stranded structures. In one embodiment the nucleic acid contains a palindromic sequence. In some embodiments when the nucleic acid is a CpG nucleic acid, a palindromic sequence used in this context refers to a palindrome in which the CpG is part of the palindrome, and optionally is the center of the palindrome. In another
5 embodiment the nucleic acid is free of a palindrome. A nucleic acid that is free of a palindrome does not have any regions of 6 nucleotides or greater in length which are palindromic. A nucleic acid that is free of a palindrome can include a region of less than 6 nucleotides which are palindromic.

A "stabilized ISNA" shall mean a nucleic acid molecule that is relatively resistant to
10 *in vivo* degradation (e.g. via an *exo*- or *endo*-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop
15 structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

Some stabilized ISNAs of the instant invention have a modified backbone. It has been demonstrated that modification of the oligonucleotide backbone provides enhanced activity of the ISNAs when administered *in vivo*. Nucleic acids, including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3'
20 end, preferably 5, may provide maximal activity and protect the oligonucleotide from degradation by intracellular *exo*- and *endo*-nucleases. Other modified oligonucleotides include phosphodiester modified oligonucleotide, combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations and their
25 particular effects on immune cells is discussed in more detail in U.S. Patent Nos. 6,194,388 and 6,207,646, the entire contents of which is hereby incorporated by reference. It is believed that these modified oligonucleotides may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization. Both phosphorothioate and phosphodiester nucleic acids are active
30 in immune cells.

Other stabilized ISNAs include: nonionic DNA analogs, such as alkyl- and aryl-

- 83 -

phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease
5 degradation.

For use *in vivo*, ISNAs are preferably relatively resistant to degradation (e.g., via endo- and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. One type of stabilized nucleic acid has at least a partial
10 phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574) can be prepared by automated
15 solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described. Uhlmann E and Peyman A, *Chem Rev* 90:544 (1990); Goodchild J, *Bioconjugate Chem* 1:165 (1990).

Other sources of immunostimulatory nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its
20 broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.
25 In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene be expressed in the cell.

A basis for certain of the screening assays is the presence of a functional TLR 7, TLR 8, or TLR9 in a cell. The functional TLR in some instances is naturally expressed by the cell.
30 In other instances, expression of the functional TLR can involve introduction or reconstitution of a species-specific TLR9 into a cell or cell line that otherwise lacks the TLR

- 84 -

or lacks responsiveness to ISNA, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an ISNA. Examples of cell lines lacking TLR9 or ISNA responsiveness include, but are not limited to, 293 fibroblasts (ATCC CRL-1573), MonoMac-6, THP-1, U937, CHO, and any TLR9 knock-out. The introduction
5 of the species-specific TLR into the cell or cell line is preferably accomplished by transient or stable transfection of the cell or cell line with a TLR-encoding nucleic acid sequence operatively linked to a gene expression sequence (as described above).

The species-specific TLR, including TLR7, TLR8, and TLR9, is not limited to a murine TLR, but rather can include a TLR derived from murine or non-murine sources.
10 Examples of non-murine sources include, but are not limited to, human, bovine, canine, feline, ovine, porcine, and equine. Other species include chicken and fish, e.g., aquaculture species.

The species-specific TLR, including TLR7, TLR8, and TLR9, also is not limited to native TLR polypeptides. In certain embodiments the TLR can be, e.g., a chimeric TLR in
15 which the extracellular domain and the cytoplasmic domains are derived from TLR polypeptides from different species. Such chimeric TLR polypeptides, as described above, can include, for example, a human TLR extracellular domain and a murine TLR cytoplasmic domain, each domain derived from the corresponding TLR7, TLR8, or TLR9 of each species. In alternative embodiments, such chimeric TLR polypeptides can include chimeras created
20 with different TLR splice variants or allotypes. Other chimeric TLR polypeptides useful for the purposes of screening ISNA mimics, agonists and antagonists can include chimeric polypeptides created with a TLR of a first type, e.g., TLR9, and another TLR, e.g., TLR7 or TLR8, of the same or another species as the TLR of the first type. Also contemplated are chimeric polypeptides which incorporate sequences derived from more than two polypeptides,
25 e.g., an extracellular domain, a transmembrane domain, and a cytoplasmic domain all derived from different polypeptide sources, provided at least one such domain derives from a TLR7, TLR8, or TLR9 polypeptide. As a further example, also contemplated are constructs such as include an extracellular domain of one TLR9, an intracellular domain of another TLR9, and a non-TLR reporter such as luciferase, GFP, etc. Those of skill in the art will recognize how to
30 design and generate DNA sequences coding for such chimeric TLR polypeptides.

The screening assays can have any of a number of possible readout systems based

- 85 -

upon either TLR/IL-1R signaling pathway or other assays useful for assaying response to ISNAs. It has been reported that immune cell activation by CpG immunostimulatory sequences is dependent in some way on endosomal processing. It is not yet known whether TLR9 is directly involved in this endosomal pathway, or if there is some intermediary
5 between TLR9 and the endosome.

In preferred embodiments, the readout for the screening assay is based on the use of native genes or, alternatively, cotransfected or otherwise co-introduced reporter gene constructs which are responsive to the TLR/IL-1R signal transduction pathway involving MyD88, TRAF6, p38, and/or ERK. Häcker H et al., *EMBO J* 18:6973-6982 (1999). These
10 pathways activate kinases including κ B kinase complex and c-Jun N-terminal kinases. Thus reporter genes and reporter gene constructs particularly useful for the assays can include a reporter gene operatively linked to a promoter sensitive to NF- κ B. Examples of such promoters include, without limitation, those for NF- κ B, IL-1 β , IL-6, IL-8, IL-12 p40, CD80, CD86, and TNF- α . The reporter gene operatively linked to the TLR7-, TLR8-, or TLR9-
15 sensitive promoter can include, without limitation, an enzyme (e.g., luciferase, alkaline phosphatase, β -galactosidase, chloramphenicol acetyltransferase (CAT), etc.), a bioluminescence marker (e.g., green-fluorescent protein (GFP, U.S. patent 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), and a secreted molecule (e.g., IL-8, IL-12 p40, TNF- α). In preferred embodiments the reporter is selected from IL-8, TNF- α , NF- κ B-
20 luciferase (NF- κ B-luc; Häcker H et al., *EMBO J* 18:6973-6982 (1999)), IL-12 p40-luc (Murphy TL et al., *Mol Cell Biol* 15:5258-5267 (1995)), and TNF-luc (Häcker H et al., *EMBO J* 18:6973-6982 (1999)). In assays relying on enzyme activity readout, substrate can be supplied as part of the assay, and detection can involve measurement of
25 chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using FACS analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many such readout systems are well known in the art and are commercially available.

In another aspect the invention provides a screening method for identifying an
30 immunostimulatory nucleic acid molecule (ISNA). The method entails contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test

- 86 -

nucleic acid molecule; detecting the presence or absence of a response mediated by a TLR signal transduction pathway in the presence of the test nucleic acid molecule arising as a result of an interaction between the functional TLR and the test nucleic acid molecule; and determining the test nucleic acid molecule is an ISNA when the presence of a response
5 mediated by the TLR signal transduction pathway is detected. "Functional TLR" and a "cell expressing functional TLR" are as described elsewhere herein. A response mediated by a TLR signal transduction pathway includes induction of a gene under control of a promoter responsive to the TLR/IL-1R signaling pathway, including but not limited to promoters responsive to NF- κ B. The biological response thus can include, e.g., secretion of IL-8 and
10 luciferase activity in a cell transfected with NF- κ B-luc, IL-12 p40-luc, or TNF-luc. A test nucleic acid molecule can include a DNA, RNA, or modified nucleic acid molecule as described herein. In some embodiments the test nucleic acid molecule is a CpG nucleic acid.

Preferably, the test nucleic acid molecule is a sequence variant of a reference ISNA, containing at least one alternative base, at least one alternative internucleotide backbone
15 linkage, or at least one alternative sugar moiety as compared to the particular reference ISNA. In a preferred embodiment the test nucleic acid molecule is a member of a library of such test nucleic acid molecules.

According to one embodiment of this method, comparison can be made to a reference ISNA. The reference ISNA may be any ISNA, including a CpG nucleic acid. In preferred
20 embodiments the screening method is performed using a plurality of test nucleic acids. Preferably comparison of test and reference responses is based on comparison of quantitative measurements of responses in each instance.

The method can be used to select a subset of test nucleic acid molecules based on their ability to induce a similar specific response mediated by the TLR signal transduction
25 pathway. For instance, the method can be used to classify test CpG nucleic acids as predominantly B-cell activating CpG nucleic acids, or as predominantly IFN- α inducing CpG nucleic acids. Other new classes of ISNAs may be identified and characterized using the method.

Application of this method permits the identification of ISNAs, delineation of
30 sequence specificity of a given TLR, and also optimization of ISNA sequences. Identification of ISNAs involves screening candidate ISNAs as above and selecting any ISNA that induces

- 87 -

a response as defined. Delineation of sequence specificity involves screening candidate ISNAs as above with reference to a particular TLR9, selecting any ISNAs that induce a response as defined, and categorizing ISNAs that do and do not induce a response on the basis of their sequence. Optimization of ISNA sequences involves an iterative application of the method as described, further including the steps of selecting the best sequence at any given stage or round in the screening and substituting it as a benchmark or reference in a subsequent round of screening. This latter process can further include selection of parameters to modify in choosing and generating candidate ISNAs to screen.

In another aspect the invention provides screening method for identifying species specificity of an ISNA. The method involves contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a first species with a test ISNA; contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a second species with the test ISNA; measuring a response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA; and comparing (a) the response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA with (b) the response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA. The functional TLR may be expressed by a cell or it may be part of a cell-free system. The functional TLR may be part of a complex, with either another TLR or with another protein, e.g., MyD88, IRAK, TRAF6, I κ B, NF- κ B, or functional homologues and derivatives thereof. Thus for example a given ODN can be tested against a panel of 293 fibroblast cells transfected with TLR7, TLR8, or TLR9 from various species and optionally cotransfected with a reporter construct (e.g., NF- κ B-luc) sensitive to TLR/IL-1R activation pathways. Thus in another aspect, the invention provides a method for screening species selectivity with respect to a given nucleic acid sequence.

As mentioned above, the invention in one aspect provides a screening method for comparing TLR signaling activity or a test compound against corresponding TLR signaling activity of a reference ISNA. The methods generally involve contacting a functional TLR

- 88 -

selected from the group consisting of TLR7, TLR8, and TLR9 with a reference ISNA and detecting a reference response mediated by a TLR signal transduction pathway; contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test compound and detecting a test response mediated by a TLR signal transduction pathway; and
5 comparing the test response with the reference response to compare the TLR signaling activity of the test compound with the ISNA. Assays in which the test compound and the reference ISNA contact the TLR independently may be used to identify test compounds that are ISNA mimics. Assays in which the test compound and the reference ISNA contact the TLR concurrently may be used to identify test compounds that are ISNA agonists and ISNA
10 antagonists.

An ISNA mimic as used herein is a compound which causes a response mediated by a TLR signal transduction pathway. As used herein the term "response mediated by a TLR signal transduction pathway" refers to a response which is characteristic of an ISNA-TLR interaction. As demonstrated herein responses which are characteristic of ISNA-TLR
15 interactions include the induction of a gene under control of an ISNA-specific promoter such as a NF- κ B promoter, increases in Th1 cytokine levels, etc. The gene under the control of the NF- κ B promoter may be a gene which naturally includes an NF- κ B promoter or it may be a gene in a construct in which an NF- κ B promoter has been inserted. Genes which naturally include the NF- κ B promoter include but are not limited to IL-8, IL-12 p40, NF- κ B-luc, IL-12
20 p40-luc, and TNF-luc. Increases in Th1 cytokine levels is another measure characteristic of an ISNA-TLR interaction. Increases in Th1 cytokine levels may result from increased production or increased stability or increased secretion of the Th1 cytokines in response to the ISNA-TLR interaction. Th1 cytokines include but are not limited to IL-2, IFN- γ , and IL-12. Other responses which are characteristic of an ISNA-TLR interaction include but are not
25 limited to a reduction in Th2 cytokine levels. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

The response which is characteristic of an ISNA-TLR interaction may be a direct response or an indirect response. A direct response is a response that arises directly as a result of the ISNA-TLR interaction. An indirect response is a response which involves the
30 modulation of other parameters prior to its occurrence.

An ISNA agonist as used herein is a compound which causes an enhanced response to

- 89 -

an ISNA mediated by a TLR signal transduction pathway. Thus an ISNA agonist as used herein is a compound which causes an increase in at least one aspect of an immune response that is ordinarily induced by the reference ISNA. For example, an immune response that is ordinarily induced by an ISNA can specifically include TLR7-, TLR8-, or TLR9-mediated signal transduction in response to immunostimulatory CpG nucleic acid. An ISNA agonist will in some embodiments compete with ISNA for binding to TLR7, TLR8, or TLR9. In other embodiments an ISNA agonist will bind to a site on TLR7, TLR8, or TLR9 that is distinct from the site for binding ISNA. In yet other embodiments an ISNA agonist will act via another molecule or pathway distinct from TLR7, TLR8, or TLR9.

An ISNA antagonist as used herein is a compound which causes a decreased response to an ISNA mediated by a TLR signal transduction pathway. Thus an ISNA antagonist as used herein is a compound which causes a decrease in at least one aspect of an immune response that is ordinarily induced by the reference ISNA. For example, an immune response that is ordinarily induced by an ISNA can specifically include TLR7-, TLR8-, or TLR9-mediated signal transduction in response to immunostimulatory CpG nucleic acid. An ISNA antagonist will in some embodiments compete with ISNA for binding to TLR7, TLR8, or TLR9. In other embodiments an ISNA antagonist will bind to a site on TLR7, TLR8, or TLR9 that is distinct from the site for binding ISNA. In yet other embodiments an ISNA antagonist will act via another molecule or pathway distinct from TLR7, TLR8, or TLR9.

The screening methods for comparing TLR signaling activity of a test compound with signaling activity of an ISNA involve contacting at least one test compound with a functional TLR selected from TLR7, TLR8, and TLR9 under conditions which, in the absence of a test compound, permit a reference ISNA to induce at least one aspect of an immune response. The functional TLR may be expressed by a cell or it may be part of a cell-free system. A cell expressing a functional TLR is a cell that either naturally expresses the TLR, or is a cell into which has been introduced a TLR expression vector, or is a cell manipulated to express TLR in a manner that allows the TLR to be expressed by the cell and to transduce a signal under conditions which normally permit signal transduction by the signal transducing portion of the TLR. The TLR can be a native TLR or it can be a fragment or variant thereof, as described above. According to these methods, the test compound is contacted with a functional TLR or TLR-expressing cell before, after, or simultaneously with contacting a reference ISNA with

- 90 -

the functional TLR or TLR-expressing cell. A response of the functional TLR or TLR-expressing cell is measured and compared with the corresponding response that results or would result under the same conditions in the absence of the test compound. Where it is appropriate, the response in the absence of the test compound can be determined as a concurrent or historical control. Examples of such responses include, without limitation, a response mediated through the TLR signal transduction pathway, secretion of a cytokine, cell proliferation, and cell activation. In a preferred embodiment, the measurement of a response involves the detection of IL-8 secretion (e.g., by ELISA). In another preferred embodiment, the measurement of the response involves the detection of luciferase activity (e.g., NF- κ B-luc, IL-12 p40-luc, or TNF-luc).

Examples of reference ISNAs include, without limitation, those listed in Table 1 (above). In some preferred embodiments the reference ISNA is a CpG nucleic acid.

Test compounds can include but are not limited to peptidic nucleic acids (PNAs), antibodies, polypeptides, carbohydrates, lipids, hormones, and small molecules. Test compounds can further include variants of a reference ISNA incorporating any one or combination of the substitutions described above. Test compounds can be generated as members of a combinatorial library of compounds.

In preferred embodiments, the methods for screening test compounds, test nucleic acid molecules, test ISNAs, and candidate pharmacological agents can be performed on a large scale and with high throughput by incorporating, e.g., an array-based assay system and at least one automated or semi-automated step. For example, the assays can be set up using multiple-well plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are well known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are well known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully

- 91 -

robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. patents 5,443,791 and 5,708,158.

5 The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

Examples

10 **Example 1. Method of cloning the mouse TLR9**

Alignment of human TLR9 protein sequence with mouse EST database using tfasta yielded 7 hits with mouse EST sequences aa197442, ai451215, aa162495, aw048117, ai463056, aw048548, and aa273731. Two primers were designed that bind to aa197442 EST sequence for use in a RACE-PCR to amplify 5' and 3' ends of the mouse TLR9 cDNA. The library used for the RACE PCR was a mouse spleen marathon-ready cDNA commercially available from Clontech. A 5' fragment with a length of 1800 bp obtained by this method was cloned into Promega pGEM-T Easy vector. After sequencing of the 5' end, additional primers were designed for amplification of the complete mouse TLR9 cDNA. The primer for the 5' end was obtained from the sequence of the 5' RACE product whereas the primer for the 15 3' end was selected from the mouse EST sequence aa273731.

Three independent PCR reactions were set up using a murine macrophage RAW264.7 (ATCC TIB-71) cDNA as a template, and the resulting amplification products were cloned into the pGEM-T Easy vector. The inserts were fully sequenced, translated into protein and aligned to the human protein sequence. One out of three clones was error-free based on alignment comparison (clone mtlr932c.pcp). The cDNA sequence for mTLR9 is SEQ ID NO:1, is presented in Table 2. The ATG start codon occurs at base 40, and a TAG termination codon occurs at base 3136. SEQ ID NO:2 (Table 3), corresponding to bases 40-3135 of SEQ ID NO:1, is the coding region for the polypeptide of SEQ ID NO:3.

30 **Table 2. cDNA Sequence for Murine TLR9 (5' to 3'; SEQ ID NO:1)**

tgtcagaggg	agcctcgga	gaatcctcca	tctcccaaca	tggttctccg	tgaaggact	60
ctgcacccct	tgtccctcct	ggtacagget	gcagtgctgg	ctgagactct	ggccctgggt	120

- 92 -

	accctgcctg	ccttctctacc	ctgtgagctg	aagcctcatg	gcctgggtgga	ctgcaattgg	180
	ctgttctctga	agtctgtacc	cgttttctct	gcggcagcat	cctgctccaa	catcaccctgc	240
	ctctccttga	tctccaaccg	tatccaccac	ctgcacaact	cggacttctg	ccacctgtcc	300
	aacctgcggc	agctgaacct	caagtggaa	tgtccaccca	ctggccttag	ccccctgcac	360
5	ttctcttggc	acatgaccat	tgagcccaga	accttctctg	ctatgcgtac	actggaggag	420
	ctgaacctga	gotataatgg	tatcaccact	gtgccccgac	tgccagctc	cctgggtgaat	480
	ctgagcctga	gccacaccaa	catcctgggt	ctagatgcta	acagcctcgc	cggcctatac	540
	agcctgcggc	ttctcttcat	ggacgggaac	tgtactaca	agaacccctg	cacaggagcg	600
	gtgaagggtga	ccccaggcgc	cctcctgggc	ctgagcaatc	tcacccatct	gtctctgaag	660
10	tataacaacc	tcacaaaggt	gccccgccaa	ctgcccccca	gcctggagta	cctcctgggtg	720
	tcctataacc	tcattgtcaa	gctggggcct	gaagacctgg	ccaatctgac	ctcccttcca	780
	gtacttgatg	tgggtgggaa	ttgccgtcgc	tgcgaccatg	cccccaatcc	ctgtatagaa	840
	tgtggccaaa	agtccctcca	cctgcaccct	gagaccttcc	atcacctgag	ccatctggaa	900
	ggcctgggtgc	tgaaggacag	ctctctccat	acactgaact	cttctctgggt	ccaaggctctg	960
15	gtcaacctct	cgggtgctgga	cctaagcgag	aactttctct	atgaaagcat	caaccacacc	1020
	aatgccttct	agaacctaac	cgcctgcgc	aagctcaacc	tgtccttcaa	ttaccgcaag	1080
	aaggatctct	ttgcccgcct	ccacctggca	agttccttca	agaacctgggt	gtcactgcag	1140
	gagctgaaca	tgaacggcat	cttcttccgc	tcgctcaaca	agtacacgct	cagatggctg	1200
	gccgatctgc	ccaaactcca	cactctgcat	cttcaaata	acttcatcaa	ccaggcacag	1260
20	ctcagcatct	ttggtacctt	cggagccctt	cgttttgtgg	acttgctcaga	caatcgcatc	1320
	agtgggcctt	caacgctgtc	agaagccacc	cctgaagagg	cagatgatgc	agagcaggag	1380
	gagctgttgt	ctgcggtacc	tcacccagct	ccactgagca	ccctgcttcc	taagaacttc	1440
	atggacaggt	gtaagaactt	caagttcacc	atggacctgt	ctcggaacaa	cctgggtgact	1500
	atcaagccag	agatgtttgt	caatctctca	cgcctccagt	gtcttagcct	gagccacaac	1560
25	tcattgcac	aggctgtcaa	tggtctctcag	ttcctgccgc	tgactaatct	gcaggtgctg	1620
	gacctgtccc	ataacaaact	ggacttgtac	cactggaaat	cgttcagtga	gtaccacag	1680
	ttgcaggccc	tggacctgag	ctacaacagc	cagcccttta	gcataagggg	tataggccac	1740
	aatttcagtt	ttgtggccca	tctgtccatg	ctacacagcc	ttagcctggc	acacaatgac	1800
	attcataccc	gtgtgtcttc	acatctcaac	agcaactcag	tgagggtttct	tgacttcagc	1860
30	ggcaacggta	tgggcccgc	gtgggatgag	gggggccttt	atctccattt	cttccaaggc	1920
	ctgagtggcc	tgctgaagct	ggacctgtct	caaaataacc	tgcataatct	cgggccccag	1980
	aaccttgaca	acctcccaa	gagcctgaag	ctgctgagcc	tccgagacaa	ctacctatct	2040
	ttctttaaact	ggaccagtct	gtccttctct	cccaacctgg	aagtcctaga	cctggcaggc	2100
	aaccagctaa	aggccctgac	caatggcacc	ctgcctaata	gcacctctct	ccagaaactg	2160
35	gatgtcagca	gcaacagtat	cgtctctgtg	gtcccagcct	tcttctgctct	ggcggctcag	2220
	ctgaaagagg	tcaacctcag	ccacaacatt	ctcaagacgg	tggatcgctc	ctgggttggg	2280
	cccattgtga	tgaacctgac	agttctagac	gtgagaagca	acctctgca	ctgtgcctgt	2340
	ggggcagcct	tcgtagactt	actgttggag	gtgcagacca	aggtgcctgg	cctggccta	2400
	gggtgtgaagt	gtggcagccc	cgccagctg	cagggccgta	gcattctcgc	acaggacctg	2460
40	cggctgtgcc	tggatgaggt	cctctcttgg	gaotgctttg	gcctttcact	cttggtctgt	2520
	gccgtgggca	tgggtgtgcc	tatactgac	catctctgcg	gctgggacgt	ctggtactgt	2580
	tttcatctgt	gcctggcatg	gtacctttg	ctggcccgca	gccgacgcag	cgcccaagct	2640

- 93 -

	ctcccctatg atgccttcgt ggtgttcgat aaggcacaga gcgcagttgc ggactgggtg	2700
	tataacgagc tgcgggtgcg gctggaggag cggcgcggtc gccgagccct acgcttgtgt	2760
	ctggaggacc gagattggct gcctggccag acgctcttcg agaacctctg ggcttccatc	2820
	tatgggagcc gcaagactct atttgtgctg gccacacgg accgcgtcag tggcctcctg	2880
5	cgcaccagct tcctgctggc tcagcagcgc ctggtggaag accgcaagga cgtgggtggtg	2940
	ttggtgatcc tgcgtccgga tggccaccgc tcccgcctatg tgcgactgcg ccagcgtctc	3000
	tgcgccaga gtgtgctctt ctggccccag cagcccaacg ggcagggggg cttctggggc	3060
	cagctgagta cagccctgac tagggacaac cgcacttct ataaccagaa cttctgcgg	3120
	ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcatctt catgctggt	3180
10	tcccagttg ctctgctgc	3200

Table 3. Coding region for murine TLR9 (SEQ ID NO:2)

	atggttctcc gtcgaaggac tctgcacccc ttgtccctcc tggtagagc tgcagtgtg	60
	gctgagactc tggccctggg taccctgcct gccttccctac cctgtgagct gaagcctcat	120
15	ggcctggtgg actgcaattg gctgttctct aagtctgtac cccgtttctc tgcggcagca	180
	tcctgctcca acatcacccg cctctccttg atctccaacc gtatccacca cctgcacaac	240
	tcgacttctg tccacctgtc caacctgcgg cagctgaacc tcaagtggaa ctgtccaccc	300
	actggcctta gccccctgca cttctcttgc cacatgacca ttgagcccag aaccttctctg	360
	gctatgcgta cactggagga gctgaacctg agctataatg gtatcaccac tgtgccccga	420
20	ctgcccagct ccctggtgaa tctgagcctg agccacacca acatcctggg tctagatgct	480
	aacagcctcg ccggcctata cagcctgcgc gttctcttca tggacgggaa ctgctaactac	540
	aagaacccct gcacaggagc ggtgaagggtg accccaggcg cctcctggg cctgagcaat	600
	ctcacccatc tgtctctgaa gtataacaac ctcaaaagg tgcgccgcca actgcccccc	660
	agcctggagt acctcctggg gtccctataac ctcatgttca agctggggcc tgaagacctg	720
25	gccaatctga cctcccttcg agtacttgat gtgggtggga attgccgtcg ctgcgacct	780
	gcccccaatc cctgtataga atgtggccaa aagtcctctc acctgcaccc tgagaccttc	840
	catcacctga gccatctgga aggcctgggt ctgaaggaca gctctctcca tacactgaac	900
	tcttctggt tccaaggctc ggtcaacctc tgggtgctgg acctaaagca gaactttctc	960
	tatgaaagca tcaaccacac caatgccttt cagaacctaa cccgcctgcg caagctcaac	1020
30	ctgtccttca attaccgcaa gaaggatcc tttgcccgcc tccacctggc aagttccttc	1080
	aagaacctgg tgtcactgca ggagctgaac atgaacggca tcttcttccg ctgctcaac	1140
	aagtacacgc tcagatggct ggccgatctg cccaaactcc aactctgca tcttcaaatg	1200
	aacttcatca accaggcaca gctcagcatc tttggtacct tcgagccct tcgctttgtg	1260
	gacttgtcag acaatcgcat cagtgggcct tcaacgctgt cagaagccac ccctgaagag	1320
35	gcagatgatg cagagcagga ggagctgttg tctgcggatc ctacccagc tccactgagc	1380
	acctctgctt ctaagaactt catggacagg tgtaagaact tcaagttcac catggacctg	1440
	tctcggaaca acctggtgac tatcaagcca gagatgtttg tcaatctctc acgctccag	1500
	tgtcttagcc tgagccacaa ctccattgca caggctgtca atggtctca gttcctgcg	1560
	ctgactaatc tgcaggtgct ggacctgtcc cataacaaac tggacttgta ccactggaaa	1620
40	tcgttcagtg agctaccaca gttgcaggcc ctggacctga gctacaacag ccagcccttt	1680
	agcatgaagg gtataggcca caatttcagt tttgtggccc atctgtccat gctacacagc	1740

- 94 -

```

cttagcctgg cacacaatga cattcatacc cgtgtgtcct cacatctcaa cagcaactca 1800
gtgagggttc ttgacttcag cggcaacggt atgggcccga tgtgggatga ggggggcctt 1860
tatctccatt tcttccaagg cctgagtggc ctgctgaagc tggacctgtc tcaaaataac 1920
ctgcatatcc tccggcccca gaaccttgac aacctcccca agagcctgaa gctgctgagc 1980
5 ctccgagaca actacctatc tttctttaac tggaccagtc tgtccttctt gcccacactg 2040
gaagtcctag acctggcagg caaccagcta aaggccctga ccaatggcac cctgcctaata 2100
ggcaccctcc tccagaaact ggatgtcagc agcaacagta tctgtctctgt ggtcccagcc 2160
ttcttctgctc tggcggtcga gctgaaagag gtcaacctca gccacaacat tctcaagacg 2220
gtggatcgct cctggtttgg gccatttggt atgaacctga cagttctaga cgtgagaagc 2280
10 aacctctctgc actgtgcctg tggggcagcc ttcgtagact tactgttggg ggtgcagacc 2340
aaggtgcctg gcctggctaa tgggtgtgaag tgtggcagcc ccggccagct gcaggggcgt 2400
agcatcttctg cacaggacct ggggctgtgc ctggatgagg tctctctctt ggactgcttt 2460
ggcctttcac tcttggctgt ggccgtgggc atgggtgtgc ctatactgca ccctctctgc 2520
ggctgggacg tctgggtactg ttttcatctg tgcctggcat ggctaccttt gctggcccg 2580
15 agccgacgca gcgcccgaagc tctcccctat gatgccttcg tgggtgttga taaggcacag 2640
agcgcagttg cggactgggt gtataacgag ctgcccgtgc ggctggagga gcggcgcggt 2700
cgccgagccc tacgcttctg tctggaggac cgagattggc tgcctggcca gacgctcttc 2760
gagaacctct gggcttccat ctatgggagc cgcaagactc tatttctgct ggccacacg 2820
gaccgcgtca gtggcctcct gcgcaccagc ttctgctgg ctcagcagcg cctgttggaa 2880
20 gaccgcaagg acgtggtggt gttggtgatc ctgctccgg atgcccaccg ctcccgtat 2940
gtgcgactgc gccagcgtct ctgcccagc agtgtgctct tctggcccca gcagcccaac 3000
gggcaggggg gcttctgggc ccagctgagt acagccctga ctagggacaa ccgccacttc 3060
tataaccaga acttctgccg gggacctaca gcagaa 3096

```

25 The deduced amino acid sequence for murine TLR9 (SEQ ID NO:3), comprising 1032 amino acid residues, is shown in Table 4 below in the aligned sequence comparison as mtlr932e.pep. The deduced amino acid sequence for human TLR9 (SEQ ID NO:6), comprising 1032 amino acid residues, is shown in Table 4 below in the aligned sequence comparison as htlr9.pro.

30

Table 4. Amino Acid Sequence of Murine and Human TLR9

```

. : . : . : . : . : . : . : 60
htlr9.pro  MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNNLFLKSVPHFSMAA 60
mtlr932e.pep  MVLRRRTLHPLSLLVQAAVLAETIALGTLPAFLPCLKPHGI VDCNNLFLKSVPRFSAAA 60
35
. : . : . : . : . : . : . : 120
htlr9.pro  PRGNVTSLSLSSNRIHHLHSDFAHLPSLRHLNLKWNCPVGLSPMHFPCHMTIEPSTFL 120
mtlr932e.pep  SCSNITRLSLISNRIHHLHNSDFVHLSNLRQLNLKWNCPFTGLSPLHFSCHMTIEPRTFL 120
40
. : . : . : . : . : . : . : 180

```

- 95 -

	htlr9.pro	AVPTLEELNLSYNNIMTVPALPKSLISLSLSTNIMLMDSASLAGLFALRFLFMDGNCY	180
	mtlr932e.pep	AMRTL EELNLSYNGITTVPRLPSSLVNLSLSHTNILVLDANSLAGLYSLRVLFMDGNCY	180
		. : . : . : . : . : . :	240
5	htlr9.pro	KNPCROALEVAPCALLGLGNLTHTLSLKYNNTLVVPRNLPSSELEYLLSYNRIVKLAPEDL	240
	mtlr932e.pep	KNPCTGAVKVTPGALLGLSNLTHTLSLKYNNTTKVPRQLPPSLEYLLVSYNLIVKLGPEDL	240
		. : . : . : . : . : . :	300
	htlr9.pro	ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLRLGLEGLVLKDSSLSWLN	300
10	mtlr932e.pep	ANLTSLRVLDVGGNCRRCDHAPNPCECGQKSLHLHPETFHHLSHLEGLVLKDSSLSHTLN	300
		. : . : . : . : . : . :	360
	aal97442.pep	LNLSSFNYRKVKVSFARLHLASSF	22
	htlr9.pro	ASWFRGLGNLRVLDLSENFLYKCITKTAKAQGLTQLRKCNLSFNYSQKRVSAHLSLAPS	360
15	mtlr932e.pep	SSWFQGLNVLSVLDLSENFLYESINHTNAFQNLTQLRKCNLSFNYSQKRVSAHLHLASSF	360
		. : . : . : . : . : . :	420
	mousepepl	C	1
	aal97442.pep	KNLVSLQELNMNGIFFRLNKYTTLRWLADLPKLHTLHLQMNFINQAQLSIFGTFRALRFV	82
20	htlr9.pro	GSIJVAIKFTIDMHGIEFRSLDETTLRLPLARLPMIQTLLRLQMNFINQAQLSIFRAFPGLRYV	420
	mtlr932e.pep	KNLVSLQELNMNGIFFRSLNKYTTLRWLADLPKLHTLHLQMNFINQAQLSIFGTFRALRFV	420
		. : . : . : . : . : . :	480
	mousepepl	DLSDNRISGPSTLSEA	17
25	humanpepl	PA2VDTPSSEDFRPNC	16
	aal97442.pep	DLSDNRISGPSTLSEATPE3ADDAEQEELLSDADPHAPLSTPASKNFMDRCKNFKFNMDL	142
	htlr9.pro	DLSDNRISCASELT-AIMG3ADGGEKVWLQPGD LAPAPVDTPSSED FRPNCSTLNF TLDL	479
	mtlr932e.pep	DLSDNRISGPSTLSEATPE3ADDAEQEELLSDADPHAPLSTPASKNFMDRCKNFKFTMDL	480
		. : . : . : . : . : . :	540
30	aal97442.pep	SRNNLVTTITAEMFVNLSRLQCCLSLSHNSIAQAVNGS	178
	htlr9.pro	SRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSRNKLDLYHEH	539
	mtlr932e.pep	SRNNLVTIKPEMFVNLSRLQCCLSLSHNSIAQAVNGSQFLPLTNLQVLDLSENKLDLYHWK	540
		. : . : . : . : . : . :	600
35	aal62495.pep	YNSQPFMSMGIGHNFSFVTHLSMLQSLSLAHNDIHTRVSSHLSNS	46
	htlr9.pro	SFTLPRLEALDLSYNSQPFMGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTS	599
	mtlr932e.pep	SFSEL PQ L QAL DLSYNSQPFMSMGIGHNFSFVAHLSMLHSLSLAHNDIHTRVSSHLSNS	600
		. : . : . : . : . : . :	660
40	aal62495.pep	VRFLDFSGNGMGRMWDEGGLYLHF FQGLSGVLKLDLSQNNLHIILRPQNLDNL PKSLKLLS	106
	htlr9.pro	I RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWL DLSQNR LH TL PQT LR NL PKSLQVLR	659
	mtlr932e.pep	VRFLDFSGNGMGRMWDEGGLYLHFFQGLSGLLKLDLSQNNLHIILRPQNLDNL PKSLKLLS	660
		. : . : . : . : . : . :	720
45	aal62495.pep	LRDNYLSFFNWTSLSFLPNLEVLDLAGNOLKALTNGTLPNGITLLQKLDVSSNSNIS	162

htlr9.pro: SEQ ID NO:6; mtlr932e.pep: SEQ ID NO:3; aa197442.pep: SEQ ID NO:8;
mousepep1: SEQ ID NO:17; humanpep1: SEQ ID NO:19; aa162495.pep: SEQ ID NO:14;

- 97 -

ai451215.pep: SEQ ID NO:16; aa273731.pep: SEQ ID NO:10; ai463056.pep: SEQ ID NO:12; humanpep2: SEQ ID NO:20; and mousepep2: SEQ ID NO:18.

Example 2. Reconstitution of TLR9 signaling in 293 fibroblasts

5 The cloned mouse TLR9 cDNA (see above) and human TLR9 cDNA (gift from B. Beutler, Howard Hughes Medical Institute, Dallas, TX) in pT-Adv vector (from Clontech) were cloned into the expression vector pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG DNA non-responsive human 293 fibroblasts
10 (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

 Since NF- κ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al., *Mol Cell* 2:253-258 (1998); Muzio M et al., *J Exp Med* 187:2097-2101 (1998)), cells were transfected with hTLR9 or co-transfected with hTLR9 and a NF- κ B-driven luciferase reporter construct. Human fibroblast 293 cells were transiently transfected
15 with (Figure 1A) hTLR9 and a six-times NF- κ B-luciferase reporter plasmid (NF- κ B-luc, kindly provided by Patrick Baeuerle, Munich, Germany) or (Figure 1B) with hTLR9 alone. After stimulus with CpG-ODN (2006, 2 μ M, TCGTCGTTTTGTCGTTTTGTCGTT, SEQ ID NO:112), GpC-ODN (2006-GC, 2 μ M, TGCTGCTTTTGTGCTTTTGTGCTT, SEQ ID
20 NO:118), LPS (100 ng/ml) or media, NF- κ B activation by luciferase readout (8h, Figure 1A) or IL-8 production by ELISA (48h, Figure 1B) were monitored. Results are representative of three independent experiments. Figure 1 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

 Figure 2 demonstrates the same principle for the transfection of mTLR9. Human
25 fibroblast 293 cells were transiently transfected with mTLR9 and the NF- κ B-luc construct (Figure 2). Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG-DNA stimulation similar to hTLR4 reconstitution of LPS responses.

 To generate stable clones expressing human TLR9, murine TLR9, or either TLR9
30 with the NF- κ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates (2x10⁶ cells/plate) with 16 μ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH,

- 98 -

Cölbe, Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in **Figure 3**. The clones were also screened for IL-8 production or NF- κ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

- 5 293-hTLR9-luc: expressing human TLR9 and 6-fold NF- κ B-luciferase reporter
- 293-mTLR9-luc: expressing murine TLR9 and 6-fold NF- κ B-luciferase reporter
- 293-hTLR9: expressing human TLR9
- 293-mTLR9: expressing murine TLR9

- 10 **Figure 4** demonstrates the responsiveness of a stable 293-hTLR9-luc clone after stimulation with CpG-ODN (2006, 2 μ M), GpC-ODN (2006-GC, 2 μ M), Me-CpG-ODN (2006 methylated, 2 μ M; TZGTZGTTTTGTZGTTTTGTZGTT, Z = 5-methylcytidine, SEQ ID NO:128), LPS (100 ng/ml) or media, as measured by monitoring NF- κ B activation. Similar results were obtained utilizing IL-8 production with the stable clone 293-hTLR9.
- 15 293-mTLR9-luc were also stimulated with CpG-ODN (1668, 2 μ M; TCCATGACGTTTCCTGATGCT, SEQ ID NO:84), GpC-ODN (1668-GC, 2 μ M; TCCATGAGCTTCCTGATGCT, SEQ ID NO:85), Me-CpG-ODN (1668 methylated, 2 μ M; TCCATGAZGTTTCCTGATGCT, Z = 5-methylcytidine, SEQ ID NO:207), LPS (100 ng/ml) or media, as measured by monitoring NF- κ B activation (**Figure 5**). Similar results were
- 20 obtained utilizing IL-8 production with the stable clone 293-mTLR9. Results are representative of at least two independent experiments. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific manner. These cells can be used for screening of optimal ligands for innate immune responses driven by TLR9 in multiple species.

25

Example 3. Expression of soluble recombinant human TLR9 in yeast cells (*Pichia pastoris*)

- Human TLR9 cDNA coding for amino acids 1 to 811 was amplified by PCR using the primers 5'-ATAGAATTCAATAATGGGTTTCTGCCGCAGCGCCCT-3' (SEQ ID NO:194)
- 30 and 5'-ATATCTAGATCCAGGCAGAGGCGCAGGTC-3' (SEQ ID NO:195), digested with EcoRI and XbaI, cloned into the yeast expression vector pPICZB (Invitrogen, Groningen,

- 99 -

Netherlands) and transfected into yeast cells (*Pichia pastoris*). Clones were selected with the antibiotic zeozin and protein production of soluble human TLR9 was induced with methanol (see Figure 6: SDS-PAGE, Coomassie stained, arrow marks hTLR9; lane 1: supernatant of culture induced with methanol; lane 2: supernatant of culture not induced). Thus TLR9 protein can be isolated from transfectants and further utilized for protein studies and vaccination purposes.

Example 4. hTLR9 expression correlates with CpG-DNA responsiveness.

Bacterial DNA has been described as a mitogen for both murine and human B cells. Although LPS is also mitogenic for murine B cells, it is generally accepted that LPS is not a mitogen for human B cells. Figure 7 demonstrates that human B cells proliferate after stimulation with *E. coli* DNA or a CpG-ODN but not Dnase-digested *E. coli* DNA or a control GpC-ODN. Purified human B cells were stimulated with 50µg/ml *E. coli* DNA, a comparable amount of DNase I-digested *E. coli* DNA, 2µM CpG-ODN (2006), 2µM GpC-ODN (2006-GC) or 100 ng/ml LPS. B cell proliferation was monitored at day two by ³H-thymidine uptake. These data demonstrate that it was DNA within the *E. coli* DNA preparation that was mitogenic and that a CpG-motif within the ODN was required.

Human dendritic cells (DC) have been claimed to be responsive to CpG-DNA. While analyzing human dendritic cell responses to CpG-DNA, we noted that plasmacytoid DC (CD123+DC) produced IFN-α, TNF, GM-CSF, and IL-8 upon exposure to CpG-DNA but not to LPS (Figure 8 and unpublished data). The converse was true for stimulation of monocyte-derived dendritic cells (MDDC) (Figure 8 and unpublished data). Purified CD123+DC or MDDC were stimulated with 50µg/ml *E. coli* DNA, a comparable amount of DNase I-digested *E. coli* DNA, 2µM CpG-ODN (2006), 2µM GpC-ODN (2006-GC) or 100 ng/ml LPS (Figure 8). IL-8 and TNF concentration was determined by enzyme-linked immunosorbent assay (ELISA). The CD123+DC response was DNA- and CpG-motif restricted. Monocyte-derived dendritic cells (MDDC) however demonstrated the converse response pattern, a response to LPS but not CpG-DNA. Due to this segregated response we analyzed TLR expression.

We have shown that CpG-DNA utilizes the Toll/IL-1R (TIR) signal transduction pathway implying the need for a TIR domain in the CpG-DNA signaling receptor. Häcker H

- 100 -

et al., *J Exp Med* 192:595-600 (2000). It was further demonstrated that TLR9-deficient mice are non-responsive to CpG-ODN. Hemmi H et al., *Nature* 408:740-5. By semi-quantitative RT-PCR both B cells and CD123+ DC yielded positive signals for hTLR9 while MDDC, monocytes and T cells were weak to negative (Figure 9). The cDNAs were prepared from

5 monocyte-derived dendritic cells (MDDC), lane 1; purified CD14+ monocytes, lane 2; B cells, lane 3; CD123+ DC, lane 4; CD4+ T cells, lane 5; and CD8+ T cells, lane 6. cDNA amounts were normalized based on GAPDH amount determined by TAG-MAN PCR (Perkin-Elmer). RT-PCR was performed for 30 cycles on normalized cDNA diluted 1:5 for human TLR2, 4 and 9, while GAPDH was diluted 1:125. We also tested for hTLR2 and hTLR4

10 expression. MDDC and monocytes were positive while B cells, T cells and CD123+DC were weak to negative (Figure 9). Weak signals delivered by PCR could be explained by contaminating cells, however a strong positive signal implies expression. These data demonstrated a clear correlation between hTLR9 mRNA expression and B cell or CD123+DC responsiveness to CpG-DNA (Figures 7 and 8). A correlation could also be

15 shown for hTLR2 and hTLR4 expression and MDDC responsiveness to LPS (Figure 8). This data demonstrates that hTLR9 is a relevant receptor for CpG-DNA responses and that its expression determines responsiveness. If TLR9 expression could be modulated, agonism or antagonism of CpG-DNA responses could be achieved.

20 Example 5. Species specificity of TLR9 signaling

By iterative examination of the flanking sequences surrounding CG dinucleotides, CpG-motifs have been identified. Paradoxically, or by twist of nature, the human optimal CpG-motif, GTCGTT (SEQ ID NO:66), is different from the murine motif, GACGTT (SEQ ID NO:129). Human peripheral blood mononuclear cells (PBMC) (Figure 10A) and murine

25 splenocytes (Figure 10B) were stimulated with ODN 2006 (filled circle, TCGTCGTTTTGTCGTTTGTGCGTT, SEQ ID NO:112), ODN 2006-GC (open circle), ODN 1668 (filled triangle, TCCATGACGTTTCCTGATGCT, SEQ ID NO:84) or ODN 1668-GC (open triangle, TCCATGAGCTTCCTGATGCT, SEQ ID NO:85) at indicated concentrations and IL-12 production was monitored after 8 hours. Figure 10A shows that titration of the

30 optimal human ODN, 2006, on PBMC induces IL-12 production. The optimal murine sequence, 1668, however was much less effective in eliciting IL-12 from PBMC. The two

- 101 -

control CpC-ODNs were essentially negative. The converse was true for murine splenocytes (Figure 10B), in that the murine sequence induced optimal IL-12 while the human sequence was much less effective. It should also be noted that the K_{ac} (concentration of half-maximal activation) of murine splenocytes for 1668 was greater than human PBMC for 2006 (compare Fig. 10A to Fig. 10B).

Because stable TLR9 transfectants mirrored primary cell responsiveness to CpG-DNA (Figures 4 and 5), it was hypothesized that stable transfectants could potentially discern species-specific CpG-motifs through TLR9 receptors. Therefore 293-hTLR9-luc (expressing human TLR9 and 6-fold NF- κ B-luc reporter), 293-mTLR9-luc (expressing murine TLR9 and 6-fold NF- κ B-luc reporter), 293-hTLR9 (expressing human TLR9) and 293-mTLR9 (expressing murine TLR9) clones were tested for CpG-DNA motif responsiveness. Figure 11 shows titration curves for 2006 or 1668 and their controls versus either hTLR9 or mTLR9 cells. Depicted are both NF- κ B-driven luciferase and IL-8 production as readout. In both 293 hTLR9-luc and 293-mTLR9-luc cells stimulation with CpG-DNA resulted in NF- κ B activation, as determined by measurement of the induced expression of firefly luciferase under the control of a minimal promoter containing six tandem NF- κ B-binding sites. After lysis of the cells luciferase can be detected photometrically based on an enzymatic reaction by luciferase which creates photons. IL-8 production was monitored using enzyme-linked immunosorbent assay (ELISA). Figure 11 depicts clones stimulated with ODN 2006 (filled circle), ODN 2006-GC (open circle), ODN 1668 (filled triangle) or ODN 1668-GC (open triangle) at indicated concentrations and NF- κ B activation or IL-8 production were measured after 10 and 48 hours, respectively. Results shown in Figure 11 are representative of three independent experiments. Strikingly, CpG-motif sequence specificity was conferred in a species-specific manner by TLR9. Additionally, the half-maximal concentration for either 2006 or 1668 appears nearly the same as those determined on primary cells (compare Figure 10 and Figure 11). These data demonstrate that TLR9 is the CpG-DNA receptor and that exquisite specificity to CpG-DNA sequence is conferred by TLR9.

Example 6. Use of stable TLR9 clones to test responsiveness to substances other than phosphorothioate ODN

As described in the foregoing Examples, the stable TLR9 clones were initially

- 102 -

screened for fidelity of phosphorothioate CpG-ODN reactivity. The 293-hTLR9 cells demonstrated reactivity to CpG-DNA and not LPS in a CpG-motif dependent manner (Figures 4 and 5). In the present example the stable TLR9 transfectants were tested for responsiveness to additional DNAs. NF- κ B activation was monitored after stimulation with *E. coli* DNA (black bars) or *E. coli* DNA digested with DNase I (gray bars) in 293-hTLR9-luc cells. Figure 12 demonstrates an *E. coli* DNA dose-dependent induction of NF- κ B-driven luciferase expression to a level comparable to phosphorothioate CpG-ODN (Figure 11). Activity was destroyed by DNase I digestion, indicating specificity of response to DNA and not contaminant bacterial products. The stable TLR9 transfectants can be used to screen the activity of DNAs from various species or vector DNAs intended for immune system stimulation. In particular, TLR9 transfectants can be used to screen and compare the immunostimulatory activity of DNAs from various species of pathogens, DNA constructs, DNAs intended for use as vaccines, gene replacement therapeutics, and nucleic acid vectors.

293-hTLR9-luc cells also were stimulated with the phosphodiester variants of ODN 2006 (filled circle), ODN 2006-GC (open circle), ODN 1668 (filled triangle) or ODN 1668-GC (open triangle) at indicated concentrations, and NF- κ B activation was monitored after 12 hours (Figure 13A). Likewise, 293-mTLR9-luc cells were stimulated with the phosphodiester variants of ODN 2006 (filled circle), ODN 2006-GC (open circle), ODN 1668 (filled triangle) or ODN 1668-GC (open triangle) at indicated concentrations, and NF- κ B activation was monitored after 12 hours (Figure 13B). These assays show that the stable TLR9 transfectants responded to DNAs other than phosphorothioate-modified ODN. These data demonstrate the utility of stable TLR transfectants for screening for agonists of the TLR9 receptor.

Example 7. TLR9 determines CpG-ODN activity

Although 2006 and 1668 are discussed in terms of CpG-motif differences, they are very different in several aspects (see Table 5 for comparison). The lengths are different, 24 versus 20 nucleotides, and 2006 has four CG dinucleotides compared to one in 1668. Additional differences are the CG position relative to the 5' and 3' ends and also 5' sequence differences. In order to determine if motif specificity is a quality of the motif and not the global sequence environment, for this experiment several sequences were produced holding

- 103 -

these variables constant. As a starting point, the 1668 sequence was modified by converting the central C to T and the distal TG to CG, thereby creating a second CG in the resulting sequence 5000 (SEQ ID NO:130, Table 5). Then point nucleotide changes were made, progressing toward a 2006-like sequence, 5007 (SEQ ID NO:98). The ODN 5002 (SEQ ID NO:132) is most like 1668 with the exception that C's at positions 12 and 19 have been converted to T's. The last 16 nucleotides of ODN 5007 are the same as the last 15 nucleotides of 2006 with the exception of an additional T. The ODN concentration of half-maximal activation (K_{ac}) was determined by producing ODN titration curves using either 293-hTLR9-luc or 293-mTLR9-luc cells and NF- κ B-driven luciferase expression as a readout. Example curves are given in Figure 14. Stable transfectants 293-hTLR9-luc and 293-mTLR9-luc were stimulated with ODN 5002 (filled circle) or ODN 5007 (open circle) at indicated concentrations and NF- κ B activation was monitored after 12 hours. Results shown in Figure 14 are representative of three independent experiments. Values for K_{ac} for multiple ODN are given in Table 5. Similar results were obtained for those ODN tested with 293-hTLR9 and 293-mTLR9 cells utilizing IL-8 as readout.

Table 5. CpG-DNA sequence specificity of human and murine TLR9 signaling activity

CpG-DNA	Sequence	293-hTLR9 K_{ac} (nM)	293-mTLR9 K_{ac} (nM)	SEQ ID NO:
1668	TCCATGACGTTCTTGATGCT	>10,000	70	84
1668-GC	TCCATGAGCTTCCTGATGCT	>10,000	>10,000	85
2006	TCGTCGTTTTGTCGTTTTGTCGTT	400	>10,000	112
2006-GC	TGCTGCTTTTGTGCTTTTGTGCTT	>10,000	>10,000	118
5000	TCCATGACGTTCTTGACGCT	10,000	82	130
5001	TCCATGACGTTCTTGACGTT	7,000	55	131
5002	TCCATGACGTTCTTGATGTT	7,000	30	132
5003	TCCATGACGTTTTTGATGTT	10,000	30	133
5004	TCCATGTCGTTCTTGATGTT	5,000	400	134
5005	TCCATGTCGTTTTTGATGTT	3,000	2,000	135
5006	TCCATGTCGTTTTTGTTGTT	3,000	650	136
5007	TCCATGTCGTTTTTGTCGTT	700	1,000	98
5002	TCCATGACGTTCTTGATGTT	ND	30	132
5008	TCCATGACGTTATTGATGTT	ND	40	137
5009	TCCATGACGTCCTTGATGTT	ND	>10,000	138
5010	TCCATGACGTCATTGATGTT	ND	>10,000	139

- 104 -

In previous unpublished work by the inventors, it had been noted that a CA substitution converting the mouse CpG-motif from GACGTTC to GACGTCA was deleterious. To extend our examination of the motif, three more ODN were created to dissect this effect (5008-5010, SEQ ID NOs:137-139, Table 5).

5 The activity displayed by the 293-hTLR9-luc clone increased with progressive nucleotide substitutions converting the mouse sequence toward the human sequence (Table 5, sequences 5000-5007). The converse was true for the 293-mTLR9-luc clone, which showed highest activity for the mouse sequences. The originally hypothesized CpG-motif was purine-purine-CG-pyrimidine-pyrimidine. Most notable to motif definition as determined by TLR9
10 genetic complementation was the non-conservative pyrimidine for purine change A to T immediately 5' of the CG (Table 5). These changes improved 293-hTLR9-luc responsiveness but diminished 293-mTLR9-luc responsiveness. These results support the notion that the preferred mouse motif contains ACG while the preferred human sequence contains TCG. The conservative pyrimidine for pyrimidine change T to C in the mouse motif, ACGTT
15 versus ACGTC (5002 versus 5009), completely destroyed 293-mTLR9 responsiveness. Although not a complete iterative analysis of the CpG-motif, the data refine our understanding of the motif. More importantly these data strongly support direct CpG-motif engagement by TLR9.

20 **Example 8. Antagonist definition**

It has been demonstrated that DNA uptake and endosomal maturation are required for signal initiation by CpG-DNA. It has been hypothesized that in order for DNA to enter the endosomal/lysosomal compartment a non-CpG dependent uptake receptor may be required. 293 cells were transiently transfected with mTLR9 treated with either medium only or 1.0 μ M
25 CpG-ODN 1668 (Figure 15). Additionally the 1668-treated TLR9 transfectants were simultaneously exposed to various doses of a non-CpG ODN (PZ2; 5'-CTCCTAGTGGGGGTGTCCTAT-3', SEQ ID NO:43). IL-8 production was monitored after 48h by ELISA. Figure 15 shows that PZ2, in a dose-dependent manner, was able to antagonize the activation of TLR9-transfected cells stimulated with a CpG ODN.

30 Figure 16 demonstrates that the stable TLR9 transfectants, 293-hTLR9-luc cells, are sensitive to non-CpG-ODN blockade. 293-hTLR9-luc cells were incubated with CpG-ODN

- 105 -

(0.5 μ M) (black bars) or TNF- α (10 ng/ml) (gray bars) and increasing concentrations of a blocking ODN (5'-HHHHHHHHHHHHHHHHWGGGGG-3', SEQ ID NO:140; H = A, T, C; W = A, T) as indicated. NF- κ B activation was monitored after 12 hours and is presented as percent yields. Thus both mTLR9 and hTLR9 activity can be blocked by non-stimulatory ODN. The blockade is specific to blocking ODN since the TNF-driven NF- κ B signal was not diminished. Antagonism of CpG-DNA responses could thus be defined in stable TLR9 cells and therefore high throughput screening can be done for TLR9 antagonist.

Bafilomycin A poisons the proton pump needed for H⁺ transport into endosomes, which is required for endosomal maturation. Figure 17 shows that blockade of endosomal maturation in 293-hTLR9-luc cells fully blocks CpG-ODN induction of NF- κ B. 293-hTLR9-luc cells were preincubated with 10 nM Bafilomycin A (gray bars) or dimethylsulfoxide (DMSO) control (black bars) for 30 min and stimulated with CpG-ODN (2006, 0.5 μ M), IL-1 (10 ng/ml) or TNF- α (10 ng/ml) as indicated. NF- κ B activation was monitored after 12 hours and is presented as percent yields. The blockade was specific to CpG-DNA generated signal because both IL-1 and TNF induction of NF- κ B was unaffected. These data demonstrate that 293 cells stably complemented with hTLR9 behave in a manner similar to primary CpG-DNA responsive cells, in that cellular uptake and endosomal maturation are required for induction of signal by CpG-DNA. Thus the stable transfectants can be used as indicator for TLR9 drug antagonist.

CpG-DNA signaling appears to occur via a Toll/IL-1R-like pathway. It was shown in the mouse that CpG-DNA signaling is dependent on MyD88, IRAK and TRAF6. Häcker H et al., *J Exp Med* 192:595-600 (2000). Hemmi et al. demonstrated that mTLR9-deficient mice lack activation of IRAK upon CpG-ODN stimulation. Hemmi H et al., *Nature* 408:740-5 (2000). Figure 18 shows that CpG-DNA signaling via human TLR9 was MyD88 dependent. hTLR9 (293-hTLR9) was co-transfected with a six-times NF- κ B luciferase reporter plasmid and increasing concentrations of the dominant negative human MyD88 expression vector. Cells were not stimulated (filled circles), stimulated with CpG-ODN (2006, 2 μ M) (open circles) or TNF- α (10 ng/ml) (filled triangles) and NF- κ B activation was monitored after 12 hours. Results are representative of at least two independent experiments. Figure 18 demonstrates that dominant negative MyD88 blocks NF- κ B induction in 293-hTLR9 cells following CpG-DNA stimulation. The blockade of MyD88 did not affect NF-

- 106 -

κB induction via TNF induced signal transduction. In general these data confirm the central role of MyD88 to TLR signaling and specifically the role of MyD88 in CpG-DNA initiation of signal. Thus human cells transfected with TLR9 can be used as indicators to find molecules to antagonize CpG-DNA via genetic mechanisms.

5

Example 9. Antibody production

Peptides for human and mouse TLR9 were designed for coupling to a carrier protein and injected into rabbits to obtain anti-peptide polyclonal antisera. Mouse peptide 1 (mousepep1, see Table 4) can be found in EST aa197442 and peptide 2 (mousepep2, see
10 Table 4) in EST aa273731 and ai463056. Human peptide 1 (humanpep1, see Table 4) and peptide 2 (humanpep2, see Table 4) were taken from the published human sequence.

Three rabbit antisera were generated by this method: anti-mousepep1, specific for the extracellular domain of murine TLR9; anti-humanpep1, specific for the extracellular domain of hTLR9; and antisera against a combination of mousepep2 and humanpep2, specific for the
15 cytoplasmic domain of both murine and human TLR9. Immunoprecipitates with anti-FLAG antibody were electrophoresed by PAGE and, using standard Western blotting techniques, transferred to membrane and probed with the various antisera. Figure 19 shows the response to hTLR9-FLAG and mTLR9-FLAG. The TLR9 in these blots are indicated with arrows, while the lower molecular weight bands represent anti-FLAG antibody.

20

Example 10. Mutation adjacent to the CXXC-domain (hTLR9-CXXCm, mTLR9-CXXCh)

The CXXC motif resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g. methyl-CpG binding protein-1 (MBD-1).
25 Fujita N et al., *Mol Cell Biol* 20:5107-5118 (2000). Human and murine TLR9 contain two CXXC motifs. The CXXC domain is highly conserved between human and murine TLR9 but followed by 6 amino acids (aa) which differ quite substantially in polarity and size. By the use of a site-specific mutagenesis kit (Stratagene, La Jolla, CA, USA) these six amino acid residues (human: PRHFPQ 269-274); mouse: GQKSLH 269-274) were interchanged between
30 human and murine TLR9. These mutations were generated by the use of the primers 5'-CTGCATGGAGTGCGGCCAAAAGTCCCTCCACCTACATCCCGATAC-3' (SEQ ID

- 107 -

NO:141) and

5'-GTATCGGGATGTAGGTGGAGGGACTTTTGGCCGCACTCCATGCAG-3' (SEQ ID NO:142) for human TLR9 and the primers

5'-CTGTATAGAATGTCCTCGTCACCTCCCCCAGCTGCACCCTGAGAC-3' (SEQ ID

5 NO:143) and

5'-GTCTCAGGGTGCAGCTGGGGGAAGTGACGAGGACATTCTATACAG-3' (SEQ ID NO:144) for murine TLR9 according to the manufacturer's protocol.

	CXXC motif:	CXXCXXXXXXXXCXXC		SEQ ID NO:145
10	Wildtype hTLR9:	CRRCDHAPNPCMECPRHFPO	aa 255-274	SEQ ID NO:146
	hTLR9-CXXCm:	CRRCDHAPNPCMECGQKSLH	aa 255-274	SEQ ID NO:147
	Wildtype mTLR9:	CRRCDHAPNPCMICGQKSLH	aa 255-274	SEQ ID NO:148
	mTLR9-CXXCh:	CRRCDHAPNPCMICPRHFPO	aa 255-274	SEQ ID NO:149

- 15 For the stimulation of the hTLR9 variant hTLR9-CXXCm, 293 cells were transiently transfected with hTLR9 or hTLR9-CXXCm and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 20). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. The data show that hTLR9 can be improved by converting the human CXXC domain to the murine CXXC
- 20 domain. For the stimulation of the mTLR9 variant mTLR9-CXXCh, 293 cells were transiently transfected with mTLR9 or mTLR9-CXXCh and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 21). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. It appears that the human CXXC domain may diminish mTLR9-CXXCh activity relative to the
- 25 wild type mTLR9.

Example 11. Mutation in the MBD motif (hTLR9-MBDmut, mTLR9-MBDmut)

- The MBD motif is a domain recently described for CpG binding in the protein MBD-1. Fujita N et al., *Mol Cell Biol* 20:5107-5118 (2000); Ohki I et al., *EMBO J* 18:6653-6661
- 30 (1999). Human and murine TLR9 contain this motif at position 524-554 and 525-555, respectively.

- 108 -

MBD-1 R-XXXXXXXX-R-X-D-X-Y-XXXXXXXXXX-R-S-XXXXXX-Y SEQ ID NO:125
 hTLR9 Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXXX-R-L-XXXXXX-Y SEQ ID NO:126
 mTLR9 Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXXX-Q-L-XXXXXX-Y SEQ ID NO:127

5

The core of this domain consists of D-L-Y in human TLR9 (aa 534-536) and mouse TLR9 (aa 535-537). Through site-specific mutagenesis D534 and Y536 in human TLR9, and D535 and Y537 in murine TLR9, were mutated to alanines creating the sequence A-L-A for human (aa 534-536) and murine TLR9 (aa 535-537). These mutations were generated by the use of the
 10 primers 5'-CACAATAAGCTGGCCCTCGCCACGAGCACTC-3' (SEQ ID NO:150) and 5'-GAGTGCTCGTGGGCGAGGGCCAGCTTATTGTG-3' (SEQ ID NO:151) for human TLR9 and the primers 5'-CATAACAAACTGGCCTTGGCCCACTGGAAATC-3' (SEQ ID NO:152) and 5'-GATTTCCAGTGGGCCAAGGCCAGTTTGTATG-3' (SEQ ID NO:153) for murine TLR9 according to the manufacturer's protocol.

15 For the stimulation of mTLR9 variant, mTLR9-MBDmut, 293 cells were transiently transfected with mTLR9 or mTLR9-MBD-mut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 22). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. For the stimulation of hTLR9 variant, hTLR9-MBDmut, 293 cells were transiently transfected with hTLR9 or
 20 hTLR9-MBD-mut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 23). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. The disruption of the putative CpG binding domain DXY in TLR9 destroyed receptor activity. These data demonstrate that the MBD motif is most likely involved in CpG-DNA binding and can be thus be manipulated to better
 25 understand CpG-DNA binding and efficacy.

Example 12. Proline to Histidine mutation in the TIR-domain (hTLR9-PHmut, mTLR9-PHmut)

Toll-like receptors have a cytoplasmic Toll/IL-1 receptor (TIR) homology domain
 30 which initiates signaling after binding of the adapter molecule MyD88. Medzhitov R et al., *Mol Cell* 2:253-8 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15-8 (1999). Reports by

- 109 -

others have shown that a single-point mutation in the signaling TIR-domain in murine TLR4 (Pro712 to His) or human TLR2 (Pro681 to His) abolishes host immune response to lipopolysaccharide or gram-positive bacteria, respectively. Poltorak A et al., *Science* 282:2085-8 (1998); Underhill DM et al., *Nature* 401:811-5 (1999). Through site-specific mutagenesis the equivalent Proline at position 915 of human and murine TLR9 were mutated to Histidine (Pro915 to His). These mutations were generated by the use of the primers 5'-GCGACTGGCTGCATGGCAAACCCCTCTTTG-3' (SEQ ID NO:154) and 5'-CAAAGAGGGTTTTGCCATGCAGCCAGTCGC-3' (SEQ ID NO:155) for human TLR9 and the primers 5'-CGAGATTGGCTGCATGGCCAGACGCTCTTC-3' (SEQ ID NO:156) and 5'-GAAGAGCGTCTGGCCATGCAGCCAATCTCG-3' (SEQ ID NO:157) for murine TLR9 according to the manufacturer's protocol.

For the stimulation of mTLR9 variant, mTLR9-PHmut, 293 cells were transiently transfected with mTLR9 or mTLR9-PHmut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 22). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. For the stimulation of hTLR9 variant, hTLR9-PHmut, 293 cells were transiently transfected with hTLR9 or hTLR9-PHmut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 23). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. These data demonstrate that TLR9 activity can be destroyed by the Pro to His mutation. This mutation has the potential to be used as a dominant negative to block TLR9 activity thus a genetic variant could compete for ligand or signaling partners and disrupt signaling.

Example 13. Exchange of the TIR-domain between murine and human TLR9 (hTLR9-TIRm, mTLR9-TIRh)

Toll-like receptors have a cytoplasmic Toll/IL-1 receptor (TIR) homology domain that initiates signaling after binding of the adapter molecule MyD88. Medzhitov R et al., *Mol Cell* 2:253-8 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15-8 (1999). This is also true for TLR9. To generate molecules consisting of human extracellular TLR9 and murine TIR domain (hTLR9-TIRm) or murine extracellular TLR9 and human TIR domain (mTLR9-TIRh), the following approach was chosen. Through site-specific mutagenesis a ClaI

- 110 -

restriction site was introduced in human and murine TLR9. For human TLR9 the DNA sequence 5'-GGCCTCAGCATCTTT-3' (3026-3040, SEQ ID NO:158) was mutated to 5'-GGCCTATCGATTTTT-3' (SEQ ID NO:159), introducing a ClaI site (underlined in the sequence) but leaving the amino acid sequence (GLSIF, aa 798-802) unchanged. For murine

5 TLR9 the DNA sequence 5'-GGCCGTAGCATCTTC-3' (2434-2447, SEQ ID NO:160) was mutated to 5'-GGCCTATCGATTTTT-3' (SEQ ID NO:161), introducing a ClaI site and creating the amino acid sequence (GLSIF, aa 799-803) which differs in one position (aa 800) from the wildtype murine TLR9 sequence (GRSIF, aa 799-803) but is identical to the human sequence.

10 **hTLR9-TIRm.** The primers used for human TLR9 were 5'-CAGCTCCAGGGCCTATCGATTTTGCACAGGACC-3' (SEQ ID NO:162) and 5'-GGTCCTGTGCAAAAATCGATAGGCCCTGGAGCTG-3' (SEQ ID NO:163). For creating an expression vector containing the extracellular portion of human TLR9 connected to the murine TIR domain, the human expression vector was cut with ClaI and limiting amounts of

15 EcoRI and the fragment coding for the murine TIR domain generated by a ClaI and EcoRI digestion of murine TLR9 expression vector was ligated in the vector fragment containing the extracellular portion of hTLR9. Transfection into *E.coli* yielded the expression vector hTLR9-TIRm (human extracellular TLR9-murine TIR-domain).

mTLR9-TIRh. The primers used for murine TLR9 were 5'-

20 CAGCTGCAGGGCCTATCGATTTTCGCACAGGACC-3' (SEQ ID NO:164) and 5'-GGTCCTGTGCGAAAATCGATAGGCCCTGCAGCTG-3' (SEQ ID NO:165). For creating an expression vector containing the extracellular portion of murine TLR9 connected to the human TIR domain, the murine expression vector was cut with ClaI and limiting amounts of EcoRI and the fragment coding for the human TIR domain generated by a ClaI and EcoRI

25 digestion of human TLR9 expression vector was ligated in the vector fragment containing the extracellular portion of mTLR9. Transfection into *E.coli* yielded the expression vector mTLR9-TIRh (murine extracellular TLR9-human TIR-domain).

For the stimulation of the mTLR9 variant, mTLR9-TIRh, 293 cells were transiently transfected with mTLR9 or mTLR9-TIRh and stimulated after 16 hours with ODN 2006 and

30 ODN 1668 at concentrations indicated (Figure 24). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. For the stimulation of the

- 111 -

hTLR9 variant, hTLR9-TIRm, 293 cells were transiently transfected with hTLR9 or hTLR9-TIRm and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 25). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. Replacement of the murine TLR9-TIR domain with human does not significantly affect mTLR9 activity. Replacement of the human TLR9-TIR with murine however appears to have a negative effect on hTLR9. These data demonstrate that manipulations could be made to influence TLR9 activities.

Example 14. TLR9-fusion protein with green-fluorescent-protein (hTLR9-GFP, mTLR9-GFP)

Human and murine TLR9 were individually cloned into the vector pEGFP-N1 (Clontech, Palo Alto, CA, USA) to create expression vectors encoding human and murine fusion proteins consisting of an N-terminal TLR9 protein fused to C-terminal green-fluorescent protein (GFP). These constructs can be used to trace TLR9 localization and expression. Such detections can be used for staining in FACS analysis, confocal microscopy and Western blot, or for purification of polypeptides and subsequent antibody production.

Example 15. TLR9-fusion protein with FLAG-peptide (hTLR9-FLAG, mTLR9-FLAG)

Human and murine TLR9 were individually cloned into the vector pFLAG-CMV-1 (Sigma, St. Louis, MO, USA) to create expression vectors encoding human and murine fusion proteins consisting of an N-terminal leader peptide (preprotrypsin, which is cleaved intracellularly during processing of the protein), FLAG-peptide (DYKDDDDK) and TLR9 protein which does not contain its own signal peptide. These constructs can be used to trace TLR9 localization and expression, e.g., using anti-FLAG antibodies. Such detections can be used for staining in FACS analysis, confocal microscopy and Western blot, or for purification of polypeptides and subsequent antibody production.

Example 16. Method of cloning human TLR7

Two accession numbers in the GenBank database, AF245702 and AF240467, describe the DNA sequence for human TLR7. To create an expression vector for human TLR7, human TLR7 cDNA was amplified from a cDNA made from human peripheral mononuclear

- 112 -

blood cells (PBMC) using the primers 5'-CACCTCTCATGCTCTGCTCTCTTC-3' (SEQ ID NO:166) and 5'-GCTAGACCGTTTCCTTGAACACCTG-3' (SEQ ID NO:167). The fragment was cloned into pGEM-T Easy vector (Promega), cut with the restriction enzyme NotI and ligated into a NotI-digested pCDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence for hTLR7 is SEQ ID NO:168, is presented in Table 6. The open reading frame starts at base 124, ends at base 3273, and codes for a protein of 1049 amino acids. SEQ ID NO:169 (Table 7), corresponding to bases 124-3273 of SEQ ID NO:168 (Table 6), is the coding region for the polypeptide of SEQ ID NO:170 (Table 8).

The protein sequence of the cloned hTLR7 cDNA matches the sequence described under the GenBank accession number AF240467. The sequence deposited under GenBank accession number AF245702 contains two amino acid changes at position 725 (L to H) and 738 (L to P).

Table 6. cDNA Sequence for Human TLR7 (5' to 3'; SEQ ID NO:168)

15	agctggcctag cgttttaaacg ggccctctag actcgagcgg ccgcgaattc actagtgatt	60
	cacctctcat gctctgctct cttcaaccag acctctacat tccattttgg aagaagacta	120
	aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt taacataatc	180
	ctaatttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg tgatgtcact	240
20	ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt	300
	cctggaggta ttcccacgaa caccacgaac ctaccctca ccattaacca cataccagac	360
	atctccccag cgtcctttca cagactggac catctggtag agatcgattt cagatgcaac	420
	tgtgtacctt ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaaa	480
	cccagaagct ttagtggaact cacttattta aaatcccttt acctggatgg aaaccagcta	540
25	ctagagatac cgcagggcct ccgccttagc ttacagcttc tcagccttga ggccaacaac	600
	atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat actctacctg	660
	ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc	720
	ttcctaaact tgacaaagt aaagtgtc tccctgaaag ataacaatgt cacagccgtc	780
	cctactgitt tgccatctac tttaacagaa ctatatctct acaacaacat gattgcaaaa	840
30	atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct aagtggaaat	900
	tgccctcggt gttataatgc ccattttcct tgtgcgcgt gtaaaaataa ttctccccta	960
	cagatccctg taaatgcttt tgatgcgctg acagaattaa aagttttacg tctacacagt	1020
	aactctcttc agcatgtgcc cccaagatgg tttaagaaca tcaacaaact ccagggaactg	1080
	gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct gcattttctc	1140
35	cccagcctca tccaattgga tctgtctttc aattttgaac ttcaggtcta tcgtgcattc	1200
	atgaatctat cacaagcatt ttcttcactg aaaagcctga aaattctgcg gatcagagga	1260
	tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt	1320

- 113 -

	gaagttcttg	atcttggcac	taactttata	aaaattgcta	acctcagcat	gtttaaacia	1380
	tttaaaagac	tgaaagtcac	agatctttca	gtgaataaaa	tatcaccttc	aggagattca	1440
	agtgaagttg	gcttctgctc	aaatgccaga	acttctgtag	aaagttatga	accccaggtc	1500
	ctggaacaat	tacattatct	cagatatgat	aagtatgcaa	ggagttgcag	attcaaaaac	1560
5	aaagaggctt	ctttcatgtc	tgtaaatgaa	agctgctaca	agtatgggca	gaccttggat	1620
	ctaagtaaaa	atagtatatt	ttttgtcaag	tcctctgatt	ttcagcatct	ttctttcttc	1680
	aaatgcctga	atctgtcagg	aaatctcatt	agccaaaactc	ttaatggcag	tgaattccaa	1740
	ccttttagcag	agctgagata	tttggacttc	tccaacaacc	ggcttgattt	actccattca	1800
	acagcatttg	aagagcttca	caaaactggaa	gttctggata	taagcagtaa	tagccattat	1860
10	tttcaatcag	aaggaattac	tcatatgcta	aactttacca	agaacctaaa	ggttctgcag	1920
	aaactgatga	tgaacgacaa	tgacatctct	tcctccacca	gcaggaccat	ggagagttag	1980
	tctcttagaa	ctctggaatt	cagaggaaat	cacttagatg	ttttatggag	agaaggtagt	2040
	aacagatact	tacaattatt	caagaatctg	ctaaaattag	aggaattaga	catctctaaa	2100
	aattccctaa	gtttcttgcc	ttctggagtt	tttgatggta	tgctccaaa	tctaaagaat	2160
15	ctctctttgg	ccaaaaatgg	gctcaaatct	ttcagttgga	agaaactcca	gtgtctaaag	2220
	aacctggaaa	ctttggacct	cagccacaac	caactgacca	ctgtccctga	gagattatcc	2280
	aactgttcca	gaagcctcaa	gaatctgatt	cttaagaata	atcaaatcag	gagtctgacg	2340
	aagtattttc	tacaagatgc	cttcagttg	cgatatctgg	atctcagctc	aaataaaatc	2400
	cagatgatcc	aaaagaccag	cttcccagaa	aatgtcctca	acaatctgaa	gatgttgctt	2460
20	ttgcatcata	atcggtttct	gtgcacctgt	gatgctgtgt	ggtttgtctg	gtgggttaac	2520
	catacggagg	tgactattcc	ttacctggcc	acagatgtga	cttggtggg	gccaggagca	2580
	cacaagggcc	aaagtgtgat	ctccctggat	ctgtacacct	gtgagttaga	tctgactaac	2640
	ctgattctgt	tctcaacttc	catactgtga	tctctcttct	tcattggtgat	gatgacagca	2700
	agtcacctct	atttctggga	tgtgtggtat	atttaccatt	tctgtaaggc	caagataaag	2760
25	gggtatcagc	gtctaataatc	accagactgt	tgctatgatg	cttttattgt	gtatgacact	2820
	aaagaccag	ctgtgaccga	gtgggttttg	gctgagctgg	tggccaaact	ggaagacca	2880
	agagagaaac	attttaattt	atgtctcgag	gaaagggact	ggttaccagg	gcagccagtt	2940
	ctggaaaacc	tttcccagag	catacagctt	agcaaaaaga	cagtgtttgt	gatgacagac	3000
	aagtatgcaa	agactgaaaa	ttttaagata	gcattttact	tgtcccatca	gaggctcatg	3060
30	gatgaaaaag	ttgatgtgat	tatcttgata	tttcttgaga	agccttttca	gaagtccaag	3120
	ttctccagc	tccggaaaag	gctctgtggg	agttctgtcc	ttgagtgagg	aacaaacccg	3180
	caagctcacc	catacttctg	gcagtgtcta	aagaacgccc	tggccacaga	caatcatgtg	3240
	gcctatagtc	aggtgttcaa	ggaaacggtc	tagaatcgaa	ttcccgccgc	cgccactgtg	3300
	ctggatatct	gcagaattcc	accacactgg	actagtggat	ccgagctcgg	taccaagctt	3360
35	aagtttaaac	cgc					3373

Table 7. Coding Region for Human TLR7 (5' to 3'; SEQ ID NO:169)

	atggtgtttc	caatgtggac	actgaagaga	caaattctta	tcctttttta	cataatccta	60
	atttccaaac	tccttggggc	tagatggttt	cctaaaactc	tgccctgtga	tgtcactctg	120
40	gatgttccaa	agaaccatgt	gatcgtggac	tgcacagaca	agcatttgac	agaaattcct	180
	ggaggatattc	ccacgaacac	cacgaacctc	accctcacca	tttaaccacat	accagacatc	240

- 114 -

	tccccagcgt	cctttcacag	actggaccat	ctggtagaga	tcgatttcag	atgcaactgt	300
	gtacctat	cactggggtc	aaaaaacaac	atgtgcatca	agaggctgca	gattaaaccc	360
	agaagcttta	gtggactcac	ttatttaaaa	tccctttacc	tggatggaaa	ccagctacta	420
	gagataaccgc	agggcctccc	gcctagctta	cagcttctca	gccttgaggc	caacaacatc	480
5	ttttccatca	gaaaagagaa	tctaacagaa	ctggccaaca	tagaaatact	ctacctgggc	540
	caaaactgtt	attatcgaaa	tccttggtat	gtttcatatt	caatagagaa	agatgccttc	600
	ctaaacttga	caaagttaaa	agtgtctctc	ctgaaagata	acaatgtcac	agccgtccct	660
	actgttttgc	catctacttt	aacagaacta	tatctctaca	acaacatgat	tgcaaaaatc	720
	caagaagatg	attttaataa	cctcaaccaa	ttacaaatc	ttgacctag	tggaaattgc	780
10	cctcgttgtt	ataatgcccc	atttccttgt	gcgcctgtga	aaaataatc	tcccctacag	840
	atccctgtaa	atgcttttga	tgcgctgaca	gaattaaaag	ttttacgtct	acacagtaac	900
	tctcttcagc	atgtgcccc	aagatggttt	aagaacatca	acaaactcca	ggaactggat	960
	ctgtcccaaa	acttcttggc	caaagaaatt	gggatgcta	aatttctgca	ttttctcccc	1020
	agcctcatcc	aattggatct	gtctttcaat	tttgaacttc	aggtctatcg	tgcactatag	1080
15	aatctatcac	aagcattttc	ttcactgaaa	agcctgaaaa	ttctgcggat	cagaggatat	1140
	gtctttaaag	agttgaaaag	ccttaacctc	tgcctattac	ataatcttca	aaatcttgaa	1200
	gttcttgatc	ttggcactaa	ccttataaaa	attgctaacc	tcagcatgtt	taacaatttt	1260
	aaaagactga	aagtcataga	tctttcagtg	aataaaatat	caccttcagg	agattcaagt	1320
	gaagttggct	tctgctcaaa	tgcagaact	tctgtagaaa	gttatgaacc	ccaggctctg	1380
20	gaacaattac	attatttcag	atatgataag	tatgcaagga	gttgcagatt	caaaaacaaa	1440
	gaggcttctt	tcatgtctgt	taatgaaagc	tgtacaagt	atgggcagac	cttggatcta	1500
	agtaaaaata	gtatatTTTT	tgtcaagtcc	tctgattttc	agcatctttc	tttctctaaa	1560
	tgcctgaatc	tgtcaggaaa	tctcattage	caaactctta	atggcagtga	attccaacct	1620
	ttagcagagc	tgagatatTT	ggacttctcc	aacaaccggc	ttgatttact	ccattcaaca	1680
25	gcatttgaag	agcttcacaa	actggaagtt	ctggatataa	gcagtaatag	ccattatTTT	1720
	caatcagaag	gaattactca	tatgctaaac	tttaccaga	acctaaagg	tctgcagaaa	1800
	ctgatgatga	acgacaatga	catctcttcc	tccaccagca	ggaccatgga	gagtggagtct	1860
	cttagaactc	tgggaattcag	aggaaatcac	ttagatgttt	tatggagaga	aggtgataac	1920
	agatacttac	aattattcaa	gaatctgcta	aaattagagg	aattagacat	ctctaaaaat	1980
30	tccctaagtt	tcttgccttc	tggagtTTTT	gatggtatgc	ctocaaatct	aaagaatctc	2040
	tctttggcca	aaaatgggct	caaactcttc	agttggaaga	aaactcagtg	tctaaagaac	2100
	ctggaaaactt	tggacctcag	ccacaaccaa	ctgaccactg	tccctgagag	attatccaac	2160
	tgttccagaa	gcctcaagaa	tctgattctt	aagaataatc	aaatcaggag	tctgacgaag	2220
	tattttctac	aagatgcctt	ccagttgcga	tatctggatc	tcagctcaaa	taaaatccag	2280
35	atgatccaaa	agaccagctt	cccagaaaat	gtcctcaaca	atctgaagat	gttgcTTTTg	2340
	catcataatc	ggtttctgtg	cacctgtgat	gctgtgtgg	ttgtctgggtg	ggttaaccat	2400
	acggagggtga	ctattcctta	cctggccaca	gatgtgactt	gtgtggggcc	aggagcacac	2460
	aagggccaaa	gtgtgatctc	cctggatctg	tacacctgtg	agttagatct	gactaacctg	2520
	attctgttct	cactttccat	atctgtatct	ctctttctca	tgggtgatgat	gacagcaagt	2580
40	cacctctatt	tctgggatgt	gtggtatatt	taccatttct	gtaaggccaa	gataaagggg	2640
	tatcagcgtc	taatatcacc	agactgttgc	tatgatgctt	ttattgtgta	tgacactaaa	2700
	gacctcagctg	tgaccgagtg	ggttttggct	gagctgggtg	ccaaactgga	agacctcaaga	2760

- 115 -

gagaaacatt ttaatttatg tctcgaggaa agggactggt taccagggca gccagttctg 2820
 gaaaaccttt cccagagcat acagcttagc aaaaagacag tgtttgat gatagacaag 2880
 tatgcaaaga ctgaaaattt taagatagca ttttacttgt cccatcagag gtcctggat 2940
 gaaaaagttg atgtgattat cttgatattt cttgagaagc cttttcagaa gtccaagttc 3000
 5 ctccagctcc ggaaaaggct ctgtgggagt tctgtccttg agtggccaac aaacccgcaa 3060
 gctcacccat acttctggca gtgtctaaag aacgccctgg ccacagacaa tcatgtggcc 3120
 tatagtcagg tgttcaagga aacggtc 3147

Table 8. Amino Acid Sequence of Human TLR7

10	. : . : . : . : . : . :	60
AF240467.pep	MVFPMWTLKRQILILFNIIILISKLLGARWFPKTLPCDVTLDVPKNEHVIVDCTDKHLTEIP	60
hTLR7.pep	MVFPMWTLKRQILILFNIIILISKLLGARWFPKTLPCDVTLDVPKNEHVIVDCTDKHLTEIP	60
AF245702.pep	MVFPMWTLKRQILILFNIIILISKLLGARWFPKTLPCDVTLDVPKNEHVIVDCTDKHLTEIP	60
15	. : . : . : . : . : . :	120
AF240467.pep	GGIPTNTTNLTTLTNHIFDISPASFHRDLHLVEIDFRNCVPIPLGSKNNMCIKRLQIKP	120
hTLR7.pep	GGIPTNTTNLTTLTNHIFDISPASFHRDLHLVEIDFRNCVPIPLGSKNNMCIKRLQIKP	120
AF245702.pep	GGIPTNTTNLTTLTNHIFDISPASFHRDLHLVEIDFRNCVPIPLGSKNNMCIKRLQIKP	120
20	. : . : . : . : . : . :	180
AF240467.pep	RSFSGLYLKSLEYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYL	180
hTLR7.pep	RSFSGLYLKSLEYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYL	180
AF245702.pep	RSFSGLYLKSLEYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYL	180
25	. : . : . : . : . : . :	240
AF240467.pep	QNCYYRNPCYVSYSIEKDAFLNLTCLKVLSLKDNNTAVPTVLPSTLTLEYLYNNMIAKI	240
hTLR7.pep	QNCYYRNPCYVSYSIEKDAFLNLTCLKVLSLKDNNTAVPTVLPSTLTLEYLYNNMIAKI	240
AF245702.pep	QNCYYRNPCYVSYSIEKDAFLNLTCLKVLSLKDNNTAVPTVLPSTLTLEYLYNNMIAKI	240
30	. : . : . : . : . : . :	300
AF240467.pep	QEDDFNNLNQLQLLDLSGNCPRCYNAPFPAPCKNNSPLQIPVNAFDALTELKVLRLHSN	300
hTLR7.pep	QEDDFNNLNQLQLLDLSGNCPRCYNAPFPAPCKNNSPLQIPVNAFDALTELKVLRLHSN	300
AF245702.pep	QEDDFNNLNQLQLLDLSGNCPRCYNAPFPAPCKNNSPLQIPVNAFDALTELKVLRLHSN	300
35	. : . : . : . : . : . :	360
AF240467.pep	SLQHVPPRWFKNINKLQELDLSQNFLAKEIGDAKFLHFLPSLIQLDLSFNFELOVYRASM	360
hTLR7.pep	SLQHVPPRWFKNINKLQELDLSQNFLAKEIGDAKFLHFLPSLIQLDLSFNFELOVYRASM	360
AF245702.pep	SLQHVPPRWFKNINKLQELDLSQNFLAKEIGDAKFLHFLPSLIQLDLSFNFELOVYRASM	360
40	. : . : . : . : . : . :	420
AF240467.pep	NLSQAFSSLKSLKILIRIRGYVFKELKSFNLSPLHNLQNLEVLDLGTNFIKIANLSMFKQF	420
hTLR7.pep	NLSQAFSSLKSLKILIRIRGYVFKELKSFNLSPLHNLQNLEVLDLGTNFIKIANLSMFKQF	420
AF245702.pep	NLSQAFSSLKSLKILIRIRGYVFKELKSFNLSPLHNLQNLEVLDLGTNFIKIANLSMFKQF	420
45	. : . : . : . : . : . :	480

- 116 -

	AF240467.pep	KRLKVIDLSVNKISPSGDSSEVGFCNARTSVESYEPQVLEQLHYFRYDKYARSCRFXNK	480
	hTLR7.pep	KRLKVIDLSVNKISPSGDSSEVGFCNARTSVESYEPQVLEQLHYFRYDKYARSCRFXNK	480
	AF245702.pep	KRLKVIDLSVNKISPSGDSSEVGFCNARTSVESYEPQVLEQLHYFRYDKYARSCRFXNK	480
5		. : . : . : . : . : . : . : . :	540
	AF240467.pep	EASFMSVNESCYKYQQTLDLSKNSEFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP	540
	hTLR7.pep	EASFMSVNESCYKYQQTLDLSKNSEFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP	540
	AF245702.pep	EASFMSVNESCYKYQQTLDLSKNSEFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP	540
10		. : . : . : . : . : . : . : . :	600
	AF240467.pep	LAELRYLDPSNNRDLHLHSTAFEELHKLEVLDISSNSHYFQSEGITHTMLNFTKNLKVQK	600
	hTLR7.pep	LAELRYLDPSNNRDLHLHSTAFEELHKLEVLDISSNSHYFQSEGITHTMLNFTKNLKVQK	600
	AF245702.pep	LAELRYLDPSNNRDLHLHSTAFEELHKLEVLDISSNSHYFQSEGITHTMLNFTKNLKVQK	600
15		. : . : . : . : . : . : . : . :	660
	AF240467.pep	LMMNDNDISSSTSRTESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISK	660
	hTLR7.pep	LMMNDNDISSSTSRTESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISK	660
	AF245702.pep	LMMNDNDISSSTSRTESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISK	660
20		. : . : . : . : . : . : . : . :	720
	AF240467.pep	SLSFLPSGVFDGMPNPNLKNLSLAKNGLKSFWSKKLQCLKNLETLDLSHNQLTTVPERLSN	720
	hTLR7.pep	SLSFLPSGVFDGMPNPNLKNLSLAKNGLKSFWSKKLQCLKNLETLDLSHNQLTTVPERLSN	720
	AF245702.pep	SLSFLPSGVFDGMPNPNLKNLSLAKNGLKSFWSKKLQCLKNLETLDLSHNQLTTVPERLSN	720
25		. : . : . : . : . : . : . : . :	780
	AF240467.pep	CSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQXTSFPENVLNNLXMLLL	780
	hTLR7.pep	CSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQXTSFPENVLNNLXMLLL	780
	AF245702.pep	CSRSHKNLILKNNQIRSPTKYFLQDAFQLRYLDLSSNKIQMIQXTSFPENVLNNLXMLLL	780
30		. : . : . : . : . : . : . : . :	840
	AF240467.pep	HHRFLCTCDAVWFVWVWNHTEVTIPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNL	840
	hTLR7.pep	HHRFLCTCDAVWFVWVWNHTEVTIPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNL	840
	AF245702.pep	HHRFLCTCDAVWFVWVWNHTEVTIPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNL	840
35		. : . : . : . : . : . : . : . :	900
	AF240467.pep	ILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK	900
	hTLR7.pep	ILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK	900
	AF245702.pep	ILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK	900
40		. : . : . : . : . : . : . : . :	960
	AF240467.pep	DPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLNLSQSIQLSKKTVFVMTDK	960
	hTLR7.pep	DPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLNLSQSIQLSKKTVFVMTDK	960
	AF245702.pep	DPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLNLSQSIQLSKKTVFVMTDK	960
45		. : . : . : . : . : . : . : . :	1020
	AF240467.pep	YAKTENFKIAFYLSHQRLMDEKVDVILIIFLEKPPQKSKFLQLRKRLCGSSVLEWPTNPQ	1020

- 117 -

	hTLR7 .pep	YAKTENFKIAFYLSHQRLMDEKVDVI ILIFLEKPPQKSZFLQLRKRLCGSSVLEWPTNPQ	1020
	AF245702 .pep	YAKTENFKIAFYLSHQRLMDEKVDVI ILIFLEKPPQKSZFLQLRKRLCGSSVLEWPTNPQ	1020
		. : . : . : . : . : . : . : . : . :	1080
5	AF240467 .pep	AHPYFWQCLKNALATDNHVAYSQVFKETV	1049
	hTLR7 .pep	AHPYFWQCLKNALATDNHVAYSQVFKETV	1049
	AF245702 .pep	AHPYFWQCLKNALATDNHVAYSQVFKETV	1049

In Table 8 the sequences are assigned as follows: hTLR7.pep, SEQ ID NO:170;

10 AF240467.pep, SEQ ID NO:171; AF245702.pep, SEQ ID NO:172.

Example 17. Method of cloning the murine TLR7

Alignment of human TLR7 protein sequence with mouse EST database using tfasta yielded 4 hits with mouse EST sequences bb116163, aa266744, bb210780 and aa276879.

15 Two primers were designed that bind to aa266744 sequence for use in a RACE-PCR to amplify 5' and 3' ends of the murine TLR7 cDNA. The library used for the RACE PCR was a mouse spleen marathon-ready cDNA commercially available from Clontech. A 5' fragment with a length of 3000 bp obtained by this method was cloned into Promega pGEM-T Easy vector. After sequencing of the 5' end, additional primers were designed for amplification of

20 the complete murine TLR7 cDNA. The primer for the 5' end was obtained from the sequence of the 5' RACE product whereas the primer for the 3' end was selected from the mouse EST sequence aa266744.

Three independent PCR reactions were set up using a murine macrophage RAW264.7 (ATCC TIB-71) cDNA as a template with the primers 5'-

25 CTCCTCCACCAGACCTCTTGATTCC-3' (SEQ ID NO:208) and 5'-CAAGGCATGTCCTAGGTGGTGACATTC-3' (SEQ ID NO:209). The resulting amplification products were cloned into pGEM-T Easy vector and fully sequenced (SEQ ID NO:173; Table 9). The open reading frame of mTLR7 (SEQ ID NO:174; Table 10) starts at base 49, ends at base 3201 and codes for a protein of 1050 amino acids (SEQ ID NO:175; Table 11). To create an expression vector for murine TLR7 cDNA, pGEM-T Easy vector plus

30 mTLR7 inscrt was cut with NotI, the fragment isolated and ligated into a NotI digested pCDNA3.1 expression vector (Invitrogen).

Table 9. cDNA Sequence for Murine TLR7 (5' to 3'; SEQ ID NO:173)

- 118 -

	ATTCTCCTCC	ACCAGACCTC	TTGATTCCAT	TTTGAAAGAA	AACTGAAAAT	GGTGTTCG	60
	ATGTGGACAC	GGAAGAGACA	AATTTTGATC	TTTTTAAATA	TGCTCTTAGT	TTCTAGAGTC	120
	TTTGGGTTTC	GATGGTTTCC	TAAAACTCTA	CCTTGTGAAG	TTAAAGTAAA	TATCCCAGAG	180
	GCCCATGTGA	TCGTGGACTG	CACAGACAAG	CATTTGACAG	AAATCCCTGA	GGGCATTCCC	240
5	ACTAACACCA	CCAATCTTAC	CCTTACCATC	AACCACATAC	CAAGCATCTC	TCCAGATTCC	300
	TTCCGTAGGC	TGAACCATCT	GGAAGAAATC	GATTTAAGAT	GCAATTGTGT	ACCTGTTCTA	360
	CTGGGGTCCA	AAGCCAATGT	GTGTACCAAG	AGGCTGCAGA	TTAGACCTGG	AAGCTTTAGT	420
	GGACTCTCTG	ACTTAAAGC	CCTTTACCTG	GATGGAAACC	AACTTCTGGA	GATACCACAG	480
	GATCTGCCAT	CCAGCTTACA	TCTTCTGAGC	CTTGAGGCTA	ACAACATCTT	CTCCATCACG	540
10	AAGGAGAATC	TAACAGAACT	GGTCAACATT	GAAACACTCT	ACCTGGGTCA	AAACTGTTAT	600
	TATCGAAATC	CTTGCAATGT	TTCTATTCT	ATTGAAAAAG	ATGCTTTCCT	AGTTATGAGA	660
	AATTTGAAGG	TTCTCTCACT	AAAAGATAAC	AATGTCACAG	CTGTCCCCAC	CACTTTGCCA	720
	CCTAATTAC	TAGAGCTCTA	TCTTTATAAC	AATATCATT	AGAAAATCCA	AGAAAATGAT	780
	TTTAATAACC	TCAATGAGTT	GCAAGTTCTT	GACCTAAGTG	GAAATTGCCC	TCGATGTTAT	840
15	AATGTCCCAT	ATCCGTGTAC	ACCGTGTGAA	AATAATTCCC	CCTTACAGAT	CCATGACAAT	900
	GCTTTCAATT	CATTGACAGA	ATTAAAAGTT	TTACGTTTAC	ACAGTAATTC	TCTTCAGCAT	960
	GTGCCCCCAA	CATGGTTTAA	AAACATGAGA	AACCTCCAGG	AACTAGACCT	CTCCCCAAAC	1020
	TACTTGCCCA	GAGAAATTGA	GGAGGCCAAA	TTTTTGCAAT	TTCTTCCCAA	CCTTGTTGAG	1080
	TTGGATTTTT	CTTTCAATTA	TGAGCTGCAG	GTCTACCATG	CATCTATAAC	TTTACCACAT	1140
20	TCACTCTCTT	CATTGGAAAA	CTTGAAAAAT	CTGCGTGTCA	AGGGGTATGT	CTTTAAAGAG	1200
	CTGAAAAACT	CCAGCTTTTC	TGTATTGCAC	AAGCTTCCCA	GGCTGGAAGT	TCTTGACCTT	1260
	GGCACTAACT	TCATAAAAAT	TGCTGACCTC	AACATATTCA	AACATTTTGA	AAACCTCAAA	1320
	CTCATAGACC	TTTCAGTGAA	TAAGATATCT	CCTTCAGAAG	AGTCAAGAGA	AGTTGGCTTT	1380
	TGTCCTAATG	CTCAAACTTC	TGTAGACCGT	CATGGGCCCC	AGGTCTTGA	GGCCTTACAC	1440
25	TATTTCCGAT	ACGATGAATA	TGCACGGAGC	TGCAGGTTCA	AAAACAAAGA	GCCACCTTCT	1500
	TTCTTGCCCT	TGAATGCAGA	CTGCCACATA	TATGGGCAGA	CCTTAGACTT	AAGTAGAAAT	1560
	AACATATTTT	TTATTAAACC	TTCTGATTTT	CAGCATCTTT	CATTCTCTCA	ATGCCTCAAC	1620
	TTATCAGGAA	ACACCATGG	CCAAACTCTT	AATGGCAGTG	AACTCTGGCC	GTGAGAGAG	1680
	TTGCGGTACT	TAGACTTCTC	CAACAACCGG	CTTGATTTAC	TCTACTCAAC	AGCCTTTGAA	1740
30	GAGCTCCAGA	GTCTTGAAGT	TCTGGATCTA	AGTAGTAACA	GCCACTATTT	TCAAGCAGAA	1800
	GGAATTACTC	ACATGCTAAA	CTTTACCAAG	AAATTACGGC	TTCTGGACAA	ACTCATGATG	1860
	AATGATAATG	ACATCTCTAC	TTCGGCCAGC	AGGACCATGG	AAAGTGACTC	TCTTCGAATT	1920
	CTGGAGTTCA	GAGGCAACCA	TTTAGATGTT	CTATGGAGAG	CCGGTGATAA	CAGATACTTG	1980
	GACTTCTTCA	AGAATTTGTT	CAATTTAGAG	GTATTAGATA	TCTCCAGAAA	TTCCCTGAAT	2040
35	TCCTTGCCCT	CTGAGGTTT	TGAGGGTATG	CCGCCAAATC	TAAAGAATCT	CTCCTTGGCC	2100
	AAAAATGGGC	TCAAATCTTT	CTTTTGGGAC	AGACTCCAGT	TACTGAAGCA	TTTGGAATTT	2160
	TTGGACCTCA	GCCATAACCA	GCTGACAAAA	GTACCTGAGA	GATTGGCCAA	CTGTTCCAAA	2220
	AGTCTCACAA	CACGTATTCT	TAAGCATAAT	CAAATCAGGC	AATTGACAAA	ATATTTTCTA	2280
	GAAGATGCTT	TGCAATTGCG	CTATCTAGAC	ATCAGTTCAA	ATAAAATCCA	GGTCATTGAG	2340
40	AAGACTAGCT	TCCCAGAAAA	TGTCCTCAAC	AATCTGGAGA	TGTTGGTTTT	ACATCACAAT	2400
	CGCTTTCTTT	GCAACTGTGA	TGCTGTGTGG	TTTGTCTGGT	GGGTTAACCA	TACAGATGTT	2460
	ACTATTCCAT	ACCTGGCCAC	TGATGTGACT	TGTGTAGGTC	CAGGAGCACA	CAAAGGTCAA	2520

- 119 -

	AGTGTTCATAT	CCCTTGATCT	GTATACGTGT	GAGTTAGATC	TCACAAACCT	GATTCTGTTC	2580
	TCAGTTTCCA	TATCATCAGT	CCTCTTTCTT	ATGGTAGTTA	TGACAACAAG	TCACCTCTTT	2640
	TTCTGGGATA	TGTGGTACAT	TTATTTATTT	TGGAAAGCAA	AGATAAAGGG	GTATCAGCAT	2700
	CTGCAATCCA	TGGAGTCTTG	TTATGATGCT	TTTATTGTGT	ATGACACTAA	AAACTCAGCT	2760
5	GTGACAGAAT	GGGTTTTGCA	GGAGCTGGTG	GCAAAATTGG	AAGATCCAAG	AGAAAAACAC	2820
	TTCAATTGT	GTCTAGAAGA	AAGAGACTGG	CTACCAGGAC	AGCCAGTTCT	AGAAAACCTT	2880
	TCCCAGAGCA	TACAGCTCAG	CAAAAAGACA	GTGTTTGTGA	TGACACAGAA	ATATGCTAAG	2940
	ACTGAGAGTT	TTAAGATGGC	ATTTTATTTG	TCTCATCAGA	GGCTCCTGGA	TGAAAAAGTG	3000
	GATGTGATTA	TCTTGATATT	CTTGAAAAG	CCTCTTCAGA	AGTCTAAGTT	TCTTCAGCTC	3060
10	AGGAAGAGAC	TCTGCAGGAG	CTCTGTCTCT	GAGTGGCCTG	CAAATCCACA	GGCTCACCCA	3120
	TACTTCTGGC	AGTGCCTGAA	AAATGCCCTG	ACCACAGACA	ATCATGTGGC	TTATAGTCAA	3180
	ATGTTCAAGG	AAACAGTCTA	GCTCTCTGAA	GAATGTCACC	ACCTAGGACA	TGCCTTGAAT	3240
	CGA						3243

15 **Table 10. Coding Region for Murine TLR7 (5' to 3'; SEQ ID NO:174)**

	ATGGTGTTT	CGATGTGGAC	ACGGAAGAGA	CAAATTTTGA	TCTTTTAAA	TATGCTCTTA	60
	GTTTCTAGAG	TCTTTGGGTT	TCGATGGTTT	CCTAAACTC	TACCTTGTGA	AGTTAAAGTA	120
	AATATCCCAG	AGGCCCATGT	GATCGTGGAC	TGCACAGACA	AGCATTTGAC	AGAAATCCCT	180
	GAGGGCATT	CCACTAACAC	CACCAATCTT	ACCTTACCA	TCAACCACAT	ACCAAGCATC	240
20	TCTCCAGATT	CCTTCCGTAG	GCTGAACCAT	CTGGAAGAAA	TCGATTAAAG	ATGCAATTGT	300
	GTACCTGTTC	TACTGGGGTC	CAAAGCCAAT	GTGTGTACCA	AGAGGCTGCA	GATTAGACCT	360
	GGAAGCTTTA	GTGGACTCTC	TGACTTAAAA	GCCCTTTACC	TGGATGGAAA	CCAACCTCTG	420
	GAGATACCAC	AGGATCTGCC	ATCCAGCTTA	CATCTTCTGA	GCCTTGAGGC	TAACAACATC	480
	TTCTCCATCA	CGAAGGAGAA	TCTAACAGAA	CTGGTCAACA	TTGAAACACT	CTACCTGGGT	540
25	CAAACTGTT	ATTATCGAAA	TCCTTGCAAT	GTTTCCTATT	CTATTGAAAA	AGATGCTTTC	600
	CTAGTTATGA	GAAATTTGAA	GGTCTCTCA	CTAAAAGATA	ACAATGTCAC	AGCTGTCCCC	660
	ACCACTTTGC	CACCTAATTT	ACTAGAGCTC	TATCTTTATA	ACAATATCAT	TAAGAAAATC	720
	CAAGAAAATG	ATTTTAATAA	CCTCAATGAG	TTGCAAGTTC	TTGACCTAAG	TGGAAATTGC	780
	CCTCGATGTT	ATAATGTCCC	ATATCCGTGT	ACACCGTGIG	AAAATAATTC	CCCCTTACAG	840
30	ATCCATGACA	ATGCTTTCAA	TTCAATTGACA	GAATTAAGAG	TTTACGTTT	ACACAGTAAT	900
	TCTCTTCAGC	ATGTGCCCCC	AACATGGTTT	AAAAACATGA	GAAACCTCCA	GGAACCTAGC	960
	CTCTCCCAAA	ACTACTTGGC	CAGAGAAATT	GAGGAGGCCA	AATTTTTECA	TTTTCTTCCC	1020
	AACCTTGTTG	AGTTGGATT	TTCTTTCAAT	TATGAGCTGC	AGGTCTACCA	TGCATCTATA	1080
	ACTTTACCAC	ATTCACTCTC	TTCAATTGAA	AACCTGAAAA	TTCTGCGTGT	CAAGGGGTAT	1140
35	GTCTTTAAAG	AGCTGAAAAA	CTCCAGTCTT	TCTGTATTGC	AQAAGCTTCC	CAGGCTGGAA	1200
	GTTCTTGACC	TTGGCACTAA	CTTCATAAAA	ATTGCTGACC	TCAACATATT	CAAACATTTT	1260
	GAAAACCTCA	AACTCATAGA	CCTTTCAGTG	AATAAGATAT	CTCCTTCAGA	AGAGTCAAGA	1320
	GAAGTTGGCT	TTTGTCCCTAA	TGCTCAAAC	TCTGTAGACC	GTGATGGGCC	CCAGGTCTCT	1380
	GAGGCCCTTAC	ACTATTTCCG	ATACGATGAA	TATGCACGGA	GCTGCAGGTT	CAAAAACAAA	1440
40	GAGCCACCTT	CTTCTCTGCC	TTTGAATGCA	GACTGCCACA	TATATGGGCA	GACCTTAGAC	1500
	TTAAGTAGAA	ATAACATATT	TTTTATTAAA	CCTTCTGATT	TTCAGCATCT	TTCATTCCTC	1560

- 120 -

5	AAATGCCTCA	ACTTATCAGG	AAACACCATT	GGCCAAACTC	TTAATGGCAG	TGAACCTCGG	1620
	CCGTTGAGAG	AGTTGCGGTA	CTTAGACTTC	TCCAACAACC	GGCTTGATTT	ACTCTACTCA	1680
	ACAGCCTTTG	AAGAGCTCCA	GAGTCTTGAA	GTTCTGGATC	TAAGTAGTAA	CAGCCACTAT	1740
	TTTCAAGCAG	AAGGAATTAC	TCACATGCTA	AACTTTACCA	AGAAATTACG	GCTTCTGGAC	1800
	AAACTCATGA	TGAATGATAA	TGACATCTCT	ACTTCGGCCA	GCAGGACCAT	GGAAAGTGAC	1860
	TCTCTTCGAA	TTCTGGAGTT	CAGAGGCAAC	CATTTAGATG	TTCTATGGAG	AGCCGGTGTAT	1920
	AACAGATACT	TGGACTTCTT	CAAGAATTTG	TTCAATTTAG	AGGTATTAGA	TATCTCCAGA	1980
	AATTCCCTGA	ATTCCCTTGC	TCCTGAGGTT	TTTGAGGGTA	TGCCGCCAAA	TCTAAAGAAT	2040
10	CTCTCCTTGG	CCAAAAATGG	GCTCAAATCT	TTCTTTTGGG	ACAGACTCCA	GTTACTGAAG	2100
	CATTTGGAAA	TTTTGGACCT	CAGCCATAAC	CAGCTGACAA	AAGTACCTGA	GAGATTGGCC	2160
	AACTGTTCCA	AAAGTCTCAC	AACACTGATT	CTTAAGCATA	ATCAAATCAG	GCAATTGACA	2220
	AAATATTTTC	TAGAAGATGC	TTTGCAATTG	CGCTATCTAG	ACATCAGTTC	AAATAAAATC	2280
	CAGGTCAATC	AGAAGACTAG	CTTCCCAGAA	AATGTCCTCA	ACAATCTGGA	GATGTTGGTT	2340
	TTACATCACA	ATCGCTTTCT	TTGCAACTGT	GATGCTGTGT	GGTTTGTCTG	GTGGGTTAAC	2400
	CATACAGATG	TTACTATTCC	ATACCTGGCC	ACTGATGTGA	CTTGTTGATG	TCCAGGAGCA	2460
	CACAAAGGTC	AAAGTGTCT	ATCCCTTGAT	CTGTATACGT	GTGAGTTAGA	TCTCACAAAC	2520
15	CTGATTCTGT	TCTCAGTTTC	CATATCATCA	GTCTCTTTTC	TTATGGTAGT	TATGACAACA	2580
	AGTCACCTCT	TTTTCTGGGA	TATGTGGTAC	ATTTATTATT	TTTGAAAAGC	AAAGATAAAG	2640
	GGGTATCAGC	ATCTGCAATC	CATGGAGTCT	TGTTATGATG	CTTTTATTGT	GTATGACACT	2700
	AAAAACTCAG	CTGTGACAGA	ATGGGTTTTG	CAGGAGCTGG	TGCAAAAATT	GGAAGATCCA	2760
	AGAGAAAAAC	ACTTCAATTT	GTGTCTAGAA	GAAAGAGACT	GGCTACCAGG	ACAGCCAGTT	2820
	CTAGAAAAAC	TTTCCCAGAG	CATACAGCTC	AGCAAAAAGA	CAGTGTTTGT	GATGACACAG	2880
	AAATATGCTA	AGACTGAGAG	TTTTAAGATG	GCATTTTATT	TGTCTCATCA	GAGGCTCCTG	2940
	GATGAAAAAG	TGGATGTGAT	TATCTTGATA	TTCTTGAAAA	AGCCTCTTCA	GAAGTCTAAG	3000
25	TTTCTTCAGC	TCAGGAAGAG	ACTCTGCAGG	AGCTCTGTCC	TTGAGTGGCC	TGCAAAATCCA	3060
	CAGGCTCACC	CATACTTCTG	GCAGTGCCTG	AAAAATGCCC	TGACCACAGA	CAATCATGTG	3120
	GCTTATAGTC	AAATGTTCAA	GGAAACAGTC				3150

Table 11. Amino Acid Sequences of Murine TLR7 and Human TLR7

30		. : . : . : . : . : . :	60
	hTLR7.pep	MVFPMWTLKRQILILFNIIILISKLLGARWFPKTLPCDVTLDVPKNHVIVECTIDKHLTEIP	60
	mTLR7.pep	MVFSMWTRKRQILIFLNMLLSRVVFGFRWFPKTLPCEVKVNIFEAHVIVDCTDKHLTEIP	60
35		. : . : . : . : . : . :	120
	hTLR7.pep	GGIPTNTTNLTLTINHIPIDISPASFRRLDHLVEIDFRNCVPIPLGSKNNMCIKRLQIKP	120
	mTLR7.pep	EGIPTNTTNLTLTINHIPIISPDSPFRRLNHLEEDLRNCVPIVLLGSKANVCTKRLQIRP	120
40		. : . : . : . : . : . :	180
	hTLR7.pep	RSFSGLTYLKSLYLDGNQLLEIPIQGLPPSLQLLSLEANNIFSIRKENLTELANIETLYLG	180
	mTLR7.pep	GSFSGLSDLKALYLDGNQLLEIPIQDLPSLHLLSLEANNIFSITKENLTELVNIETLYLG	180
		. : . : . : . : . : . :	240
	hTLR7.pep	QNCYYRNPCYVSYSIEKDAFLNLTCLKVLSLKDNNVTAVPTVLPSTLTELYLYNNMIAKI	240

- 121 -

	mTLR7.pep	QNCYYRNPCNVSYSEKDAFLVMRNKLVLSLKONNVTAVPPTLPPNLLBLVLYNNIIKKI	240
		. : . : . : . : . : . : . : . : . :	300
	hTLR7.pep	QEDDFNNLNQLQILDLSGNCPRCYNAPFPCAPCKNNSPLQIPVNAFDALTELKVLRLHSN	300
5	mTLR7.pep	QENDFNNLNELQVLDLSGNCPRCYNVPYPCIPCENNNSPLQIHDAFNLSLTELKVLRLHSN	300
		. : . : . : . : . : . : . : . : . :	360
	hTLR7.pep	SLQHVPPRWFKNINKLQELDLSQNPLAKEIGDAKFLHFLPSLIQLDLSFNZELQVYRASM	360
10	mTLR7.pep	SLQHVPPPTWFKNMRNLQELDLSQNYLAREIKRAKFLHFLPNLVELDFSFNYELQVYHASI	360
		. : . : . : . : . : . : . : . : . :	420
	hTLR7.pep	NLSQAFSSLKSLKILRIRGYVFKELKSFNLSPLHNLQNLLEVLDLGTNFIKIANLSMFKQF	420
	mTLR7.pep	TLPHSLSSLENLKILRVKGYVFKELKNSSLSVLHKLPRLEVLDLGTNFIKIADLNIFKHF	420
		. : . : . : . : . : . : . : . : . :	480
15	hTLR7.pep	KRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYRQVLSQLHYFRYDKYARSCRFFKNK	480
	mTLR7.pep	ENLKLIDLSVNKISPSSEESREVGFCPNAQTSDVRHGPQVL3ALHYFRYDEYARSCRFFKNK	480
		. : . : . : . : . : . : . : . : . :	540
20	hTLR7.pep	EA-SFMSVNESCYKYGQTLDSLKNSIFFVKSSDFQHL5FLKCLNLSGNLISQTLNGSEFQ	539
	mTLR7.pep	EPPSFPLPLNADCHIYGQTLDSLNRNIIFFIKPSDFQHL5FLKCLNLSGKTIGQTLNGSELW	540
		. : . : . : . : . : . : . : . : . :	600
	hTLR7.pep	PLAELRYLDFSNNRDLHLHSTAFEEHLKLEVLDISSNSHYFQSEGITHMLNFTKNLKVQL	599
25	mTLR7.pep	PLRELRYLDFSNNRDLHLYSTAFEEHQ5LEVLDISSNSHYFQAEGITHMLNFTKKLRLLD	600
		. : . : . : . : . : . : . : . : . :	660
	hTLR7.pep	KLMMNDNDISSSTSRMTSESRLTLEFRGNHLDVLWRAGDNRYLQLFKNLKLEELDISK	659
30	mTLR7.pep	KLMMNDNDISTSASRTMESDSLRILEFRGNHLDVLWRAGDNRYLDDFFKNLFNLEVLDISR	660
		. : . : . : . : . : . : . : . : . :	720
	hTLR7.pep	NSLSFLPSGVFDGMPNPKNL5LAKNGLKSF5WKQLQCLKNLETLDLSHNQLTTVPERLS	719
	mTLR7.pep	NSLNSLPPEVFEGMPNPKNL5LAKNGLKSF5WDRLQLLKHLEIIDL5HNQLTKVPERLA	720
		. : . : . : . : . : . : . : . : . :	780
35	hTLR7.pep	NCSRLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFFENVLNNLMMLL	779
	mTLR7.pep	NCSKSLTTLILKNNQIRQLTKYFLEDALQLRYLDLSSNKIQVIQKTSFFENVLNNLEMLV	780
		. : . : . : . : . : . : . : . : . :	840
40	hTLR7.pep	LHENRFLCTCDVWVFWVWVNHTEVTIPYLATDVT5CVGPGAHKGQSVISLDLYTCFLDLTN	839
	mTLR7.pep	LHENRFLCNCDAVWVFWVWVNHTEVTIPYLATDVT5CVGPGAHKGQSVISLDLYTCFLDLTN	840
		. : . : . : . : . : . : . : . : . :	900
	hTLR7.pep	LILFSL5ISVSLFLMVMMTASHLY5WDVWYTYHFC5AKIKGYQRLISPDCCYDAFIVYDT	899
45	mTLR7.pep	LILF5SV5ISSVFLMVMMTSHL5FWDMWYIY5FW5AKIKGYQHLQSMESCYDAFIVYDT	900

- 123 -

under the GenBank accession number AF245703. The sequence deposited under GenBank accession number AF246971 contains an insertion at the N-terminus of 15 amino acids (MKESLQNSSCSLGKETKK; SEQ ID NO:185) and three single amino acid changes at positions 217 (P to S), 266 (L to P) and 867 (V to I).

5

Table 12. cDNA Sequence for Human TLR8 (5' to 3'; SEQ ID NO:182)

	gctcccgcc gccatggcgg ccgcggaat tcgattctgc gctgctgcaa gttacggaat	60
	gaaaaattag aacaacagaa acatggaaaa catgttcctt cagtcgtcaa tgctgacctg	120
	cattttcctg ctaatatctg gttcctgtga gttatgcgcc gaagaaaatt tttctagaag	180
10	ctatccttgt gatgagaaaa agcaaaatga ctcaagttatt gcagagtgcg gcaatcgtcg	240
	actacaggaa gttccccaaa cgggtgggcaa atatgtgaca gaactagacc tgtctgataa	300
	tttcatcaca cacataacga atgaatcatt tcaagggtcg caaaatctca ctaaaataaa	360
	tctaaaccac aaccccaatg tacagcacca gaacggaaat cccggtatac aatcaaatgg	420
	cttgaatatc acagacgggg cattcctcaa cctaaaaaac ctaagggagt tactgcttga	480
15	agacaaccag ttaccccaaa taccctctgg ttgcccagag tctttgacag aacttagtct	540
	aattcaaaac aatatataca acataactaa agagggcatt tcaagactta taaacttgaa	600
	aaatctctat ttggcctgga actgctatct taacaaagtt tgcgagaaaa ctaacataga	660
	agatggagta tttgaaacgc tgacaaatct ggagttgcta tcaactatct tcaattctct	720
	ttcacacgtg ccacccaaac tgccaagctc cctacgcaaa ctttttctga gcaacacca	780
20	gatcaaatac attagtgaag aagatttcaa gggattgata aatttaacat tactagattt	840
	aagcgggaac tgtccgaggt gcttcaatgc cccatttcca tgcgtgcctt gtgatggtgg	900
	tgcttcaatt aatatagatc gttttgcttt tcaaaaactg acccaacttc gatacctaaa	960
	cctctctagc acttccctca ggaagattaa tgcgtgctgg tttaaaaata tgcctcatct	1020
	gaagggtgctg gatcttgaat tcaactatct agtgggagaa atagcctctg gggcattttt	1080
25	aacgatgctg ccccgcttag aaatacttga cttgtctttt aactatataa aggggagtta	1140
	tccacagcat attaatatct ccagaaactt ctctaaactt ttgtctctac gggcattgca	1200
	tttaagaggt tatgtgttcc aggaactcag agaagatgat ttccagcccc tgatgcagct	1260
	tccaaactta tcgactatca acttgggtat taattttatt aagcaaatcg atttcaaact	1320
	tttccaaaat ttctccaatc tggaaattat ttacttgtca gaaaacagaa tatcacggtt	1380
30	ggtaaaagat acccggcaga gttatgcaaa tagttcctct tttcaacgtc atatccggaa	1440
	acgacgtcga acagattttg agtttgacct acattogaac ttttatcatt tcacccgtcc	1500
	tttaataaag ccacaatgtg ctgcttatgg aaaagcctta gatttaagcc tcaacagtat	1560
	tttcttcatt gggccaaacc aatttgaaaa tcttctctgac attgacctgt taaatctgtc	1620
	tgcaaatagc aatgctcaag tgtaagtgg aactgaattt tcagccattc ctcatgtcaa	1680
35	atatttggat ttgacaaaca atagactaga ctttgataat gctagtgtc ttactgaatt	1740
	gtccgacttg gaagttctag atctcagcta taattcacac tatttcagaa tagcaggcgt	1800
	aacacatcat ctagaattta ttcaaaatct cacaatctta aaagttttaa acttgagcca	1860
	caacaacatt tatactttta cagataagta taacctggaa agcaagtccc tggtagaatt	1920
	agttttcagt ggcaatcgcc ttgacatctt gtggaatgat gatgacaaca ggtatatctc	1980
40	cattttcaaa ggtctcaaga atctgacacg tctggattta tcccttaata ggctgaagca	2040

- 124 -

	catcccaa	at	gaagcattcc	ttaatttgcc	agcgagtc	ctc	actgaactac	atataaatga	2100
	taat	atgttta	aagtttttta	actggacatt	actccagcag	tttctctg	tc	cgagttgct	2160
	tgacttac	gt	ggaaacaaac	tactcttttt	aactgatagc	ctatctgact	ttacatcttc		2220
	ccttcggaca	ct	gtctgctga	gtcataacag	gatttcccac	ctacctctg	gctttctttc		2280
5	tgaagtcagt	agt	ctgaagc	acctcgattt	aagttccaat	ctgctaaaa	caatcaacaa		2340
	atccgcactt	gaa	actaaga	ccaccaccaa	attatctatg	ttggaactac	acggaaaccc		2400
	ctttgaatgc	acct	gtgaca	ttggagattt	ccgaagatgg	atggatgaac	atctgaatgt		2460
	caaaattccc	agact	ggtag	atgtcatttg	tgccagtcct	ggggatcaaa	gagggaagag		2520
	tattgtgagt	ctgg	agctaa	caacttgtgt	ttcagatgtc	actgcagtga	tattattttt		2580
10	cttcacgttc	tttat	cacca	ccatggttat	gttggctgcc	ctggctcacc	atttgtttta		2640
	ctgggatgtt	tgg	tttatat	ataatgtgtg	tttagctaag	gtaaaaggct	acaggtctct		2700
	ttccacatcc	caaa	ctttct	atgatgctta	catttcttat	gacaccaaag	acgcctctgt		2760
	tactgactgg	gtgata	aatg	agctgcgcta	ccaccttgaa	gagagccgag	acaaaaacgt		2820
	tctcctttgt	ctag	aggaga	gggaltggga	cccgggattg	gccatcatcg	acaacctcat		2880
15	gcagagcatc	aaccaa	agca	agaaaacagt	atttgtttta	accaaaaaat	atgcaaaaag		2940
	ctggaacttt	aaa	acagctt	tttacttggc	tttgcaagg	ctaattggatg	agaacatgga		3000
	tgtgattata	tttat	cctgc	tggagccagt	gttacagcat	tctcagtatt	tgaggctacg		3060
	gcagcggatc	tgt	aagagct	ccatcctcca	gtggcctgac	aaccggaagg	cagaaggctt		3120
	gttttgga	caa	actctgagaa	atgtggtctt	gactgaaaat	gattcacggt	ataacaatat		3180
20	gtatgtcgat	tccat	taagc	aatactaact	gacgttaagt	catgatttcg	cgcaatcact		3240
	agtgaattcg	cggc	cgctg	caggtcgacc	atatgggaga	gtccccaacg	cgttggatgc		3300
	atagcttgag								3310

Table 13. Coding Region for Human TLR8 (5' to 3'; SEQ ID NO:183)

25	atggaaaaca	tg	tctcttca	gtcgtcaatg	ctgacctgca	ttttctctgct	aatatctgg	60
	tctgtgagt	tat	gcgccga	agaaaatttt	tctagaagct	atccttgtga	tgagaaaaag	120
	caaaatgact	cag	ttattgc	agagtgcagc	aatcgtcgac	tacaggaagt	tccccaaacg	180
	gtgggcaaat	at	gtgacaga	actagacctg	tctgataaatt	tcatcacaca	cataacgaat	240
	gaatcatttc	aagg	gctgca	aaatctcact	aaaataaatc	taaaccacaa	ccccaatgta	300
30	cagcaccaga	ac	ggaatcc	cggatatacaa	tcaaattggct	tgaatatcac	agacggggca	360
	ttctcaacc	t	aaaaaacct	aaggagggtta	ctgcttgaag	acaaccagtt	accccaata	420
	ccctctgggt	t	gccagagtc	tttgacagaa	cttagtctaa	ttcaaaacaa	tatatacaac	480
	ataactaaag	ag	ggcatttc	aagacttata	aacttgaaaa	atctctattt	ggcctggaac	540
	tgctatttta	ac	aaagt	tg	cgagaaaact	aacatagaag	atggagtatt	600
35	acaaatttgg	ag	ttgctatc	actatctttc	aattctcttt	cacacgtgcc	acccaaactg	660
	ccaagctccc	tac	gcaaaact	ttttctgagc	aacaccacga	tcaaatacat	tagtgaagaa	720
	gatttcaagg	gatt	gataaaa	tttaacatta	ctagattttaa	gcgggaactg	tccgaggtgc	780
	ttcaatgccc	catt	tccatg	cgtgccttgt	gatgggtggg	cttcaattaa	tatagatcgt	840
	tttgcttttc	aaa	acttgac	ccaacttcga	tacctaaacc	tctctagcac	ttccctcagg	900
40	aagattaatg	ct	gcctgggt	t	aaaaatatg	cctcatctga	aggtgctgga	960
	aactatttag	t	gggagaaat	agcctctggg	gcatttttaa	cgatgctgcc	ccgcttagaa	1020

- 125 -

	ataacttgact	tgtcttttaa	ctatataaag	gggagttatc	cacagcatat	taatatattcc	1080
	agaaacttct	ctaaactttt	gtctctacgg	gcattgcatt	taagaggtta	tgtgttccag	1140
	gaactcagag	aagatgattt	ccagccctcg	atgcagcttc	caaacttatc	gactatcaac	1200
	ttgggtatta	attttattaa	gcaaatcgat	ttcaaacttt	tccaaaattt	ctccaatctg	1260
5	gaaattattt	acttgtcaga	aaacagaata	tcaccgttgg	taaaagatac	ccggcagagt	1320
	tatgcaaata	gttcctcttt	tcaacgtcat	atccggaaac	gacgctcaac	agattttgag	1380
	tttgaccac	attcgaactt	ttatcatttc	acccgtcctt	taataaagcc	acaatgtgct	1440
	gcttatggaa	aagccttaga	tttaagcctc	aacagtattt	tcttcattgg	gccaaaccaa	1500
	tttgaaaatc	ttctgacat	tgctgttcta	aatctgtctg	caaatagcaa	tgctcaagtg	1560
10	ttaagtggaa	ctgaattttc	agccattcct	catgtcaaat	atttggtatt	gacaaacaat	1620
	agactagact	ttgataatgc	tagtgctctt	actgaattgt	ccgacttgga	agttctagat	1680
	ctcagctata	attcacacta	tttcagaata	gcaggcgtaa	cacatcatct	agaatttatt	1740
	caaaatttca	caaatctaaa	agttttaaac	ttgagccaca	acaacattta	tactttaaca	1800
	gataagtata	acctggaaag	caagtcctcg	gtagaattag	ttttcagtgg	caatcgcttt	1860
15	gacattttgt	ggaatgatga	tgacaacagg	tatatctcca	ttttcaaagg	tctcaagaat	1920
	ctgacacgtc	tggattttatc	ccttaatagg	ctgaagcaca	tcccaaata	agcatttcct	1980
	aatttgccag	cgagtctcac	tgaactacat	ataaatgata	atatgttaaa	gttttttaac	2040
	tggacattac	tccagcagtt	tctctgtctc	gagttgcttg	acttacgtgg	aaacaaacta	2100
	ctctttttta	ctgatagcct	atctgacttt	acatcttccc	ttcggacact	gctgctgagt	2160
20	cataacagga	tttcccacct	acctctctgg	tttctttctg	aagtcagtag	tctgaagcac	2220
	ctcgatttaa	gttccaatct	gctaaaaaca	atcaacaaat	ccgcacttga	aactaagacc	2280
	accaccaaat	tatctatggt	ggaactacac	ggaaaccctt	ttgaatgcac	ctgtgacatt	2340
	ggagatttcc	gaagatggat	ggatgaacat	ctgaatgtca	aaattcccag	actggttagat	2400
	gtcattttgtg	ccagtcctgg	ggatcaaaga	gggaagagta	ttgtgagttc	ggagctaaca	2460
25	acttgtgttt	cagatgtcac	tgcagtgata	ttatttttct	tcacgttctt	tatcaccacc	2520
	atggttatgt	tggctgcctt	ggctcaccat	ttgttttact	gggatgtttg	gtttatatat	2580
	aatgtgtgtt	tagctaaggt	aaaaggctac	aggtctcttt	ccacatccca	aactttctat	2640
	gatgcttaca	tttcttatga	caccaaaagac	gcctctgtta	ctgactgggt	gataaatgag	2700
	ctgcgctacc	accttgaaga	gagccgagac	aaaaacgttc	tcctttgtct	agaggagagg	2760
30	gatttgggacc	cgggattggc	catcatcgac	aacctcatgc	agagcatcaa	ccaaagcaag	2820
	aaaacagtat	ttgttttaac	caaaaaatat	gcaaaaagct	ggaacttta	aacagctttt	2880
	tacttggctt	tgcagaggct	aatggatgag	aacatggatg	tgattatatt	tatcctgctg	2940
	gagccagtg	tacagcattc	tcagtatttg	aggctacggc	agcggatctg	taagagctcc	3000
	atcctccagt	ggcctgacaa	cccgaaggca	gaaggcttgt	tttggcaaac	tctgagaaat	3060
35	gtggtcttga	ctgaaaatga	ttcacgggat	aacaatatgt	atgtcgattc	cattaagcaa	3120
	tac						3123

Table 14. Amino Acid Sequence of Human TLR8

	.	:	.	:	.	:	.	:	.	:	.	:	60
40	AF245703.pep			MENMFLQSSMLTCTI	PLLISGSC	ELCAEENF	SRSYP	CDEKKQN					42
	htLR8.pep			MENMFLQSSMLTCTI	PLLISGSC	ELCAEENF	SRSYP	CDEKKQN					42
	AF246971.pep	MKESSLQNSSCSL	GKETK	KKENMFLO	SSMLTCTI	PLLISGSC	ELCAEENF	SRSYP	CDEKKQN				60

	AF245703.pep	DSVIAECSNRRLQEVFQTVGKYVTELDLSDNFIITHITNESFQGLQNLTKINLNHNPNVQH	102
	hTLR8.pep	DSVIAECSNRRLQEVFQTVGKYVTELDLSDNFIITHITNESFQGLQNLTKINLNHNPNVQH	102
5	AF246971.pep	DSVIAECSNRRLQEVFQTVGKYVTELDLSDNFIITHITNESFQGLQNLTKINLNHNPNVQH	120
			180
	AF245703.pep	QNGNPGIQSNGLNITDGAFLNLKKNLRELLLEDNQLPQIPSGLPESLTELSIIQNNIYNIT	162
	hTLR8.pep	QNGNPGIQSNGLNITDGAFLNLKKNLRELLLEDNQLPQIPSGLPESLTELSIIQNNIYNIT	162
10	AF246971.pep	QNGNPGIQSNGLNITDGAFLNLKKNLRELLLEDNQLPQIPSGLPESLTELSIIQNNIYNIT	180
			240
	AF245703.pep	KEGISRLINLNKLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLP	222
	hTLR8.pep	KEGISRLINLNKLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLP	222
15	AF246971.pep	KEGISRLINLNKLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVSPKLP	240
			300
	AF245703.pep	SLRKFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFCVPCDGGASINIDRFA	282
	hTLR8.pep	SLRKFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFCVPCDGGASINIDRFA	282
20	AF246971.pep	SLRKFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFCVPCDGGASINIDRFA	300
			360
	AF245703.pep	FQNLTLRLYNLSSTSLRKINAAWFKNMPHLKVLDFEFNYLVGEIASGAFLTMLPRLEIL	342
	hTLR8.pep	FQNLTLRLYNLSSTSLRKINAAWFKNMPHLKVLDFEFNYLVGEIASGAFLTMLPRLEIL	342
25	AF246971.pep	FQNLTLRLYNLSSTSLRKINAAWFKNMPHLKVLDFEFNYLVGEIASGAFLTMLPRLEIL	360
			420
	AF245703.pep	DLSFNYYKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQPLNLSTINLG	402
	hTLR8.pep	DLSFNYYKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQPLNLSTINLG	402
30	AF246971.pep	DLSFNYYKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQPLNLSTINLG	420
			480
	AF245703.pep	INFIKQIDFKLFQNFNSLEIIYLSNRIPLVKDTRQSYANSSSFQRHIRKRRSTDPEFD	462
	hTLR8.pep	INFIKQIDFKLFQNFNSLEIIYLSNRIPLVKDTRQSYANSSSFQRHIRKRRSTDPEFD	462
35	AF246971.pep	INFIKQIDFKLFQNFNSLEIIYLSNRIPLVKDTRQSYANSSSFQRHIRKRRSTDPEFD	480
			540
	AF245703.pep	PHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLANSNAQVLS	522
	hTLR8.pep	PHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLANSNAQVLS	522
40	AF246971.pep	PHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLANSNAQVLS	540
			600
	AF245703.pep	GTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLLEVLDLSYNSHYFRIAGVTHHLEFIQN	582
	hTLR8.pep	GTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLLEVLDLSYNSHYFRIAGVTHHLEFIQN	582
45	AF246971.pep	GTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLLEVLDLSYNSHYFRIAGVTHHLEFIQN	600

In Table 14 the sequences are assigned as follows: hTLR8.p_{ep}, SEQ ID NO:184; AF245703.p_{ep}, SEQ ID NO:186; and AF246971.p_{ep}, SEQ ID NO:187.

Example 19. Method of cloning the murine TLR8

- 128 -

Alignment of human TLR8 protein sequence with mouse EST database using tfasta yielded 1 hit with mouse EST sequence bf135656. Two primers were designed that bind to bf135656 sequence for use in a RACE-PCR to amplify 5' and 3' ends of the murine TLR8 cDNA. The library used for the RACE PCR was a mouse spleen marathon-ready cDNA commercially available from Clontech. A 5' fragment with a length of 2900 bp and a 3' fragment with a length of 2900 bp obtained by this method were cloned into Promega pGEM-T Easy vector. After sequencing of the 5' end and 3' end of each fragment, partial sequences of mTLR8 were obtained and allowed the design of primers for amplification of the complete murine TLR8 cDNA.

Three independent PCR reactions were set up using a spleen murine cDNA from Clontech as a template with the primers 5'-GAGAGAAACAAACGTTTTACCTTC-3' (SEQ ID NO:188) and 5'-GATGGCAGAGTCGTGACTTCCC-3' (SEQ ID NO:189). The resulting amplification products were cloned into pGEM-T Easy vector, fully sequenced, translated into protein, and aligned to the human TLR8 protein sequence (GenBank accession number AF245703). The cDNA sequence for mTLR8 is SEQ ID NO:190, presented in Table 15. The open reading frame of mTLR8 starts at base 59, ends at base 3157, and codes for a protein of 1032 amino acids. SEQ ID NO:191 (Table 16), corresponding to bases 59-3154 of SEQ ID NO:190 (Table 15), is the coding region for the polypeptide of SEQ ID NO:192 (Table 17). To create an expression vector for murine TLR8, cDNA pGEM-T Easy vector with the mTLR8 insert was cut with NotI, the fragment isolated, and ligated into a NotI-digested pCDNA3.1 expression vector (Invitrogen).

Table 15. cDNA Sequence for Murine TLR8 (5' to 3'; SEQ ID NO:190)

	attcagagtt	ggatgttaag	agagaaacaa	acgtttttacc	ttcctttgtc	tatagaacat	60
25	ggaaaacatg	ccccctcagt	catggattct	gacgtgcttt	tgtctgctgt	cctctggaac	120
	cagtgccatc	ttccataaag	cgaactatc	cagaagctat	ccttgtgacg	agataaggca	180
	caactccctt	gtgattgcag	aatgcaacca	togtcaactg	catgaagttc	cccaactat	240
	aggcaagtat	gtgacaaaca	tagacttgct	agacaatgcc	attacacata	taacgaaaga	300
	gtcctttcaa	aagctgcaaa	acctcactaa	aatcgatctg	aaccacaatg	ccaaacaaca	360
30	gcacccaaat	gaaaataaaa	atggtatgaa	tattacagaa	ggggcacttc	tcagcctaag	420
	aaatctaaca	gttttactgc	tggagacaa	ccagttatat	actatacctg	ctgggttgcc	480
	tgagtctttg	aaagaactta	gcctaattca	aaacaatata	tttcaggtaa	ctaaaaacaa	540
	cacttttggg	cttaggaact	tggaaagact	ctatttgggc	tggaaactgct	attttaaatg	600
	taatcaaacc	tttaaggtag	aagatggggc	atttaaaaat	cttatacact	tgaaggtagt	660

- 129 -

	ctcattatct	ttcaataacc	ttttctatgt	gcccccaaaa	ctaccaagtt	ctctaaggaa	720
	actttttctg	agtaatgcc	aaatcatgaa	catcactcag	gaagacttca	aaggactgga	780
	aaatttaaca	ttactagatc	tgagtggaaa	ctgtccaagg	tgttacaatg	ctccatttcc	840
	ttgcacacct	tgcaaggaaa	actcatccat	ccacatacat	cctctggctt	ttcaaagtct	900
5	cacccaactt	ctctatctaa	acctttccag	cacttccctc	aggacgatcc	cttctacctg	960
	gtttgaaaat	ctgtcaaata	tgaaggaaat	ccatcttgaa	ttcaactatt	tagttcaaga	1020
	aattgacctg	ggggcatttt	taacaaaact	accagtttta	caaatacctg	atttgccttt	1080
	caactttcaa	tataaggaat	atttacaatt	tattaatatt	tctctaaaat	tctctaagct	1140
	tcgttctctc	aagaagttgc	acttaagagg	ctatgtgttc	cgagaactta	aaaagaagca	1200
10	tttcgagcat	ctccagagtc	ttccaaactt	ggcaaccatc	aacttgggca	ttaactttat	1260
	tgagaaaatt	gatttcaaag	ctttccagaa	tttttccaaa	ctcgacgtta	tctattttatc	1320
	aggaaatcgc	atagcatctg	tattagatgg	tacagattat	tctctctggc	gaaatcgctc	1380
	tcggaaacct	ctctcaacag	acgatgatga	gtttgatcca	cacgtgaatt	tttaccatag	1440
	caccaaacct	ttaataaagc	cacagtgtac	tgtttatggc	aaggccttgg	atttaagttt	1500
15	gaacaatatt	ttcattattg	ggaaaagcca	atttgaaggt	tttcaggata	tcgcctgctt	1560
	aatctgtccc	ttcaatgcc	atactcaagt	gtttaatggc	acagaattct	cctccatgcc	1620
	ccacattaaa	tatttggtat	taaccaacaa	cagactagac	tttgatgata	acaatgcttt	1680
	cagtgtatct	cacgatctag	aagtgtctgga	cctgagccac	aatgcacact	atttcagtat	1740
	agcaggggta	acgcaccgtc	taggatttat	ccagaactta	ataaacctca	gggtgttaaa	1800
20	cctgagccac	aatggcattt	acaccctcac	agaggaaagt	gagctgaaaa	gcatctcact	1860
	gaaagaattg	gttttcagt	gaaatcgtct	tgaccatttg	tggaaatgca	atgatggcaa	1920
	atactggccc	attttttaaa	gtctccagaa	tttgatacgc	ctggacttat	catacaataa	1980
	ccttcaacaa	atcccaaata	gagcattcct	caatttgcct	cagagcctcc	aagagttact	2040
	tatcagtggg	aacaaattac	gtttctttta	ttggacatta	ctccagtatt	ttctcacct	2100
25	tcacttgcct	gatttatcga	gaaatgagct	gtattttcta	cccaattgcc	tatctaagtt	2160
	tgacatttcc	ctggagacac	tgctactgag	ccataatcat	ttctctcacc	tacctctctg	2220
	cttctctctc	gaagccagga	atctgggtgca	cctggatcta	agtttcaaca	caataaagat	2280
	gatcaataaa	tctctcctgc	aaaccaagat	gaaaacgaac	ttgtctattc	tggagctaca	2340
	tgggaactat	tttgactgca	cgtgtgacat	aagtgttttt	cgaagctggc	tagatgaaaa	2400
30	tctgaatata	acaattccta	aattggtaaa	tgttatatgt	tccaatcctg	gggatcaaaa	2460
	atcaaagagt	atcatgagcc	tagatctcac	gacttgtgta	tcggatacca	ctgcagctgt	2520
	cctgtttttc	ctcacattcc	ttaccacctc	catggttatg	ttggctgctc	tggttcacca	2580
	cctgtttttac	tgggatgttt	ggtttatcta	tcacatgtgc	tctgctaagt	taaaaggcta	2640
	caggacttca	tccacatccc	aaactttcta	tgatgcttat	atttcttatg	acaccaaaga	2700
35	tgcatctggt	actgactggg	taatcaatga	actgcgctac	caccttgaag	agagtgaaga	2760
	caaaagtgtc	ctcctttgtt	tagaggagag	ggattgggat	ccaggattac	ccatcattga	2820
	taacctcatg	cagagcataa	accagagcaa	gaaaacaata	tttgttttaa	ccaagaaata	2880
	tgccaagagc	tggaaacttta	aaacagcttt	ctacttggcc	ttgcagaggc	taatggatga	2940
	gaacatggat	gtgattatgt	tcacctcctc	ggaaccagt	ttacagtact	cacagtacct	3000
40	gaggcttcgg	cagaggatct	gtaagagctc	catcctccag	tggcccaaca	atcccaaagc	3060
	agaaaacttg	ttttggcaaa	gtctgaaaaa	tgtggtcttg	actgaaaatg	attcacggta	3120
	tgacgatttg	tacattgatt	ccattaggca	atactagtga	tgggaagtca	cgactctgcc	3180

- 130 -

atcataaaaa cacacagctt ctccctacaa tgaaccgaat

3220

Table 16. Coding Region for Murine TLR8 (5' to 3'; SEQ ID NO:191)

	atggaaaaaca	tgccccctca	gtcatggatt	ctgacgtgct	tttgtctgct	gtcctctgga	60
5	accagtgcc	tctccataa	agcgaactat	tccagaagct	atccttgtga	cgagataaag	120
	cacaactccc	ttgtgattgc	agaatgcaac	catcgtcaac	tgcatgaagt	tccccaact	180
	ataggcaagt	atgtgacaaa	catagacttg	tcagacaatg	ccattacaca	tataacgaaa	240
	gagtcctttc	aaaagctgca	aaacctcact	aaaatcgatc	tgaaccacaa	tgccaaacaa	300
	cagcacccaa	atgaaaataa	aatgggtatg	aatattacag	aaggggact	tctcagccta	360
10	agaaatctaa	cagttttact	gctggaagac	aaccagttat	atactatacc	tgctgggttg	420
	cctgagtctt	tgaaagaact	tagcctaatt	caaaacaata	tatttcaggt	aactaaaaac	480
	aacacttttg	ggcttaggaa	cttggaaga	ctctatttgg	gctggaactg	ctattttaaa	540
	tgtaatcaaa	cctttaaggt	agaagatggg	gcatttaaaa	atcttataca	cttgaaggta	600
	ctctcattat	ctttcaataa	ccttttctat	gtgcccccca	aactaccaag	ttctctaagg	660
15	aaactttttc	tgagtaatgc	caaatcatg	aacatcactc	aggaagactt	caaaggactg	720
	gaaaatttaa	cattactaga	tctgagtgg	aactgtccaa	ggtgttaca	tgctccattt	780
	ccttgccac	cttgcaagga	aaactcatcc	atccacatac	atcctctggc	ttttcaaagt	840
	ctcaccaca	ttctctatct	aaacctttcc	agcacttccc	tcaggacgat	tccttctacc	900
	tggtttgaaa	atctgtcaaa	tctgaaggaa	ctccatcttg	aattcaacta	tttagttcaa	960
20	gaaattgcct	cgggggcatt	tttaacaaaa	ctaccagtt	tacaaatcct	tgatttgtcc	1020
	ttcaactttc	aatataagga	atatttaca	tttattaata	tttctcaaa	tttctctaag	1080
	cttcgttctc	tcaagaagtt	gcacttaaga	ggctatgtgt	tccgagaact	taaaaaaag	1140
	catttcgagc	atctccagag	tcttccaaac	ttggcaacca	tcaacttggg	cattaacttt	1200
	attgagaaaa	ttgatttcaa	agctttccag	aatttttcca	aactcgacgt	tatctattta	1260
25	tcaggaaatc	gcatagcac	tgtattagat	ggtacagatt	attcctcttg	gcgaaatcgt	1320
	cttcggaaac	ctctctcaac	agacgatgat	gagtttgatc	cacacgtgaa	tttttaccat	1380
	agcaccaaac	ctttaataaa	gccacagtgt	actgcttatg	gcaaggcctt	ggatttaagt	1440
	ttgaacaata	ttttcattat	tgggaaaagc	caatttgaag	gttttcagga	tatcgcttgc	1500
	ttaaatctgt	ccttcaatgc	caatactcaa	gtgtttaatg	gcacagaatt	ctctctcatg	1560
30	ccccacatta	aatatttgg	tttaaccaac	aacagactag	actttgatga	taacaatgct	1620
	ttcagtgatc	ttcacgatct	agaagtgtcg	gacctgagcc	acaatgcaca	ctatttcagt	1680
	atagcagggg	taacgcaccg	tctaggattt	atccagaact	taataaacct	cagggtgtta	1740
	aacctgagcc	acaatggcat	ttacaccctc	acagaggaaa	gtgagctgaa	aagcatctca	1800
	ctgaaagaat	tggttttcag	tggaaatcgt	cttgaccatt	tgtggaatgc	aatgatggc	1860
35	aaatactggg	ccatttttaa	aagtctccag	aatttgatac	gcctggactt	atcatacaat	1920
	aaccttcaac	aatcccaaa	tggagcattc	ctcaatttgc	ctcagagcct	ccaagagtta	1980
	cttatcagtg	gtaacaaatt	acgtttcttt	aattggacat	tactccagta	ttttctcac	2040
	cttcacttgc	tggattttatc	gagaaatgag	ctgtattttc	tacccaattg	cctatctaag	2100
	tttgacatt	ccctggagac	actgctactg	agccataatc	atctctctca	cctaccctct	2160
40	ggcttctct	ccgaagccag	gaatctggtg	cacctggatc	taagtttcaa	cacaataaag	2220
	atgatcaata	aatcctccct	gcaaaccaag	atgaaaacga	acttgtctat	tctggagcta	2280

5	catgggaact	atttttgactg	cacgtgtgac	ataagtgtatt	ttcgaagctg	gctagatgaa	2340
	aatctgaata	tcacaattcc	taaattggta	aatgtttatat	gttccaatcc	tggggatcaa	2400
	aaatcaaaga	gtatcatgag	cctagatctc	acgacttgtg	tatcgggatac	cactgcagct	2460
	gtcctgtttt	tcctcacatt	ccttaccacc	tcctatgggta	tgttggtctg	tctgggtcac	2520
	cacctgtttt	actgggatgt	ttggtttatc	tatcacatgt	gctctgctaa	gttaaaaggc	2580
	tacaggactt	catccacatc	ccaaactttc	tatgatgctt	atatttctta	tgacacccaa	2640
	gatgcatctg	ttactgactg	ggtaatcaat	gaactgcgct	accaccttga	agagagttaa	2700
	gacaaaagtg	tcctcctttg	tttagaggag	agggatggg	atccaggatt	acccatcatt	2760
10	gataacctca	tgcagagcat	aaaccagagc	aagaaaacaa	tctttgtttt	aaccaagaaa	2820
	tatgccaaaga	gctggaactt	taaaacagct	ttctacttgg	ccttgagag	gctaattgat	2880
	gagaacatgg	atgtgattat	tttcatcctc	ctggaaccag	tgttacagta	ctcacagtac	2940
	ctgaggcttc	ggcagaggat	ctgtaagagc	tcctatcctc	agtggcccaa	caatcccaaa	3000
	gcagaaaact	tgttttggca	aagtctgaaa	aatgtgggtc	tgactgaaaa	tgattcacgg	3060
	tatgacgatt	tgtacattga	ttccattaga	caatac			3096

Table 17. Amino Acid Sequences of Murine TLR8 and Human TLR8

[illegible]

- 132 -

		. : . : . : . : . : . :	480
	mTLR8.pep	LDVIYLSGNRIASVLDGT--DY--SSWRNRLRKPLSTDDDEFDPHVNFYHSTKPLIKPQ	469
	hTLR8.pep	LEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDF-EFDPHSNFYHFTRPLIKPQ	478
5		. : . : . : . : . : . :	540
	mTLR8.pep	CTAYGKALDLSLNNIFIIGKSQFEGFQDIACLNLSFNANTQVFNGTEFSSMPHIKYLDLT	529
	hTLR8.pep	CAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLT	538
		. : . : . : . : . : . :	600
10	mTLR8.pep	NNRLDFFDNNAFSDLHDLEVLDSLHNAHYFSIAGVTHRLGFIONLINLRVLNLSHNGIYT	589
	hTLR8.pep	NNRLDFDNASALTELSDEVLDSLNSHYFRIAGVTHLEFIQNTNLKVLNLSINNIYT	598
		. : . : . : . : . : . :	660
	mTLR8.pep	LTESELKSISLKELVFSGNRLDHLWNANDGKYWSIFKSLQNLIRLDLSYNNLQQIPNGA	649
15	hTLR8.pep	LTDKYNLESKSLVELVFGNRLDILWDDDNRYISIFKGLKNIATRIIDLNLRIKHIPNEA	658
		. : . : . : . : . : . :	720
	mTLR8.pep	FLNLPQSLQELLISGNKLRFFNWTLQYFPHLHLLDLRNELYFLPNCLSKFAHSLETLL	709
	hTLR8.pep	FLNLPASLTELHINDNMLKFFNWTLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRITLL	718
20		. : . : . : . : . : . :	780
	bf135656.pep	NHPSHLPSGFLSEARNLVHLDLSYNTIKMINKSSIQTKMKTNLSILELHGNYFDCTC	57
	mTLR8.pep	LSHNHPSHLPSGFLSEARNLVHLDLSFNTIKMINKSSIQTKMKTNLSILELHGNYFDCTC	769
	hTLR8.pep	LSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTKL SMLLEHGKPFECTC	778
25		. : . : . : . : . : . :	840
	bf135656.pep	DISDFRSWLDENLNITIPKLVNVCISNPGDQK9KSIMSLDLTTCVSDTTAAVLFFLTFLT	127
	mTLR8.pep	DISDFRSWLDENLNITIPKLVNVCISNPGDQKSKSIMSLDLTTCVSDTTAAVLFFLTFLT	829
	hTLR8.pep	DIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILFFFTFFI	838
30		. : . : . : . : . : . :	900
	bf135656.pep	TSMVMLAALVHHLFYWDVWFYIHMCSAKLKGVRTSSSTSQTIFYDAYISYDTKDASVTDWVI	177
	mTLR8.pep	TSMVMLAALVHHLFYWDVWFYIHMCSAKLKGVRTSSSTSQTIFYDAYISYDTKDASVTDWVI	889
	hTLR8.pep	TTMVMLAALAHHLFYWDVWFYIYNVCLAKVKGYRSLSTSQTIFYDAYISYDTKDASVTDWVI	898
35		. : . : . : . : . : . :	960
	bf135656.pep	NELRYHLE	185
	mTLR8.pep	NELRYHLEESSEDKSVLLCLEERDWDPLPIIDNLMQSINQSKKTI FVLTKKYAKSWNFKT	949
	hTLR8.pep	NELRYHLEESRDKNVLLCLEERDWDPLAIIDNLMQSINQSKKTVFVLTKKYAKSWNFKT	958
40		. : . : . : . : . : . :	1020
	mTLR8.pep	AFYLALQRLMDENMDVIIIFILLEPVLQYSQYLRLRQRICKSSILQWPNPKAENLFWQSL	1009
	hTLR8.pep	AFYLALQRLMDENMDVIIIFILLEPVLQHSQYLRLRQRICKSSILQWPDNPKAEGFWQTL	1018
45		. : . : . : . : . : . :	1080
	mTLR8.pep	KNVVLTEENDSRYDDLYIDSIRQY	1032

- 133 -

hTLR8 . pep RNVVLTEENDSRYNMYVDSIKQY

1041

In Table 17 the sequences are assigned as follows: mTLR8.pep, SEQ ID NO:192;
hTLR8.pep, SEQ ID NO:184; and bfl35656.pep, SEQ ID NO:193.

5

Example 20. Transient transfectants expressing TLR8 and TLR7

The cloned human TLR7 and human TLR8 cDNA (our result) were cloned into the expression vector pCDNA3.1(-) from Invitrogen using the NotI site. Utilizing a "gain of function" assay, hTLR7 and hTLR8 expression vectors were transiently expressed in human
10 293 fibroblasts (ATCC, CRL-1573) using the calcium phosphate method. Activation was monitored by IL-8 production after stimulus with CpG-ODN (2006 or 1668, 2 μ M) or LPS (100 ng/ml). None of the stimuli used activated 293 cells transfected with either hTLR7 or hTLR8.

Example 21. Screening for TLR9, 8 and 7 modulators

Human TLR receptors 9, 8 and 7 are expressed differentially among tissues which may be due to differences in promoter structure. Du X et al., *Eur Cytokine Netw* 11:362-71 (2000); Chuang TH et al., *Eur Cytokine Netw* 11:372-8 (2000). For the human Toll-like receptors 9, 8 and 7 the genomic locus has been defined and sequenced. TLR9 is located on
20 chromosome 3 (GenBank accession numbers NT_005985, AC006252), TLR7 on chromosome X (GenBank accession numbers NT_011774, AC005859, AC003046) and TLR8 close to TLR7 also on chromosome X (GenBank accession numbers NT_011774, AC005859). To verify differences in the promoter regions the putative promoter region of each gene are cloned in reporter vectors like pGL2-Basic (Promega, Madison, WI, USA)
25 which contains the luciferase gene (luc) adjacent to a multiple cloning site. After transient transfection of these constructs in various cell lines, different stimuli can be tested for the activation of the inserted promoter region which is detected by luciferase activity. The promoter regions defined by the cloning of mTLR9, mTLR8 and mTLR7 can be utilized in the same manner. Definition of compounds that agonize or antagonize TLR9, 8, or 7
30 expression can be used to enhance or dampen responses to nucleic acid ligands or to any TLR9, 8 or 7 ligand defined by screening. These constructs can be adapted to high throughput screening after stable transfection similar to the use of TLR9 stable transfectants.

- 134 -

Each of the foregoing patents, patent applications and references is hereby incorporated by reference. While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

Example 22. Method cloning the murine and human extracellular TLR9 domain fused to human IgG1 Fc

Human IgG1 Fc was amplified from human B cell cDNA using the sense and antisense primers 5' TATGGATCCTCTTGTGACAAACTCACACATGC (SEQ ID NO:216) and 5' ATA AAGCTTTCATTTACCCGGAGACAGGGAGAG (SEQ ID NO:217) and ligated into pCDNA3.1(-) (Invitrogen) after digestion with the restriction endonucleases BamHI and HindIII creating the vector pcDNA-IgGFc. The extracellular domain of human TLR9 (amino acids 1 to 815) was amplified with the sense and antisense primers 5' TATGAATCCCCACCATGGGTTTCTGCCGAG (SEQ ID NO:218) and 5' ATAGGATCCCCGGGGCACCAGGCCGCCGCCGCCGCCGAGAGGGCCTCATCCAGGC (SEQ ID NO:219). The primers amplify the extracellular domain of human TLR9 and create adjacent to amino acid 815 an additional NotI restriction site, a glycine linker and thrombin protease recognition site. The translated sequence of this region starting at amino acid 812 is DEALSGGRGGGI.VPRGS (SEQ ID NO:220). The fragment was cut with EcoRI and BamHI and cloned into pcDNA-IgGFc, creating the vector coding for the fusion protein of the extracellular domain of human TLR9 fused to the Fc part of human IgG1 (pcDNAhTLR9IgGFc). Expressed extracellular TLR9 protein can be separated from the IgG1 Fc fragment by digestion with Thrombin (see figure).

The extracellular part of murine TLR9 (amino acids 1 to 816) was amplified with the sense and antisense primers 5' TATATGCGGCCGCCACCATGGTTCTCCGTCGAAG (SEQ ID NO:221) and 5' TATATGCGGCCGCCAGAGAGGACCTCATCCAGGC (SEQ ID NO:222) and cloned into pcDNAhTLR9IgGFc after NotI digestion of PCR fragment and vector. This procedure exchanged the human extracellular part of TLR9 with the murine counterpart.

Example 23. Method of expression and purification of the extracellular domain of TLR9 fused to human IgG1 Fc

Vector DNA coding for the human or murine TLR9 human IgGFc fusion protein was
 5 transfected by Ca_2PO_4 method into 293 fibroblast cells. Transfected cells were selected with
 0.7 mg/ml G418 and cloned. Expression of fusion protein was monitored by enzyme-linked
 immunosorbent assay (ELISA). Cells were lysed in lysis buffer (PBS, 1% Triton X-100) and
 supernatant was applied to ELISA plates coated with polyclonal antibody against human IgG-
 Fc. Bound fusion protein was detected by incubation with biotinylated polyclonal antibodies
 10 against human IgG-Fc and streptavidin-horseradish peroxidase conjugate.

For purification of the fusion protein cell lysates from 10^9 cells were produced and
 incubated with Protein A sepharose which binds tightly to human IgG-Fc. Incubation with
 the protease thrombin releases the soluble extracellular domain of human TLR9. **Figure 27**
 shows an example of the TLR9 fusion protein visualized by a silver stained SDS-gel. **Figure**
 15 **27** demonstrates that lysates of transfected cells included a strong band travelling between
 100 and 150 kD which was not present either in lysates of mock-transfected cells or in
 supernatants transfected or mock-transfected cells. The apparent molecular weight of the
 band decreased following thrombin treatment, consistent with cleavage at the thrombin
 protease recognition site interposed between the extracellular TLR9 domain and the Fc
 20 fragment.

Example 24. Method of cloning the murine and human extracellular TLR7 and TLR8 domain fused to human IgG1 Fc and its expression in 293 cells

The extracellular domains of murine TLR7 (amino acids 1 to 837), human TLR7
 25 (amino acids 1 to 836), murine TLR8 (amino acids 1 to 816) and human TLR8 (amino acids 1
 to 825) were amplified with the primer pairs

5' TATATGCGGCCGCCCACCATGGTGTTCGATGTGGACACG (SEQ ID NO:223)
 and 5' TATATGCGGCCGCCCATCTAACTCACACGTATACAGATC (SEQ ID NO:224);
 5' TATATGCGGCCGCCCACCATGGTGTTCGAATGTGGACACTG (SEQ ID NO:225)
 30 and 5' TATATGCGGCCGCCCATCTAACTCACAGGTGTACAGATC (SEQ ID NO:226);
 5' TATATGCGGCCGCCCACCATGGAAAACATGCCCCCTCAG (SEQ ID NO:227) and

- 136 -

5' TATATGCGGCCGCCATCCGATACACAAGTCGTGAGATC (SEQ ID NO:228); and
5' TATATGCGGCCGCCACCATGGAAAACATGTTCTTCAGTC (SEQ ID NO:229)
and 5' TATATGCGGCCGCCATCTGAAACACAAGTTGTTAGCTC (SEQ ID NO:230),
respectively. Fragments were cloned into pcDNA-IgGFc after NotI digestion.

5 Vector DNA coding for the extracellular domain of human or murine TLR7 or TLR8
fused to human IgGFc fusion protein was transfected by Ca_2PO_4 method into 293 fibroblast
cells. Transfected cells were selected with 0.7 mg/ml G418 and cloned. Expression of fusion
protein was monitored by ELISA. Cells were lysed in lysis buffer (PBS, 1% Triton X-100)
and supernatant was applied to ELISA plates coated with polyclonal antibody against human
10 IgG-Fc. Bound fusion protein was detected by incubation with biotinylated polyclonal
antibodies against human IgG-Fc and Streptavidin-horseradish peroxidase conjugate.

**Example 25. Method of antibody production against murine and human TLR9 and
characterization of activity**

15 C57/B6 mice were immunized three times by intraperitoneal administration of 20 μg
of the extracellular domain of human TLR9 mixed with 10 nmol of the CpG-ODN 1668.
B cells taken from immunized mice were fused with a non antibody producing B-cell
hybridoma P3XAG8 using standard protocols. Hybridoma supernatants were screened for
reactivity in ELISA using murine and human TLR9 fusion proteins. For identification of
20 positive hybridomas ELISA plates were coated with polyclonal antibody against human IgG-
Fc and incubated with lysate containing murine or human TLR9 IgG-Fc fusion protein.
Plates were then incubated with individual hybridoma supernatants, and bound TLR9-specific
antibodies were detected by incubation with biotinylated polyclonal antibodies against murine
IgG and Streptavidin-horseradish peroxidase conjugate.

25 Ten antibodies have been isolated which are of IgG1, IgG2a and IgG2b isotype. They
have been tested for reactivity against human and murine TLR9 and their performance in
western blotting or intracellular staining. Table 18 shows the names (ID), isotypes, reactivity
and performance in western blotting and intracellular staining.

All isolated antibodies were readily purified using standard protein A affinity
30 chromatography.

Table 18. Monoclonal Antibodies Raised Against Murine and Human TLR9

#	ID	Isotype	Reactivity in ELISA		Western Blotting	Intracellular Staining
			mTLR9	hTLR9		
1	1-3A11	G1	YES	YES	YES	NO
2	1-1B1	G1	YES	YES	YES	NO
3	1-2A9	G2a	NO	YES	YES	YES
4	1-3F2	G1	YES	YES	YES	NO
5	2-1E2	G2a	NO	YES	YES	YES
6	1-5G5	G2a	YES	YES	YES	YES
7	1-2F1	G1	YES	YES	YES	NO
8	1-5F12	G2b	NO	YES	NO	NO
9	1-3C9	G2a	NO	YES	YES	YES
10	1-3F5	G2b	NO	YES	NO	NO

Example 26. Method for Intracellular Staining

Mock transfected 293 cells and human TLR9 transfected 293 cells were seeded on
 5 cover slips and cultured overnight. The following day cells were washed in PBS and fixed
 with 2% formalin for 10 minutes at room temperature. Cells were permeabilized with 0.2%
 saponin in PBS and incubated with 2µg/ml anti human TLR9-specific antibody 2-1E2 for 1h.
 After two wash steps cells were incubated with Alexis488-conjugated goat anti-mouse IgG
 antibody and TLR9 was visualized utilizing confocal microscopy on a Zeiss LSM510
 10 microscope. Results indicated that cytoplasm of human TLR9 transfected 293 cells, but not
 mock transfected 293 cells, stained positive for human TLR9.

Example 27. Method for Western Blotting

Lysates of 293 cells transfected with murine TLR9, human TLR9 or murine TLR2
 15 IgG1-Fc fusion protein were separated by SDS-PAGE. Proteins were transferred to a nylon
 membrane utilizing a BioRad semi dry blotter according to the manufacturer's protocol. The
 membrane was incubated with 2µg/ml of the human TLR9-specific antibody 2-1E2, and
 human TLR9 was detected by polyclonal goat anti-mouse peroxidase conjugate. Peroxidase
 activity was monitored with ECL reagent (Amersham) and incubation of the membrane on
 20 film (see Figure 29).

What is claimed is:

- 138 -

Claims

1. An isolated nucleic acid molecule selected from the group consisting of
 - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:1, and which code for a murine TLR9 having an amino acid sequence set forth as SEQ ID NO:3,
 - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and
 - (c) complements of (a) or (b).
2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule codes for SEQ ID NO:3.
3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:1.
4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:2.
5. An isolated TLR9 polypeptide or fragment thereof comprising at least one amino acid of murine TLR9 selected from the group consisting of amino acids 2, 3, 4, 6, 7, 18, 19, 22, 38, 44, 55, 58, 61, 62, 63, 65, 67, 71, 80, 84, 87, 88, 91, 101, 106, 109, 117, 122, 123, 134, 136, 140, 143, 146, 147, 157, 160, 161, 167, 168, 171, 185, 186, 188, 189, 191, 199, 213, 217, 220, 227, 231, 236, 245, 266, 269, 270, 271, 272, 273, 274, 278, 281, 285, 297, 298, 301, 305, 308, 311, 322, 323, 325, 326, 328, 332, 335, 346, 348, 353, 355, 358, 361, 362, 365, 367, 370, 372, 380, 381, 382, 386, 389, 392, 394, 397, 409, 412, 413, 415, 416, 419, 430, 432, 434, 435, 438, 439, 443, 444, 446, 447, 448, 450, 451, 452, 454, 455, 459, 460, 463, 465, 466, 468, 469, 470, 472, 473, 474, 475, 478, 488, 489, 494, 495, 498, 503, 508, 510, 523, 531, 539, 540, 543, 547, 549, 561, 563, 565, 576, 577, 579, 580, 587, 590, 591, 594, 595, 597, 599, 601, 603, 610, 611, 613, 616, 619, 632, 633, 640, 643, 645, 648, 650, 657, 658, 660, 667, 670, 672, 675, 679, 689, 697, 700, 703, 705, 706, 711, 715, 716, 718, 720, 723, 724, 726, 729, 731, 735, 737, 743, 749, 750, 751, 752, 754, 755, 759, 760,

- 139 -

- 772, 774, 780, 781, 786, 787, 788, 800, 814, 821, 829, 831, 832, 835, 844, 857, 858, 859, 862, 864, 865, 866, 879, 893, 894, 898, 902, 910, 917, and 927 of SEQ ID NO:3, wherein the TLR9 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR9 polypeptide or fragment thereof except for the at least one amino acid of murine TLR9.
6. The isolated TLR9 polypeptide or fragment thereof of claim 5, further comprising at least one amino acid of murine TLR9 selected from the group consisting of amino acids 949, 972, 975, 976, 994, 997, 1000, 1003, 1004, 1010, 1011, 1018, 1023, and 1027 of SEQ ID NO:3.
 7. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the human TLR9 has an amino acid sequence set forth as SEQ ID NO:6.
 8. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof has an amino acid sequence selected from the group consisting of SEQ ID NO:3 and fragments of SEQ ID NO:3.
 9. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof is an extracytoplasmic domain of TLR9.
 10. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof comprises an MBD motif as set forth as SEQ ID NO:126 or SEQ ID NO:127.
 11. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof selectively binds to an immunostimulatory nucleic acid (ISNA).
 12. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof selectively binds to a CpG nucleic acid.

- 140 -

13. An isolated nucleic acid molecule which encodes the isolated TLR9 polypeptide or fragment thereof of claim 5.
14. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.
15. A host cell comprising the expression vector of claim 14.
16. The host cell of claim 15, further comprising at least one expression vector selected from the group consisting of:
 - (a) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR7 polypeptide operably linked to a promoter, and
 - (b) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR8 polypeptide operably linked to a promoter.
17. The host cell of claim 15, further comprising a reporter construct capable of interacting with a TIR domain.
18. An expression vector comprising the isolated nucleic acid molecule of claim 13 operably linked to a promoter.
19. A host cell comprising the expression vector of claim 18.
20. The host cell of claim 19, further comprising at least one expression vector selected from the group consisting of:
 - (a) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR7 polypeptide operably linked to a promoter, and
 - (b) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR8 polypeptide operably linked to a promoter.

- 141 -

21. The host cell of claim 19, further comprising a reporter construct capable of interacting with a TIR domain.
22. An isolated nucleic acid molecule selected from the group consisting of
 - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:173, and which code for a murine TLR7 having an amino acid sequence set forth as SEQ ID NO:175,
 - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and
 - (c) complements of (a) or (b).
23. The isolated nucleic acid molecule of claim 22, wherein the isolated nucleic acid molecule codes for SEQ ID NO:175.
24. The isolated nucleic acid molecule of claim 22, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:173.
25. The isolated nucleic acid molecule of claim 22, wherein the isolated nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:174.
26. An isolated TLR7 polypeptide or fragment thereof comprising at least one amino acid of murine TLR7 selected from the group consisting of amino acids 4, 8, 15, 16, 18, 21, 23, 24, 25, 27, 37, 39, 40, 41, 42, 44, 45, 61, 79, 83, 86, 89, 92, 96, 103, 109, 111, 113, 119, 121, 127, 128, 131, 145, 148, 151, 164, 172, 176, 190, 202, 203, 204, 205, 222, 225, 226, 228, 236, 238, 243, 250, 253, 266, 268, 271, 274, 282, 283, 287, 288, 308, 313, 314, 315, 325, 328, 331, 332, 341, 343, 344, 347, 351, 357, 360, 361, 362, 363, 364, 365, 366, 370, 371, 377, 378, 387, 388, 389, 392, 397, 398, 413, 415, 416, 419, 421, 422, 425, 437, 438, 440, 446, 449, 453, 454, 455, 456, 462, 470, 482, 486, 487, 488, 490, 491, 493, 494, 503, 505, 509, 511, 529, 531, 539, 540, 543, 559, 567, 568, 574, 583, 595, 597, 598, 600, 611, 613, 620, 624, 638, 645, 646, 651, 652, 655, 660, 664, 665, 668, 669, 672, 692, 694, 695, 698, 701, 704, 714, 720, 724, 727, 728, 733, 738, 745, 748, 755, 762, 777, 780, 789,

- 142 -

803, 846, 850, 851, 860, 864, 868, 873, 875, 884, 886, 888, 889, 890, 902, 903, 911, 960, 967, 970, 980, 996, 1010, 1018, 1035, and 1045 of SEQ ID NO:175, wherein the TLR7 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR7 polypeptide or fragment thereof except for the at least one amino acid of murine TLR7.

27. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the human TLR7 has an amino acid sequence set forth as SEQ ID NO:170.
28. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof has an amino acid sequence selected from the group consisting of SEQ ID NO:175 and fragments of SEQ ID NO:175.
29. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof is an extracytoplasmic domain of TLR7.
30. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof comprises an MBD motif as set forth as any one of SEQ ID NOs: 203, 204, 212, and 213.
31. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof selectively binds to an ISNA.
32. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof selectively binds to a CpG nucleic acid.
33. An isolated nucleic acid molecule which encodes the isolated TLR7 polypeptide or fragment thereof of claim 26.
34. An expression vector comprising the isolated nucleic acid molecule of claim 22 operably linked to a promoter.

- 143 -

35. A host cell comprising the expression vector of claim 34.
36. The host cell of claim 35, further comprising a reporter construct capable of interacting with a TIR domain.
37. An expression vector comprising the isolated nucleic acid molecule of claim 33 operably linked to a promoter.
38. A host cell comprising the expression vector of claim 37.
39. The host cell of claim 38, further comprising a reporter construct capable of interacting with a TIR domain.
40. An isolated nucleic acid molecule selected from the group consisting of
 - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:190, and which code for a murine TLR8 having an amino acid sequence set forth as SEQ ID NO:192,
 - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and
 - (c) complements of (a) or (b).
41. The isolated nucleic acid molecule of claim 40, wherein the isolated nucleic acid molecule codes for SEQ ID NO:192.
42. The isolated nucleic acid molecule of claim 40, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:190.
43. The isolated nucleic acid molecule of claim 40, wherein the isolated nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:191.

- 144 -

44. An isolated TLR8 polypeptide or fragment thereof comprising at least one amino acid of murine TLR8 selected from the group consisting of amino acids 5, 6, 9, 10, 14, 15, 18, 21, 22, 23, 24, 25, 26, 27, 28, 30, 39, 40, 41, 43, 44, 50, 51, 53, 55, 61, 67, 68, 74, 80, 85, 93, 98, 99, 100, 104, 105, 106, 107, 110, 114, 117, 119, 121, 124, 125, 134, 135, 138, 145, 155, 156, 157, 160, 161, 162, 163, 164, 166, 169, 170, 174, 180, 182, 183, 186, 187, 191, 193, 194, 196, 197, 199, 200, 207, 209, 210, 227, 228, 230, 231, 233, 234, 241, 256, 263, 266, 267, 268, 269, 272, 274, 275, 276, 280, 285, 296, 298, 299, 300, 303, 305, 306, 307, 310, 312, 320, 330, 333, 335, 343, 344, 345, 346, 347, 349, 351, 356, 362, 365, 366, 375, 378, 379, 380, 381, 383, 384, 386, 387, 392, 402, 403, 408, 414, 416, 417, 422, 426, 427, 428, 429, 430, 431, 433, 437, 438, 439, 440, 441, 444, 445, 449, 456, 461, 463, 471, 483, 486, 489, 490, 494, 495, 496, 505, 507, 509, 512, 513, 519, 520, 523, 537, 538, 539, 541, 542, 543, 545, 554, 556, 560, 567, 569, 574, 575, 578, 586, 592, 593, 594, 595, 597, 599, 602, 613, 617, 618, 620, 621, 623, 628, 630, 633, 639, 641, 643, 644, 648, 655, 658, 661, 663, 664, 666, 668, 677, 680, 682, 687, 688, 690, 692, 695, 696, 697, 700, 702, 703, 706, 714, 715, 726, 727, 728, 730, 736, 738, 739, 741, 746, 748, 751, 752, 754, 757, 764, 766, 772, 776, 778, 781, 784, 785, 788, 791, 795, 796, 801, 802, 806, 809, 817, 820, 821, 825, 828, 829, 831, 839, 852, 853, 855, 858, 863, 864, 900, 903, 911, 918, 934, 977, 997, 1003, 1008, 1010, 1022, 1023, 1024, 1026, and 1030 of SEQ ID NO:192, wherein the TLR8 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR8 polypeptide or fragment thereof except for the at least one amino acid of murine TLR8.
45. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the human TLR8 has an amino acid sequence set forth as SEQ ID NO:184.
46. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof has an amino acid sequence selected from the group consisting of SEQ ID NO:192 and fragments of SEQ ID NO:192.
47. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof is an extracytoplasmic domain of TLR8.

- 145 -

48. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof comprises an MBD motif as set forth as any one of SEQ ID NOs: 205, 206, 214, and 215.
49. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof selectively binds to an ISNA.
50. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof selectively binds to a CpG nucleic acid.
51. An isolated nucleic acid molecule which encodes the isolated TLR8 polypeptide or fragment thereof of claim 44.
52. An expression vector comprising the isolated nucleic acid molecule of claim 40 operably linked to a promoter.
53. A host cell comprising the expression vector of claim 52.
54. The host cell of claim 53, further comprising a reporter construct capable of interacting with a TIR domain.
55. An expression vector comprising the isolated nucleic acid molecule of claim 51 operably linked to a promoter.
56. A host cell comprising the expression vector of claim 55.
57. The host cell of claim 56, further comprising a reporter construct capable of interacting with a TIR domain.
58. An isolated nucleic acid molecule which hybridizes under stringent conditions to the

isolated nucleic acid molecule of claim 1 or claim 13.

59. A method for inhibiting TLR9 signaling activity in a cell, comprising:
contacting the cell with an isolated nucleic acid molecule of claim 58 in an amount effective to inhibit expression of TLR9 polypeptide in the cell.
60. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the isolated nucleic acid molecule of claim 1 or claim 13.
61. A method for inhibiting TLR9 signaling activity in a cell, comprising:
contacting the cell with an isolated nucleic acid molecule of claim 60 in an amount effective to inhibit expression of TLR9 polypeptide in the cell.
62. A method for identifying nucleic acid molecules which interact with a TLR polypeptide or a fragment thereof, comprising:
contacting a TLR polypeptide selected from the group consisting of TLR7, TLR8, TLR9, and nucleic acid-binding fragments thereof with a test nucleic acid molecule; and
measuring an interaction of the test nucleic acid molecule with the TLR polypeptide or fragment thereof.
63. The method of claim 62, wherein the TLR polypeptide or fragment thereof is expressed in a cell.
64. The method of claim 62, wherein the TLR polypeptide or fragment thereof is an isolated TLR polypeptide or fragment thereof.
65. The method of claim 64, wherein the isolated TLR polypeptide or fragment thereof is immobilized on a solid support.
66. The method of claim 62, wherein the TLR polypeptide or fragment thereof is fused

- 147 -

with an Fc fragment of an antibody.

67. The method of claim 66, wherein the TLR polypeptide or fragment thereof comprises a TLR extracytoplasmic domain.
68. The method of claim 62, wherein the interaction is binding.
69. The method of claim 68, wherein the measuring is accomplished by a method selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), biomolecular interaction assay (BIA), electromobility shift assay (EMSA), radioimmunoassay (RIA), polyacrylamide gel electrophoresis (PAGE), and Western blotting.
70. The method of claim 63, wherein the measuring is accomplished by a method comprising measuring a response mediated by a TLR signal transduction pathway.
71. The method of claim 70, wherein the response mediated by a TLR signal transduction pathway is selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine.
72. The method of claim 71, wherein the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
73. The method of claim 71, wherein the cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.
74. The method of claim 70, further comprising:
comparing (a) the response mediated by a TLR signal transduction pathway as measured in presence of the test nucleic acid molecule with (b) a response mediated by a TLR signal transduction pathway as measured in absence of the test nucleic acid molecule; and

- 148 -

determining the test nucleic acid molecule is an ISNA when (a) exceeds (b).

75. The method of claim 70, further comprising:
comparing the response to a reference response when the TLR polypeptide is independently contacted with a reference nucleic acid molecule; and
determining if the response is stronger or weaker than the reference response.
76. The method of claim 70, further comprising:
comparing the response to a reference response when the TLR polypeptide is concurrently contacted with a reference nucleic acid molecule; and
determining if the response is stronger or weaker than the reference response.
77. The method of claim 62, wherein the TLR polypeptide or fragment thereof is TLR7.
78. The method of claim 62, wherein the TLR polypeptide or fragment thereof is TLR8.
79. The method of claim 62, wherein the TLR polypeptide or fragment thereof is TLR9.
80. A screening method for identifying an ISNA, comprising:
contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test nucleic acid molecule;
detecting presence or absence of a response mediated by a TLR signal transduction pathway in the presence of the test nucleic acid molecule arising as a result of an interaction between the functional TLR and the test nucleic acid molecule; and
determining the test nucleic acid molecule is an ISNA when the presence of a response mediated by the TLR signal transduction pathway is detected.
81. The method of claim 80, further comprising comparing the response mediated by the TLR signal transduction pathway arising as a result of an interaction between the functional TLR and the test nucleic acid molecule with a response arising as a result of an interaction between the functional TLR and a reference ISNA.

82. The method of claim 81, wherein the screening method is performed on a plurality of test nucleic acid molecules.
83. The method of claim 82, wherein the response mediated by the TLR signal transduction pathway is measured quantitatively and wherein the response mediated by the TLR signal transduction pathway associated with each of the plurality of test nucleic acid molecules is compared with a response arising as a result of an interaction between the functional TLR and a reference ISNA.
84. The method of claim 83, wherein a subset of the plurality of test nucleic acid molecules is selected based on ability of the subset to produce a specific response mediated by the TLR signal transduction pathway.
85. The method of claim 80, wherein the functional TLR is expressed in a cell.
86. The method of claim 85, wherein the cell is an isolated mammalian cell that naturally expresses the functional TLR.
87. The method of claim 86, wherein the cell comprises an expression vector comprising an isolated nucleic acid which encodes a reporter construct selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
88. The method of claim 80, wherein the functional TLR is part of a cell-free system.
89. The method of claim 80, wherein the functional TLR is part of a complex with another TLR.
90. The method of claim 89, wherein the complex is a complex of TLR9 and TLR7.
91. The method of claim 89, wherein the complex is a complex of TLR9 and TLR8.

- 150 -

92. The method of claim 80, wherein the functional TLR is part of a complex with a non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B, and functional homologues and derivatives thereof.
93. The method of claim 80, wherein the reference ISNA is a CpG nucleic acid.
94. The method of claim 80, wherein the test nucleic acid molecule is a CpG nucleic acid.
95. The method of claim 80, wherein the response mediated by a TLR signal transduction pathway is selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine.
96. The method of claim 95, wherein the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
97. The method of claim 95, wherein the cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.
98. A screening method for comparing TLR signaling activity of a test compound with an ISNA, comprising:
- contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a reference ISNA and detecting a reference response mediated by a TLR signal transduction pathway;
 - contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test compound and detecting a test response mediated by a TLR signal transduction pathway; and
 - comparing the test response with the reference response to compare the TLR signaling activity of the test compound with the ISNA.

- 151 -

99. The method of claim 98, wherein the functional TLR is contacted with the reference ISNA and the test compound independently.
100. The method of claim 99, wherein the screening method is a method for identifying an ISNA mimic, and wherein when the test response is similar to the reference response the test compound is an ISNA mimic.
101. The method of claim 98, wherein the functional TLR is contacted with the reference ISNA and the test compound concurrently to produce a test-reference response mediated by a TLR signal transduction pathway and wherein the test-reference response may be compared to the reference response.
102. The method of claim 101, wherein the screening method is a method for identifying an ISNA agonist, and wherein when the test-reference response is greater than the reference response the test compound is an ISNA agonist.
103. The method of claim 101, wherein the screening method is a method for identifying an ISNA antagonist, and wherein when the test-reference response is less than the reference response the test compound is an ISNA antagonist.
104. The method of claim 98, wherein the functional TLR is expressed in a cell.
105. The method of claim 104, wherein the cell is an isolated mammalian cell that naturally expresses the functional TLR9.
106. The method of claim 105, wherein the cell comprises an expression vector comprising an isolated nucleic acid which encodes a reporter construct selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
107. The method of claim 98, wherein the functional TLR is part of a cell-free system.

- 152 -

108. The method of claim 98, wherein the functional TLR is part of a complex with another TLR.
109. The method of claim 98, wherein the functional TLR is part of a complex with a non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B, and functional homologues and derivatives thereof.
110. The method of claim 98, wherein the reference ISNA is a CpG nucleic acid.
111. The method of claim 98, wherein the test compound is not a nucleic acid molecule.
112. The method of claim 98, wherein the test compound is a polypeptide.
113. The method of claim 98, wherein the test compound is a part of a combinatorial library of compounds.
114. A screening method for identifying species specificity of an ISNA, comprising:
 - contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a first species with a test ISNA;
 - contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a second species with the test ISNA;
 - measuring a response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA;
 - measuring a response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA; and
 - comparing (a) the response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA with (b) the response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA.
115. The method of claim 114, wherein the functional TLR is expressed in a cell.

116. The method of claim 115, wherein the cell is an isolated mammalian cell that naturally expresses the functional TLR.
117. The method of claim 114, wherein the functional TLR is part of a cell-free system.
118. The method of claim 114, wherein the functional TLR is part of a complex with another TLR.
119. The method of claim 114, wherein the functional TLR is part of a complex with a non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B, and functional homologues and derivatives thereof.
120. A method for identifying lead compounds for a pharmacological agent useful in treatment of disease associated with TLR9 signaling activity, comprising
providing a cell comprising a TLR9 as provided in claim 5;
contacting the cell with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of TLR9 signaling activity; and
determining a second amount of TLR9 signaling activity as a measure of the effect of the pharmacological agent on the TLR9 signaling activity, wherein a second amount of TLR9 signaling activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces TLR9 signaling activity and wherein a second amount of TLR9 signaling activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases TLR9 signaling activity.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12

A



B




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26





Figure 27

SEQUENCE LISTING

<110> Coley Pharmaceutical GmbH

<120> PROCESS FOR HIGH THROUGHPUT SCREENING OF
CpG-BASED IMMUNO-AGONIST/ANTAGONIST

<130> C1041/7016WO (AWS)

<150> US 60/233,035

<151> 2000-09-15

<150> US 60/263,657

<151> 2001-01-23

<150> US 60/291,726

<151> 2001-05-17

<150> US 60/300,210

<151> 2001-06-22

<160> 16

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 3200

<212> DNA

<213> unknown

<400> 1

tgtagagggg	agcctcgga	gaatcctcca	tctccaaca	tggttctcgc	tcgaaggact	60
ctgcaccct	tgccctcct	ggtacaggct	gcagtgtctg	ctgagactct	ggccctgggt	120
accctgectg	ccttcctacc	ctgtgagctg	aagcctcatg	gcctgggtga	ctgcaattgg	180
ctgttctga	agtctgtacc	cgtttctct	gcggcagcat	cctgctccaa	catcacccgc	240
ctctcctga	tctccaaccg	tatccaccac	ctgcacaact	cggacttcgt	ccacctgtcc	300
aacctgcggc	agctgaacct	caagtggaa	tgccaccaca	ctggccttag	ccccctgcac	360
ttctcttgc	acatgacct	tgagcccaga	accttctctg	ctatgcgtac	actggaggag	420
ctgaacctga	gctataatgg	tatcaaccat	gtgcccgcac	tgcccagctc	cctgggtgaat	480
ctgagcctga	gccacaccaa	catcctgggt	ctagatgcta	acagcctcgc	cggcctatac	540
agcctgcgcg	ttctcttcat	ggacgggaac	tgctactaca	agaacccctg	cacaggagcg	600
gtgaaggtag	ccccaggcgc	cctcctgggc	ctgagcaatc	tcacccatct	gtctctgaag	660
tataacaacc	tcacaaagg	gccccgccaa	ctgcccccca	gcctggagta	cctcctgggtg	720
tcctataacc	tcattgtcaa	gctggggcct	gaagacctgg	ccaatctgac	ctcccttcga	780
gtacttgatg	tggttgaggaa	ttgcctgcgc	tgcgaccatg	cccccaatcc	ctgtatagaa	840
tgtagccaaa	agtcctctcca	cctgcaccct	gagaccttcc	atcacctgag	ccatctggaa	900
ggcctgggtg	tgaaggacag	ctctctccat	acactgaact	cttctctgggt	ccaagggtctg	960
gtcaacctct	cgggtgctgga	cctaagcgag	aactttctct	atgaaagcat	caaccacacc	1020
aatgccttcc	agaacctaac	ccgcctgcgc	aagctcaacc	tgctcttcaa	ttaccgcaag	1080
aaggatctct	ttgcctcgct	ccacctggga	agttccttca	agaacctgggt	gtcactgcag	1140
gagctgaaca	tgaacggcat	cttcttccgc	tcgctcaaca	agtacacgct	cagatggctg	1200
gccgatctgc	ccaaactcca	cactctgcat	cttcaaatga	acttcatcaa	ccaggcacag	1260
ctcagcatct	ttggtacctt	cggagccctt	cgttttgtgg	acttgtcaga	caatgcctac	1320
agtgggctct	caacgctgtc	agaagccacc	cctgaagagg	cagatgatgc	agagcaggag	1380
gagctgttgt	ctgcggatcc	tcacccagct	ccactgagca	ccctgcttc	taagaacttc	1440
atggacaggt	gtaagaactt	caagttcacc	atggacctgt	ctcggaaaca	cctgggtgact	1500
atcaagccag	agatgtttgt	caatctctca	cgcctccagt	gtcttagcct	gagccacaac	1560

tccattgcac	aggctgtcaa	tggctctcag	ttcctgcgcg	tgactaatct	gcaggtgctg	1620
gacctgtccc	ataacaaact	ggacttgtac	cactggaaat	cgttcagtga	gctaccacag	1680
ttgcaggccc	tggacctgag	ctacaacage	cagcccttta	gcatgaaggg	tataggccac	1740
aattttcagtt	ttgtggccca	tctgtccatg	ctacacagcc	ttagcctggc	acacaatgac	1800
attcatatccc	gtgtgtctct	acatctcaac	agcaactcag	tgagggtttct	tgacttcagc	1860
ggcaacggta	tgggcccgcg	gtgggatgag	gggggccttt	atctccattt	cttccaaggc	1920
ctgagtggcc	tgctgaagct	ggacctgtct	caaaataacc	tgcatactct	ccggccccag	1980
aaccttgaca	acctccccaa	gagcctgaag	ctgctgagcc	tccgagacaa	ctacctatct	2040
ttcttttaact	ggaccagtct	gtccttcctg	cccaacctgg	aagtccctaga	cctggcaggc	2100
aaccagctaa	aggccctgac	caatggcacc	ctgcctaattg	gcacctctct	ccagaaactg	2160
gatgtcagca	gcaacagtat	cgtctctgtg	gtcccagcct	tcttcgctct	ggcggtcgag	2220
ctgaaagagg	tcaacctcag	ccacaacatt	ctcaagacgg	tggatcgctc	ctggtttggg	2280
cccattgtga	tgaacctgac	agttctagac	gtgagaagca	acctctctgca	ctgtgcctgt	2340
ggggcagcct	tcgtagactt	actggtggag	gtgcagacca	aggtgcctgg	cctggctaata	2400
ggtgtgaagt	gtggcagccc	cggccagctg	cagggccgta	gcatcttcgc	acaggacctg	2460
cggctgtgcc	tggatgaggt	cctctcttgg	gactgctttg	gcctttcact	cttggctgtg	2520
gccgtgggca	tgggtgggtcc	tatactgcac	catctctgcg	gctgggacgt	ctggtactgt	2580
tttcatctgt	gcctggcatg	gctacctttg	ctggcccgca	gccgacgcag	cgccccagct	2640
ctccctatg	atgccttcgt	ggtgttcgat	aaggcacaga	gcgcagttgc	ggactgggtg	2700
tataacgagc	tgccgggtcg	gctggaggag	cggcgcggtc	gccgagccct	acgcttgtgt	2760
ctggaggacc	gagattggct	gcctggccag	acgtctcttcg	agaacctctg	ggcttccatc	2820
tatgggagcc	gcaagactct	atttgtgtctg	gcccacacgg	accgcgtcag	tggcctcctg	2880
cgcaccagct	tctgtctggc	tcagcagcgc	ctggtggaag	accgcaagga	cgtggtgggtg	2940
ttggtgatcc	tgcgtccgga	tgcaccgcgc	tcccgctatg	tgcgactgcg	ccagcgctctc	3000
tgccgccaga	gtgtgtctct	ctggccccag	cagcccaacg	ggcagggggg	cttctggggc	3060
cagctgagta	cagccctgac	tagggacaac	cggcacttct	ataaccagaa	cttctgcggg	3120
ggacctacag	cagaatagct	cagagcaaca	gctggaaaca	gctgcactct	catgcctggt	3180
tcccgagttg	ctctgcctgc					3200

<210> 2

<211> 3096

<212> DNA

<213> unknown

<400> 2

atggttctcc	gtcgaaggac	tctgcacccc	ttgtccctcc	tggtacaggg	tgcagtgctg	60
gctgagactc	tggccctggg	taccctgcct	gccttccctac	cctgtgagct	gaagcctcat	120
ggcctggtgg	actgcaattg	gctgttcctg	aagtctgtac	cccgtttctc	tgccgcagca	180
tctgtctcca	acatcacccg	cctctccttg	atctccaacc	gtatccacca	cctgcacaac	240
tccgactctg	tccacctgtc	caacctgcgg	cagctgaacc	tcaagtggaa	ctgtccaccc	300
actggcctta	gccccctgca	cttctctctg	cacatgaacca	ttgagccccg	aaccttcctg	360
gctatgcgta	cactggagga	gctgaacctg	agctataatg	gtatcaccac	tgtgccccga	420
ctgcccagct	ccctggtgaa	tctgagcctg	agccacacca	acatcctggt	tctagatgct	480
aacagcctcg	cgggcctata	cagcctgcgc	gttctcttca	tggacgggaa	ctgctactac	540
aagaacccct	gcacaggagc	gggtgaagggt	accccaggcg	ccctcctggg	cctgagcaat	600
ctcaccatc	tgtctctgaa	gtataacaac	ctcacaagg	tgccccgcc	actgcccccc	660
agcctggagt	acctcctggt	gtcctataac	ctcattgtca	agctggggcc	tgaagacctg	720
gccaatctga	cctccctctg	agtacttgat	gtgggtggga	attgcccgtc	ctgcgaccat	780
gcccccaatc	cctgtataga	atgtggccaa	aagtcctctc	acctgcaccc	tgagaccttc	840
catcacctga	gccatctgga	aggcctggtg	ctgaaggaca	gctctctcca	tacactgaac	900
tcttccctgg	tccaaggctc	ggtcaacctc	tgggtgctgg	acctaaagcg	gaactttctc	960
tatgaaagca	tcaaccacac	caatgccttt	cagaacctaa	ccgcctgcg	caagctcaac	1020
ctgtccttca	attaccgcaa	gaaggatcc	tttgcccgcc	tccacctggc	aagttccttc	1080
aagaacctgg	tgtcactgca	ggagctgaac	atgaacggca	tcttcttccg	ctcgcctaac	1140
aagtacacgc	tcagatggct	ggccgatctg	cccaaactcc	acactctgca	tcttcaaattg	1200
aacttcatca	accaggcaca	gctcagcatc	tttggtacct	tccgagccct	tgcgtttgtg	1260
gacttgtag	acaatcgcat	cagtgggcct	tcaacgcgtg	cagaagccac	ccctgaagag	1320
gcagatgatg	cagagcagga	ggagctgttg	tctgcccgatc	ctcaccacgc	tccactgagc	1380
accctgctt	ctaagaactt	catggacagg	tgtgaagaact	tcaagttcac	catggacctg	1440

tctcggaaaca	acctgggtgac	tatcaagcca	gagatggttg	tcaatctctc	acgcctccag	1500
tgtcttagcc	tgagccacaa	ctccattgca	caggctgtca	atggctctca	gttcctgccg	1560
ctgactaatc	tgacgggtgct	ggacctgtcc	cataacaaac	tggaacttgta	ccactggaaa	1620
tcgttcagtg	agctaccaca	gttgacggcc	ctggacctga	gctacaacag	ccagcccttt	1680
agcatgaagg	gtataggcca	caatttcagt	tttgtggccc	atctgtccat	gctacacagc	1740
cttagcctgg	cacacaatga	cattcatacc	cgtgtgtcct	cacatctcaa	cagcaactca	1800
gtgaggtttc	ttgacttcag	cggcaacggg	atgggcccga	tgtgggatga	ggggggcctt	1860
tatctccatt	tcttccaagg	cctgagtggc	ctgctgaagc	tggaacctgtc	tcaaaataac	1920
ctgcatatcc	tccggcccca	gaaccttgac	aacctcccca	agagcctgaa	gctgctgagc	1980
ctccgagaca	actacctatc	tttctttaac	tggaaccagtc	tgtccttccct	gcccacacctg	2040
gaagtcctag	acctggcagg	caaccagcta	aaggccctga	ccaatggcac	cctgcctaata	2100
ggcaccctcc	tccagaaact	ggatgtcagc	agcaacagta	togtctctgt	ggtcccagcc	2160
ttcttcgctc	tggcgggtcga	gctgaaagag	gtcaacctca	gccacaacat	tctcaagacg	2220
gtggatcgct	cctggttttg	gccattgtg	atgaacctga	cagttctaga	cgtgagaagc	2280
aacctctctg	actgtgectg	tggggcagcc	ttcgttagact	tactgttgga	ggtgcagacc	2340
aaggtgcctg	gcctggctaa	tgggtgtaag	tttggcagcc	ccggccagct	gcagggccgt	2400
agcatcttcg	cacaggacct	gcggctgtgc	ctggatgagg	tcctctcttg	ggactgcttt	2460
ggcctttcac	tcttggctgt	ggcctgtggc	atgggtgtgc	ctatactgca	ccatctctgc	2520
ggctgggacg	tctgtgactg	ttttcatctg	tgcctggcat	ggctaccttt	gctggcccgc	2580
agccgacgca	gcgcccagc	tctcccctat	gatgccttcg	tgggtgttca	taaggcacag	2640
agcgcagttg	cggactgggt	gtataacgag	ctgcgggtgc	ggctggagga	gcggcgcggt	2700
cgccgagccc	tacgcttgtg	tctggaggac	cgagattggc	tgcctggcca	gacgctcttc	2760
gagaacctct	gggcttccat	ctatgggagc	cgcaagactc	tatttgtgct	ggccacacag	2820
gaccgcgtca	gtggcctcct	gcgcaccagc	ttcctgtctg	ctcagcagcg	cctgtttgaa	2880
gaccgcaagg	acgtggtggt	gttggtgac	ctgcgtccgg	atgcccacgc	ctcccgtat	2940
gtgcgactgc	gccagcgtct	ctgccgccag	agtgtgtctc	tctggcccca	gcagcccaac	3000
gggcaggggg	gcttctgggc	ccagctgagt	acagccctga	ctagggacaa	ccgccacttc	3060
tataaccaga	acttctgccc	gggacctaca	gcagaa			3096

<210> 3

<211> 3352

<212> DNA

<213> unknown

<400> 3

aggtcgggtat	aaaaatctta	cttctcttat	tctctgagcc	gctgctgccc	ctgtgggaag	60
ggacctcgag	tgtgaagcat	ccttccctgt	agctgctgtc	cagtctgccc	gccagacctc	120
ctggagaagc	ccctgcccc	cagcatgggt	ttctgcccga	gcgccctgca	cccgctgtct	180
ctcctgggtgc	aggccatcat	gctggccatg	accttgcccc	tgggtacctt	gcctgccttc	240
ctacctgtg	agctccagcc	ccacggcctg	gtgaactgca	actggctgtt	cctgaagtct	300
gtgccccact	tctccatggc	agcaccctgt	ggcaatgtca	ccagcctttc	cttgtcctcc	360
aaccgcaccc	accacctcca	tgattctgac	tttgcccacc	tgccagacct	gcggcatctc	420
aaactcaagt	ggaactgccc	gccggttggc	ctcagcccca	tgcacttccc	ctgccacatg	480
accatcgagc	ccagcacctt	cctggctgtg	cccaccctgg	aagagctaaa	cctgagctac	540
aacaacatca	tgactgtgcc	tgcgtgccc	aaatccctca	tatccctgtc	cctcagccat	600
accaacatcc	tgatgctaga	ctctgccagc	ctcgccggcc	tgcattgccc	gcgcttccca	660
ttcatggacg	gcaactgtta	ttacaagaac	ccctgcaggc	aggcactgga	ggtggccccg	720
ggtgccctcc	ttggcctggg	caacctcacc	cacctgtcac	tcaagtacaa	caacctcact	780
gtggtgcccc	gcaacctgcc	ttccagcctg	gagtatctgc	tgttgtccca	caaccgcctc	840
gtcaaaactgg	cgctgagga	cctggccaat	ctgaccgccc	tgcgtgtgct	cgatgtgggc	900
ggaaattggc	gcgctgcca	ccacgtccc	aaccttgca	tggagtgcct	tcgtcacttc	960
ccccagctac	atcccagatac	cttcagccac	ctgagccgtc	ttgaaggcct	ggtgttgaag	1020
gacagttctc	tctcctggct	gaatgccagt	tgggtccgtg	ggctgggaaa	cctccgagtg	1080
ctggacctga	gtgagaactt	cctctacaaa	tgcataccta	aaaccaaggc	cttccagggc	1140
ctaaccacagc	tgcgcaagct	taacctgtcc	ttcaattacc	aaaagagggt	gtcctttgcc	1200
caactgtctc	tggcccttcc	cttcgggagc	ctggtcgccc	tgaaggagct	ggacatgcac	1260
ggcatcttct	tccgctcact	cgatgagacc	acgctccggc	cactggcccc	cctgcccctg	1320
ctccagactc	tgcgtctgca	gatgaacttc	atcaaccagg	cccagctcgg	catcttcagg	1380
gccttccctg	gcctgcgcta	cgtggacctg	tccgacaacc	gcatacagcg	agcttcggag	1440

ctgacagcca	ccatggggga	ggcagatgga	ggggagaagg	tctggctgca	gcctggggac	1500
cttgctccgg	ccccagtgga	cactcccagc	tctgaagact	tcaggcccaa	ctgcagcacc	1560
ctcaacttca	ccttgatctt	gtcacggaac	aacctggtga	ccgtgcagcc	ggagatgttt	1620
gcccagctct	cgcacctgca	gtgcctgcgc	ctgagccaca	actgcatctc	gcaggcagtc	1680
aatggctccc	agttcctgcc	gctgaccggt	ctgcagggtg	tagacctgtc	ccgcaataag	1740
ctggacctct	accacgagca	ctcattcacg	gagctaccgc	gactggaggc	cctggacctc	1800
agctacaaca	gccagccctt	tggcatgcag	ggcgtggggc	acaacttcag	cttcgtggct	1860
cacctgcgca	ccctgcgcca	cctcagcctg	gcccacaaca	acatccacag	ccaagtgtcc	1920
cagcagctct	gcagtacgtc	getgcggggc	ctggacttca	gcggcaatgc	actggggccat	1980
atgtgggccc	agggagacct	ctatctgcac	ttcttccaag	gcctgagcgg	tttgatctgg	2040
ctggacttgt	cccagaaccg	cctgcacacc	ctcctgcccc	aaacctgcg	caacctcccc	2100
aagagcctac	aggtgctgcg	tctccgtgac	aattacctgg	ccttctttaa	gtggtggagc	2160
ctccacttcc	tgcccaaac	ggaagtccct	gacctggcag	gaaaccggct	gaaggccctg	2220
accaatggca	gcctgcctgc	tggcaccg	ctccggaggc	tggatgtcag	ctgcaacagc	2280
atcagcttgc	tggcccccgg	cttcttttcc	aaggccaagg	agctgcgaga	gctcaacctt	2340
agcgccaacg	ccctcaagac	agtggaccac	tcctggtttg	ggccctggc	gagtgcctg	2400
caaatactag	atgtaagcgc	caacctctct	cactgcgcct	gtggggcggc	ctttatggac	2460
ttcctgctgg	aggtgcaggc	tgcctgccc	ggtctgcccc	gcgggtgaa	gtgtggcagt	2520
ccgggcccagc	tccagggcct	cagcatcttt	gcacaggacc	tgcgcctctg	cctggatgag	2580
gcccctctct	gggactgttt	cgcctctctg	ctgctggctg	tggctctggg	cctgggtgtg	2640
cccatgctgc	atcacctctg	tggctgggac	ctctgggtact	gcttccacct	gtgcctggcc	2700
tggcttccct	ggcggggggc	gcaaagtggg	cgagatgagg	atgccctgcc	ctacgatgcc	2760
ttcgtggctt	tcgacaaaac	gcagagcgca	gtggcagact	gggtgtacaa	cgagctctcg	2820
gggcagctgg	aggagtgcgc	tgggcgctgg	gcactccgcc	tgtgcctgga	ggaaccgcgac	2880
tggctgcctg	gcaaaaccct	ctttgagaac	ctgtgggccc	cggctctatg	cagccgcaag	2940
acgctgtttg	tgttgcccca	cacggaccgg	gtcagtggct	tcttgccg	cagcttccctg	3000
ctggcccagc	agcgccctgt	ggaggaccgc	aaggacgtcg	tgggtgctgg	gatcctgagc	3060
cctgacggcc	gcccgtcccg	ctacgtgcgg	ctgcgccagc	gcctctgccg	ccagagtgtc	3120
ctcctctggc	cccaccagcc	cagtggctcag	cgcagcttct	gggcccagct	gggcatggcc	3180
ctgaccaggg	acaaccacca	cttctataac	cggaaacttct	gccagggacc	cacggccgaa	3240
tagccgtgag	ccggaatcct	gcacgggtgc	acctccacac	tcacctcacc	tctgcctgccc	3300
tggctctgacc	ctccctctgt	cgcctccctc	acccacacac	tgacacagag	ca	3352

<210> 4

<211> 3868

<212> DNA

<213> unknown

<400> 4

ggaggtcttg	tttccggaag	atgttgcaag	gctgtggtga	aggcagggtgc	agcctagcct	60
cctgtctcaag	ctacaccctg	gccctccacg	catgaggccc	tgcagaaatc	tggagatggg	120
gcctacaagg	gcagaaaagg	acaagtccgc	agccgctgtc	ctgaggggcac	cagctgtggg	180
gcaggagcca	agacctgagg	gtggaagtgt	cctcttagaa	tggggagtgc	ccagcaagg	240
gtaccgccta	ctgggtctat	ccagaattcc	catctctccc	tgtctctctg	ctgagctctg	300
ggccttagct	cctccctggg	cttggtagag	gacagggtgt	aggccctcat	gggatgtagg	360
ctgtctgaga	ggggagtggg	aagaggaagg	ggtgaaggag	ctgtctgcc	tttgactatg	420
caaatggcct	ttgactcatg	ggaccctgtc	ctcctcactg	ggggcagggt	ggagtggagg	480
gggagctact	aggtcgttat	aaaatcttta	cttctcttat	tctctgagcc	gctgctgccc	540
ctgtgggaag	ggacctcgag	tgtgaagcat	ccttccctgt	agctgctgtc	cagtctgccc	600
gccagaccct	ctggagaagc	ccctgcccc	cagcatgggt	ttctgccgca	gcgccctgca	660
cccgctgtct	ctcctgggtg	aggccatcat	gctggccatg	acctgggcc	tgggtacctt	720
gctgccttcc	ctaccctgtg	agctccagcc	ccacggcctg	gtgaactgca	actggctgtt	780
cctgaagtct	gtgccccact	tctccatggc	agcaccctgt	ggcaatgtca	ccagccttcc	840
cttgcctctc	aaccgcatcc	accacctcca	tgattctgac	tttgcccacc	tgccagcctt	900
gcggcatctc	aacctcaagt	ggaactgccc	gccggttgcc	ctcagcccca	tgcacttccc	960
ctggccacatg	accatcgagc	ccagcacctt	cttggctgtg	cccaccctgg	aagagctaaa	1020
cctgagctac	aacaacatca	tgactgtgcc	tgcgtgccc	aaatccctca	tatccctgtc	1080
cctcagccat	accaacatcc	tgatgctaga	ctctgccagc	ctcgccggcc	tgcattgccc	1140
gcgcttcccta	ttcatggacg	gcaactgtta	ttacaagaac	ccctgcaggc	aggcactgga	1200

ggtggccccg	ggtgccctcc	ttggcctggg	caacctcacc	cacctgtcac	tcaagtacaa	1260
caacctcact	gtggtgcccc	gcaacctgcc	ttccagcctg	gagtatctgc	tggtgtccta	1320
caaccgcac	gtcaaaactgg	cgctgagga	cctggccaat	ctgaccgcc	tgctgtgct	1380
cgatgtgggc	ggaaattgcc	gccgtgcga	ccacgtccc	aacctctgca	tggagtggcc	1440
tctgacttc	cccagctac	atcccgatac	cttcagccac	ctgagccgtc	ttgaaggcct	1500
ggtgttgaag	gacagttctc	tctcctggct	gaatgccagt	tggttccgtg	ggctgggaaa	1560
cctccgagtg	ctggacctga	gtgagaactt	cctctacaaa	tgcatcacta	aaaccaaggc	1620
cttccagggc	ctaacacagc	tgcgcaagct	taacctgtcc	ttcaattacc	aaaagagggt	1680
gtcctttggc	cacctgtctc	tggcccttcc	cttcgggagc	ctggtcgccc	tgaaggagct	1740
ggacatgcac	ggcatcttct	tccgtcact	cgatgagacc	acgtccggc	cactggcccg	1800
cctgcccattg	ctccagactc	tgcgtctgca	gatgaacttc	atcaaccagg	cccagctcgg	1860
catcttcagg	gccttccctg	gcctgcgcta	cgtggacctg	toggacaacc	gcacagcgg	1920
agcttcggag	ctgacagcca	ccatggggga	ggcagatgga	ggggagaagg	tctggctgca	1980
gcctggggac	cttgctccgg	ccccagtggg	cactcccagc	tctgaagact	tcaggcccaa	2040
ctgcagcacc	ctcaacttca	ccttggatct	gtcacggaac	aacctgggtga	ccgtgcagcc	2100
ggagatgttt	gccagctctc	cgacactgca	gtgcctgcg	ctgagccaca	actgcatctc	2160
gcaggcagtc	aatggctccc	agttcctgcc	ctgaccggt	ctgcagggtc	tagacctgtc	2220
ccacaataag	ctggacctct	accacgagca	ctcattcacg	gagctaccac	gactggaggc	2280
cctggacctc	agctacaaca	gccagccctt	tggcatgcag	ggcgtggggc	acaacttcag	2340
cttcgtggct	cacctgcgca	ccctgcgcca	cctcagcctg	gcccacacaa	acatccacag	2400
ccaagtgtcc	cagcagctct	gcagtacgtc	gctgcggggc	ctggacttca	gcggaatgc	2460
actgggcat	atgtggggcg	agggagacct	ctatctgcac	ttcttccaag	gcctgagcgg	2520
tttgatctgg	ctggacttgt	cccagaaccg	ctgcacacc	ctcctgcccc	aaacctgcg	2580
caacctcccc	aagagcctac	aggtgtgtcg	tctccgtgac	aattacctgg	ccttctttaa	2640
gtggtggagc	ctccacttcc	tgcctaaact	ggaagtcttc	gacctggcag	gaaaccagct	2700
gaaggccctg	accaatggca	gcctgcctgc	tggcaccggg	ctccggaggc	tggatgtcag	2760
ctgcaacagc	atcagcttcg	tggcccccg	cttcttttcc	aaggccaagg	agctgcgaga	2820
gctcaacctt	agcgccaacg	ccctcaagac	agtggaccac	tcctggtttg	ggccccctggc	2880
gagtgccttg	caaatactag	atgtaagcgc	caacctctg	cactgcgcct	gtggggcgccg	2940
ctttatggac	ttctgtctgg	aggtgcaggc	tgcgtgccc	ggtctgccc	gccgggtgaa	3000
gtgtggcagt	cggggccagc	tccaggccct	cagcatcttt	gcacaggacc	tgcgcctctg	3060
cctggatgag	gccctctcct	gggactgttt	cgccctctcg	ctgctggctg	tggctctggg	3120
cctgggtgtg	cccagctgct	atcacctctg	tggctgggac	ctctggtact	gcttccacct	3180
gtgcctggcc	tggcttccct	ggcggggggc	gcaaagtggg	cgagatgagg	atgccctgcc	3240
ctacgatgcc	ttcgtggtct	tgcacaaaac	gcagagcgca	gtggcagact	gggtgtacaa	3300
cgagcttcgg	gggcagctgg	aggagtgcgc	tgggcgctgg	gcactccgcc	tgtgccttga	3360
ggaacgcgac	tggctgcttg	gcaaaaccct	ctttgagaac	ctgtgggccc	cggctctagg	3420
cagcgcgaag	acgctgtttg	tgcctggcca	cacggaccgg	gtcagtggtc	tcttgcgcgc	3480
cagcttctctg	ctggcccagc	agcgcctgct	ggaggaccgc	aaggacgtcg	tgggtgctgg	3540
gacctgagc	cctgacggcc	gccgtctccg	ctacgtgcgg	ctgcgcagc	gcctctgccc	3600
ccagagtgtc	ctcctctggc	cccaccagcc	cagtgttcag	cgcagcttct	gggccagct	3660
gggcatggcc	ctgaccaggg	acaaccacca	cttctataac	cggaaacttct	gccaggggacc	3720
cacggccgaa	tagccgtgag	cgggaatcct	gcacggtgcc	acctccacac	tcacctcacc	3780
tctgcctgcc	tggctctgac	ctccctgct	cgcctccctc	acccacacac	tgacacagag	3840
caggcaactca	ataaatgcta	ccgaaggc				3868

<210> 5

<211> 557

<212> DNA

<213> unknown

<400> 5

ggctttcaac	ctaaccgctg	gcactcaacc	tgtccttcaa	ttaccgcaag	aaggatcct	60
ttgcccgcct	ccacctggca	agttccttta	agaacctgg	gtcactgcag	gagctgaaca	120
tgaacggcat	cttcttccgc	ttgtcaca	agtacacgct	cagatggctg	gccgatctgc	180
ccaaactcca	cactctgcac	cttcaaatga	acttcatcaa	ccaggcacag	ctcagcatct	240
ttggtacctt	cagagccctt	cgttttgtgg	acttgtcaga	caatcgcatc	agtgggcctt	300
caacgctgtc	agaagccacc	cctgaagagg	cagatgatgc	agagcaggag	gagctgttgt	360
ctgcggtacc	tcacccagct	cgcgtgagca	cccctgcttc	taagaacttc	atggacagg	420

gtaagaactt	caagttcaac	atggacctgt	ctcggaacaa	cctgggtgact	atcacagcag	480
agatgtttgt	aaatctctca	cgccctccagt	gtcttagcct	gagccacaac	tcaattgcac	540
aggctgtcaa	tggtctct					557

<210> 6
 <211> 497
 <212> DNA
 <213> unknown

<400> 6						
gtgggttttg	tgtctatctt	cactctcctg	aaagatgcat	gggaagaaaa	ctacccttta	60
cagccaacct	ttgctccgtg	ggcctgggtg	cttggttagca	tatatgctgc	acttgccaaa	120
tagcgggtga	gtaagacaga	gcaaggcagg	cagagcaact	cgggaaccag	acatgaagat	180
gcagctgttt	ccagctgttg	ctctgagcta	ttctgctgta	ggtccccggc	agaagtctctg	240
gttatagaag	tggtcggttg	ccctagtcag	ggctgtactc	agctgggccc	agaagcccc	300
ctgcccggtg	ggtcgctggg	gccagaagag	cacactctgg	cggcagagac	gctggcgag	360
tcgcacatag	cgggacggtn	gggcattccg	acgcaggatc	accaacacca	ccacgtcctt	420
gcggtcttcc	aacaggcget	gctgagccag	caggaagctg	gtgcgcagga	ggccactgac	480
gcggctccgtg	tgggcca					497

<210> 7
 <211> 373
 <212> DNA
 <213> unknown

<400> 7						
tggaggaccg	agattggctg	cctggccaga	cgctcttcga	gaacctctgg	gcttccatct	60
atgggagccg	caagactcta	tttgtgctgg	cccacacgga	ccgcgtcagt	ggcctcctgc	120
gcaccagctt	cctgctggct	cagcagcgcc	tggtggaaga	ccgcaaggac	gtgggtgggtg	180
tggtgatcct	gcgtccggat	gcccaccgct	cccgctatgt	gcgactgcgc	cagcgtctct	240
gccgccagag	tgtgctcttc	tggtcccccagc	agcccaacgg	gcaggggggc	ttctggggccc	300
agctgagtac	agcctgact	agggacaacc	gccacttcta	taaccagaac	ttctgccggg	360
gacctacagc	aga					373

<210> 8
 <211> 489
 <212> DNA
 <213> unknown

<400> 8						
gctacaacag	ccagcccttt	agcatgaagg	gtataggcca	caatttcagt	tttgtgaccc	60
atctgtccat	gctacagagc	cttagccctg	cacacaatga	cattcatacc	cgtgtgtcct	120
cacatctcaa	cagcaactca	gtgaggttcc	ttgacttcag	cggcaacggc	atggggccgca	180
tgtgggatga	ggggggcctt	tatctccatt	tcttccaagg	cctgagtggc	gtgctgaagc	240
tggaactgtc	tcaaaataac	ctgcataatc	tccggcccca	gaacottgac	aacctcccca	300
agagcctgaa	gctgctgagc	ctccgagaca	actacctatc	tttctttaac	tggaaccagtc	360
tgtccttcct	acccaacctg	gaagtccctag	acctggcagg	caaccagcta	aaggccctga	420
ccaatggcac	cctgcctaata	ggcaccctcc	tccagaaact	cgatgtcagt	agcaacagta	480
tcgtctctg						489

<210> 9
 <211> 462
 <212> DNA
 <213> unknown

<400> 9						
gcggccgcgc	cgctcctcca	gccgcaccgc	cagctcggtta	tacaccagct	cggcaactgc	60
gctctgtgcc	ttatcgaaca	ccacgaaggc	atcataaggg	agagtttggg	cgctgcgtcg	120
gctgcgggct	agcaaaaggta	gccatgccag	gcacagatga	aaacagtacc	agacgtccca	180

```

gccgcagaga tgggtgcagta taggcaccac catgcccacg gccacagcca agagtgaag      240
gcccagagcag tcccaagaga ggacctcatc caggcacagc cgcaggtcct gcgcgaagat      300
gctacggccc tgcagctggc cggggctgcc acacttcaca ccattagcca ggccaggcac      360
cttgggtctgc acctccaaca gtaagtctac gaaggctgcc ccacaggcac agtgcagagg      420
gttgcttctc acgtctagaa ctgtcagggt catcacaatg gg                          462

```

<210> 10

<211> 1032

<212> PRT

<213> unknown

<400> 10

```

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
 1          5          10          15
Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
          20          25          30
Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
          35          40          45
Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn
          50          55          60
Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
          65          70          75          80
Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
          85          90          95
Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
          100          105          110
Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
          115          120          125
Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
          130          135          140
Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
          145          150          155          160
Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
          165          170          175
Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
          180          185          190
Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
          195          200          205
Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
          210          215          220
Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
          225          230          235          240
Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
          245          250          255
Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
          260          265          270
Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
          275          280          285
Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
          290          295          300
Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
          305          310          315          320
Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu
          325          330          335
Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala
          340          345          350
Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu
          355          360          365
Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu

```

370	375	380
Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met		
385	390	395
Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala		400
	405	410
Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr		415
	420	425
Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu		430
	435	440
Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser		445
	450	455
Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu		460
465	470	475
Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu		480
	485	490
Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala		495
	500	505
Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp		510
	515	520
Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu		525
530	535	540
Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe		545
545	550	555
Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser		560
	565	570
Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val		575
	580	585
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly		590
	595	600
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe		605
610	615	620
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn		625
625	630	635
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu		640
	645	650
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr		655
	660	665
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn		670
	675	680
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu		685
690	695	700
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala		705
	710	715
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn		720
	725	730
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn		735
	740	745
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly		750
	755	760
Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly		765
	770	775
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg		780
785	790	795
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser		800
	805	810
Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val		815
	820	825
Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe		830
	835	840
		845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser
 850 855 860
 Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
 865 870 875 880
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
 885 890 895
 Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
 900 905 910
 Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
 915 920 925
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
 930 935 940
 Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
 945 950 955 960
 Asp Arg Lys Asp Val Val Leu Val Ile Leu Arg Pro Asp Ala His
 965 970 975
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
 980 985 990
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln
 995 1000 1005
 Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln Asn
 1010 1015 1020
 Phe Cys Arg Gly Pro Thr Ala Glu
 1025 1030

<210> 11
 <211> 1032
 <212> PRT
 <213> unknown

<400> 11
 Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 10 15
 Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
 20 25 30
 Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
 35 40 45
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
 50 55 60
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
 65 70 75 80
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
 85 90 95
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
 100 105 110
 Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
 115 120 125
 Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
 130 135 140
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
 145 150 155 160
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
 165 170 175
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
 180 185 190
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
 195 200 205
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
 210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
 225 230 235 240
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
 245 250 255
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
 260 265 270
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
 275 280 285
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
 290 295 300
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
 305 310 315 320
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
 325 330 335
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
 340 345 350
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu
 355 360 365
 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
 370 375 380
 Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
 385 390 395 400
 Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
 405 410 415
 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu
 420 425 430
 Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
 435 440 445
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu
 450 455 460
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser
 465 470 475 480
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
 485 490 495
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val
 500 505 510
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
 515 520 525
 Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu
 530 535 540
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
 545 550 555 560
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
 565 570 575
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
 580 585 590
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
 595 600 605
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
 610 615 620
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
 625 630 635 640
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
 645 650 655
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
 660 665 670
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg
 675 680 685
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg

690	695	700
Arg Leu Asp Val Ser	Cys Asn Ser Ile Ser	Phe Val Ala Pro Gly Phe
705	710	715
Phe Ser Lys Ala Lys	Glu Leu Arg Glu Leu Asn	Leu Ser Ala Asn Ala
	725	730
Leu Lys Thr Val Asp	His Ser Trp Phe Gly	Pro Leu Ala Ser Ala Leu
	740	745
Gln Ile Leu Asp Val	Ser Ala Asn Pro Leu His	Cys Ala Cys Gly Ala
	755	760
Ala Phe Met Asp Phe	Leu Leu Glu Val Gln	Ala Ala Val Pro Gly Leu
	775	780
Pro Ser Arg Val Lys	Cys Gly Ser Pro Gly	Gln Leu Gln Gly Leu Ser
785	790	795
Ile Phe Ala Gln Asp	Leu Arg Leu Cys Leu	Asp Glu Ala Leu Ser Trp
	805	810
Asp Cys Phe Ala Leu	Ser Leu Leu Ala Val	Ala Leu Gly Leu Gly Val
	820	825
Pro Met Leu His His	Leu Cys Gly Trp Asp	Leu Trp Tyr Cys Phe His
	835	840
Leu Cys Leu Ala Trp	Leu Pro Trp Arg Gly	Arg Gln Ser Gly Arg Asp
	850	855
Glu Asp Ala Leu Pro	Tyr Asp Ala Phe Val	Val Phe Asp Lys Thr Gln
865	870	875
Ser Ala Val Ala Asp	Trp Val Tyr Asn Glu	Leu Arg Gly Gln Leu Glu
	885	890
Glu Cys Arg Gly Arg	Trp Ala Leu Arg Leu	Cys Leu Glu Glu Arg Asp
	900	905
Trp Leu Pro Gly Lys	Thr Leu Phe Glu Asn	Leu Trp Ala Ser Val Tyr
	915	920
Gly Ser Arg Lys Thr	Leu Phe Val Leu Ala	His Thr Asp Arg Val Ser
	930	935
Gly Leu Leu Arg Ala	Ser Phe Leu Leu Ala	Gln Gln Arg Leu Leu Glu
945	950	955
Asp Arg Lys Asp Val	Val Val Leu Val Ile	Leu Ser Pro Asp Gly Arg
	965	970
Arg Ser Arg Tyr Val	Arg Leu Arg Gln Arg	Leu Cys Arg Gln Ser Val
	980	985
Leu Leu Trp Pro His	Gln Pro Ser Gly Gln	Arg Ser Phe Trp Ala Gln
	995	1000
Leu Gly Met Ala Leu	Thr Arg Asp Asn His	His Phe Tyr Asn Arg Asn
	1010	1015
Phe Cys Gln Gly Pro	Thr Ala Glu	
1025	1030	

<210> 12
 <211> 178
 <212> PRT
 <213> unknown

<400> 12
 Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala Arg Leu
 1 5 10 15
 His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu Leu Asn
 20 25 30
 Met Asn Gly Ile Phe Phe Arg Leu Leu Asn Lys Tyr Thr Leu Arg Trp
 35 40 45
 Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met Asn Phe
 50 55 60
 Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala Leu Arg

[illegible]

```
<210> 13
<211> 95
<212> PRT
<213> unknown
```

<400> 13															
Ala	His	Thr	Asp	Arg	Val	Ser	Gly	Leu	Leu	Arg	Thr	Ser	Phe	Leu	Leu
1				5					10					15	
Ala	Gln	Gln	Arg	Leu	Leu	Glu	Asp	Arg	Lys	Asp	Val	Val	Val	Leu	Val
			20					25					30		
Ile	Leu	Arg	Pro	Asp	Ala	Xaa	Pro	Ser	Arg	Tyr	Val	Arg	Leu	Arg	Gln
		35					40					45			
Arg	Leu	Cys	Arg	Gln	Ser	Val	Leu	Phe	Trp	Pro	Gln	Arg	Pro	Asn	Gly
	50					55					60				
Gln	Gly	Gly	Phe	Trp	Ala	Gln	Leu	Ser	Thr	Ala	Leu	Thr	Arg	Asp	Asn
65					70					75					80
Arg	His	Phe	Tyr	Asn	Gln	Asn	Phe	Cys	Arg	Gly	Pro	Thr	Ala	Glu	
				85					90					95	

```
<210> 14
<211> 123
<212> PRT
<213> unknown
```

<400> 14															
Glu	Asp	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Thr	Leu	Phe	Glu	Asn	Leu	Trp
1				5					10					15	
Ala	Ser	Ile	Tyr	Gly	Ser	Arg	Lys	Thr	Leu	Phe	Val	Leu	Ala	His	Thr
			20					25					30		
Asp	Arg	Val	Ser	Gly	Leu	Leu	Arg	Thr	Ser	Phe	Leu	Leu	Ala	Gln	Gln
		35					40					45			
Arg	Leu	Leu	Glu	Asp	Arg	Lys	Asp	Val	Val	Val	Leu	Val	Ile	Leu	Arg
	50					55					60				
Pro	Asp	Ala	His	Arg	Ser	Arg	Tyr	Val	Arg	Leu	Arg	Gln	Arg	Leu	Cys
65					70						75				80
Arg	Gln	Ser	Val	Leu	Phe	Trp	Pro	Gln	Gln	Pro	Asn	Gly	Gln	Gly	Gly
				85					90					95	
Phe	Trp	Ala	Gln	Leu	Ser	Thr	Ala	Leu	Thr	Arg	Asp	Asn	Arg	His	Phe
			100					105					110		
Tyr	Asn	Gln	Asn	Phe	Cys	Arg	Gly	Pro	Thr	Ala					
		115					120								

<210> 15

<211> 162
 <212> PRT
 <213> unknown

<400> 15
 Tyr Asn Ser Gln Pro Phe Ser Met Lys Gly Ile Gly His Asn Phe Ser
 1 5 10 15
 Phe Val Thr His Leu Ser Met Leu Gln Ser Leu Ser Leu Ala His Asn
 20 25 30
 Asp Ile His Thr Arg Val Ser Ser His Leu Asn Ser Asn Ser Val Arg
 35 40 45
 Phe Leu Asp Phe Ser Gly Asn Gly Met Gly Arg Met Trp Asp Glu Gly
 50 55 60
 Gly Leu Tyr Leu His Phe Phe Gln Gly Leu Ser Gly Val Leu Lys Leu
 65 70 75 80
 Asp Leu Ser Gln Asn Asn Leu His Ile Leu Arg Pro Gln Asn Leu Asp
 85 90 95
 Asn Leu Pro Lys Ser Leu Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu
 100 105 110
 Ser Phe Phe Asn Trp Thr Ser Leu Ser Phe Leu Pro Asn Leu Glu Val
 115 120 125
 Leu Asp Leu Ala Gly Asn Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu
 130 135 140
 Pro Asn Gly Thr Leu Leu Gln Lys Leu Asp Val Ser Ser Asn Ser Ile
 145 150 155 160
 Val Ser

<210> 16

<400> 16

000

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/022809 A3

(51) International Patent Classification⁷: **C07K 14/705**,
C12N 15/12, G01N 33/50, 33/68, C12N 15/62, 15/63,
15/10, A61K 38/17

(21) International Application Number: PCT/US01/29229

(22) International Filing Date:
17 September 2001 (17.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/233,035 15 September 2000 (15.09.2000) US
60/263,657 23 January 2001 (23.01.2001) US
60/291,726 17 May 2001 (17.05.2001) US
60/300,210 22 June 2001 (22.06.2001) US

(71) Applicant (for all designated States except US): **COLEY
PHARMACEUTICAL GMBH** [DE/DE]; Elisabeth-Sel-
bert-Strasse 9, 40764 Langenfeld (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAUER, Stefan**
[DE/DE]; Waisenhausstrasse 13, 80637 Munchen (DE);
LIPFORD, Grayson [US/US]; Innere Wiener Strasse 7A,
81667 Munchen (DE); **WAGNER, Hermann** [DE/DE];
Knaagangerstrasse 36, 82279 Eching (DE).

(74) Agent: **STEELE, Alan, W.**; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SI, SG, SL,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GI, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NI, SN, TD,
TG).

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
2 October 2003

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 12/2003 of 20 March 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST

(57) Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes frag-
ments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8.



WO 02/022809 A3

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 01/29229

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 C12N15/12 G01N33/50 G01N33/68 C12N15/62
C12N15/63 C12N5/10 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBL, WPI Data, PAJ, CHEM ABS Data, SEQUENCE SEARCH, MEDLIN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL [Online] EBI; Human Toll protein PR0286, 2 August 1999 (1999-08-02) retrieved from EMBL Database accession no. AAY05867 XP002221249 see sequence	5-8,13
A	--- TAKEUCHI D ET AL: "TLR6: A novel member of an expanding Toll-like receptor family." GENE (AMSTERDAM), vol. 231, no. 1-2, 29 April 1999 (1999-04-29), pages 59-65, XP004166778 ISSN: 0378-1119 the whole document --- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 December 2002

Date of mailing of the international search report

22.07.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2260 IV Rijswijk
Tel. (+31-70) 340-2040; Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Bassias, I

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/29229

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim: No.
A	<p>DU XIN ET AL: "three novel mammalian toll-like receptors: Gene structure, expression, and evolution." EUROPEAN CYTOKINE NETWORK, vol. 11, no. 3, September 2000 (2000-09), pages 362-371, XP009000972 ISSN: 1148-5493 cited in the application the whole document</p> <p>---</p>	
A	<p>HOSHINO K ET AL: "Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 APR 1999, vol. 162, no. 7, 1 April 1999 (1999-04-01), pages 3749-3752, XP002221244 ISSN: 0022-1767 the whole document</p> <p>---</p>	
A	<p>XIN DU ET AL: "THREE NOVEL MAMMALIAN TOLL-LIKE RECEPTORS: GENE STRUCTURE, EXPRESSION, AND EVOLUTION" EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD., MONTROUGE, FR, vol. 11, no. 3, September 2000 (2000-09), pages 1-14, XP002944897 ISSN: 1148-5493 the whole document</p> <p>---</p>	
A	<p>KOPP E B ET AL: "The Toll-receptor family and control of innate immunity" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 11, no. 1, 1 February 1999 (1999-02-01), pages 13-18, XP004257650 ISSN: 0952-7915 the whole document</p> <p>---</p>	
A	<p>MUZIO MARTA ET AL: "Toll-like receptors." MICROBES AND INFECTION, vol. 2, no. 3, March 2000 (2000-03), pages 251-255, XP002221245 ISSN: 1286-4579 the whole document</p> <p>---</p>	
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/29229

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>HEMMI HIROAKI ET AL: "A Toll-like receptor recognizes bacterial DNA." NATURE (LONDON), vol. 408, no. 6813, 2000, pages 740-745, XP002221246 ISSN: 0028-0836 the whole document, in particular the figures -& NATURE, vol. 409, February 2001 (2001-02), page 646 XP002224870 *Erratum from page 741, Figure 1*</p>	<p>1-21, 58-76, 79-120</p>
P,X	<p>WO 01 55386 A (GLAXOSMITHKLINE ;RAY KEITH PAUL (GB); LEWIS ALAN PETER (GB)) 2 August 2001 (2001-08-02)</p> <p>the whole document, in particular SEQ ID NO: 1, 2 and claims</p>	<p>5-13,18, 19, 58-76, 79-120</p>
P,X	<p>BAUER STEFAN ET AL: "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 16, 31 July 2001 (2001-07-31), pages 9237-9242, XP002221247 July 31, 2001 ISSN: 0027-8424 the whole document</p>	<p>59, 61-76, 79-120</p>
P,X	<p>-& DATABASE ENBL [Online] EBI; Mus musculus toll-like receptor 9 (Tlr9), 5 April 2001 (2001-04-05) retrieved from EMBL Database accession no. AF348140 XP002221250 see sequence</p>	<p>1-13,58, 60</p>
T	<p>CHUANG TSUNG-HSIEN ET AL: "Toll-like receptor 9 mediates CpG-DNA signaling." JOURNAL OF LEUKOCYTE BIOLOGY, vol. 71, no. 3, March 2002 (2002-03), pages 538-544, XP009001226 March, 2002 ISSN: 0741-5400 the whole document</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/29229

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in the international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-21, 58-61, 120(all completely); 62-76, 79-119 (all partially, relating to TLR9)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Present claim 5 relates to an extremely large number of possible TLR9 polypeptides. In fact, the claim contains so many options, variables, possible permutations and provisos that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claim impossible. Furthermore, such a claim is not sufficiently disclosed over its whole breadth. It cannot be assumed automatically that each of the potentially possible polypeptides has the requested properties.

Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise) and which are considered to be sufficiently disclosed, namely the TLR9 polypeptide having the amino acid sequence as set forth in SEQ ID NO: 3. All following claims referring to claim 5 (claims 6-13, 18-21, 58-61 and 120) are accordingly searched in the limited manner.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination or matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-21, 58-61, 120 (all completely); 62-76, 79-119 (all partially, relating to TLR9)

Nucleic acid molecules encoding murine TLR9, thereof encoded polypeptides, corresponding expression vectors and host cells, methods for inhibiting TLR9 signaling activity, methods for identifying nucleic acid molecules which interact with TLR9, screening methods for identifying ISNA binding to TLR9 and determining species specificity of ISNA, screening methods for comparing TLR9 signaling activity of a test compound with an ISNA and a method for identifying lead compounds for a pharmacological agent useful in treating a disease associated with TLR9 signaling activity.

2. Claims: 22-39 (all completely); 62-77, 80-89, 92-104, 107-119 (all partially, relating to TLR7)

Nucleic acid molecules encoding murine TLR7, thereof encoded polypeptides, corresponding expression vectors and host cells, methods for inhibiting TLR7 signaling activity, methods for identifying nucleic acid molecules which interact with TLR7, screening methods for identifying ISNA binding to TLR7 and determining species specificity of ISNA, and screening methods for comparing TLR7 signaling activity of a test compound with an ISNA.

3. Claims: 40-57 (all completely); 62-76, 78, 80-89, 92-104, 107-119 (all partially, relating to TLR8)

Nucleic acid molecules encoding murine TLR8, thereof encoded polypeptides, corresponding expression vectors and host cells, methods for inhibiting TLR8 signaling activity, methods for identifying nucleic acid molecules which interact with TLR8, screening methods for identifying ISNA binding to TLR8 and determining species specificity of ISNA, and screening methods for comparing TLR8 signaling activity of a test compound with an ISNA.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/29229

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0155386	A	02-08-2001	AU 2866501 A	07-08-2001
			EP 1250436 A1	23-10-2002
			WO 0155386 A1	02-08-2001
			US 2003022302 A1	30-01-2003

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/022809 A2

(51) International Patent Classification: C12N 15/00

(21) International Application Number: PCT/US01/29229

(22) International Filing Date:
17 September 2001 (17.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/233,035 15 September 2000 (15.09.2000) US
60/263,657 23 January 2001 (23.01.2001) US
60/291,726 17 May 2001 (17.05.2001) US
60/300,210 22 June 2001 (22.06.2001) US(71) Applicant (for all designated States except US): COLEY
PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Sel-
bert-Strasse 9, 40764 Langenfeld (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAUER, Stefan
[DE/DE]; Waisenhausstrasse 13, 80637 Munchen (DE).
LIPFORD, Grayson [US/US]; Innere Wiener Strasse 7A,
81667 Munchen (DE). WAGNER, Hermann [DE/DE];
Kaugangerstrasse 36, 82279 Faching (DE).(74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI,
GM, HR, HU, ID, IL, IN, IS, JP, KI, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SI, SG, SL,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.(84) Designated States (regional): ARIPO patent (GI, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, AU, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NI, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report(48) Date of publication of this corrected version:
20 March 2003(15) Information about Correction:
see PCT Gazette No. 12/2003 of 20 March 2003, Section IIFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/022809 A2

(54) Title: PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST

(57) Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8.

- 1 -

**PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED
IMMUNO-AGONIST/ANTAGONIST**

Related Applications

5 This invention claims benefit of U.S. Provisional Application 60/233,035, filed September 15, 2000; U.S. Provisional Application 60/263,657, filed January 23, 2001; U.S. Provisional Application 60/291,726, filed May 17, 2001; and U.S. Provisional Application 60/300,210, filed June 22, 2001.

10 **Field of the Invention**

The invention pertains to signal transduction by immunostimulatory nucleic acids.

Background of the Invention

Bacterial DNA is a potent immunomodulatory substance. Yamamoto S et al.,
15 *Microbiol Immunol* 36:983-997 (1992). It has been hypothesized to be a pathogen-derived ligand recognized by an unidentified pathogen recognition receptor that initiates a host of innate and adaptive immune responses. Wagner H, *Adv Immunol* 73:329-368 (1999). CpG motif-containing oligodeoxynucleotides (CpG ODN) can mimic the biology of bacterial DNA. Krieg AM et al., *Nature* 374:546-549 (1995). CpG ODN and DNA vectors have
20 recently been shown to be of clinical value due to immunostimulatory, hematopoietic and adjuvant qualities.

The adaptive immune system appeared approximately 450 million years ago when a transposon that carried the forerunners of the recombinase activating genes, RAG-1 and RAG-2, was inserted into the germ line of early jawed vertebrates. Agarwal A. et al., *Nature*
25 394:744 (1998). The ability to mount an adaptive immune response allowed organisms to remember the pathogens that they had already encountered, and natural selection made the adaptive immune response a virtually universal characteristic of vertebrates. However, this did not lead to discarding the previous form of host defense, the innate immune system. Indeed, this earlier form of host defense has been coopted to serve a second function,
30 stimulating and orienting the primary adaptive immune response by controlling the expression of costimulatory molecules.

- 2 -

It had been surmised for a decade that cells of the innate immune system bear receptors for conserved molecular patterns associated with microbial pathogens. According to this model, when the protein antigens derived from pathogens are processed and presented as peptides that serve as the stimulus for specific T cell receptors, pattern recognition
5 receptors (PRRs) on the antigen-presenting cells also induce the synthesis of costimulatory molecules, cytokines, and chemokines. These activated antigen-presenting cells serve to attract and activate the antigen-specific T cells that are essential to all adaptive immune responses. Janeway CAJ, *Cold Spring Harbor Symp Quant Biol* 54:1 (1989); Fearon DT et al., *Science* 272:50 (1996); and Medzhitov R et al., *Cell* 91:295 (1997). It was known that the
10 substances that can induce costimulation include bacterial lipopolysaccharide (LPS), synthetic double-stranded RNA, glycans, and mannans. Furthermore, experimental evidence indicated that the processed antigen ligand for the T cell had to be on the same cell as the costimulatory molecule. This is obviously of crucial importance for maintaining self-tolerance; bystander presentation of costimulatory molecules would mean that tolerance would be lost whenever
15 an infection occurred.

To validate this model, it was necessary to identify receptors for microbial patterns that, upon binding pathogen ligands, initiate signaling cascades leading to the production of costimulatory molecules and cytokines. Molecules such as mannose binding protein (MBP) do not qualify for this role, because they activate proteolytic cascades or promote
20 phagocytosis but are not known to induce costimulation. The break-through came with the identification of a human homologue of *Drosophila* Toll initially cloned as a cDNA and later named hTLR4 (for human Toll-like receptor). Medzhitov R et al., *Nature* 388:394 (1997); Rock FL et al., *Proc Natl Acad Sci USA* 95:588 (1998); Chaudhary PM et al., *Blood* 91:4020-4027 (1998).

25 Toll-like receptors (TLRs) are a family of germline-encoded transmembrane proteins that facilitate pathogen recognition and activation of the innate immune system. Hoffmann JA et al., *Science* 284, 1313-1318 (1999); Rock FL et al., *Proc Natl Acad Sci USA* 95:588-593 (1998). TLRs engage conserved pathogen-derived ligands and subsequently activate the TLR/IL-1R signal transduction pathway to induce a variety of effector genes. Medzhitov R et al., *Mol Cell* 2:253-258 (1998); Muzio M et al., *J Exp Med* 187:2097-2101 (1998).
30

So far, ten different mammalian TLRs have been described. Rock FL et al., *Proc Natl*

- 3 -

Acad Sci USA 95:588-593 (1998); Chaudhary PM et al., *Blood* 91:4020-4027 (1998); Takeuchi O et al., *Gene* 231:59-65 (1999); Aderem A. et al., *Nature* 406:782-7 (2000). So far, genetic data suggest that the TLRs have unique functions and are not redundant. Ligands for and the function of most of these TLRs, aside from TLR2 and TLR4, remain to be elucidated.

It turns out that an LPS-binding and signaling receptor complex is assembled when hTLR4 interacts with LPS bound to CD14, a peripheral membrane protein held to the cell surface by a glycosyl-phosphoinositol tail. The presence of LPS binding protein (LBP) further increases signaling. The hTLR4 protein has a leucine-rich repeat sequence in its extracellular domain that interacts with CD14 complexed with LPS. TLR4 then transduces the LPS signal across the membrane because destructive mutation of this gene lead to an LPS-unresponsive state in mice, which are also deficient in the clearance of Gram-negative bacteria. Poltorak A et al., *Science* 282:2085 (1998); Qureshi ST et al., *J Exp Med* 189:615-625 (1999); Eden CS et al., *J Immunol* 140:180 (1988). It has since become apparent that humans, like flies, have numerous Toll-like receptors (TLRs).

TLR4 and other TLRs have a cytoplasmic Toll/IL-1 receptor (TIR) homology domain. This domain communicates with a similar domain on an adapter protein (MyD88) that interacts with TLR4 by means of a like:like interaction of TIR domains. The next interaction is between the adapter and a kinase, through their respective "death domains." The kinase in turn interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I κ B and its dissociation from NF- κ B. The first kinase is a mitogen-activated kinase kinase kinase (MAPKKK) known as NIK, for NF- κ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I κ B kinase α (IKK α) and I κ B kinase β (IKK β), that together form a heterodimer of IKK α :IKK β , which phosphorylates I κ B. NF- κ B translocates to the nucleus to activate genes with κ B binding sites in their promoters and enhancers such as the genes encoding interleukin-1 β (IL-1 β), IL-6, IL-8, the p40 protein of IL-12, and the costimulatory molecules CD80 and CD86.

The types of cells that respond to CpG DNA - B cells, dendritic cells (DCs) and macrophages - are also stimulated by other pathogen-derived pattern-recognition factors, such

- 4 -

as LPS. In general, the PRRs of the innate immune system are situated on the cell surface, where they are probably best able to detect microbes. Although cell-surface proteins that bind DNA are well described, and have been proposed to mediate immune activation by CpG motif (Liang H et al., *J Clin Invest* 98:1119-1129 (1998)), this binding is sequence-
5 independent and does not bring about cell activation. Krieg AM et al., *Nature* 374:546-549 (1995); Yamamoto T et al., *Microbiol Immunol* 38:831-836 (1994); Häcker H et al., *EMBO J* 17:6230-6240 (1998). Because CpG ODNs that have been immobilized to prevent cell uptake are nonstimulatory (Krieg AM et al., *Nature* 374:546-549 (1995); Manzel L et al., *Antisense Nucleic Acid Drug Dev* 9:459-464 (1999)), it appears that CpG ODN probably
10 work by binding to an intracellular receptor. In support of this hypothesis, drugs such as chloroquine, which interfere with the endosomal acidification/processing of ODNs, specifically block the immune stimulatory effects of CpG DNA. Häcker H et al., *EMBO J* 17:6230-6240 (1998); Macfarlane DE et al., *J Immunol* 160:1122-1131 (1998); Yi AK et al., *J Immunol* 160:4755-4761 (1998). It has been proposed that an endosomal step is required
15 for the CpG-induced signal transduction pathways. Häcker H et al., *EMBO J* 17:6230-6240 (1998); Yi AK et al., *J Immunol* 160:4755-4761 (1998). How the information contained in unmethylated CpG-motifs of bacterial DNA trigger changes in gene expression has not previously been discovered.

Since the receptor for bacterial DNA has been unknown, development of screening for
20 optimal CpG motifs through direct binding analysis has been limited. An additional complication appears to be species-specific selectivity for CpG sequence, i.e., an optimal sequence for one species may not be optimal for another.

Summary of the Invention

25 Nucleic acids encoding three Toll-like receptors, Toll-like receptor 7 (TLR7), TLR8, and TLR9 of the mouse have now been identified, isolated, cloned and sequenced by the inventors. The invention in general provides isolated nucleic acid molecules encoding TLRs and isolated fragments of those nucleic acid molecules; isolated TLR polypeptides and isolated fragments of those polypeptides; expression vectors containing the foregoing nucleic
30 acid molecules; host cells having the foregoing expression vectors; fusion proteins including the TLR polypeptides and fragments thereof; and screening methods useful for identifying,

- 5 -

comparing, and optimizing agents which interact with these TLRs, particularly agents that alter the expression of and signaling associated with these TLR molecules. In preferred embodiments the screening methods are high throughput screening methods.

The invention in some aspects arises from the surprising discovery that TLR9 is involved in immunostimulatory nucleic acid (ISNA)-induced immunostimulation. The invention also stems in part from the surprising discovery that TLR9 transduces immune activating signals in response to ISNA in a manner that is both sequence-specific and species-specific.

In a first aspect the invention provides isolated nucleic acid molecules which encode full-length murine TLR9. According to this aspect of the invention, isolated nucleic acid molecules are provided which are selected from the group consisting of (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:1, and which code for a murine TLR9 having an amino acid sequence set forth as SEQ ID NO:3; (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code; and (c) complements of (a) or (b). In a certain embodiment, the isolated nucleic acid molecule codes for SEQ ID NO:3, where SEQ ID NO:3 represents the deduced amino acid sequence of full-length murine TLR9. In some embodiments the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2, where these correspond to full-length cDNA and the open reading frame for murine TLR9, respectively.

The term "stringent conditions" as used herein refers to combined conditions based on parameters including salt, temperature, organic solvents, and optionally other factors with which the practitioner skilled in the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% bovine serum albumin, 2.5mM NaH₂PO₄ (pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulfate; and EDTA is ethylenediaminetetraacetic

- 6 -

acid. After hybridization, the membrane upon which the DNA is transferred is washed with 2 x SSC at room temperature and then with 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C. There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of alleles of murine TLR nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

The invention in a second aspect provides isolated TLR9 polypeptides or fragments thereof. The isolated TLR9 polypeptides or fragments thereof include at least one amino acid of a murine TLR9 selected from the group consisting of amino acids 2, 3, 4, 6, 7, 18, 19, 22, 38, 44, 55, 58, 61, 62, 63, 65, 67, 71, 80, 84, 87, 88, 91, 101, 106, 109, 117, 122, 123, 134, 136, 140, 143, 146, 147, 157, 160, 161, 167, 168, 171, 185, 186, 188, 189, 191, 199, 213, 217, 220, 227, 231, 236, 245, 266, 269, 270, 271, 272, 273, 274, 278, 281, 285, 297, 298, 301, 305, 308, 311, 322, 323, 325, 326, 328, 332, 335, 346, 348, 353, 355, 358, 361, 362, 365, 367, 370, 372, 380, 381, 382, 386, 389, 392, 394, 397, 409, 412, 413, 415, 416, 419, 430, 432, 434, 435, 438, 439, 443, 444, 446, 447, 448, 450, 451, 452, 454, 455, 459, 460, 463, 465, 466, 468, 469, 470, 472, 473, 474, 475, 478, 488, 489, 494, 495, 498, 503, 508, 510, 523, 531, 539, 540, 543, 547, 549, 561, 563, 565, 576, 577, 579, 580, 587, 590, 591, 594, 595, 597, 599, 601, 603, 610, 611, 613, 616, 619, 632, 633, 640, 643, 645, 648, 650, 657, 658, 660, 667, 670, 672, 675, 679, 689, 697, 700, 703, 705, 706, 711, 715, 716, 718, 720, 723, 724, 726, 729, 731, 735, 737, 743, 749, 750, 751, 752, 754, 755, 759, 760, 772, 774, 780, 781, 786, 787, 788, 800, 814, 821, 829, 831, 832, 835, 844, 857, 858, 859, 862, 864, 865, 866, 879, 893, 894, 898, 902, 910, 917, and 927 of SEQ ID NO:3, wherein the TLR9 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR9 polypeptide or fragment thereof except for the at least one amino acid of murine TLR9. The TLR9 polypeptide or fragment thereof in certain embodiments according to this aspect of the invention further includes at least one amino acid of murine TLR9 selected from the group consisting of amino acids 949, 972, 975, 976, 994, 997, 1000, 1003, 1004, 1010,

- 7 -

1011, 1018, 1023, and 1027 of SEQ ID NO:3. Thus specifically excluded from this aspect of the invention are TLR9 fragments restricted to the C-terminal 95 amino acids and fragments thereof.

5 In certain embodiments the TLR9 polypeptide and fragments thereof according to this aspect of the invention exclude those TLR9 polypeptides and fragments thereof which differ from human TLR9 and fragments thereof only by one or more conservative amino acid substitutions at particular sites noted above. As is well known in the art, a "conservative amino acid substitution" refers to an amino acid substitution which generally does not alter the relative charge or size characteristics of the polypeptide in which the amino acid
10 substitution is made. Conservative substitutions of amino acids typically include substitutions made amongst amino acids within the following groups: methionine (M), isoleucine (I), leucine (L), valine (V); phenylalanine (F), tyrosine (Y), tryptophan (W); lysine (K), arginine (R), histidine (H); alanine (A), glycine (G); serine (S), threonine (T); glutamine (Q), asparagine (N); and glutamic acid (E), aspartic acid (D).

15 According to this and other aspects of the invention, with reference to TLR "polypeptides and fragments thereof," "fragments thereof" refers to polypeptide fragments having stretches of contiguous amino acid residues that are at least about 8 amino acids long. Generally the fragments are at least about 10 amino acids long; more generally at least 12 amino acids long; often at least about 14 amino acids long; more often at least about 16
20 amino acids long; typically at least 18 amino acids long; more typically at least 20 amino acids long; usually at least 22 amino acids long; and more usually at least 24 amino acids long. Certain preferred embodiments include larger fragments that are, for example, at least about 30 amino acids long, at least about 40 amino acids long, at least about 50 amino acids long, at least about 100 amino acids long, at least about 200 amino acids long, and so on, up
25 to and including fragments that are a single amino acid shorter than full-length TLR polypeptide.

In certain embodiments, the human TLR9 has an amino acid sequence set forth as SEQ ID NO:6.

30 In preferred embodiments, the isolated TLR9 polypeptides or fragments thereof include an amino acid sequence selected from the group consisting of SEQ ID NO:3 and fragments of SEQ ID NO:3. In some embodiments according to this aspect of the invention,

- 8 -

the isolated TLR9 polypeptides or fragments thereof include combinations of the foregoing human and murine TLR9 polypeptides.

In certain preferred embodiments the isolated TLR9 polypeptide or fragment thereof is an extracytoplasmic domain (also referred to herein as extracellular domain) of TLR9, or a portion thereof. As described in greater detail further herein, TLR7, TLR8, and TLR9 have certain structural and functional domains. Structural domains of these TLRs include but are not limited to an extracytoplasmic domain, a transmembrane domain, and a cytoplasmic domain. The extracytoplasmic domain extends into the lumen of endosomal/lysosomal vesicles. The cytoplasmic domain includes a Toll/interleukin-1 receptor-like domain (also referred to as Toll/IL-1R domain, TIR homology domain, or TIR domain). In murine TLR9 the extracytoplasmic, transmembrane, and cytoplasmic domains correspond to amino acids 1 to about 819, about 820 to about 837, and about 838 to about 1032, respectively.

As mentioned above, it has been discovered according to the invention that TLR9 is involved in immune activation induced by certain nucleic acid molecules referred to in the art as immunostimulatory nucleic acids (ISNAs), including CpG nucleic acids. It is believed by the inventors that binding of ISNA to TLR9 leads to signal transduction involving the TIR domain of TLR9. Thus in certain embodiments according to this aspect of the invention, the isolated TLR9 polypeptide or fragment thereof selectively binds to an ISNA, including an ISNA that is a CpG nucleic acid.

Also included according to this aspect of the invention are isolated TLR9 polypeptides or fragments thereof which are portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids such as CpG nucleic acids. In certain embodiments such portions include an MBD motif set forth as any one of SEQ ID NOs: 126, 127, 210, and 211. In certain embodiments portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids include a CXXC motif set forth as any one of SEQ ID NOs: 196, 197, and 198.

According to a third aspect of the invention, isolated nucleic acid molecules are provided which encode the foregoing isolated TLR9 polypeptides or fragments thereof. The isolated nucleic acid molecules according to this aspect of the invention specifically exclude certain expressed sequence tags (ESTs) identified by the following GenBank accession numbers: AA162495, AA197442, AA273731, AA794083, AA915125, AA968074,

- 9 -

AI428529, AI451215, AI463056, AI893951, AV142833, AV326033, AV353853,
AW048117, AW048548, AW215685, AW549817, BB179985, BB215203, BB283380,
BB285606, BB312895, BB497196, BB622397, BF016670, BF150116, BF161011,
BF300296, BF385702, BF539367, BF784415, BG863184, BG922959, BG967012,
5 BG974917, BI105291, BI153921, BI651868, BI653892, and W76964.

In a fourth aspect the invention provides isolated nucleic acid molecules which encode full-length murine TLR7. According to this aspect of the invention, isolated nucleic acid molecules are provided which are selected from the group consisting of (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a
10 nucleotide sequence set forth as SEQ ID NO:173, and which code for a murine TLR7 having an amino acid sequence set forth as SEQ ID NO:175; (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code; and (c) complements of (a) or (b). In a certain embodiment, the isolated nucleic acid molecule codes for SEQ ID NO:175, where SEQ ID NO:175 represents the deduced amino
15 acid sequence of full-length murine TLR7. In some embodiments the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:173 or SEQ ID NO:174, where these correspond to full-length cDNA and the open reading frame for murine TLR7, respectively.

The invention in a fifth aspect provides isolated TLR7 polypeptides or fragments
20 thereof. The isolated TLR7 polypeptides or fragments thereof include at least one amino acid of a murine TLR7 selected from the group consisting of amino acids 4, 8, 15, 16, 18, 21, 23, 24, 25, 27, 37, 39, 40, 41, 42, 44, 45, 61, 79, 83, 86, 89, 92, 96, 103, 109, 111, 113, 119, 121, 127, 128, 131, 145, 148, 151, 164, 172, 176, 190, 202, 203, 204, 205, 222, 225, 226, 228, 236, 238, 243, 250, 253, 266, 268, 271, 274, 282, 283, 287, 288, 308, 313, 314, 315, 325,
25 328, 331, 332, 341, 343, 344, 347, 351, 357, 360, 361, 362, 363, 364, 365, 366, 370, 371, 377, 378, 387, 388, 389, 392, 397, 398, 413, 415, 416, 419, 421, 422, 425, 437, 438, 440, 446, 449, 453, 454, 455, 456, 462, 470, 482, 486, 487, 488, 490, 491, 493, 494, 503, 505, 509, 511, 529, 531, 539, 540, 543, 559, 567, 568, 574, 583, 595, 597, 598, 600, 611, 613, 620, 624, 638, 645, 646, 651, 652, 655, 660, 664, 665, 668, 669, 672, 692, 694, 695, 698,
30 701, 704, 714, 720, 724, 727, 728, 733, 738, 745, 748, 755, 762, 777, 780, 789, 803, 846, 850, 851, 860, 864, 868, 873, 875, 884, 886, 888, 889, 890, 902, 903, 911, 960, 967, 970,

- 10 -

980, 996, 1010, 1018, 1035, and 1045 of SEQ ID NO:175, wherein the TLR7 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR7 polypeptide or fragment thereof except for the at least one amino acid of murine TLR7.

5 In certain embodiments the TLR7 polypeptide and fragments thereof according to this aspect of the invention exclude those TLR7 polypeptides and fragments thereof which differ from human TLR7 and fragments thereof only by one or more conservative amino acid substitutions at particular sites noted above.

In certain embodiments, the human TLR7 has an amino acid sequence set forth as SEQ ID NO:170.

10 In preferred embodiments, the isolated TLR7 polypeptides or fragments thereof include an amino acid sequence selected from the group consisting of SEQ ID NO:175 and fragments of SEQ ID NO:175. In some embodiments according to this aspect of the invention, the isolated TLR7 polypeptides or fragments thereof include combinations of the foregoing human and murine TLR7 polypeptides.

15 In certain preferred embodiments the isolated TLR7 polypeptide or fragment thereof is an extracytoplasmic domain of TLR7, or a portion thereof. In certain embodiments according to this aspect of the invention, the isolated TLR7 polypeptide or fragment thereof selectively binds to an ISNA, including an ISNA that is a CpG nucleic acid. Also included according to this aspect of the invention are isolated TLR7 polypeptides or fragments thereof which are
20 portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids such as CpG nucleic acids. In certain embodiments such portions include an MBD motif set forth as any one of SEQ ID NOs: 203, 204, 212, and 213. In certain embodiments portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids include a CXXC motif set forth as any one of
25 SEQ ID NOs: 196, 199, and 200.

According to a sixth aspect of the invention, isolated nucleic acid molecules are provided which encode the foregoing isolated TLR7 polypeptides or fragments thereof. The isolated nucleic acid molecules according to this aspect of the invention specifically exclude certain ESTs identified by the following GenBank accession numbers: AA176010,
30 AA210352, AA241310, AA266000, AA266744, AA276879, AA288480, AA871870, AI119722, AI449297, AI466859, AI604175, AV322307, BB033376, BB116163, BB210788,

- 11 -

BB464985, BB466708, BB636153, BF101884, BF124798, BF143871, BG067922, BG080980, BG082140, BG871070, BG964747, BG976560, BI150306, BI411471, and C87987.

In a seventh aspect the invention provides isolated nucleic acid molecules which
5 encode full-length murine TLR8. According to this aspect of the invention, isolated nucleic acid molecules are provided which are selected from the group consisting of (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:190, and which code for a murine TLR8 having an amino acid sequence set forth as SEQ ID NO:192; (b) nucleic acid molecules that differ
10 from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code; and (c) complements of (a) or (b). In a certain embodiment, the isolated nucleic acid molecule codes for SEQ ID NO:192, where SEQ ID NO:192 represents the deduced amino acid sequence of full-length murine TLR8. In some embodiments the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:190 or SEQ ID NO:191, where
15 these correspond to full-length cDNA and the open reading frame for murine TLR8, respectively.

The invention in an eighth aspect provides isolated TLR8 polypeptides or fragments thereof. The isolated TLR8 polypeptides or fragments thereof include at least one amino acid of a murine TLR8 selected from the group consisting of amino acids 5, 6, 9, 10, 14, 15, 18,
20 21, 22, 23, 24, 25, 26, 27, 28, 30, 39, 40, 41, 43, 44, 50, 51, 53, 55, 61, 67, 68, 74, 80, 85, 93, 98, 99, 100, 104, 105, 106, 107, 110, 114, 117, 119, 121, 124, 125, 134, 135, 138, 145, 155, 156, 157, 160, 161, 162, 163, 164, 166, 169, 170, 174, 180, 182, 183, 186, 187, 191, 193, 194, 196, 197, 199, 200, 207, 209, 210, 227, 228, 230, 231, 233, 234, 241, 256, 263, 266, 267, 268, 269, 272, 274, 275, 276, 280, 285, 296, 298, 299, 300, 303, 305, 306, 307, 310,
25 312, 320, 330, 333, 335, 343, 344, 345, 346, 347, 349, 351, 356, 362, 365, 366, 375, 378, 379, 380, 381, 383, 384, 386, 387, 392, 402, 403, 408, 414, 416, 417, 422, 426, 427, 428, 429, 430, 431, 433, 437, 438, 439, 440, 441, 444, 445, 449, 456, 461, 463, 471, 483, 486, 489, 490, 494, 495, 496, 505, 507, 509, 512, 513, 519, 520, 523, 537, 538, 539, 541, 542, 543, 545, 554, 556, 560, 567, 569, 574, 575, 578, 586, 592, 593, 594, 595, 597, 599, 602,
30 613, 617, 618, 620, 621, 623, 628, 630, 633, 639, 641, 643, 644, 648, 655, 658, 661, 663, 664, 666, 668, 677, 680, 682, 687, 688, 690, 692, 695, 696, 697, 700, 702, 703, 706, 714,

- 12 -

715, 726, 727, 728, 730, 736, 738, 739, 741, 746, 748, 751, 752, 754, 757, 764, 766, 772, 776, 778, 781, 784, 785, 788, 791, 795, 796, 801, 802, 806, 809, 817, 820, 821, 825, 828, 829, 831, 839, 852, 853, 855, 858, 863, 864, 900, 903, 911, 918, 934, 977, 997, 1003, 1008, 1010, 1022, 1023, 1024, 1026, and 1030 of SEQ ID NO:192, wherein the TLR8 polypeptide
5 or fragment thereof has an amino acid sequence which is identical to a human TLR8 polypeptide or fragment thereof except for the at least one amino acid of murine TLR8.

In certain embodiments the TLR8 polypeptide and fragments thereof according to this aspect of the invention exclude those TLR8 polypeptides and fragments thereof which differ from human TLR8 and fragments thereof only by one or more conservative amino acid
10 substitutions at particular sites noted above.

In certain embodiments, the human TLR8 has an amino acid sequence set forth as SEQ ID NO:184.

In preferred embodiments, the isolated TLR8 polypeptides or fragments thereof include an amino acid sequence selected from the group consisting of SEQ ID NO:192 and
15 fragments of SEQ ID NO:192. In some embodiments according to this aspect of the invention, the isolated TLR8 polypeptides or fragments thereof include combinations of the foregoing human and murine TLR8 polypeptides.

In certain preferred embodiments the isolated TLR8 polypeptide or fragment thereof is an extracytoplasmic domain of TLR8, or a portion thereof. In certain embodiments according
20 to this aspect of the invention, the isolated TLR8 polypeptide or fragment thereof selectively binds to an ISNA, including an ISNA that is a CpG nucleic acid. Also included according to this aspect of the invention are isolated TLR8 polypeptides or fragments thereof which are portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids such as CpG nucleic acids. In certain embodiments such
25 portions include an MBD motif set forth as any one of SEQ ID NOs: 205, 206, 214, and 215.

In certain embodiments portions of the extracytoplasmic domain believed by the inventors to interact with immunostimulatory nucleic acids include a CXXC motif set forth as any one of SEQ ID NOs: 196, 201, and 202.

According to a ninth aspect of the invention, isolated nucleic acid molecules are
30 provided which encode the foregoing isolated TLR8 polypeptides or fragments thereof. The isolated nucleic acid molecules according to this aspect of the invention specifically exclude

- 13 -

certain ESTs identified by the following GenBank accession numbers: AA116795, AA268605, AA920337, AI529457, AI849892, AV097766, AV117427, AV164719, AV169968, AW551677, BB143750, BB214171, BB243478, BB244318, BB254686, BB256660, BB258368, BB278984, BB291470, BB292008, BB364655, BB373674, 5 BB428800, BB439876, BB444812, BB445724, BB465766, BB470182, BB535086, BB573907, BB573981, BB607650, BF135656, BF722808, BG299237, BG918020, BG919592, and W39977.

In a further aspect, the invention provides TLR expression vectors comprising the foregoing isolated nucleic acid molecules operably linked to a promoter. Thus in certain 10 embodiments pertaining to TLR9, the expression vector includes an isolated nucleic acid molecule according to the first aspect or the third aspect of the invention, operably linked to a promoter. In other embodiments, relating to TLR7, the expression vector includes an isolated nucleic acid molecule according to the fourth aspect or the sixth aspect of the invention, operably linked to a promoter. In yet other embodiments, relating to TLR8, the expression 15 vector includes an isolated nucleic acid molecule according to the seventh aspect or the ninth aspect of the invention, operably linked to a promoter.

The expression vectors according to this aspect of the invention are designed and constructed so that when they are introduced into a cell, under proper conditions they direct expression of the gene product encoded by the incorporated isolated nucleic acid molecule. 20 For example, the promoter can be constitutively active or it can be inducible or repressible upon interaction with a suitable inducer or repressor compound.

According to another aspect, host cells are provided that include a TLR expression vector of the invention. While any suitable method can be used, an expression vector typically is introduced into a cell by transfection or transformation. The host cells 25 transformed or transfected with the TLR expression vectors are in some embodiments co-transformed or co-transfected with another expression vector useful for the expression of another polypeptide. Alternatively, a host cell can be transformed or transfected with an expression vector capable of directing expression of a TLR polypeptide or fragment thereof of the invention and (i) at least one additional TLR polypeptide or fragment thereof, or (ii) at 30 least one non-TLR polypeptide or fragment thereof. In certain preferred embodiments, the host cell includes separate expression vectors for any combination of TLR7, TLR8, and

- 14 -

TLR9. In some embodiments, a co-transformed or co-transfected expression vector may be useful for detection or regulation of TLR expression or TLR-related signaling. Specifically, in certain preferred embodiments the host cell includes an expression vector providing a reporter construct capable of interacting with a TIR domain.

5 In another aspect, the invention provides agents which selectively bind the isolated TLR polypeptides and fragments thereof of the invention. In certain embodiments the agent does not bind a human TLR polypeptide or fragment thereof, wherein the human TLR is selected from human TLR7, TLR8, and TLR9. In certain embodiments the agent is a polypeptide, preferably one selected from the group consisting of monoclonal antibodies,
10 polyclonal antibodies, Fab antibody fragments, F(ab')₂ antibody fragments, Fv antibody fragments, antibody fragments including a CDR3 region, and fusion proteins and other polypeptides including any such antibodies or antibody fragments.

Also provided are agents which selectively bind the foregoing isolated nucleic acid molecules, preferably antisense nucleic acid molecules which selectively bind to any of the
15 foregoing isolated nucleic acid molecules encoding a TLR polypeptide or fragment thereof. In some embodiments the agent is an isolated nucleic acid molecule which hybridizes under stringent conditions to an isolated nucleic acid molecule provided according to any of the first, third, fourth, fifth, sixth, and eighth aspects of the invention. In certain preferred embodiments the agent is an isolated nucleic acid molecule having a nucleotide sequence
20 which is complementary to an isolated nucleic acid molecule provided according to any of the first, third, fourth, fifth, sixth, and eighth aspects of the invention.

In still other aspects of the invention, methods for inhibiting TLR expression and TLR signaling in a cell are provided. The methods include contacting the cell with an amount of an agent effective to inhibit TLR expression and TLR signaling in the cell, wherein the TLR
25 is selected from the group consisting of TLR7, TLR8, and TLR9. In some embodiments the agent brought into contact with the cell is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab')₂ antibody fragments, Fv antibody fragments, antibody fragments including a CDR3 region, and fusion proteins and other polypeptides that include any such antibodies or antibody fragments. In some
30 embodiments the cell is contacted with an antisense nucleic acid specific for the TLR, in an amount effective to inhibit TLR expression in the cell. In some embodiments the cell is

contacted with an agent such as a cytokine or small molecule, in an amount effective to inhibit TLR expression in the cell.

In yet another aspect the invention provides a method for identifying nucleic acid molecules which interact with a TLR polypeptide or a fragment thereof. The method involves contacting a TLR polypeptide selected from the group consisting of TLR7, TLR8, TLR9, and nucleic acid-binding fragments thereof with a test nucleic acid molecule; and measuring an interaction of the test nucleic acid molecule with the TLR polypeptide or fragment thereof. Nucleic acid-binding fragments of TLRs preferably include the extracytoplasmic domain or subportions thereof, such as those which include at least an MBD motif, a CXXC motif, or both an MBD motif and a CXXC motif.

In this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is TLR7. Likewise in this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is TLR8. Also in this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is TLR9.

In this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is expressed in a cell. The cell expressing the TLR polypeptide or fragment thereof may naturally express the TLR polypeptide or fragment thereof, or it may be a host cell as provided by other aspects of the instant invention.

In this and other aspects of the invention involving methods of use of TLR polypeptides and fragments thereof, in some embodiments the TLR polypeptide or fragment thereof is an isolated TLR polypeptide or fragment thereof. In certain preferred embodiments the isolated TLR polypeptide or fragment thereof is immobilized on a solid support, for example a multiwell plate, a slide, a BIAcore chip, a bead, a column, and the like. The immobilization can be accomplished by any chemical or physical method suitable for the purpose of the assay to be performed according to the method of the invention.

In certain embodiments the TLR polypeptide or fragment thereof is fused with an Fc fragment of an antibody. The Fc fragment portion of such a fusion molecule may be useful,

- 16 -

for example, for attaching the TLR polypeptide or fragment thereof to a substrate, or for providing a target for detecting the presence of the TLR polypeptide or fragment thereof. The Fc fragment can be selected from any suitable vertebrate species and will typically, but not necessarily, be derived from an antibody belonging to the IgG class of antibodies. For
5 example, the Fc can be a human or a murine Fc γ . In certain embodiments the TLR polypeptide or fragment thereof is fused with an Fc fragment of an antibody with a specific cleavage site at or near the junction between the TLR polypeptide or fragment thereof and the Fc fragment. In one preferred embodiment the cleavage site is a thrombin protease recognition site. In a preferred embodiment the TLR polypeptide or fragment thereof fused
10 with the Fc fragment includes a TLR extracytoplasmic domain.

In certain embodiments the interaction involving the TLR polypeptide or fragment thereof and the test nucleic acid molecule is binding between the TLR polypeptide or fragment thereof and the test nucleic acid molecule.

In certain embodiments according to this aspect of the invention, the measuring is
15 accomplished by a method selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), biomolecular interaction assay (BIA), electromobility shift assay (EMSA), radioimmunoassay (RIA), polyacrylamide gel electrophoresis (PAGE), and Western blotting.

In certain embodiments the measuring is accomplished by a method comprising
20 measuring a response mediated by a TLR signal transduction pathway. For example, the response mediated by a TLR signal transduction pathway can be selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine. In certain preferred embodiments the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and
25 TNF-luc. In certain preferred embodiments the secreted cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.

In another embodiment the method according to this aspect of the invention can be used to determine if the test nucleic acid molecule is an immunostimulatory nucleic acid. The method involves the additional steps of comparing (a) the response mediated by a TLR signal
30 transduction pathway as measured in the presence of the test nucleic acid molecule with (b) a response mediated by a TLR signal transduction pathway as measured in the absence of the

- 17 -

test nucleic acid molecule; and determining the test nucleic acid molecule is an immunostimulatory nucleic acid when (a) exceeds (b).

In yet another embodiment the method according to this aspect of the invention can be used to determine if the response to the test nucleic acid molecule is stronger or weaker than a response to a reference nucleic acid molecule. The method involves the additional steps of
5 comparing the response to a reference response when the TLR polypeptide is independently contacted with a reference nucleic acid molecule; and determining if the response is stronger or weaker than the reference response. In this embodiment the test nucleic acid molecule and the reference nucleic acid molecule are not able to compete or interact. For example, the
10 reference response can be a parallel control or a historical control.

In another embodiment the method involves the additional steps of comparing the response to a reference response when the TLR polypeptide is concurrently contacted with a reference nucleic acid molecule; and determining if the response is stronger or weaker than the reference response. In this embodiment the test nucleic acid molecule and the reference
15 nucleic acid molecule are potentially able to compete or interact since they are both present, for example, in a single reaction.

In another aspect the invention provides a screening method for identifying an immunostimulatory nucleic acid. The method according to this aspect involves contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test
20 nucleic acid molecule; detecting presence or absence of a response mediated by a TLR signal transduction pathway in the presence of the test nucleic acid molecule arising as a result of an interaction between the functional TLR and the test nucleic acid molecule; and determining the test nucleic acid molecule is an ISNA when the presence of a response mediated by the TLR signal transduction pathway is detected. A functional TLR refers to a TLR polypeptide
25 or fragment thereof that can bind with a ligand and as a consequence of the binding engage at least one step or additional polypeptide in a TLR signal transduction pathway.

In one embodiment the method according to this aspect of the invention includes the further step of comparing (a) the response mediated by the TLR signal transduction pathway arising as a result of an interaction between the functional TLR and the test nucleic acid
30 molecule with (b) a response arising as a result of an interaction between the functional TLR and a reference ISNA. In this and other screening assays of the instant invention, in preferred

- 18 -

embodiments the screening method is performed on a plurality of test nucleic acids. In certain preferred embodiments the response mediated by the TLR signal transduction pathway is measured quantitatively, and the response mediated by the TLR signal transduction pathway associated with each of the plurality of test nucleic acid molecules is compared with a response arising as a result of an interaction between the functional TLR and a reference ISNA.

In certain preferred embodiments a subset of the plurality of test nucleic acid molecules is selected based on the ability of the subset to produce a specific response mediated by the TLR signal transduction pathway. For example, the specific response can be induction of a specific cytokine or panel of cytokines, e.g., Th1 cytokines, or, alternatively, inhibition of a specific cytokine or panel of cytokines, e.g., Th2 cytokines. The specific response can be induction, or, alternatively, inhibition of a specific class or subclass of antibody or panel of classes or subclasses of antibodies, e.g., Th1-associated antibodies or Th2-associated antibodies. The specific response in some embodiments can be activation or inhibition of certain types of immune cells, e.g., B cells, dendritic cells (DCs), and natural killer (NK) cells. In some embodiments the specific response can be induction or inhibition of proliferation of certain types of immune cells, e.g., B cells, T cells, NK cells, dendritic cells, monocytes/macrophages. The subset of the plurality of test nucleic acids is therefore selected on the basis of the common association between the test nucleic acids of the subset and the particular type of response mediated by the TLR signal transduction pathway. The particular type of response mediated by the TLR signal transduction pathway is typically, but not necessarily, an immune cell response.

In certain embodiments the response mediated by a TLR signal transduction pathway is selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine. In certain preferred embodiments the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc. In certain preferred embodiments the cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.

In certain preferred embodiments the reference ISNA is a CpG nucleic acid.

In certain preferred embodiments the test nucleic acid molecule is a CpG nucleic acid.

According to this and other aspects of the invention involving functional TLR in a

- 19 -

screening assay, in some embodiments the functional TLR is expressed in a cell. In some embodiments the functional TLR is naturally expressed by the cell. In certain preferred embodiments the cell is an isolated mammalian cell that naturally expresses the functional TLR. Whether the cell expresses the TLR naturally or the cell expresses the TLR because an expression vector having an isolated nucleic acid molecule encoding the TLR operatively linked to a promoter has been introduced into the cell, in some embodiments the cell further includes an expression vector comprising an isolated nucleic acid which encodes a reporter construct selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc, operatively linked to a promoter.

Also according to this and other aspects of the invention involving functional TLR in a screening assay, in certain embodiments the functional TLR is part of a cell-free system.

Also according to this and other aspects of the invention involving functional TLR in a screening assay, in certain embodiments the functional TLR is part of a complex with another TLR. In certain preferred embodiments the complex is a complex of TLR9 and TLR7. In certain preferred embodiments the complex is a complex of TLR9 and TLR8.

Also according to this and other aspects of the invention involving functional TLR in a screening assay, in certain embodiments the functional TLR is part of a complex with a non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B, and functional homologues and derivatives thereof.

Further according to this and other aspects of the invention involving functional TLR in a screening assay, in certain embodiments the response mediated by a TLR signal transduction pathway is selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine.

Also according to this and other aspects of the invention involving functional TLR in a screening assay, in certain embodiments the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.

Also according to this and other aspects of the invention involving functional TLR in a screening assay, in certain embodiments wherein the cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.

In a further aspect, the invention provides a screening method for comparing TLR

- 20 -

signaling activity of a test compound with an ISNA. The method entails contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a reference ISNA and detecting a reference response mediated by a TLR signal transduction pathway; contacting a functional TLR selected from the group consisting of TLR7, TLR8,
5 and TLR9 with a test compound and detecting a test response mediated by a TLR signal transduction pathway; and comparing the test response with the reference response to compare the TLR signaling activity of the test compound with the ISNA.

In certain embodiments according to this aspect of the invention, the reference ISNA is a CpG nucleic acid.

10 In certain embodiments according to this aspect of the invention, the test compound is a polypeptide. In certain embodiments the test compound is part of a combinatorial library of compounds.

In certain embodiments the functional TLR is contacted with the reference ISNA and the test compound independently. Accordingly, in certain embodiments the screening method
15 is a method for identifying an ISNA mimic, and the test compound is determined to be an ISNA mimic when the test response is similar to the reference response obtained with the reference ISNA. A test response is similar to the reference response when the test and reference responses are qualitatively alike, even if not quantitatively alike. Thus, for example, the test and reference responses are considered alike when both responses include
20 induction of a Th1-like immune response. The test response can be quantitatively less than, about the same as, or greater than the reference response.

In certain other embodiments the functional TLR is contacted with the reference ISNA and the test compound concurrently to produce a test-reference response mediated by a TLR signal transduction pathway, wherein the test-reference response may be compared to the
25 reference response. In certain preferred embodiments the screening method is a method for identifying an ISNA agonist, wherein the test compound is an ISNA agonist when the test-reference response is greater than the reference response. In certain preferred embodiments the screening method is a method for identifying an ISNA antagonist, wherein the test compound is an ISNA antagonist when the test-reference response is less than the reference
30 response.

In a further aspect the invention provides a screening method for identifying species

- 21 -

specificity of an ISNA. The method according to this aspect of the invention involves contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a first species with a test ISNA; contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a second species with the test ISNA; measuring a response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA; and comparing (a) the response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA with (b) the response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA. In preferred embodiments the TLR of the first species corresponds to the TLR of the second species, e.g., the TLR of the first species is human TLR9 and the TLR of the second species is murine TLR9. In certain embodiments the functional TLR may be expressed in a cell, part of cell-free system, or part of a complex with another TLR or with a non-TLR protein, as previously described.

In yet another aspect the invention provides a method for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with TLR9 signaling activity. The method according to this aspect of the invention involves providing a cell comprising a TLR9 polypeptide or fragment thereof as provided in the second aspect of the invention; contacting the cell with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of TLR9 signaling activity; and determining a second amount of TLR9 signaling activity as a measure of the effect of the pharmacological agent on the TLR9 signaling activity, wherein a second amount of TLR9 signaling activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces TLR9 signaling activity and wherein a second amount of TLR9 signaling activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases TLR9 signaling activity.

These and other aspects of the invention are described in greater detail below.

Brief Description of the Figures

FIG. 1 is two paired bar graphs showing (A) the induction of NF- κ B and (B) the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

5 FIG. 2 is a bar graph showing the induction of NF- κ B produced by 293 fibroblast cells transfected with murine TLR9 in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS, and medium.

FIG.3 is a series of gel images depicting the results of reverse transcriptase-polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

FIG. 4 is a graph showing the degree of induction of NF- κ B-luc by various stimuli in stably transfected 293-hTLR9 cells.

15 FIG. 5 is a graph showing the degree of induction of NF- κ B-luc by various stimuli in stably transfected 293-mTLR9 cells.

FIG. 6 is an image of a Coomassie-stained polyacrylamide gel depicting the presence of soluble hTLR9 in the supernatants of yeast cells transfected with hTLR9, either induced (lane 1) or not induced (lane 2).

20 FIG. 7 is a graph showing proliferation of human B cells in response to various stimuli, including *Escherichia coli* (*E. coli*) DNA, DNase-digested *E. coli* DNA, CpG-ODN, GpC-ODN, and LPS.

FIG. 8 is two paired bar graphs showing induction of (top) IL-8 and (bottom) TNF in plasmacytoid dendritic cells (CD123+ DC) and monocyte-derived dendritic cells (MDDC) in response to various stimuli, including *E. coli* DNA, DNase-digested *E. coli* DNA, CpG-ODN, GpC-ODN, and LPS.

FIG. 9 is a series of images of stained gels showing results of semi-quantitative RT-PCR comparing relative levels of human TLR9, TLR2, and TLR4 mRNA expression in human peripheral blood cells: MDDC (lane 1), purified CD14+ monocytes (lane 2), B cells (lane 3), CD123+ DC (lane 4), CD4+ T cells (lane 5), and CD8+ T cells (lane 6). GAPDH is a control for equalizing amounts of cDNA.

FIG. 10 is a pair of graphs showing amounts of IL-12 induced in (A) human peripheral blood mononuclear cells (PBMC) and (B) murine splenocytes in response to shown concentrations of various ODN, including ODN 2006 (filled circles), 2006-GC (open circles), 1668 (filled triangles), and 1668-GC (open triangles).

5 FIG. 11 is a quartet of graphs depicting responsiveness of 293 cells transfected with hTLR9 (left panels) or mTLR9 (right panels) upon stimulation with shown concentrations of various ODN, including ODN 2006 (filled circles), 2006-GC (open circles), 1668 (filled triangles), and 1668-GC (open triangles). Responses are shown in terms of induction of NF- κ B-luc (upper panels) and IL-8 (lower panels).

10 FIG. 12 is a bar graph depicting the dose-response of 293-hTLR9 cells to *E. coli* DNA (black bars) and to DNase-digested *E. coli* DNA (gray bars).

FIG. 13 is a pair of graphs showing the responsiveness of (A) 293-hTLR9 and (B) 293-mTLR9 cells to shown concentrations of phosphodiester versions of ODN 2006 (filled circles), 2006-GC (open circles), 1668 (filled triangles), and 1668-GC (open triangles).

15 Fig. 14 is a pair of graphs showing the responsiveness of 293-hTLR9 and 293-mTLR9 cells to shown concentrations of ODN 5002 (filled circles) and ODN 5007 (open circles).

FIG. 15 is a bar graph showing the response of 293 cells transfected with mTLR9 to CpG-ODN 1668 is inhibited in a dose-dependent manner by co-exposure to non-CpG-ODN PZ2.

20 FIG. 16 is a bar graph showing the response of 293-hTLR9 cells to CpG-ODN (black bars) or to TNF (gray bars) in the presence of shown amounts of blocking non-CpG-ODN.

FIG. 17 is a bar graph showing blockade of response of 293-hTLR9 cells to CpG-ODN, but not to IL-1 or TNF, in the presence of Bafilomycin A (gray bars). Control treatment with dimethyl sulfoxide (DMSO) is shown in black bars.

25 FIG. 18 is a graph showing the effect of varying concentrations of dominant negative human MyD88 on the induction of NF- κ B in 293-hTLR9 cells stimulated with CpG-ODN (open circles), TNF- α (filled circles), or control (filled triangles).

FIG. 19 is a series of three Western blot images showing the response of various polyclonal antibodies to purified hTLR9-FLAG and mTLR9-FLAG: upper panel, anti-human and anti-mouse intracellular; middle, anti-mouse extracellular; and lower, anti-human extracellular. Arrows indicate position of TLR9 in each blot.

30

FIG. 20 is a bar graph depicting the responsiveness of native form hTLR9 and hTLR9 variant form hTLR9-CXXCm to various stimuli at different concentrations.

FIG. 21 is a bar graph depicting the responsiveness of native form mTLR9 and mTLR9 variant form mTLR9-CXXCm to various stimuli at different concentrations.

5 FIG. 22 is a bar graph showing the responsiveness of native form mTLR9, mTLR9 variant form mTLR9-Phmut, and mTLR9 variant form mTLR9-MBDmut to various stimuli at different concentrations.

FIG. 23 is a bar graph showing the responsiveness of native form hTLR9, hTLR9 variant form hTLR9-PHmut, and hTLR9 variant form hTLR9-MBDmut to various stimuli at
10 different concentrations.

FIG. 24 is a bar graph showing the responsiveness of native form mTLR9 and mTLR9 variant form mTLR9-TIRh to various stimuli at different concentrations.

FIG. 25 is a bar graph showing the responsiveness of native form hTLR9 and hTLR9 variant form hTLR9-TIRm to various stimuli at different concentrations.

15 FIG. 26 is a series of linear maps representing various features of human TLR7, TLR8, and TLR9 polypeptides.

FIG. 27 is an image of a silver stained polyacrylamide gel and schematic representation of a fusion protein in which the extracellular domain of human TLR9 (hTLR9) is fused to a human IgG1 Fc domain (hIgG-Fc) with a thrombin protease recognition site
20 interposed. From left to right, the gel was loaded with (1) supernatant of transfectants; (2) lysates of transfectants, treated with thrombin; (3) untreated lysates of transfectants; (4) molecular weight markers; (5) supernatant of mock transfectants; (6) lysates of mock transfectants, treated with thrombin; and (7) untreated lysates of mock transfectants. Soluble hTLR9 and Fc are the products released from intact hTLR9-IgG-Fc following thrombin
25 treatment. Molecular weights are indicated along the right side of the silver stain gel image.

Brief Description of Selected Sequences

SEQ ID NO:1 is the nucleotide sequence encoding a cDNA for murine TLR9.

SEQ ID NO:2 is the nucleotide sequence encoding the coding region of murine TLR9.

30 SEQ ID NO:3 is the amino acid sequence of a murine TLR9 encoded by SEQ ID NO:1.

- 25 -

SEQ ID NO:173 is the nucleotide sequence encoding a cDNA for murine TLR7.

SEQ ID NO:174 is the nucleotide sequence encoding the coding region of murine TLR7.

SEQ ID NO:175 is the amino acid sequence of a murine TLR7 encoded by SEQ ID
5 NO:173.

SEQ ID NO:190 is the nucleotide sequence encoding a cDNA for murine TLR8.

SEQ ID NO:191 is the nucleotide sequence encoding the coding region of murine TLR8.

SEQ ID NO:192 is the amino acid sequence of a murine TLR8 encoded by SEQ ID
10 NO:190.

Detailed Description of the Invention

The present invention in one aspect involves the identification of cDNAs encoding mouse TLR9, referred to herein as murine TLR9 and, equivalently, mTLR9. The nucleotide
15 sequence of the cDNA for murine TLR9 is presented as SEQ ID NO:1, the coding region of the cDNA for murine TLR9 is presented as SEQ ID NO:2, and the amino acid sequence of the murine TLR9 is presented as SEQ ID NO:3. The closely related human TLR9 (equivalently, hTLR9) was deposited in GenBank under accession numbers AF245704 and NM_017742.

20 The nucleotide sequence of the cDNA for murine TLR9 presented as SEQ ID NO:1 is 3200 nucleotides long and includes the open reading frame (ORF, bases 40-3135) presented as SEQ ID NO:2 which spans 3096 nucleotides (excluding the stop codon). The amino acid sequence of the murine TLR9 presented as SEQ ID NO:3 is 1032 amino acids (aa) long, and it is believed to include an extracellular domain (aa 1-819), a transmembrane domain (aa 820-
25 837), and an intracellular domain (aa 838-1032).

The amino acid sequence of human TLR9 (SEQ ID NO:6) and the amino acid sequence of the murine TLR9 (SEQ ID NO:3) are thus both 1032 amino acids long. Comparison of the aligned amino acid sequences for the murine and the human TLR9 molecules reveals a single base insertion at aa 435 of the murine TLR9 and a single base
30 deletion at aa 860 of the human TLR9. (See Table 4 below.)

Whereas much of the polypeptide presented herein is identical to human TLR9,

- 26 -

murine TLR9 has several single amino acid differences. These differences in amino acids are specifically amino acids 2, 3, 4, 6, 7, 18, 19, 22, 38, 44, 55, 58, 61, 62, 63, 65, 67, 71, 80, 84, 87, 88, 91, 101, 106, 109, 117, 122, 123, 134, 136, 140, 143, 146, 147, 157, 160, 161, 167, 168, 171, 185, 186, 188, 189, 191, 199, 213, 217, 220, 227, 231, 236, 245, 266, 269, 270, 271, 272, 273, 274, 278, 281, 285, 297, 298, 301, 305, 308, 311, 322, 323, 325, 326, 328, 332, 335, 346, 348, 353, 355, 358, 361, 362, 365, 367, 370, 372, 380, 381, 382, 386, 389, 392, 394, 397, 409, 412, 413, 415, 416, 419, 430, 432, 434, 435, 438, 439, 443, 444, 446, 447, 448, 450, 451, 452, 454, 455, 459, 460, 463, 465, 466, 468, 469, 470, 472, 473, 474, 475, 478, 488, 489, 494, 495, 498, 503, 508, 510, 523, 531, 539, 540, 543, 547, 549, 561, 563, 565, 576, 577, 579, 580, 587, 590, 591, 594, 595, 597, 599, 601, 603, 610, 611, 613, 616, 619, 632, 633, 640, 643, 645, 648, 650, 657, 658, 660, 667, 670, 672, 675, 679, 689, 697, 700, 703, 705, 706, 711, 715, 716, 718, 720, 723, 724, 726, 729, 731, 735, 737, 743, 749, 750, 751, 752, 754, 755, 759, 760, 772, 774, 780, 781, 786, 787, 788, 800, 814, 821, 829, 831, 832, 835, 844, 857, 858, 859, 862, 864, 865, 866, 879, 893, 894, 898, 902, 910, 917, 927, 949, 972, 975, 976, 994, 997, 1000, 1003, 1004, 1010, 1011, 1018, 1023, and 1027 of SEQ ID NO:3

In some forms the mouse protein mTLR9 contains a signal sequence at the N-terminus (amino acids 1-26) which allows transport to the endoplasmic reticulum and subsequently to the cell surface or intracellular compartments. A transmembrane region (amino acids 820-837) anchors the protein to the cell membrane. The cytoplasmic tail contains a Toll/IL-1 receptor (TIR) homology domain which is believed to function in signaling upon ligand binding. Leucine-rich-repeats (LRR) can be found in the extracellular region (a common feature of TLRs) and may be involved in ligand binding or dimerization of the molecule.

Both mouse and human TLR9 have an N-terminal extension of approximately 180 amino acids compared to other TLRs. An insertion also occurs at amino acids 253-268, which is not found in TLRs 1-6 but is present in human TLR7 and human TLR8. (See **Figure 26.**) This insert has two CXXC motifs which participate in forming a CXXC domain. The CXXC domain resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g., methyl-CpG binding protein-1 (MBD-1). Fujita N et al., *Mol Cell Biol* 20:5107-5118 (2000). Both human and mouse TLR9 CXXC domains occur at aa 253-268:

- 27 -

CXXC motif:	GNCXXCXXXXXXCXXC	SEQ ID NO:196
Human TLR9:	GNCRRCDHAPNPCMEC	SEQ ID NO:197
Murine TLR9:	GNCRRCDHAPNPCMIC	SEQ ID NO:198

5

An additional motif involved in CpG binding is the MBD motif, also found in MBD-1, listed below as SEQ ID NO:125. Fujita, N et al., *Mol Cell Biol* 20:5107-18 (2000); Ohki I et al., *EMBO J* 18:6653-6661 (1999). Amino acids 524-554 of hTLR9 and aa 525-555 of mTLR9 correspond to the MBD motif of MBD-1 as shown:

10

MBD motif:

MBD-1	R-XXXXXXXX-R-X-D-X-Y-XXXXXXXXX-R-S-XXXXXX-Y	SEQ ID NO:125
hTLR9	Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXX-R-L-XXXXXX-Y	SEQ ID NO:126
mTLR9	Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXX-Q-L-XXXXXX-Y	SEQ ID NO:127

15

hTLR9	Q-VLDLSRN-K-L-D-L-Y-HEHSFTELP-R-L-EALDLS-Y	SEQ ID NO:210
mTLR9	Q-VLDLSHN-K-L-D-L-Y-HWKSFSLELP-Q-L-QALDLS-Y	SEQ ID NO:211

20

Although the signaling functions of MBD-1 and TLR9 are quite different, the core D-X-Y is involved in CpG binding and is conserved. The C-terminal octamer S-XXXXXX-Y of the MBD motif may not be involved in binding and the S is not conserved by TLR9. The other mismatches are highly conserved or moderately conserved; example R to K or R to Q. These changes could explain MBD-1 as a methyl-CpG binder and TLR9 as a non-methyl-CpG binder. The differences between mouse and human TLR9 may explain inter-species differences in CpG-motif sequence selectivity. See **Figure 14** for inter-species sequence selectivity.

25

30

As discussed in Example 11 below and shown in **Figures 22 and 23**, the D-X-Y core of this MBD motif occurs as D-L-Y in both mTLR9 (aa 535-537) and hTLR9 (aa 534-536). Substitution of A for D and A for Y in the D-X-Y core, resulting in A-L-A in place of D-L-Y, destroys receptor activity for mTLR9 and hTLR9 alike.

The invention involves in one aspect murine TLR9 nucleic acids and polypeptides, as

- 28 -

well as therapeutics relating thereto. The invention also embraces isolated functionally equivalent variants, useful analogs and fragments of the foregoing nucleic acids and polypeptides; complements of the foregoing nucleic acids; and molecules which selectively bind the foregoing nucleic acids and polypeptides.

5 The murine TLR9 nucleic acids and polypeptides of the invention are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA
10 techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which PCR primer sequences have been disclosed is considered isolated, but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may
15 comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

 As used herein with respect to polypeptides, "isolated" means separated from its
20 native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term
25 "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may
30 comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e., isolated from other proteins.

As used herein a murine TLR9 nucleic acid refers to an isolated nucleic acid molecule which codes for a murine TLR9 polypeptide. Such nucleic acid molecules code for murine TLR9 polypeptides which include the sequence of SEQ ID NO:3 and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:1, SEQ ID NO:2, and
5 nucleotide sequences which differ from the sequences of SEQ ID NO:1 and SEQ ID NO:2 in codon sequence due to the degeneracy of the genetic code. The murine TLR9 nucleic acids of the invention also include alleles of the foregoing nucleic acids, as well as fragments of the foregoing nucleic acids. Such fragments can be used, for example, as probes in hybridization assays and as primers in a polymerase chain reaction. Preferred murine TLR9 nucleic acids
10 include the nucleic acid sequence of SEQ ID NO:1 and SEQ ID NO:2. Complements of the foregoing nucleic acids also are embraced by the invention.

As used herein a murine TLR9 nucleic acid or murine TLR9 polypeptide also embraces homologues and alleles of murine TLR9. In general homologues and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to
15 the sequences of specified nucleic acids and polypeptides, respectively. Thus homologues and alleles of murine TLR9 typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to the sequences of murine TLR9 nucleic acids and TLR9 polypeptides, respectively. In some instances homologues and alleles will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances will
20 share at least 60% nucleotide identity and/or at least 75% amino acid identity. Preferably the homologues and alleles will share at least 80% nucleotide identity and/or at least 90% amino acid identity, and more preferably will share at least 90% nucleotide identity and/or at least 95% amino acid identity. Most preferably the homologues and alleles will share at least 95% nucleotide identity and/or at least 99% amino acid identity. The homology can be calculated
25 using various publicly available software tools developed by the National Center for Biotechnology Information (NCBI, Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available from the NCBI at <http://www.ncbi.nlm.nih.gov>, used with default settings. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic
30 analysis can be obtained, for example, using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also

- 30 -

are embraced by the invention.

Alleles of the murine TLR9 nucleic acids of the invention can be identified by conventional techniques. For example, alleles of murine TLR9 can be isolated by hybridizing a probe which includes at least a fragment of SEQ ID NO:1 or SEQ ID NO:2 under stringent
5 conditions with a cDNA library and selecting positive clones. Thus, an aspect of the invention is those nucleic acid sequences which code for murine TLR9 polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:1 or SEQ ID NO:2 under stringent conditions.

In screening for murine TLR nucleic acids, a Southern blot may be performed using
10 the foregoing stringent conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. Corresponding non-radioactive methods are also well known in the art and can be used to similar effect.

The murine TLR nucleic acids of the invention also include degenerate nucleic acids
15 which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons AGC, AGT, and TCA, TCC, TCG and TCT. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a
20 serine residue into an elongating murine TLR polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). As is well known by those of ordinary skill in the
25 art, other specific amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code. The above-noted codon degeneracy notwithstanding, it is well appreciated by those skilled in the art that there are certain codon usage preferences in specific host organisms,
30 such that in practice it may be preferred to select or to avoid certain degenerate codons in a particular host.

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. The modified nucleic acid molecules according to this aspect of the invention exclude fully native human TLR9 nucleic acid molecules (GenBank Accession No. AF245704 (SEQ ID NO:4) or GenBank Accession No. NM_017442 (SEQ ID NO:5)). In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as signaling activity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated fragments of SEQ ID NO:1 and SEQ ID NO:2. The fragments can be used as probes in Southern blot assays to identify such nucleic acids, or

- 32 -

they can be used in amplification assays such as those employing PCR. Smaller fragments are those comprising 12, 13, 14, 15, 16, 17, 18, 20, 22, 25, 30, 40, 50, or 75 nucleotides, and every integer therebetween, and are useful, e.g., as primers for nucleic acid amplification procedures. As known to those skilled in the art, larger probes such as 200, 250, 300, 400 or
5 more nucleotides are preferred for certain uses such as Southern blots, while smaller fragments will be preferred for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments. Likewise, fragments can be employed to produce non-fused fragments of the murine TLR9 polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and the
10 like. The foregoing nucleic acid fragments further can be used as antisense molecules to inhibit the expression of murine TLR9 nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

The invention also includes functionally equivalent variants of the murine TLR9, which include variant nucleic acids and polypeptides which retain one or more of the
15 functional properties of the murine TLR9. Preferably such variants include the murine-specific N-terminal domain (e.g., amino acids 1-819 or amino acids 1-837 of SEQ ID NO:3). For example, variants include a fusion protein which includes the extracellular and transmembrane domains of the murine TLR9 (i.e., amino acids 1-837) which retains the ability to interact with extracellular molecules in a manner similar to intact murine TLR9.
20 Alternative variants include, for example, a fusion protein which includes the cytoplasmic domain of murine TLR9 (i.e., amino acids 838-1032) which retains the ability to interact with intracellular molecules in a manner similar to intact murine TLR9. Still other functionally equivalent variants include truncations, deletions, point mutations, or additions of amino acids to the sequence of SEQ ID NO:3 which retain functions of SEQ ID NO:3. For example,
25 the FLAG peptide sequence (DYKDDDDK) can be added at the N-terminal end, or green fluorescent protein (GFP) can be added at the C-terminal end. All such addition variant polypeptides are preferably made by translation of modified nucleic acids based on SEQ ID NO:1 or SEQ ID NO:2 with corresponding appropriate coding nucleic acid sequence appended thereto with maintenance of the proper reading frame.

30 Functionally equivalent variants also include a murine TLR9 which has had a portion (e.g., of the N-terminus) removed or replaced by a similar domain from another TLR (e.g., a

- 33 -

“domain-swapping” variant). Examples of such domain-swapping variants include at least two types: those involving swapping a TLR9 domain from one species with a TLR9 domain from another species, and those involving swapping a TLR domain from TLR9 with a TLR domain from another TLR. In certain preferred embodiments the swapping involves
5 corresponding domains between the different TLR molecules. It is believed that certain such domain-swapping variants are not functionally equivalent in a literal sense, insofar as they can function in a manner superior to either or both intact parent TLR molecules from which a particular domain-swapping variant derives. For example, the TLR/IL-1R signaling mediated by human TLR9 could be limited, not by the capacity of its extracellular domain to interact
10 with CpG ODN, but rather by the capacity of its cytoplasmic domain to engage the TLR/IL-1R signaling pathway. In such a circumstance, it could be advantageous to substitute a more potent cytoplasmic domain from a TLR9 from another species. Such a domain-swapping variant, e.g., chimeric hTLR9/mTLR9, could be used in screening assays for CpG immuno-agonist/antagonists to increase the sensitivity of the assay, without changing the species
15 specificity.

Other functionally equivalent variants will be known to one of ordinary skill in the art, as will be methods for preparing such variants. The activity of a functionally equivalent variant can be determined using the methods provided herein, and in references that have described assays using other TLRs and TLRs of other species. Such variants are useful, *inter*
20 *alia*, for evaluating bioavailability of drugs, in assays for identification of compounds which bind to and/or regulate the signaling function of the murine TLR9, and for determining the portions of the murine TLR9 which are required for signaling activity.

Variants which are non-functional also can be prepared as described above. Such variants are useful, for example, as negative controls in experiments testing TLR9 signaling
25 activity. Examples of non-functional variants include those incorporating a mutation of proline at aa 915 to histidine (P915H) which renders both mTLR9 and hTLR9 nonfunctional with respect to signaling. Further examples of non-functional variants include those incorporating a mutation of the D-X-Y core of the MBD motif to A-L-A, as discussed above, to render both mTLR9 and hTLR9 nonfunctional with respect to CpG DNA binding.

30 A murine TLR9 nucleic acid, in one embodiment, is operably linked to a gene expression sequence which can direct the expression of the murine TLR9 nucleic acid within

- 34 -

a eukaryotic or prokaryotic cell. A "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably linked. With respect to murine TLR9 nucleic acid, the "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the murine TLR9 nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPRT), adenosine deaminase, pyruvate kinase, β -actin promoter, and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus (e.g., SV40), papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus (RSV), cytomegalovirus (CMV), the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase (TK) promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothioncin (MT) promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined murine TLR9 nucleic acid. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

Generally a nucleic acid coding sequence and a gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the nucleic acid coding sequence under the influence or

- 35 -

control of the gene expression sequence. Thus the murine TLR9 nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the murine TLR9 coding sequence under the influence or control of the gene expression sequence. If it is desired that the murine TLR9 sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the murine TLR9 sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the murine TLR9 sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a murine TLR9 nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that murine TLR9 nucleic acid sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The murine TLR9 nucleic acid molecules and the murine TLR9 polypeptides (including the murine TLR9 inhibitors described below) of the invention can be delivered to the eukaryotic or prokaryotic cell alone or in association with a vector. In its broadest sense, a "vector" is any vehicle capable of facilitating: (1) delivery of a nucleic acid or polypeptide to a target cell, (2) uptake of a nucleic acid or polypeptide by a target cell, or (3) expression of a nucleic acid molecule or polypeptide in a target cell. In this particular setting, a "vector" is any vehicle capable of facilitating: (1) delivery of a murine TLR9 nucleic acid or polypeptide to a target cell, (2) uptake of a murine TLR9 nucleic acid or polypeptide by a target cell, or (3) expression of a murine TLR9 nucleic acid molecule or polypeptide in a target cell. Preferably, the vectors transport the murine TLR9 nucleic acid or polypeptide into the target cell with reduced degradation relative to the extent of degradation that would result in the absence of the vector. Optionally, a "targeting ligand" can be attached to the vector to selectively deliver the vector to a cell which expresses on its surface the cognate receptor (e.g., a receptor, an antigen recognized by an antibody) for the targeting ligand. In this manner, the vector (containing a murine TLR9 nucleic acid or a murine TLR9 polypeptide) can be selectively delivered to a specific cell. In general, the vectors useful in the invention are divided into two classes: biological vectors and chemical/physical vectors. Biological

- 36 -

vectors are more useful for delivery/uptake of murine TLR9 nucleic acids to/by a target cell. Chemical/physical vectors are more useful for delivery/uptake of murine TLR9 nucleic acids or murine TLR9 proteins to/by a target cell.

Biological vectors include, but are not limited to, plasmids, phagemids, viruses, other
5 vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the nucleic acid sequences of the invention, and free nucleic acid fragments which can be linked to the nucleic acid sequences of the invention. Viral vectors are a preferred type of biological vector and include, but are not limited to, nucleic acid sequences from the following viruses: retroviruses, such as Moloney murine leukemia virus; Harvey
10 murine sarcoma virus; murine mammary tumor virus; Rous sarcoma virus; adenovirus; adeno-associated virus; SV40-type viruses; polyoma viruses; poxviruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; and polio virus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-
15 essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered
20 retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target
25 cells with viral particles) are provided in Kriegler, M., *"Gene Transfer and Expression, A Laboratory Manual,"* W.H. Freeman Co., New York (1990) and Murray, E.J., ed., *"Methods in Molecular Biology,"* vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Another preferred virus for certain applications is the adeno-associated virus (AAV), a double-stranded DNA virus. The AAV can be engineered to be replication-deficient and is
30 capable of infecting a wide range of cell types and species. It further has advantages, such as heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages; and

- 37 -

lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the AAV can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type AAV infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the AAV genomic integration is a relatively stable event. The AAV can also function in an extrachromosomal fashion.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a murine TLR9 polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human CMV enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nucleic Acids Res* 18:5322 (1990)), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol Cell Biol* 16:4710-4716 (1996)). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J Clin Invest* 90:626-630 (1992)).

In addition to the biological vectors, chemical/physical vectors may be used to deliver a nucleic acid or polypeptide to a target cell and facilitate uptake thereby. As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived

- 38 -

from bacteriological or viral sources, capable of delivering an isolated nucleic acid or polypeptide to a cell. As used herein with respect to a murine TLR9 nucleic acid or polypeptide, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the isolated murine TLR9 nucleic acid or polypeptide to a cell.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vesicles which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2 - 4.0 μm can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley et al., *Trends Biochem Sci* 6:77 (1981)). In order for a liposome to be an efficient nucleic acid transfer vector, one or more of the following characteristics should be present: (1) encapsulation of the nucleic acid of interest at high efficiency with retention of biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to a particular cell will depend on the particular cell or tissue type. Additionally when the vector encapsulates a nucleic acid, the vector may be coupled to a nuclear targeting peptide, which will direct the murine TLR9 nucleic acid to the nucleus of the host cell.

Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleoyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications.

Other exemplary compositions that can be used to facilitate uptake by a target cell of nucleic acids in general, and nucleic acids encoding the murine TLR9 in particular, include

- 39 -

calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a murine TLR9 nucleic acid into a preselected location within a target cell chromosome).

5 The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

10 It will also be recognized that the invention embraces the use of the murine TLR9 cDNA sequences in expression vectors to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., 293 fibroblast cells (ATCC, CRL-1573), MonoMac-6, THP-1, U927, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, pig, goat, primate, rodent, guinea pig, etc. They may be of a wide variety of tissue
15 types, and include primary cells and cell lines. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

20 The invention also provides isolated murine TLR9 polypeptides which include the amino acid sequences of SEQ ID NO:3 and fragments thereof, encoded by the murine TLR9 nucleic acids described above. Murine TLR9 polypeptides also embrace alleles, functionally equivalent variants and analogs (those non-allelic polypeptides which vary in amino acid sequence from the disclosed murine TLR9 polypeptides by 1, 2, 3, 4, 5, or more amino acids) provided that such polypeptides retain TLR9 activity. Non-functional variants also are embraced by the invention; these are useful as antagonists of TLR9 signaling function, as
25 negative controls in assays, and the like. Such alleles, variants, analogs and fragments are useful, for example, alone or as fusion proteins for a variety of purposes including as a component of assays.

30 Fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the intact polypeptide, in particular as a receptor of various molecules. Accordingly, fragments of a TLR9 polypeptide preferably are those fragments which retain a distinct functional capability of the TLR9 polypeptide, in particular as a receptor of various molecules. Of particular interest are fragments that bind to ISNAs, including, for example,

- 40 -

fragments that bind CpG nucleic acids. Other functional capabilities which can be retained in a fragment of a polypeptide include signal transduction (e.g., TLR/IL-1R signaling by murine TLR9), interaction with antibodies and interaction with other polypeptides (such as would be found in a protein complex). Those skilled in the art are well versed in methods that can be applied for selecting fragments which retain a functional capability of the murine TLR9. Confirmation of the functional capability of the fragment can be carried out by synthesis of the fragment and testing of the capability according to standard methods. For example, to test the signaling activity of a murine TLR9 fragment, one inserts or expresses the fragment in a cell in which signaling can be measured. Such methods, which are standard in the art, are described further herein.

The invention embraces variants of the murine TLR9 polypeptides described above. As used herein, a "variant" of a polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a polypeptide. Accordingly, a "variant" of a murine TLR9 polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a murine TLR9 polypeptide. Modifications which create a murine TLR9 variant can be made to a murine TLR9 polypeptide for a variety of reasons, including 1) to reduce or eliminate an activity of a murine TLR9 polypeptide, such as signaling; 2) to enhance a property of a murine TLR9 polypeptide, such as signaling, binding affinity for nucleic acid ligand or other ligand molecule, protein stability in an expression system, or the stability of protein-protein binding; 3) to provide a novel activity or property to a murine TLR9 polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety, e.g., luciferase, FLAG peptide, GFP; 4) to establish that an amino acid substitution does or does not affect molecular signaling activity; or 5) reduce immunogenicity of a murine TLR9 polypeptide. Modifications to a murine TLR9 polypeptide are typically made to the nucleic acid which encodes the murine TLR9 polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety (for example, biotin, fluorophore, radioisotope, enzyme, or peptide), addition of a fatty acid, and the like.

Modifications also embrace fusion proteins comprising all or part of the murine TLR9

- 41 -

amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant murine TLR9 according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87 (1997), whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a murine TLR9 polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants include murine TLR9 polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a murine TLR9 polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a murine TLR9 polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with a desired property. Further mutations can be made to variants (or to non-variant murine TLR9 polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a murine TLR9 gene or cDNA clone to enhance expression of the polypeptide.

The activity of variants of murine TLR9 polypeptides can be tested by cloning the gene encoding the variant murine TLR9 polypeptide into a prokaryotic or eukaryotic (e.g., mammalian) expression vector, introducing the vector into an appropriate host cell,

- 42 -

expressing the variant murine TLR9 polypeptide, and testing for a functional capability of the murine TLR9 polypeptides as disclosed herein. For example, the variant murine TLR9 polypeptide can be tested for ability to provide signaling, as set forth below in the examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in murine TLR9 polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the murine TLR9 polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the polypeptide in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the murine TLR9 polypeptides include conservative amino acid substitutions of SEQ ID NO:3. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Conservative amino acid substitutions in the amino acid sequence of murine TLR9 polypeptide to produce functionally equivalent variants of murine TLR9 typically are made by alteration of the nucleic acid sequence encoding murine TLR9 polypeptides (e.g., SEQ ID NO:1 and SEQ ID NO:2). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc Natl Acad Sci USA* 82:488-492 (1985)), or by chemical synthesis of a gene encoding a murine TLR9 polypeptide. The activity of functionally equivalent fragments of murine TLR9 polypeptides can be tested by cloning the gene encoding the altered murine TLR9 polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered murine TLR9 polypeptide, and testing for the ability of the

- 43 -

murine TLR9 polypeptide to mediate a signaling event. Peptides which are chemically synthesized can be tested directly for function.

A variety of methodologies well known to the skilled practitioner can be utilized to obtain isolated murine TLR9 polypeptide molecules. The polypeptide may be purified from
5 cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation
10 of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating murine TLR9 polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention as described herein has a number of uses, some of which are described
15 elsewhere herein. For example, the invention permits isolation of the murine TLR9 polypeptide molecules by, e.g., expression of a recombinant nucleic acid to produce large quantities of polypeptide which may be isolated using standard protocols. As another example, the isolation of the murine TLR9 gene makes it possible for murine TLR9 to be used in methods for assaying molecular interactions involving TLR9.

As discussed further in the Examples below, it has been discovered according to one
20 aspect of the invention that responsiveness to ISNA can be reconstituted in ISNA-unresponsive cells by introducing into ISNA-unresponsive cells an expression vector that directs the expression of murine TLR9 (and certain homologues and variants thereof). Cells so reconstituted also exhibit responses to substances other than phosphorothioate ISNA, e.g.,
25 *E. coli* DNA, phosphodiester CpG-ODN, and even methylated CpG-ODN.

Also as discussed further in the Examples below, it has been discovered according to certain aspects of the instant invention that TLR9 not only confers upon cells the ability to signal in response to binding ISNA, but also confers both sequence specificity and species
30 specificity to such signaling responses. Thus murine TLR9 signaling in response to CpG-ODN 1668, reportedly an optimal murine ISNA, was found to be significantly stronger than the corresponding murine TLR9 signaling response to CpG-ODN 2006, reportedly an optimal

- 44 -

human ISNA. The converse was also found to be true, i.e., human TLR9 signaling in response to CpG-ODN 2006 was found to be significantly stronger than the corresponding human TLR9 signaling response to CpG-ODN 1668. Furthermore, it has been discovered according to the instant invention that certain types of cells preferentially express TLR9. For example, TLR9 is strongly expressed in B cells and plasmacytoid dendritic cells (CD123+ DC), but only weakly by T cells, monocyte-derived dendritic cells (MDDC), and CD14+ monocytes. In contrast, TLR2 and TLR4 are strongly expressed by MDDC and CD14+ monocytes, but relatively weakly by B cells, CD123+ DC, and T cells.

The invention also embraces agents which bind selectively to the murine TLR9 nucleic acid molecules or polypeptides as well as agents which bind to variants and fragments of the polypeptides and nucleic acids as described herein. The agents include polypeptides which bind to murine TLR9, and antisense nucleic acids, both of which are described in greater detail below. The agents can inhibit or increase murine TLR9-mediated signaling activity (antagonists and agonists, respectively).

Some of the agents are inhibitors. A murine TLR9 inhibitor is an agent that inhibits murine TLR9-mediated signaling across a cell membrane.

As used herein "TLR9 signaling" refers to an ability of a TLR9 polypeptide to activate the TLR/IL-1R (TIR) signaling pathway, also referred to herein as the TLR signal transduction pathway. Without meaning to be held to any particular theory, it is believed that the TLR/IL-1R signaling pathway involves signaling via the molecules myeloid differentiation marker 88 (MyD88) and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), leading to activation of kinases of the I κ B kinase complex and the c-jun NH₂-terminal kinases (e.g., JNK 1/2). Häcker H et al., *J Exp Med* 192:595-600 (2000). A molecule which inhibits TLR9 activity (an antagonist) is one which inhibits TLR9-mediated activation of the TLR/IL-1R signaling pathway, and a molecule which increases TLR9 signaling (an agonist) is one which increases TLR9-mediated activation of the TLR/IL-1R signaling pathway. Changes in TLR9 activity can be measured by assays such as those disclosed herein, including expression of genes under control of κ B-sensitive promoters and enhancers. Such naturally occurring genes include the genes encoding IL-1 β , IL-6, IL-8, the p40 subunit of interleukin 12 (IL-12p40), and the costimulatory molecules CD80 and CD86. Other genes can be placed under the control of such regulatory elements (see below) and thus

- 45 -

serve to report the level of TLR9 signaling. Additional nucleotide sequence can be added to SEQ ID NO:1 or SEQ ID NO:2, preferably to the 5' or the 3' end of SEQ ID NO:2, to yield a nucleotide sequence encoding a chimeric polypeptide that includes a detectable or reporter moiety, e.g., FLAG, luciferase (luc), green fluorescent protein (GFP) and others known by those skilled in the art. These are discussed in greater detail in the Examples below.

In one embodiment the murine TLR9 inhibitor is an antisense oligonucleotide that selectively binds to a murine TLR9 nucleic acid molecule, to reduce the expression of murine TLR9 (or TLR9 of another species) in a cell. This is desirable in virtually any medical condition wherein a reduction of TLR9 signaling activity is desirable.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions.

Based upon SEQ ID NO:1 and SEQ ID NO:2, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides. Wagner RW et al., *Nat Biotechnol* 14:840-844 (1996). Most preferably, the antisense oligonucleotides comprise

- 46 -

a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol Neurobiol* 14(5):439-457 (1994)) and at which polypeptides are not expected to bind. Thus, the present invention also provides for antisense oligonucleotides which are complementary to allelic or homologous cDNAs and genomic DNAs corresponding to murine TLR9 nucleic acid containing SEQ ID NO:1 or SEQ ID NO:2.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art-recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a

- 47 -

covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding murine TLR9 polypeptides, together with pharmaceutically acceptable carriers.

Agents which bind murine TLR9 also include binding peptides and other molecules which bind to the murine TLR9 polypeptide and complexes containing the murine TLR9 polypeptide. When the binding molecules are inhibitors, the molecules bind to and inhibit the activity of murine TLR9. When the binding molecules are activators, the molecules bind to and increase the activity of murine TLR9. To determine whether a murine TLR9 binding agent binds to murine TLR9 any known binding assay may be employed. For example, the binding agent may be immobilized on a surface and then contacted with a labeled murine TLR9 polypeptide. The amount of murine TLR9 which interacts with the murine TLR9 binding agent or the amount which does not bind to the murine TLR9 binding agent may then be quantitated to determine whether the murine TLR9 binding agent binds to murine TLR9.

The murine TLR9 binding agents include molecules of numerous size and type that bind selectively or preferentially to murine TLR9 polypeptides, and complexes of both murine TLR9 polypeptides and their binding partners. These molecules may be derived from a variety of sources. For example, murine TLR9 binding agents can be provided by screening degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using, e.g., m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array.

- 48 -

One then can select phage-bearing inserts which bind to the murine TLR9 polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the murine TLR9 polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the murine TLR9 polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the murine TLR9 polypeptides. Thus, the murine TLR9 polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the murine TLR9 polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of murine TLR9 and for other purposes that will be apparent to those of ordinary skill in the art.

The invention also embraces agents which bind selectively to certain regulatory sequences associated with the murine TLR9 nucleic acid molecules described herein. The agents include polypeptides which bind to transcription and translation regulatory sequences of murine TLR9, and antisense nucleic acids, both of which are described in greater detail below. The agents can inhibit or increase murine TLR9 expression, as well as signaling activity (antagonists and agonists, respectively). Agents which bind selectively to regulatory sequences associated with the murine TLR9 nucleic acid molecules can be identified using methods familiar to those of skill in the art. For example, a promoter region including at least 100, 200, 300, 400, 500, or more nucleotides upstream (5') of the coding region of murine TLR9 can be identified by isolating, from appropriate genomic DNA, such nucleotide sequences using the sequences of SEQ ID NO:1 or SEQ ID NO:2 as primers or as probes, and then inserting the promoter region DNA into an appropriate expression vector so as to control the expression of TLR9 or some other reporter gene, introducing the TLR9 promoter vector into an appropriate host cell, and screening for TLR9 or reporter expression by those cells following their incubation in the presence and absence of various test agents. A reporter gene other than TLR9 can include, for example, an enzyme, a cytokine, a cell surface antigen,

- 49 -

luciferase, chloramphenicol acetyl transferase (CAT), etc. An agent that inhibits expression of TLR9 or the reporter under the control of the TLR9 promoter is classified as a TLR9 expression inhibitor. Conversely, an agent that augments expression of TLR9 or reporter under the control of the TLR9 promoter is classified as a TLR9 expression enhancer. It was
5 discovered according to the instant invention, for example, that the cytokine IL-4 inhibits the expression of TLR9. In this manner it is possible to identify agents that can be administered in conjunction with ISNA, for example by local administration, to enhance response to the ISNA. Such an enhancing effect might be desirable, for example, in the setting of immunization or vaccination. Conversely, it is possible to identify agents that can be
10 administered in conjunction with a ISNA, for example by local administration, to inhibit response to the ISNA. Such an inhibiting response might be desirable, for example, in the setting of gene replacement therapy.

Therefore the invention generally provides efficient methods of identifying pharmacological agents or lead compounds for agents useful in the treatment of conditions
15 associated with TLR9 activity and the compounds and agents so identified. Generally, the screening methods involve assaying for compounds which inhibit or enhance signaling through murine TLR9. Such methods are adaptable to automated, high throughput screening of compounds. Examples of such high throughput screening methods are described in U.S. patents 6,103,479; 6,051,380; 6,051,373; 5,998,152; 5,876,946; 5,708,158; 5,443,791;
20 5,429,921; and 5,143,854.

A variety of assays for pharmacological agents are provided, including labeled *in vitro* protein binding assays, signaling assays using detectable molecules, etc. For example, protein binding screens are used to rapidly examine the binding of candidate pharmacological agents to a murine TLR9. The candidate pharmacological agents can be derived from, for example,
25 combinatorial peptide or nucleic acid libraries. Convenient reagents for such assays are known in the art. An exemplary cell-based assay of signaling involves contacting a cell having a murine TLR9 with a candidate pharmacological agent under conditions whereby the induction of a detectable molecule can occur. Specific conditions are well known in the art and are described, for example, in Häcker H et al., *J Exp Med* 192:595-600 (2000), and
30 references cited therein. A reduced degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological

- 50 -

agent reduces the signaling activity of murine TLR9. An increased degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent increases the signaling activity of murine TLR9.

Murine TLR9 used in the methods of the invention can be added to an assay mixture
5 as an isolated polypeptide (where binding of a candidate pharmaceutical agent is to be measured) or as a cell or other membrane-encapsulated space which includes a murine TLR9 polypeptide. In the latter assay configuration, the cell or other membrane-encapsulated space can contain the murine TLR9 as a polypeptide or as a nucleic acid (e.g., a cell transfected with an expression vector containing a murine TLR9). In the assays described herein, the
10 murine TLR9 polypeptide can be produced recombinantly, isolated from biological extracts, or synthesized *in vitro*. Murine TLR9 polypeptides encompass chimeric proteins comprising a fusion of a murine TLR9 polypeptide with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, enhancing signaling capability, facilitating detection, or enhancing stability of the murine TLR9 polypeptide under assay conditions. A
15 polypeptide fused to a murine TLR9 polypeptide or fragment thereof may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The assay mixture also comprises a candidate pharmacological agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a
20 different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate pharmaceutical agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight
25 of more than 50 yet less than about 2500. Polymeric candidate agents can have higher molecular weights, e.g., oligonucleotides in the range of about 2500 to about 12,500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides, and may include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of
30 the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more

- 51 -

of the above-identified functional groups. Candidate agents also can be biomolecules such as nucleic acids, peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified
5 nucleic acids having non-natural bonds or subunits are also contemplated.

Candidate agents are obtained from a wide variety of sources, including libraries of natural, synthetic, or semisynthetic compounds, or any combination thereof. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides,
10 synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further, known pharmacological agents may be subjected
15 to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc., to produce structural analogs of the agents.

Therefore, a source of candidate agents are libraries of molecules based on known TLR9 ligands, e.g., CpG oligonucleotides shown herein to interact with TLR9, in which the structure of the ligand is changed at one or more positions of the molecule to contain more or
20 fewer chemical moieties or different chemical moieties. The structural changes made to the molecules in creating the libraries of analog inhibitors can be directed, random, or a combination of both directed and random substitutions and/or additions. One of ordinary skill in the art in the preparation of combinatorial libraries can readily prepare such libraries based on existing TLR9 ligands.

25 A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease
30 inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby,

- 52 -

but for the presence of the candidate pharmacological agent, the murine TLR9 mediates TLR/IL-1R signaling. For determining the binding of a candidate pharmaceutical agent to a murine TLR9, the mixture is incubated under conditions which permit binding. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 1 minute and 10 hours.

After incubation, the level of signaling or the level of specific binding between the murine TLR9 polypeptide and the candidate pharmaceutical agent is detected by any convenient method available to the user. For cell-free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. For example, separation can be accomplished in solution, or, conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximize signal-to-noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as measurement of an induced polypeptide within, on the surface of, or secreted by the cell. Examples of detection methods useful in such cell-based assays include fluorescence-activated cell sorting (FACS) analysis, bioluminescence, fluorescence, enzyme-linked

- 53 -

immunosorbent assay (ELISA), reverse transcriptase-polymerase chain reaction (RT-PCR), and the like.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly
5 detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc., or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The murine TLR9 binding agent may also be an antibody or a functionally active
10 antibody fragment. Antibodies are well known to those of ordinary skill in the science of immunology. As used herein, the term "antibody" means not only intact antibody molecules but also fragments of antibody molecules retaining specific target binding ability. Such fragments are also well known in the art and are regularly employed both *in vitro* and *in vivo*. In particular, as used herein, the term "antibody" means not only intact immunoglobulin
15 molecules but also the well-known active fragments $F(ab')_2$ and Fab. $F(ab')_2$ and Fab fragments which lack the Fc fragment of intact antibody clear more rapidly from the circulation and may have less non-specific tissue binding than an intact antibody (Wahl RL et al., *J Nucl Med* 24:316-325 (1983)).

Monoclonal antibodies may be made by any of the methods known in the art utilizing
20 murine TLR9, or a fragment thereof, as an immunogen. Alternatively the antibody may be a polyclonal antibody specific for murine TLR9 which inhibits murine TLR9 activity. The preparation and use of polyclonal antibodies are also known to one of ordinary skill in the art.

Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in
25 general, Clark, W.R. (1986) *The Experimental Foundations of Modern Immunology*, Wiley & Sons, Inc., New York; Roitt, I. (1991) *Essential Immunology*, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated
30 an $F(ab')_2$ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been

- 54 -

produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

The sequences of the antigen-binding Fab' portion of the anti-murine TLR9 monoclonal antibodies identified as being useful according to the invention in the assays provided above, as well as the relevant FR and CDR regions, can be determined using amino acid sequencing methods that are routine in the art. It is well established that non-CDR regions of a mammalian antibody may be replaced with corresponding regions of non-specific or hetero-specific antibodies while retaining the epitope specificity of the original antibody. This technique is useful for the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Techniques to humanize antibodies are particularly useful when non-human animal (e.g., murine) antibodies which inhibit murine TLR9 activity are identified. These non-human animal antibodies can be humanized for use in the treatment of a human subject in the methods according to the invention. Examples of methods for humanizing a murine antibody are provided in U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Other antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂ and Fab fragments of an anti-murine TLR9 monoclonal antibody;

- 55 -

chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR9 antibody have been replaced by homologous human or non-human sequences; chimeric F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR9 antibody have been replaced by homologous human or non-human sequences; and chimcric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences.

According to the invention murine TLR9 inhibitors also include "dominant negative" polypeptides derived from SEQ ID NO:3. A dominant negative polypeptide is an inactive variant of a polypeptide, which, by interacting with the cellular machinery, displaces an active polypeptide from its interaction with the cellular machinery or competes with the active polypeptide, thereby reducing the effect of the active polypeptide. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the receptor. As shown in the Examples below, TLR9 polypeptides which incorporate the substitution of histidine for proline at aa 915 (P915H mutation) are functionally inactive and are dominant negative with respect to the native TLR9 polypeptide.

The end result of the expression of a dominant negative murine TLR9 polypeptide of the invention in a cell is a reduction in TLR9 activity such as signaling through the TIR pathway. One of ordinary skill in the art can assess the potential for a dominant negative variant of a murine TLR9 polypeptide and, using standard mutagenesis techniques, create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of a murine TLR9 polypeptide, one of ordinary skill in the art can modify the sequence of the murine TLR9 polypeptide by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in murine TLR9 activity and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a murine TLR9 polypeptide will be apparent to one of ordinary skill in the art.

- 56 -

Each of the compositions according to this aspect of the invention is useful for a variety of therapeutic and non-therapeutic purposes. For example, the murine TLR9 nucleic acids of the invention are useful as oligonucleotide probes. Such oligonucleotide probes can be used herein to identify genomic or cDNA library clones possessing an identical or
5 substantially similar nucleic acid sequence. A suitable oligonucleotide or set of oligonucleotides, which is capable of hybridizing under stringent hybridization conditions to the desired sequence, a variant or fragment thereof, or an anti-sense complement of such an oligonucleotide or set of oligonucleotides, can be synthesized by means well known in the art (see, for example, *Synthesis and Application of DNA and RNA*, S.A. Narang, ed., 1987,
10 Academic Press, San Diego, CA) and employed as a probe to identify and isolate the desired sequence, variant or fragment thereof by techniques known in the art. Techniques of nucleic acid hybridization and clone identification are disclosed by Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.

15 To facilitate the detection of a desired nucleic acid sequence, or variant or fragment thereof, whether for cloning purposes or for the mere detection of the presence of the sequence, the above-described probes may be labeled with a detectable group. Such a detectable group may be any material having a detectable physical or chemical property. Such materials have been well developed in the field of nucleic acid hybridization and, in
20 general, many labels useful in such methods can be applied to the present invention. Particularly useful are radioactive labels. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life. If single stranded, the oligonucleotide may be radioactively labeled using kinase reactions. Alternatively, oligonucleotides are also useful as nucleic acid hybridization probes when labeled with a non-
25 radioactive marker such as biotin, an enzyme or a fluorescent group. See, for example, Leary JJ et al., *Proc Natl Acad Sci USA* 80:4045 (1983); Renz M et al., *Nucleic Acids Res* 12:3435 (1984); and Renz M, *EMBO J* 6:817 (1983).

Additionally, complements of the murine TLR9 nucleic acids can be useful as antisense oligonucleotides, e.g., by delivering the antisense oligonucleotide to an animal to
30 induce a murine TLR9 "knockout" phenotype. The administration of antisense RNA probes to block gene expression is discussed in Lichtenstein C, *Nature* 333:801-802 (1988).

- 57 -

Alternatively, the murine TLR9 nucleic acid of the invention can be used to prepare a non-human transgenic animal. A "transgenic animal" is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), Harlan (Indianapolis, IN), etc. Transgenic animals having a particular property associated with a particular disease can be used to study the effects of a variety of drugs and treatment methods on the disease, and thus serve as genetic models for the study of a number of human diseases. The invention, therefore, contemplates the use of murine TLR9 knockout and transgenic animals as models for the study of disorders involving TLR9-mediated signaling. A variety of methods known to one of ordinary skill in the art are available for the production of transgenic animals associated with this invention.

Inactivation or replacement of the endogenous TLR9 gene can be achieved by a homologous recombination system using embryonic stem cells. The resultant transgenic non-human mammals having a TLR9^{-/-} knockout phenotype may be made transgenic for the murine TLR9 and used as a model for screening compounds as modulators (agonists or antagonists/inhibitors) of the murine TLR9. In this manner, such therapeutic drugs can be identified.

Additionally, a normal or mutant version of murine TLR9 can be inserted into the germ line to produce transgenic animals which constitutively or inducibly express the normal or mutant form of murine TLR9. These animals are useful in studies to define the role and function of murine TLR9 in cells.

Generally, doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable and in one or several administrations per day. Lower doses will result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of

- 58 -

compound, although fewer doses typically will be given when compounds are prepared as slow release or sustained release medications.

The antagonists, agonists, nucleic acids, and polypeptides of murine TLR9 useful according to the invention may be combined, optionally, with a pharmaceutically acceptable carrier. Thus the invention also provides pharmaceutical compositions and a method for preparing the pharmaceutical compositions which contain compositions of this aspect of the invention. The pharmaceutical compositions include any one or combination of the antagonists, agonists, nucleic acids and polypeptides of murine TLR9 useful according to the invention and, optionally, a pharmaceutically acceptable carrier. Each pharmaceutical composition is prepared by selecting an antagonist, agonist, nucleic acid or polypeptide of murine TLR9 useful according to the invention, as well as any combination thereof, and, optionally, combining it with a pharmaceutically acceptable carrier.

The term "pharmaceutically acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including, without limitation: acetic acid in a salt; citric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as benzalkonium chloride, chlorobutanol, parabens, and thimerosal.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically acceptable amounts and in pharmaceutically acceptable compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic,

- 59 -

sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

A variety of administration routes are available. The particular mode selected will
5 depend, of course, upon the particular compound selected, the severity of the condition being treated, and the dosage required for therapeutic efficacy. The methods of the invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral,
10 rectal, topical, nasal, intradermal, or parenteral routes. The term "parenteral" includes, without limitation, subcutaneous, transdermal, intravenous, intra-arterial, intrathecal, intramuscular, intraperitoneal, mucosal (apart from gastrointestinal mucosa), pulmonary, intralesional, and infusion.

The pharmaceutical compositions may conveniently be presented in unit dosage form
15 and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

20 Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile
25 aqueous preparation of the antagonists, agonists, nucleic acids, or polypeptides of murine TLR9, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example,
30 as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition,

- 60 -

sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intrathecal, intramuscular, etc.

5 administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

Other delivery systems can include time-release, delayed release or sustained release delivery systems such as the biological/chemical vectors is discussed above. Such systems can avoid repeated administrations of the active compound, increasing convenience to the
10 subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary
15 skill in the art and include some of the release systems described above.

In another aspect the invention involves the identification of cDNAs encoding mouse TLR7 and mouse TLR8, referred to herein as murine TLR7 and murine TLR8 and, equivalently, mTLR7 and mTLR8, respectively. The nucleotide sequence of the cDNA for murine TLR7 is presented as SEQ ID NO:173, the coding region of the cDNA for murine
20 TLR7 is presented as SEQ ID NO:174, and the amino acid sequence of the murine TLR7 is presented as SEQ ID NO:175. The closely related human TLR7 (equivalently, hTLR7) was previously deposited in GenBank under accession numbers AF245702 and AF240467. The nucleotide sequence of the cDNA for murine TLR7 presented as SEQ ID NO:173 is 3357 nucleotides long and includes the ORF spanning bases 117-3266, presented as SEQ ID
25 NO:174, which spans 3150 nucleotides (excluding the stop codon). The amino acid sequence of the murine TLR7 presented as SEQ ID NO:175 is 1050 amino acids long.

The nucleotide sequence of the cDNA for murine TLR8 is presented as SEQ ID NO:190, the coding region of the cDNA for murine TLR8 is presented as SEQ ID NO:191, and the amino acid sequence of the murine TLR8 is presented as SEQ ID NO:192. The
30 closely related human TLR8 (equivalently, hTLR8) was previously deposited in GenBank under accession numbers AF245703 and AF246971.

- 61 -

Like both human and murine TLR9, human TLR7 and human TLR8 each contains one CXXC motif and one MBD motif. The hTLR7 CXXC motif contains amino acids 258-273, and the hTLR8 CXXC motif contains amino acids 255-270.

5

CXXC motif:	GNCXXCXXXXXXXXCXXC	SEQ ID NO:196
hTLR9:	GNCRRCDHAPNPCMEC	SEQ ID NO:197
mTLR9:	GNCRRCDHAPNPCMIC	SEQ ID NO:198
hTLR7:	GNCPRCYNAPFPCAPC	SEQ ID NO:199
10 mTLR7:	GNCPRCYNVPYPCTPC	SEQ ID NO:200
hTLR8:	GNCPRCFNAPFPCVPC	SEQ ID NO:201
mTLR8:	GNCPRCYNAPFPCTPC	SEQ ID NO:202

Also like human and murine TLR9, human TLR7 and TLR8 also have a single MBD motif. The the hTLR7 MBD motif spans amino acids 545-575, and the hTLR8 MBD motif amino acids spans 533-563.

MBD motif		
MBD-1	R-XXXXXXX-R-X-D-X-Y-XXXXXXXXXX-R-S-XXXXXX-Y	SEQ ID NO:125
20 hTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXXX-R-L-XXXXXX-Y	SEQ ID NO:126
mTLR9	Q-XXXXXXX-K-X-D-X-Y-XXXXXXXXXX-Q-L-XXXXXX-Y	SEQ ID NO:127
hTLR7	R-XXXXXXX-R-X-D-X-L-XXXXXXXXXX-K-L-XXXXXX-S	SEQ ID NO:203
mTLR7	R-XXXXXXX-R-X-D-X-L-XXXXXXXXXX-S-L-XXXXXX-S	SEQ ID NO:204
hTLR8	K-XXXXXXX-R-X-D-X-D-XXXXXXXXXX-D-L-XXXXXX-Y	SEQ ID NO:205
25 mTLR8	K-XXXXXXX-R-X-D-X-D-XXXXXXXXXX-D-L-XXXXXX-H	SEQ ID NO:206
hTLR7	R-YLDFSNN-R-L-D-L-L-HSTAFEELH-K-L-EVLDIS-S	SEQ ID NO:212
mTLR7	R-YLDFSNN-R-L-D-L-L-YSTAFEELQ-S-L-EVLDLS-S	SEQ ID NO:213
30 hTLR8	K-YLDLTNN-R-L-D-F-D-NASALTELS-D-L-EVLDLS-Y	SEQ ID NO:214
mTLR8	K-YLDLTNN-R-L-D-F-D-DNNAPSDLH-D-L-EVLDLS-H	SEQ ID NO:215

- 62 -

The core D-X-Y in the MBD motif is involved in CpG binding of the MBD-1 protein and is conserved in TLR9 but only partially conserved in TLR8 and TLR7 (Y to D or L). The other mismatches are highly or moderately conserved; example R to K, Q, or D. These changes could explain MBD-1 as a methyl-CpG binder and TLR9 as a binder for CpG-DNA. The modification in the core sequence (D-X-Y) in hTLR7 (D-X-L) and TLR8 (D-X-D) is likely a structural basis for the recognition of different nucleic acid motifs. Combined with the presence of a CXXC domain TLR7 and TLR8 appear certainly to be nucleic acid binding receptors relevant to the innate immune system and thus clinical value.

The invention involves in one aspect murine TLR7 and murine TLR8 nucleic acids and polypeptides, as well as therapeutics relating thereto. The invention also embraces isolated functionally equivalent variants, useful analogs and fragments of the foregoing murine TLR7 and murine TLR8 nucleic acids and polypeptides; complements of the foregoing murine TLR7 and murine TLR8 nucleic acids; and molecules which selectively bind the foregoing murine TLR7 and murine TLR8 nucleic acids and polypeptides.

The murine TLR7 and murine TLR8 nucleic acids and polypeptides of the invention are isolated. The term "isolated," with respect to murine TLR7 and murine TLR8 nucleic acids and polypeptides, has the same meaning as used elsewhere herein.

As used herein a murine TLR7 nucleic acid refers to an isolated nucleic acid molecule which codes for a murine TLR7 polypeptide. Such nucleic acid molecules code for murine TLR7 polypeptides which include the sequence of SEQ ID NO:175 and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:173, SEQ ID NO:174, and nucleotide sequences which differ from the sequences of SEQ ID NO:173 and SEQ ID NO:174 in codon sequence due to the degeneracy of the genetic code.

Also as used herein a murine TLR8 nucleic acid refers to an isolated nucleic acid molecule which codes for a murine TLR8 polypeptide. Such nucleic acid molecules code for murine TLR8 polypeptides which include the sequences of SEQ ID NO:193, and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:190, SEQ ID NO:191, and nucleotide sequences which differ from the sequences of SEQ ID NO:190 and SEQ ID NO:191 in codon sequence due to the degeneracy of the genetic code.

The murine TLR7 and murine TLR8 nucleic acids of the invention also include alleles

as well as fragments of the foregoing nucleic acids. Such fragments can be used, for example, as probes in hybridization assays and as primers in a polymerase chain reaction. Preferred murine TLR7 nucleic acids include the nucleic acid sequence of SEQ ID NO:173 and SEQ ID NO:174. Preferred murine TLR8 nucleic acids include the nucleic acid sequence of SEQ ID NO:190 and SEQ ID NO:191. Complements of the foregoing nucleic acids also are embraced by the invention.

As used herein a murine TLR7 nucleic acid or murine TLR7 polypeptide also embraces homologues and alleles of murine TLR7. Likewise, as used herein a murine TLR8 nucleic acid or murine TLR8 polypeptide also embraces homologues and alleles of murine TLR8. Homologues and alleles of murine TLR7 and murine TLR8 comply with the degrees of nucleotide and amino acid identity as previously set forth herein in reference to homologues and alleles of murine TLR9.

Alleles of the murine TLR7 and murine TLR8 nucleic acids of the invention can be identified by conventional techniques. For example, alleles of murine TLR7 can be isolated by hybridizing a probe which includes at least a fragment of SEQ ID NO:173 or SEQ ID NO:174 under stringent conditions with a cDNA library and selecting positive clones. Thus, an aspect of the invention is those nucleic acid sequences which code for murine TLR7 polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:173 or SEQ ID NO:174 under stringent conditions. Likewise, an aspect of the invention is those nucleic acid sequences which code for murine TLR8 polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:190 or SEQ ID NO:191 under stringent conditions. Stringent conditions in this context has the same meaning as described elsewhere herein, including the use of a suitable hybridization buffer and a temperature of about 65°C.

In screening for murine TLR7 or murine TLR8 nucleic acids, a Southern blot may be performed using the stringent conditions previously described herein, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. Corresponding non-radioactive methods are also well known in the art and can be used to similar effect.

The murine TLR7 and murine TLR8 nucleic acids of the invention also include degenerate nucleic acids which include alternative codons to those present in the native materials, as previously described herein.

- 64 -

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. The modified nucleic acid molecules according to this aspect of the invention exclude fully native human TLR7 (SEQ ID NO:168, 5 SEQ ID NO:169, GenBank Accession No. AF245702, and GenBank Accession No. AF240467) and fully native human TLR8 nucleic acid molecules (SEQ ID NO:182, SEQ ID NO:183, GenBank Accession No. AF245703, and GenBank Accession No. AF246971). In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or 10 the polypeptides, such as signaling activity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so 15 that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

The invention also provides isolated fragments of nucleotide sequences for murine TLR7 (SEQ ID NO:173 and SEQ ID NO:174) and for murine TLR8 (SEQ ID NO:190 and SEQ ID NO:191). The fragments can be used as probes in Southern blot assays to identify 20 such nucleic acids, or can be used in amplification assays such as those employing PCR. Smaller fragments are those comprising 12, 13, 14, 15, 16, 17, 18, 20, 22, 25, 30, 40, 50, or 75 nucleotides, and every integer therebetween, and are useful, e.g., as primers for nucleic acid amplification procedures. As known to those skilled in the art, larger probes such as 200, 250, 300, 400 or more nucleotides are preferred for certain uses such as Southern blots, 25 while smaller fragments will be preferred for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments. Likewise, fragments can be employed to produce non-fused fragments of the murine TLR7 and murine TLR8 polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and the like. The foregoing nucleic acid fragments further can 30 be used as antisense molecules to inhibit the expression of murine TLR7 and murine TLR8 nucleic acids and polypeptides.

The invention also includes functionally equivalent variants of the murine TLR7 and murine TLR8, which include variant nucleic acids and polypeptides which retain one or more of the functional properties of the murine TLR7 and murine TLR8. Preferably such variants include the murine-specific N-terminal domain.

5 Functionally equivalent variants also include a murine TLR7 or murine TLR8 which has had a portion (e.g., of the N-terminus) removed or replaced by a similar domain from another TLR (e.g., a "domain-swapping" variant). Examples of such domain-swapping variants include those involving swapping a TLR7 domain from another species and swapping a TLR domain from another TLR.

10 Other functionally equivalent variants will be known to one of ordinary skill in the art, as will be methods for preparing such variants. The activity of a functionally equivalent variant can be determined using the methods provided herein, and in references that have described assays using other TLRs and TLRs of other species. Such variants are useful, *inter alia*, for evaluating bioavailability of drugs, in assays for identification of compounds which
15 bind to and/or regulate the signaling function of the murine TLR7 and murine TLR8, and for determining the portions of the murine TLR7 and murine TLR8 which are required for signaling activity.

 Variants which are non-functional also can be prepared as described above. Such variants are useful, for example, as negative controls in experiments testing TLR7 and TLR8
20 signaling activity. Examples of non-functional variants include those incorporating a truncation or mutation of amino acids deemed critical to ligand binding or signaling activity.

 In certain embodiments a murine TLR7 or murine TLR8 nucleic acid is operably linked to a gene expression sequence which can direct the expression of the murine TLR7 or murine TLR8 nucleic acid within a eukaryotic or prokaryotic cell. The terms "gene
25 expression sequence" and "operably linked" are as previously described herein.

 The murine TLR7 and murine TLR8 nucleic acid molecules and the murine TLR7 and murine TLR8 polypeptides of the invention can be delivered to a eukaryotic or prokaryotic cell alone or in association with a vector. As applied to murine TLR7 and murine TLR8 nucleic acid molecules, a "vector" is any vehicle capable of facilitating: (1) delivery of a
30 murine TLR7 or murine TLR8 nucleic acid or polypeptide to a target cell, (2) uptake of a murine TLR7 or murine TLR8 nucleic acid or polypeptide by a target cell, or (3) expression

- 66 -

of a murine TLR7 or murine TLR8 nucleic acid molecule or polypeptide in a target cell.

In addition to the biological vectors, chemical/physical vectors may be used to deliver a murine TLR7 or murine TLR8 nucleic acid or polypeptide to a target cell and facilitate uptake thereby. As used herein with respect to a murine TLR7 or murine TLR8 nucleic acid or polypeptide, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the isolated murine TLR7 or murine TLR8 nucleic acid or polypeptide to a cell.

Other exemplary compositions that can be used to facilitate uptake by a target cell of the murine TLR7 or murine TLR8 nucleic acids include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a murine TLR7 or murine TLR8 nucleic acid into a preselected location within a target cell chromosome).

It will also be recognized that the invention embraces the use of the murine TLR7 and murine TLR8 cDNA sequences in expression vectors to transfect host cells and cell lines, because these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., 293 fibroblast cells (ATCC, CRL-1573), MonoMac-6, THP-1, U927, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, pig, goat, primate, rodent, guinea pig, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also provides isolated murine TLR7 and isolated murine TLR8 polypeptides which include the amino acid sequences of SEQ ID NO:175, SEQ ID NO:192, and fragments thereof, encoded by the murine TLR7 and murine TLR8 nucleic acids described above. Murine TLR7 and murine TLR8 polypeptides also embrace alleles, functionally equivalent variants and analogs (those non-allelic polypeptides which vary in amino acid sequence from the disclosed murine TLR7 and murine TLR8 polypeptides by 1, 2, 3, 4, 5, or more amino acids) provided that such polypeptides retain murine TLR7 or murine TLR8 activity. Non-functional variants also are embraced by the invention; these are useful as antagonists of TLR7 and TLR8 signaling function, as negative controls in assays, and the like. Such alleles, variants, analogs and fragments are useful, for example, alone or as fusion proteins for a variety of purposes including as a component of assays.

- 67 -

The invention also embraces variants of the murine TLR7 and murine TLR8 polypeptides described above. Modifications which create a murine TLR7 variant or murine TLR8 variant can be made to a murine TLR7 or murine TLR8 polypeptide for a variety of reasons, including 1) to reduce or eliminate an activity of a murine TLR7 or murine TLR8 polypeptide, such as signaling; 2) to enhance a property of a murine TLR7 or murine TLR8 polypeptide, such as signaling, binding affinity for nucleic acid ligand or other ligand molecule, protein stability in an expression system, or the stability of protein-protein binding; 3) to provide a novel activity or property to a murine TLR7 or murine TLR8 polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety, e.g., luciferase, FLAG peptide, GFP; 4) to establish that an amino acid substitution does or does not affect molecular signaling activity; or 5) reduce immunogenicity. Modifications to a murine TLR7 or murine TLR8 polypeptide are typically made to the nucleic acid which encodes the murine TLR7 or murine TLR8 polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety (for example, biotin, fluorophore, radioisotope, enzyme, or peptide), addition of a fatty acid, and the like.

Modifications also embrace fusion proteins comprising all or part of the murine TLR7 or murine TLR8 amino acid sequence.

Variants include murine TLR7 and murine TLR8 polypeptides which are modified specifically to alter a feature of each polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a murine TLR7 or murine TLR8 polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a murine TLR7 or murine TLR8 polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide. Methods of making mutations of murine TLR7 or murine TLR8 are as

- 68 -

described elsewhere herein with reference to making mutations of murine TLR9.

The activity of variants of murine TLR7 and murine TLR8 polypeptides can be tested by cloning the gene encoding the variant murine TLR7 or murine TLR8 polypeptide into a prokaryotic or eukaryotic (e.g., mammalian) expression vector, introducing the vector into an appropriate host cell, expressing the variant murine TLR7 or murine TLR8 polypeptide, and testing for a functional capability of the murine TLR7 or murine TLR8 polypeptides as disclosed herein.

The skilled artisan will also realize that conservative amino acid substitutions may be made in murine TLR7 and murine TLR8 polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the murine TLR7 and murine TLR8 polypeptides.

A variety of methodologies well known to the skilled practitioner can be utilized to obtain isolated murine TLR7 and murine TLR8 polypeptide molecules, as previously described in reference to murine TLR9 polypeptides.

The invention as described herein has a number of uses, some of which are described elsewhere herein. For example, the invention permits isolation of the murine TLR7 and the murine TLR8 polypeptide molecules by, e.g., expression of a recombinant nucleic acid to produce large quantities of polypeptide which may be isolated using standard protocols. As another example, the isolation of the murine TLR7 gene makes it possible for murine TLR7 to be used in methods for assaying molecular interactions involving TLR7.

The invention also embraces agents which bind selectively to the murine TLR7 or murine TLR8 nucleic acid molecules or polypeptides as well as agents which bind to variants and fragments of the polypeptides and nucleic acids as described herein. The agents include polypeptides which bind to murine TLR7 or murine TLR8, and antisense nucleic acids, both of which are described in greater detail below. Some agents can inhibit or increase murine TLR7-mediated signaling activity (antagonists and agonists, respectively), and some can inhibit or increase murine TLR8-mediated signaling activity.

In one embodiment the murine TLR7 inhibitor is an antisense oligonucleotide that selectively binds to a murine TLR7 nucleic acid molecule, to reduce the expression of murine TLR7 (or TLR7 of another species) in a cell. This is desirable in virtually any medical condition wherein a reduction of TLR7 signaling activity is desirable. Based upon SEQ ID

- 69 -

NO:173 and SEQ ID NO:174, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention.

In one embodiment the murine TLR8 inhibitor is an antisense oligonucleotide that
5 selectively binds to a murine TLR8 nucleic acid molecule, to reduce the expression of murine TLR8 (or TLR8 of another species) in a cell. This is desirable in virtually any medical condition wherein a reduction of TLR8 signaling activity is desirable. Based upon SEQ ID NO:190 and SEQ ID NO:191, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of
10 appropriate antisense molecules for use in accordance with the present invention.

Antisense oligonucleotides for murine TLR7 or murine TLR8 can include "natural" and "modified" oligonucleotides as previously described herein.

Agents which bind murine TLR7 or murine TLR8 also include binding peptides and other molecules which bind to the murine TLR7 or murine TLR8 polypeptide and complexes
15 containing the murine TLR7 or murine TLR8 polypeptide, respectively. When the binding molecules are inhibitors, the molecules bind to and inhibit the activity of murine TLR7 or murine TLR8. When the binding molecules are activators, the molecules bind to and increase the activity of murine TLR7 or murine TLR8. To determine whether a murine TLR7 or murine TLR8 binding agent binds to murine TLR7 or murine TLR8, any known binding
20 assay may be employed. For example, the binding agent may be immobilized on a surface and then contacted with a labeled murine TLR7 or murine TLR8 polypeptide. The amount of murine TLR7 or murine TLR8 which interacts with the murine TLR7 or murine TLR8 binding agent, or the amount which does not bind to the murine TLR7 or murine TLR8 binding agent, may then be quantitated to determine whether the murine TLR7 or murine
25 TLR8 binding agent binds to murine TLR7 or murine TLR8.

The murine TLR7 or murine TLR8 binding agents include molecules of numerous size and type that bind selectively or preferentially to murine TLR7 or murine TLR8 polypeptides, and to complexes involving murine TLR7 or murine TLR8 polypeptides and their binding partners. These molecules may be derived from a variety of sources. For
30 example, murine TLR7 or murine TLR8 binding agents can be provided by screening degenerate peptide libraries which can be readily prepared in solution, in immobilized form or

- 70 -

as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Exemplary methods useful for identifying murine TLR7 and murine TLR8 binding peptides are analogous to those described herein with reference to methods for identifying murine TLR9 binding peptides murine, and thus are not repeated here.

Therefore the invention generally provides efficient methods of identifying pharmacological agents or lead compounds for agents useful in the treatment of conditions associated with TLR7 and TLR8 activity, and the compounds and agents so identified. Generally, the screening methods involve assaying for compounds which inhibit or enhance the expression of or signaling through murine TLR7 or murine TLR8. Such methods are adaptable to automated, high throughput screening of compounds.

A variety of assays for pharmacological agents are provided, including labeled *in vitro* protein binding assays, signaling assays using detectable molecules, etc. For example, protein binding screens are used to rapidly examine the binding of candidate pharmacological agents to a murine TLR7 or murine TLR8. The candidate pharmacological agents can be derived from, for example, combinatorial peptide or nucleic acid libraries. Convenient reagents for such assays are known in the art. An exemplary cell-based assay of signaling involves contacting a cell having a murine TLR7 or murine TLR8 with a candidate pharmacological agent under conditions whereby the induction of a detectable molecule can occur. A reduced degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent reduces the signaling activity of murine TLR7 or murine TLR8. An increased degree of induction of the detectable molecule in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent increases the signaling activity of murine TLR7 or murine TLR8.

Murine TLR7 and murine TLR8 used in the methods of the invention can be added to an assay mixture as an isolated polypeptide (where binding of a candidate pharmaceutical agent is to be measured) or as a cell or other membrane-encapsulated space which includes a murine TLR7 or murine TLR8 polypeptide. In the latter assay configuration, the cell or other membrane-encapsulated space can contain the murine TLR7 or murine TLR8 as a

- 71 -

polypeptide or as a nucleic acid (e.g., a cell transfected with an expression vector containing a nucleic acid molecule encoding murine TLR7). In the assays described herein, the murine TLR7 or murine TLR8 polypeptide can be produced recombinantly, isolated from biological extracts, or synthesized *in vitro*. Murine TLR7 or murine TLR8 polypeptides encompass
5 chimeric proteins comprising a fusion of a murine TLR7 or murine TLR8 polypeptide with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, enhancing signaling capability, facilitating detection, or enhancing stability of the murine TLR7 or murine TLR8 polypeptide under assay conditions. A polypeptide fused to a murine TLR7 or murine TLR8 polypeptide or fragment thereof may also provide means of
10 readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The assay mixture also comprises a candidate pharmacological agent, as previously described in reference to murine TLR9. Candidate pharmacologic agents are obtained from a wide variety of sources, including libraries of natural, synthetic, or semisynthetic compounds,
15 or any combination thereof. Presently, natural ligands of murine TLR7 and murine TLR8 are unknown, but they appear not to include CpG-ODN.

A variety of other reagents also can be included in the assay mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent
20 may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the murine TLR7 or murine
25 TLR8 mediates TLR7-mediated or TLR8-mediated signaling, preferably TLR/IL-1R signaling. For determining the binding of a candidate pharmaceutical agent to a murine TLR7 or murine TLR8, the mixture is incubated under conditions which permit binding. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization
30 of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized

- 72 -

to facilitate rapid, high throughput screening, and typically are between 1 minute and 10 hours.

After incubation, the level of signaling or the level of specific binding between the murine TLR7 or murine TLR8 polypeptide and the candidate pharmaceutical agent is
5 detected by any convenient method available to the user, as described elsewhere herein.

The murine TLR7 or murine TLR8 binding agent may also be an antibody or a functionally active antibody fragment. Antibodies, including monoclonal antibodies and antibody fragments, are well known to those of ordinary skill in the science of immunology and are as described elsewhere herein. Monoclonal antibodies may be made by any of the
10 methods known in the art utilizing murine TLR7 or murine TLR8, or a fragment thereof, as an immunogen. Alternatively the antibody may be a polyclonal antibody specific for murine TLR7 or murine TLR8 which inhibits murine TLR7 or murine TLR8 activity. The preparation and use of polyclonal antibodies are also known to one of ordinary skill in the art.

The sequences of the antigen-binding Fab' portion of the anti-murine TLR7 or anti-
15 murine TLR8 monoclonal antibodies identified as being useful according to the invention in the assays provided above, as well as the relevant FR and CDR regions, can be determined using amino acid sequencing methods that are routine in the art. Such sequence information can be used to generate humanized and chimeric antibodies, as well as various fusion proteins and binding fragments, as described elsewhere herein.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also
20 provides for F(ab')₂ and Fab fragments of an anti-murine TLR7 or anti-murine TLR8 monoclonal antibody; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR7 or anti-murine TLR8 antibody have been replaced by homologous human or non-human sequences; chimeric
25 F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-murine TLR7 or anti-murine TLR8 antibody have been replaced by homologous human or non-human sequences; and chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences.

30 According to the invention murine TLR7 and murine TLR8 inhibitors also include "dominant negative" polypeptides derived from SEQ ID NO:175 or SEQ ID NO:192,

- 73 -

respectively. The end result of the expression of a dominant negative murine TLR7 or dominant negative murine TLR8 polypeptide of the invention in a cell is a reduction in TLR7 or murine TLR8 activity such as signaling through the TIR pathway. One of ordinary skill in the art can assess the potential for a dominant negative variant of a murine TLR7 or dominant negative murine TLR8 polypeptide and, using standard mutagenesis techniques, create one or more dominant negative variant polypeptides.

Each of the compositions according to this aspect of the invention is useful for a variety of therapeutic and non-therapeutic purposes. For example, the murine TLR7 and murine TLR8 nucleic acids of the invention are useful as oligonucleotide probes. Such oligonucleotide probes can be used herein to identify genomic or cDNA library clones possessing an identical or substantially similar nucleic acid sequence. Methods of hybridization, synthesis of probes, and detection are generally as described elsewhere herein.

Additionally, complements of the murine TLR7 and murine TLR8 nucleic acids can be useful as antisense oligonucleotides, e.g., by delivering the antisense oligonucleotide to an animal to induce a murine TLR7 or murine TLR8 "knockout" phenotype.

Alternatively, the murine TLR7 and murine TLR8 nucleic acids of the invention can be used to prepare a non-human transgenic animal. The invention, therefore, contemplates the use of murine TLR7 and murine TLR8 knockout and transgenic animals as models for the study of disorders involving TLR7- and murine TLR8-mediated signaling. A variety of methods known to one of ordinary skill in the art are available for the production of transgenic animals associated with this invention.

Inactivation or replacement of the endogenous TLR7 or TLR8 gene can be achieved by a homologous recombination system using embryonic stem cells. The resultant transgenic non-human mammals having a TLR7^{-/-} or TLR8^{-/-} knockout phenotype may be made transgenic for the murine TLR7 or murine TLR8 and used as a model for screening compounds as modulators (agonists or antagonists/inhibitors) of the murine TLR7 or murine TLR8. In this manner, such therapeutic drugs can be identified.

Additionally, a normal or mutant version of murine TLR7 or murine TLR8 can be inserted into the germ line to produce transgenic animals which constitutively or inducibly express the normal or mutant form of murine TLR7 or murine TLR8. These animals are useful in studies to define the role and function of murine TLR7 or murine TLR8 in cells.

- 74 -

The antagonists, agonists, nucleic acids, and polypeptides of murine TLR7 and murine TLR8 useful according to the invention may be combined, optionally, with a pharmaceutically acceptable carrier. Thus the invention also provides pharmaceutical compositions and a method for preparing the pharmaceutical compositions which contain compositions of this aspect of the invention. The pharmaceutical compositions include one or any combination of the antagonists, agonists, nucleic acids and polypeptides of murine TLR7 and murine TLR8 useful according to the invention and, optionally, a pharmaceutically acceptable carrier. Each pharmaceutical composition is prepared by selecting an antagonist, agonist, nucleic acid or polypeptide of murine TLR7 and murine TLR8 useful according to the invention, as well as any combination thereof, and, optionally, combining it with a pharmaceutically acceptable carrier.

A variety of administration routes are available, as described previously herein. The particular mode selected will depend, of course, upon the particular compound selected, the severity of the condition being treated, and the dosage required for therapeutic efficacy.

Likewise, a variety of formulations are contemplated, including, by analogy those discussed above in reference to murine TLR9, unit dose solids, liquids, extended release formulations, etc.

Screening Assays

In another aspect the invention provides methods for screening candidate compounds that act as ISNA mimics, agonists or antagonists in ISNA-induced immunomodulation via TLR7, TLR8, and TLR9. Preferably the screening method can be adapted to accommodate high throughput screening assays, as can be achieved, for example, through the use of multiwell arrays of samples in conjunction with robotic or automated array handling devices.

Immunostimulatory nucleic acids include but are not limited to CpG nucleic acids.

A "CpG nucleic acid" or a "CpG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine dinucleotide sequence, i.e. "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanine and linked by a phosphate bond) and activates a component of the immune system. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

- 75 -

In one embodiment a CpG nucleic acid is represented by at least the formula:



wherein X_1 and X_2 are nucleotides, N is any nucleotide, and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments X_1 is adenine, guanine, or thymine and/or X_2 is cytosine, adenine, or thymine. In other embodiments X_1 is cytosine and/or X_2 is guanine.

In other embodiments the CpG nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides; N is any nucleotide; and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments, X_1X_2 are nucleotides selected from the group consisting of: CpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA. In some embodiments, X_1X_2 are GpA or GpT and X_3X_4 are TpT. In other embodiments X_1 or X_2 or both are purines and X_3 or X_4 or both are pyrimidines or X_1X_2 are GpA and X_3 or X_4 or both are pyrimidines.

In another embodiment the CpG nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides; N is any nucleotide; and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N's each. In some embodiments, X_1X_2 are nucleotides selected from the group consisting of: CpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA. In some embodiments, X_1X_2 are GpA or GpT and X_3X_4 are TpT. In other embodiments X_1 or X_2 or both are purines and X_3 or X_4 or both are pyrimidines or X_1X_2 are GpA and X_3 or X_4 or both are pyrimidines.

Examples of CpG nucleic acids according to the invention include but are not limited to those listed in Table 1, such as SEQ ID NOS:21-29, 31-42, 44, 46-50, 52-62, 64-75, 77-88, 90-117, 119-124.

Table 1. Exemplary CpG nucleic acids

	AACGTTCT	SEQ ID NO: 21
	AAGCGAAATGAAATTGACT	SEQ ID NO: 22
	ACCATGGACGAACTGTTTCCCCTC	SEQ ID NO: 23
5	ACCATGGACGACCTGTTTCCCCTC	SEQ ID NO: 24
	ACCATGGACGAGCTGTTTCCCCTC	SEQ ID NO: 25
	ACCATGGACGATCTGTTTCCCCTC	SEQ ID NO: 26
	ACCATGGACGGTCTGTTTCCCCTC	SEQ ID NO: 27
	ACCATGGACGTAAGTCTGTTTCCCCTC	SEQ ID NO: 28
10	ACCATGGACGTTCTGTTTCCCCTC	SEQ ID NO: 29
	AGATTTCTAGGAATTCAATC	SEQ ID NO: 30
	AGCGGGGGCGAGCGGGGGCG	SEQ ID NO: 31
	AGCTATGACGTTCCAAGG	SEQ ID NO: 32
	ATCGACTCTCGAGCGTTCTC	SEQ ID NO: 33
15	ATGACGTTCTCTGACGTT	SEQ ID NO: 34
	ATGGAAGGTCCAACGTTCTC	SEQ ID NO: 35
	ATGGAAGGTCCAGCGTTCTC	SEQ ID NO: 36
	ATGGAAGGTCCAGCGTTCTC	SEQ ID NO: 37
	ATGGAGGCTCCATCGTTCTC	SEQ ID NO: 38
20	CAACGTT	SEQ ID NO: 39
	CACGTTGAGGGGCAT	SEQ ID NO: 40
	CAGGCATAACGTTCCGTAG	SEQ ID NO: 41
	CCAACGTT	SEQ ID NO: 42
	CTCCTAGTGGGGGTGTCCTAT	SEQ ID NO: 43
25	CTGATTTCCCCGAAATGATG	SEQ ID NO: 44
	CTGCTGAGACTGGAG	SEQ ID NO: 45
	GAGAACGATGGACCTTCCAT	SEQ ID NO: 46
	GAGAACGCTCCAGCACTGAT	SEQ ID NO: 47
	GAGAACGCTCGACCTTCCAT	SEQ ID NO: 48
30	GAGAACGCTCGACCTTCCAT	SEQ ID NO: 49
	GAGAACGCTGGACCTTCCAT	SEQ ID NO: 50
	GAGCAAGCTGGACCTTCCAT	SEQ ID NO: 51
	GATTGCCTGACGTCAGAGAG	SEQ ID NO: 52
	GCATGACGTTGAGCT	SEQ ID NO: 53
35	GCGGCGGGCGGCGCGCGCC	SEQ ID NO: 54
	GCGTGGGTTGTCGTTGTCGTT	SEQ ID NO: 55
	GCTAGACGTTAGCGT	SEQ ID NO: 56
	GCTAGACGTTAGTGT	SEQ ID NO: 57
	GCTAGATGTTAGCGT	SEQ ID NO: 58
40	GCTTGATGACTCAGCCGGAA	SEQ ID NO: 59
	GGAATGACGTTCCCTGTC	SEQ ID NO: 60
	GGGGTCAACGTTGACGGGG	SEQ ID NO: 61
	GGGGTCAGTCTTGACGGGG	SEQ ID NO: 62
	GTATTTCCCAGAAAAGGAAC	SEQ ID NO: 63
45	GTCCATTTCCCGTAAATCTT	SEQ ID NO: 64
	GTCGCT	SEQ ID NO: 65
	GTCGTT	SEQ ID NO: 66
	TACCGCGTGGGACCTCT	SEQ ID NO: 67
	TATGCATATTCTGTAAAGTG	SEQ ID NO: 68
50	TCAACGTC	SEQ ID NO: 69
	TCAACGTT	SEQ ID NO: 70
	TCAAGCTT	SEQ ID NO: 71
	TCAGCGCT	SEQ ID NO: 72
	TCAGCGTGGCC	SEQ ID NO: 73
55	TCATCGAT	SEQ ID NO: 74
	TCCACGACGTTTTCGACGTT	SEQ ID NO: 75
	TCCAGGACTTCTCTCAGGTT	SEQ ID NO: 76
	TCCATAACGTTCCCTGATGCT	SEQ ID NO: 77
	TCCATAGCGTTCCCTAGCGTT	SEQ ID NO: 78
60	TCCATCAGGTGCTGATGCT	SEQ ID NO: 79
	TCCATGACGGTCCCTGATGCT	SEQ ID NO: 80
	TCCATGACGTCCTGATGCT	SEQ ID NO: 81

- 77 -

	TCCATGACGTCCTGATGCT	SEQ ID NO: 82
	TCCATGACGTTCCCTGACGTT	SEQ ID NO: 83
	TCCATGACGTTCCCTGATGCT	SEQ ID NO: 84
5	TCCATGAGCTTCCTGATGCT	SEQ ID NO: 85
	TCCATGCCGGTCCTGATGCT	SEQ ID NO: 86
	TCCATGCCGTGCCGTGCGTTT	SEQ ID NO: 87
	TCCATGCCGTTGCGTTGCGTT	SEQ ID NO: 88
	TCCATGCTGGTCCTGATGCT	SEQ ID NO: 89
10	TCCATGGCGGTCCTGATGCT	SEQ ID NO: 90
	TCCATGTCGATCCTGATGCT	SEQ ID NO: 91
	TCCATGTCGCTCCTGATGCT	SEQ ID NO: 92
	TCCATGTCGGTCCTGATGCT	SEQ ID NO: 93
	TCCATGTCGGTCCTGCTGAT	SEQ ID NO: 94
	TCCATGTCGTCCTGATGCT	SEQ ID NO: 95
15	TCCATGTCGTTCCCTGATGCT	SEQ ID NO: 96
	TCCATGTCGTTCCCTGTCGTT	SEQ ID NO: 97
	TCCATGTCGTTTTTGTGCGTT	SEQ ID NO: 98
	TCCTGACGTTCCCTGACGTT	SEQ ID NO: 99
20	TCCTGTGCTTCCTGTCGTT	SEQ ID NO: 100
	TCCTGTGCTTCCTGTGTCGTT	SEQ ID NO: 101
	TCCTGTGCTTTTTTGTGTCGTT	SEQ ID NO: 102
	TCCTGTGCTTCCTGTGTCGTT	SEQ ID NO: 103
	TCGATCGGGGCGGGCGAGC	SEQ ID NO: 104
	TCGTGCTGTCTCCGCTTCTT	SEQ ID NO: 105
25	TCGTGCTGTCTCCGCTTCTTCTTGCC	SEQ ID NO: 106
	TCGTGCTGTCTGCCCTTCTT	SEQ ID NO: 107
	TCGTGCTGTGTGTCGTTTCTT	SEQ ID NO: 108
	TCGTGCTGTCGTT	SEQ ID NO: 109
	TCGTGCTTGTGCTTGTGTCGTT	SEQ ID NO: 110
30	TCGTGCTTGTGCTTTTGTGTCGTT	SEQ ID NO: 111
	TCGTGCTTTTGTGCTTTTGTGTCGTT	SEQ ID NO: 112
	TCTCCAGCGCGCGCCAT	SEQ ID NO: 113
	TCTCCAGCGGGCGCAT	SEQ ID NO: 114
	TCTCCAGCGTGCGCCAT	SEQ ID NO: 115
35	TCTTCGAA	SEQ ID NO: 116
	TGCAGATTGCGCAATCTGCA	SEQ ID NO: 117
	TGCTGCTTTTGTGCTTTTGTGCTT	SEQ ID NO: 118
	TGTCGCT	SEQ ID NO: 119
	TGTCGTT	SEQ ID NO: 120
40	TGTCGTTGTGTCGTT	SEQ ID NO: 121
	TGTCGTTGTGTCGTTGTGTCGTT	SEQ ID NO: 122
	TGTCGTTGTGCTTGTGTCGTTGTGTCGTT	SEQ ID NO: 123
	TGTCGTTTGTGCTTGTGTCGTT	SEQ ID NO: 124

45 Other ISNAs include but are not limited to T-rich nucleic acids, poly G nucleic acids, and nucleic acids having phosphate modified backbones, such as phosphorothioate backbones.

A "T rich nucleic acid" or "T rich immunostimulatory nucleic acid" is a nucleic acid which includes at least one poly T sequence and/or which has a nucleotide composition of
50 greater than 25% T nucleotide residues and which activates a component of the immune system. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'TTTT3'. Preferably the T rich nucleic acid includes more than one poly T sequence. In preferred embodiments the T rich nucleic acid may have 2, 3, 4, etc poly T sequences. One of

- 78 -

the most highly immunostimulatory T rich oligonucleotides discovered according to the invention is a nucleic acid composed entirely of T nucleotide residues. Other T rich nucleic acids have a nucleotide composition of greater than 25% T nucleotide residues, but do not necessarily include a poly T sequence. In these T rich nucleic acids the T nucleotide residues may be separated from one another by other types of nucleotide residues, i.e., G, C, and A. In some embodiments the T rich nucleic acids have a nucleotide composition of greater than 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 99%, T nucleotide residues and every integer % in between. Preferably the T rich nucleic acids have at least one poly T sequence and a nucleotide composition of greater than 25% T nucleotide residues.

In one embodiment the T rich nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In one embodiment $X_1 X_2$ is TT and/or $X_3 X_4$ is TT. In another embodiment $X_1 X_2$ are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and $X_3 X_4$ are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

In some embodiments it is preferred that the T-rich nucleic acid does not contain poly C (CCCC), poly A (AAAA), poly G (GGGG), CpG motifs, or multiple GGs. In other embodiments the T-rich nucleic acid includes these motifs. Thus in some embodiments of the invention the T rich nucleic acids include CpG dinucleotides and in other embodiments the T rich nucleic acids are free of CpG dinucleotides. The CpG dinucleotides may be methylated or unmethylated.

Poly G containing nucleic acids are also immunostimulatory. A variety of references, including Pisetsky and Reich, 1993 *Mol. Biol. Reports*, 18:217-221; Krieger and Herz, 1994, *Ann. Rev. Biochem.*, 63:601-637; Macaya et al., 1993, *PNAS*, 90:3745-3749; Wyatt et al., 1994, *PNAS*, 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, ed. Krieg and Stein, p. 335-352; and Kimura et al., 1994, *J. Biochem.* 116, 991-994 also describe the immunostimulatory properties of poly G nucleic acids.

Poly G nucleic acids preferably are nucleic acids having the following formulas:



- 79 -

wherein X₁, X₂, X₃, and X₄ are nucleotides. In preferred embodiments at least one of X₃ and X₄ are a G. In other embodiments both of X₃ and X₄ are a G. In yet other embodiments the preferred formula is 5' GGGNNGGG 3', or 5' GGGNNGGGNNGGG 3' wherein N represents between 0 and 20 nucleotides. In other embodiments the Poly G nucleic acid is free of unmethylated CG dinucleotides. In other embodiments the poly G nucleic acid includes at least one unmethylated CG dinucleotide.

Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Patents Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

The ISNAs may be double-stranded or single-stranded. Generally, double-stranded molecules may be more stable *in vivo*, while single-stranded molecules may have increased activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)) or a modified base. As used herein, the terms refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base-containing polymer. The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide- nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

- 80 -

The substituted purines and pyrimidines of the ISNAs include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases. Wagner RW et al., *Nat Biotechnol* 14:840-844 (1996). Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

The ISNA is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5' to 3' order from left to right and that "A" denotes adenine, "C" denotes cytosine, "G" denotes guanine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

Immunostimulatory nucleic acid molecules useful according to the invention can be obtained from natural nucleic acid sources (e.g., genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g., produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic acid encompasses both synthetic and isolated nucleic acids.

The term "isolated" as used herein with reference to an ISNA means substantially free of or separated from components which it is normally associated with in nature, e.g., nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids are sufficiently pure and are sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid of the invention may be admixed with a pharmaceutically-acceptable carrier in a pharmaceutical preparation,

- 81 -

the nucleic acid may comprise only a small percentage by weight of the preparation. The nucleic acid is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

The ISNAs can be produced on a large scale in plasmids, (see *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

For use in the instant invention, the ISNAs can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the β -cyanoethyl phosphoramidite method (Beaucage SL and Caruthers MH, *Tetrahedron Let* 22:1859 (1981)); nucleoside H-phosphonate method (Garegg et al., *Tetrahedron Let* 27:4051-4054 (1986); Froehler et al., *Nucl Acid Res* 14:5399-5407 (1986); Garegg et al., *Tetrahedron Let* 27:4055-4058 (1986); Gaffney et al., *Tetrahedron Let* 29:2619-2622 (1988)). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

ISNAs having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Patents Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.

The ISNA may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Immunostimulatory nucleic acids can be produced on a large scale in plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

"Palindromic sequence" shall mean an inverted repeat (i.e., a sequence such as ABCDEED'C'B'A' in which A and A', B and B', etc., are bases capable of forming the usual Watson-Crick base pairs and which includes at least 6 nucleotides in the palindromic. *In vivo*,

- 82 -

such sequences may form double-stranded structures. In one embodiment the nucleic acid contains a palindromic sequence. In some embodiments when the nucleic acid is a CpG nucleic acid, a palindromic sequence used in this context refers to a palindrome in which the CpG is part of the palindrome, and optionally is the center of the palindrome. In another
5 embodiment the nucleic acid is free of a palindrome. A nucleic acid that is free of a palindrome does not have any regions of 6 nucleotides or greater in length which are palindromic. A nucleic acid that is free of a palindrome can include a region of less than 6 nucleotides which are palindromic.

A "stabilized ISNA" shall mean a nucleic acid molecule that is relatively resistant to
10 *in vivo* degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop
15 structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

Some stabilized ISNAs of the instant invention have a modified backbone. It has been demonstrated that modification of the oligonucleotide backbone provides enhanced activity of the ISNAs when administered *in vivo*. Nucleic acids, including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3'
20 end, preferably 5, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases. Other modified oligonucleotides include phosphodiester modified oligonucleotide, combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations and their
25 particular effects on immune cells is discussed in more detail in U.S. Patent Nos. 6,194,388 and 6,207,646, the entire contents of which is hereby incorporated by reference. It is believed that these modified oligonucleotides may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization. Both phosphorothioate and phosphodiester nucleic acids are active
30 in immune cells.

Other stabilized ISNAs include: nonionic DNA analogs, such as alkyl- and aryl-

- 83 -

phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease

5 degradation.

For use *in vivo*, ISNAs are preferably relatively resistant to degradation (e.g., via endo- and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. One type of stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using

10 automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574) can be prepared by automated

15 solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described. Uhlmann E and Peyman A, *Chem Rev* 90:544 (1990); Goodchild J, *Bioconjugate Chem* 1:165 (1990).

Other sources of immunostimulatory nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its

20 broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.

25 In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene be expressed in the cell.

A basis for certain of the screening assays is the presence of a functional TLR 7, TLR 8, or TLR9 in a cell. The functional TLR in some instances is naturally expressed by the cell.

30 In other instances, expression of the functional TLR can involve introduction or reconstitution of a species-specific TLR9 into a cell or cell line that otherwise lacks the TLR

- 84 -

or lacks responsiveness to ISNA, resulting in a cell or cell line capable of activating the TLR/IL-1R signaling pathway in response to contact with an ISNA. Examples of cell lines lacking TLR9 or ISNA responsiveness include, but are not limited to, 293 fibroblasts (ATCC CRL-1573), MonoMac-6, THP-1, U937, CHO, and any TLR9 knock-out. The introduction
5 of the species-specific TLR into the cell or cell line is preferably accomplished by transient or stable transfection of the cell or cell line with a TLR-encoding nucleic acid sequence operatively linked to a gene expression sequence (as described above).

The species-specific TLR, including TLR7, TLR8, and TLR9, is not limited to a murine TLR, but rather can include a TLR derived from murine or non-murine sources.
10 Examples of non-murine sources include, but are not limited to, human, bovine, canine, feline, ovine, porcine, and equine. Other species include chicken and fish, e.g., aquaculture species.

The species-specific TLR, including TLR7, TLR8, and TLR9, also is not limited to native TLR polypeptides. In certain embodiments the TLR can be, e.g., a chimeric TLR in
15 which the extracellular domain and the cytoplasmic domains are derived from TLR polypeptides from different species. Such chimeric TLR polypeptides, as described above, can include, for example, a human TLR extracellular domain and a murine TLR cytoplasmic domain, each domain derived from the corresponding TLR7, TLR8, or TLR9 of each species.

In alternative embodiments, such chimeric TLR polypeptides can include chimeras created
20 with different TLR splice variants or allotypes. Other chimeric TLR polypeptides useful for the purposes of screening ISNA mimics, agonists and antagonists can include chimeric polypeptides created with a TLR of a first type, e.g., TLR9, and another TLR, e.g., TLR7 or TLR8, of the same or another species as the TLR of the first type. Also contemplated are chimeric polypeptides which incorporate sequences derived from more than two polypeptides,
25 e.g., an extracellular domain, a transmembrane domain, and a cytoplasmic domain all derived from different polypeptide sources, provided at least one such domain derives from a TLR7, TLR8, or TLR9 polypeptide. As a further example, also contemplated are constructs such as include an extracellular domain of one TLR9, an intracellular domain of another TLR9, and a non-TLR reporter such as luciferase, GFP, etc. Those of skill in the art will recognize how to
30 design and generate DNA sequences coding for such chimeric TLR polypeptides.

The screening assays can have any of a number of possible readout systems based

- 85 -

upon either TLR/IL-1R signaling pathway or other assays useful for assaying response to ISNAs. It has been reported that immune cell activation by CpG immunostimulatory sequences is dependent in some way on endosomal processing. It is not yet known whether TLR9 is directly involved in this endosomal pathway, or if there is some intermediary
5 between TLR9 and the endosome.

In preferred embodiments, the readout for the screening assay is based on the use of native genes or, alternatively, cotransfected or otherwise co-introduced reporter gene constructs which are responsive to the TLR/IL-1R signal transduction pathway involving MyD88, TRAF6, p38, and/or ERK. Häcker H et al., *EMBO J* 18:6973-6982 (1999). These
10 pathways activate kinases including κ B kinase complex and c-Jun N-terminal kinases. Thus reporter genes and reporter gene constructs particularly useful for the assays can include a reporter gene operatively linked to a promoter sensitive to NF- κ B. Examples of such promoters include, without limitation, those for NF- κ B, IL-1 β , IL-6, IL-8, IL-12 p40, CD80, CD86, and TNF- α . The reporter gene operatively linked to the TLR7-, TLR8-, or TLR9-
15 sensitive promoter can include, without limitation, an enzyme (e.g., luciferase, alkaline phosphatase, β -galactosidase, chloramphenicol acetyltransferase (CAT), etc.), a bioluminescence marker (e.g., green-fluorescent protein (GFP, U.S. patent 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), and a secreted molecule (e.g., IL-8, IL-12 p40, TNF- α). In preferred embodiments the reporter is selected from IL-8, TNF- α , NF- κ B-
20 luciferase (NF- κ B-luc; Häcker H et al., *EMBO J* 18:6973-6982 (1999)), IL-12 p40-luc (Murphy TL et al., *Mol Cell Biol* 15:5258-5267 (1995)), and TNF-luc (Häcker H et al., *EMBO J* 18:6973-6982 (1999)). In assays relying on enzyme activity readout, substrate can be supplied as part of the assay, and detection can involve measurement of
25 chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using FACS analysis or functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many such readout systems are well known in the art and are commercially available.

In another aspect the invention provides a screening method for identifying an
30 immunostimulatory nucleic acid molecule (ISNA). The method entails contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test

- 86 -

nucleic acid molecule; detecting the presence or absence of a response mediated by a TLR signal transduction pathway in the presence of the test nucleic acid molecule arising as a result of an interaction between the functional TLR and the test nucleic acid molecule; and determining the test nucleic acid molecule is an ISNA when the presence of a response
5 mediated by the TLR signal transduction pathway is detected. "Functional TLR" and a "cell expressing functional TLR" are as described elsewhere herein. A response mediated by a TLR signal transduction pathway includes induction of a gene under control of a promoter responsive to the TLR/IL-1R signaling pathway, including but not limited to promoters responsive to NF- κ B. The biological response thus can include, e.g., secretion of IL-8 and
10 luciferase activity in a cell transfected with NF- κ B-luc, IL-12 p40-luc, or TNF-luc. A test nucleic acid molecule can include a DNA, RNA, or modified nucleic acid molecule as described herein. In some embodiments the test nucleic acid molecule is a CpG nucleic acid.

Preferably, the test nucleic acid molecule is a sequence variant of a reference ISNA, containing at least one alternative base, at least one alternative internucleotide backbone
15 linkage, or at least one alternative sugar moiety as compared to the particular reference ISNA. In a preferred embodiment the test nucleic acid molecule is a member of a library of such test nucleic acid molecules.

According to one embodiment of this method, comparison can be made to a reference ISNA. The reference ISNA may be any ISNA, including a CpG nucleic acid. In preferred
20 embodiments the screening method is performed using a plurality of test nucleic acids. Preferably comparison of test and reference responses is based on comparison of quantitative measurements of responses in each instance.

The method can be used to select a subset of test nucleic acid molecules based on their ability to induce a similar specific response mediated by the TLR signal transduction
25 pathway. For instance, the method can be used to classify test CpG nucleic acids as predominantly B-cell activating CpG nucleic acids, or as predominantly IFN- α inducing CpG nucleic acids. Other new classes of ISNAs may be identified and characterized using the method.

Application of this method permits the identification of ISNAs, delineation of
30 sequence specificity of a given TLR, and also optimization of ISNA sequences. Identification of ISNAs involves screening candidate ISNAs as above and selecting any ISNA that induces

- 87 -

a response as defined. Delination of sequence specificity involves screening candidate ISNAs as above with reference to a particular TLR9, selecting any ISNAs that induce a response as defined, and categorizing ISNAs that do and do not induce a response on the basis of their sequence. Optimization of ISNA sequences involves an iterative application of the method as described, further including the steps of selecting the best sequence at any given stage or round in the screening and substituting it as a benchmark or reference in a subsequent round of screening. This latter process can further include selection of parameters to modify in choosing and generating candidate ISNAs to screen.

In another aspect the invention provides screening method for identifying species specificity of an ISNA. The method involves contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a first species with a test ISNA; contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a second species with the test ISNA; measuring a response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA; measuring a response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA; and comparing (a) the response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA with (b) the response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA. The functional TLR may be expressed by a cell or it may be part of a cell-free system. The functional TLR may be part of a complex, with either another TLR or with another protein, e.g., MyD88, IRAK, TRAF6, I κ B, NF- κ B, or functional homologues and derivatives thereof. Thus for example a given ODN can be tested against a panel of 293 fibroblast cells transfected with TLR7, TLR8, or TLR9 from various species and optionally cotransfected with a reporter construct (e.g., NF- κ B-luc) sensitive to TLR/IL-1R activation pathways. Thus in another aspect, the invention provides a method for screening species selectivity with respect to a given nucleic acid sequence.

As mentioned above, the invention in one aspect provides a screening method for comparing TLR signaling activity or a test compound against corresponding TLR signaling activity of a reference ISNA. The methods generally involve contacting a functional TLR

- 88 -

selected from the group consisting of TLR7, TLR8, and TLR9 with a reference ISNA and detecting a reference response mediated by a TLR signal transduction pathway; contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test compound and detecting a test response mediated by a TLR signal transduction pathway; and
5 comparing the test response with the reference response to compare the TLR signaling activity of the test compound with the ISNA. Assays in which the test compound and the reference ISNA contact the TLR independently may be used to identify test compounds that are ISNA mimics. Assays in which the test compound and the reference ISNA contact the TLR concurrently may be used to identify test compounds that are ISNA agonists and ISNA
10 antagonists.

An ISNA mimic as used herein is a compound which causes a response mediated by a TLR signal transduction pathway. As used herein the term "response mediated by a TLR signal transduction pathway" refers to a response which is characteristic of an ISNA-TLR interaction. As demonstrated herein responses which are characteristic of ISNA-TLR
15 interactions include the induction of a gene under control of an ISNA-specific promoter such as a NF- κ B promoter, increases in Th1 cytokine levels, etc. The gene under the control of the NF- κ B promoter may be a gene which naturally includes an NF- κ B promoter or it may be a gene in a construct in which an NF- κ B promoter has been inserted. Genes which naturally include the NF- κ B promoter include but are not limited to IL-8, IL-12 p40, NF- κ B-luc, IL-12
20 p40-luc, and TNF-luc. Increases in Th1 cytokine levels is another measure characteristic of an ISNA-TLR interaction. Increases in Th1 cytokine levels may result from increased production or increased stability or increased secretion of the Th1 cytokines in response to the ISNA-TLR interaction. Th1 cytokines include but are not limited to IL-2, IFN- γ , and IL-12. Other responses which are characteristic of an ISNA-TLR interaction include but are not
25 limited to a reduction in Th2 cytokine levels. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

The response which is characteristic of an ISNA-TLR interaction may be a direct response or an indirect response. A direct response is a response that arises directly as a result of the ISNA-TLR interaction. An indirect response is a response which involves the
30 modulation of other parameters prior to its occurrence.

An ISNA agonist as used herein is a compound which causes an enhanced response to

an ISNA mediated by a TLR signal transduction pathway. Thus an ISNA agonist as used herein is a compound which causes an increase in at least one aspect of an immune response that is ordinarily induced by the reference ISNA. For example, an immune response that is ordinarily induced by an ISNA can specifically include TLR7-, TLR8-, or TLR9-mediated signal transduction in response to immunostimulatory CpG nucleic acid. An ISNA agonist will in some embodiments compete with ISNA for binding to TLR7, TLR8, or TLR9. In other embodiments an ISNA agonist will bind to a site on TLR7, TLR8, or TLR9 that is distinct from the site for binding ISNA. In yet other embodiments an ISNA agonist will act via another molecule or pathway distinct from TLR7, TLR8, or TLR9.

An ISNA antagonist as used herein is a compound which causes a decreased response to an ISNA mediated by a TLR signal transduction pathway. Thus an ISNA antagonist as used herein is a compound which causes a decrease in at least one aspect of an immune response that is ordinarily induced by the reference ISNA. For example, an immune response that is ordinarily induced by an ISNA can specifically include TLR7-, TLR8-, or TLR9-mediated signal transduction in response to immunostimulatory CpG nucleic acid. An ISNA antagonist will in some embodiments compete with ISNA for binding to TLR7, TLR8, or TLR9. In other embodiments an ISNA antagonist will bind to a site on TLR7, TLR8, or TLR9 that is distinct from the site for binding ISNA. In yet other embodiments an ISNA antagonist will act via another molecule or pathway distinct from TLR7, TLR8, or TLR9.

The screening methods for comparing TLR signaling activity of a test compound with signaling activity of an ISNA involve contacting at least one test compound with a functional TLR selected from TLR7, TLR8, and TLR9 under conditions which, in the absence of a test compound, permit a reference ISNA to induce at least one aspect of an immune response. The functional TLR may be expressed by a cell or it may be part of a cell-free system. A cell expressing a functional TLR is a cell that either naturally expresses the TLR, or is a cell into which has been introduced a TLR expression vector, or is a cell manipulated to express TLR in a manner that allows the TLR to be expressed by the cell and to transduce a signal under conditions which normally permit signal transduction by the signal transducing portion of the TLR. The TLR can be a native TLR or it can be a fragment or variant thereof, as described above. According to these methods, the test compound is contacted with a functional TLR or TLR-expressing cell before, after, or simultaneously with contacting a reference ISNA with

- 90 -

the functional TLR or TLR-expressing cell. A response of the functional TLR or TLR-expressing cell is measured and compared with the corresponding response that results or would result under the same conditions in the absence of the test compound. Where it is appropriate, the response in the absence of the test compound can be determined as a concurrent or historical control. Examples of such responses include, without limitation, a response mediated through the TLR signal transduction pathway, secretion of a cytokine, cell proliferation, and cell activation. In a preferred embodiment, the measurement of a response involves the detection of IL-8 secretion (e.g., by ELISA). In another preferred embodiment, the measurement of the response involves the detection of luciferase activity (e.g., NF- κ B-luc, IL-12 p40-luc, or TNF-luc).

Examples of reference ISNAs include, without limitation, those listed in Table 1 (above). In some preferred embodiments the reference ISNA is a CpG nucleic acid.

Test compounds can include but are not limited to peptide nucleic acids (PNAs), antibodies, polypeptides, carbohydrates, lipids, hormones, and small molecules. Test compounds can further include variants of a reference ISNA incorporating any one or combination of the substitutions described above. Test compounds can be generated as members of a combinatorial library of compounds.

In preferred embodiments, the methods for screening test compounds, test nucleic acid molecules, test ISNAs, and candidate pharmacological agents can be performed on a large scale and with high throughput by incorporating, e.g., an array-based assay system and at least one automated or semi-automated step. For example, the assays can be set up using multiwell plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are well known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are well known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully

- 91 -

robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. patents 5,443,791 and 5,708,158.

5 The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

Examples

10 **Example 1. Method of cloning the mouse TLR9**

Alignment of human TLR9 protein sequence with mouse EST database using tfasta yielded 7 hits with mouse EST sequences aa197442, ai451215, aa162495, aw048117, ai463056, aw048548, and aa273731. Two primers were designed that bind to aa197442 EST sequence for use in a RACE-PCR to amplify 5' and 3' ends of the mouse TLR9 cDNA. The library used for the RACE PCR was a mouse spleen marathon-ready cDNA commercially available from Clontech. A 5' fragment with a length of 1800 bp obtained by this method was cloned into Promega pGEM-T Easy vector. After sequencing of the 5' end, additional primers were designed for amplification of the complete mouse TLR9 cDNA. The primer for the 5' end was obtained from the sequence of the 5' RACE product whereas the primer for the 20 3' end was selected from the mouse EST sequence aa273731.

Three independent PCR reactions were set up using a murine macrophage RAW264.7 (ATCC TIB-71) cDNA as a template, and the resulting amplification products were cloned into the pGEM-T Easy vector. The inserts were fully sequenced, translated into protein and aligned to the human protein sequence. One out of three clones was error-free based on 25 alignment comparison (clone mtlr932e.pep). The cDNA sequence for mTLR9 is SEQ ID NO:1, is presented in Table 2. The ATG start codon occurs at base 40, and a TAG termination codon occurs at base 3136. SEQ ID NO:2 (Table 3), corresponding to bases 40-3135 of SEQ ID NO:1, is the coding region for the polypeptide of SEQ ID NO:3.

30 **Table 2. cDNA Sequence for Murine TLR9 (5' to 3'; SEQ ID NO:1)**

tgtagagagg agcctcgga gaactctcca tctcccaaca tgggtctccg tcgaaggact	60
ctgcacccct tgtccctcct ggtacaggct gcagtgtctgg ctgagactct ggccttgggt	120

- 92 -

	accctgcctg	ccttcctacc	ctgtgagctg	aagcctcatg	gcctgggtgga	ctgcaattgg	180
	ctgttcctga	agtctgtacc	cgtttctct	gcggcagcat	cctgctccaa	catcaccgcg	240
	ctctccttga	tctccaaccg	tatccaccac	ctgcacaact	cggacttcgt	ccacctgtcc	300
	aacctgcggc	agctgaacct	caagtggaa	tgtccacca	ctggccttag	ccccctgcac	360
5	ttctcttgcc	acatgaccat	tgagcccaga	accttcctgg	ctatgcgtac	actggaggag	420
	ctgaacctga	gctataatgg	tatcaccact	gtgccccgac	tgcccagctc	cctgggtgaat	480
	ctgagcctga	gccacaccaa	catcctgggt	ctagatgcta	acagcctcgc	cggcctatac	540
	agcctgcgcg	ttctcttcat	ggacgggaac	tgtactaca	agaaccctcg	cacaggagcg	600
	gtgaagggtga	ccccaggcgc	cctcctgggc	ctgagcaatc	tcaccatct	gtctctgaag	660
10	tataacaacc	tcacaaaggt	gccccgccaa	ctgcccccca	gcctggagta	cctcctgggtg	720
	tcctataacc	tcattgtcaa	gctggggcct	gaagacctgg	ccaatctgac	ctcccttcga	780
	gtacttgatg	tgggtgggaa	ttgccgtcgc	tgcgaccatg	cccccaatcc	ctgtatagaa	840
	tgtggccaaa	agtccctcca	cctgcaccct	gagaccttcc	atcacctgag	ccatctggaa	900
	ggcctgggtgc	tgaaggacag	ctctctccat	acactgaact	cttcctgggt	ccaagggtctg	960
15	gtcaacctct	cgggtgctgga	cctaagcgag	aactttctct	atgaaagcat	caaccacacc	1020
	aatgccttcc	agaacctaac	cgcctgcgc	aagctcaacc	tgtccttcaa	ttaccgcaag	1080
	aaggatcct	ttgcccgcc	ccacctggca	agttccttca	agaacctggg	gtcactgcag	1140
	gagctgaaca	tgaacggcat	cttcttccgc	tcgctcaaca	agtacacgct	cagatggctg	1200
	gccgatctgc	ccaaactcca	cactctgcat	cttcaaatga	acttcatcaa	ccaggcacag	1260
20	ctcagcatct	ttggtacctt	cggagccctt	cgttttgtgg	acttgtcaga	caatcgcatc	1320
	agtgggcctt	caacgctgtc	agaagccacc	cctgaagagg	cagatgatgc	agagcaggag	1380
	gagctgttgt	ctgaggatcc	tcaccagct	ccactgagca	cccctgcttc	taagaacttc	1440
	atggacaggt	gtaagaactt	caagttcacc	atggacctgt	ctcggaacaa	cctgggtgact	1500
	atcaagccag	agatgtttgt	caatctctca	cgcctccagt	gtcttagcct	gagccacaac	1560
25	tccattgcac	aggctgtcaa	tggctctcag	ttcctgccgc	tgactaatct	gcagggtgctg	1620
	gacctgtccc	ataacaaact	ggacttgtag	cactggaaat	cgttcagtga	gctaccacag	1680
	ttgcaggccc	tggacctgag	ctacaacagc	cagcccttta	gcatgaaggg	tataggccac	1740
	aatttcagtt	ttgtggccca	tctgtccatg	ctacacagcc	ttagcctggc	acacaatgac	1800
	attcataccc	gtgtgtcttc	acatctcaac	agcaactcag	tgaggtttct	tgacttcagc	1860
30	ggcaacggta	tgggcccgc	gtgggatgag	gggggccttt	atctccattt	cttccaaggc	1920
	ctgagtggcc	tgtgaagct	ggacctgtct	caaaataacc	tgcatatcct	ccggccccag	1980
	aaccttgaca	acctccccaa	gagcctgaag	ctgctgagcc	tccgagacaa	ctacctatct	2040
	ttctttaact	ggaccagtct	gtccttcctg	cccaacctgg	aagtcctaga	cctggcaggc	2100
	aaccagctaa	aggccctgac	caatggcacc	ctgcctaata	gcacctcct	ccagaaactg	2160
35	gatgtcagca	gcaacagtat	cgtctctgtg	gtcccagcct	tcttcgctct	ggcgggtcgag	2220
	ctgaaagagg	tcaacctcag	ccacaacatt	ctcaagacgg	tggatcgctc	ctgggttggg	2280
	cccattgtga	tgaacctgac	agttctagac	gtgagaagca	acctctgca	ctgtgcctgt	2340
	ggggcagcct	tcgtagactt	actgttggag	gtgcagacca	agggtgcctgg	cctggctaata	2400
	gggtgtgaagt	gtggcagccc	cggccagctg	cagggccgta	gcattctcgc	acaggacctg	2460
40	cggctgtgcc	tggatgaggt	cctctcttgg	gactgctttg	gcctttcact	cttggctgtg	2520
	gccgtgggca	tgggtgtgcc	tatactgcac	catctctgcg	gctgggacgt	ctgggtactgt	2580
	tttcatctgt	gcctggcatg	gctacctttg	ctggcccgca	gccgacgcag	cgcaccaagct	2640

- 93 -

	ctccccatg atgccttcgt ggtgttcgat aaggcacaga gcgcagttgc ggactgggtg	2700
	tataacgagc tgcgggtgcg gctggaggag cggcgcggtc gccgagccct acgcttgtgt	2760
	ctggaggacc gagattggct gcctggccag acgctcttcg agaacctctg ggctccatc	2820
	tatgggagcc gcaagactct atttgtgctg gccacacagg accgcgtcag tggcctcctg	2880
5	cgcaccagct tcctgctggc tcagcagcgc ctggtggaag accgcaagga cgtggtggtg	2940
	ttggtgatcc tgcgtccgga tgcccaccgc tcccgcctatg tgcgactgcg ccagcgtctc	3000
	tgcgccaga gtgtgctctt ctggccccag cagcccaacg ggcagggggg cttctggggc	3060
	cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgccgg	3120
	ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcattct catgcctggt	3180
10	tcccagttg ctctgcctgc	3200

Table 3. Coding region for murine TLR9 (SEQ ID NO:2)

	atggttctcc gtccaaggac tctgcacccc ttgtccctcc tggtaacaggc tgcagtgcgt	60
	gctgagactc tggccctggg taccctgcct gccttccctac cctgtgagct gaagcctcat	120
15	ggcctggtgg actgcaattg gctgttctct aagtctgtac ccggtttctc tgcggcagca	180
	tcctgctcca acatcacccg cctctccttg atctccaacc gtatccacca cctgcacaac	240
	tccgacttcg tccacctgtc caacctgcgg cagctgaacc tcaagtggaa ctgtccaccc	300
	actggcctta gcccctgca cttctcttgc cacatgacca ttgagcccag aaccttctctg	360
	gctatgcgta cactggagga gctgaacctg agctataatg gtatcaccac tgtgccccga	420
20	ctgccagct cctggtgaa tctgagcctg agccacacca acatcctggt tctagatgct	480
	aacagcctcg ccggcctata cagcctgcgc gttctcttca tggacgggaa ctgctactac	540
	aagaaccctt gcacaggagc ggtgaagggtg accccaggcg cctcctggg cctgagcaat	600
	ctcaccatc tgtctctgaa gtataacaac ctcaaaaagg tgccccgcca actgcccccc	660
	agcctggagt acctcctggt gtccataaac ctcatgttca agctggggcc tgaagacctg	720
25	gccaatctga cctcccttcg agtacttgat gtgggtggga attgcccgtc ctgcgacct	780
	gcccccaatc cctgtataga atgtggccaa aagtccttcc acctgcaccc tgagaccttc	840
	catcacctga gccatctgga aggcctggtg ctgaaggaca gctctctcca tacactgaac	900
	tcttctggt tccaaggctc ggtcaacctc tcggtgctgg acctaaagca gaactttctc	960
	tatgaaagca tcaaccacac caatgccttt cagaacctaa ccgcctgcg caagctcaac	1020
30	ctgtccttca attaccgcaa gaaggatctc ttgtcccgcc tccacctggc aagttccttc	1080
	aagaacctgg tgtcactgca ggagctgaac atgaacggca tcttcttccg ctgctcaac	1140
	aagtacacgc tcagatggct ggccgatctg cccaaactcc acactctgca tcttcaaatg	1200
	aacttcatca accaggcaca gctcagcatc tttggtacct tccgagccct tcgctttgtg	1260
	gacttgtcag acaatcgcat cagtgggcct tcaacgctgt cagaagccac ccctgaagag	1320
35	gcagatgatg cagagcagga ggagctgttg tctgcggatc ctacccagc tccactgagc	1380
	acctctgctt ctaagaactt catggacagg tgtaagaact tcaagttcac catggacctg	1440
	tctcggaaaca acctggtgac tatcaagcca gagatgtttg tcaatctctc acgcctccag	1500
	tgtcttagcc tgagccacaa ctccattgca caggctgtca atggtctctc gttcctgccg	1560
	ctgactaate tgcaggtgct ggacctgtcc cataacaaac tggacttgta ccactggaaa	1620
40	tcgttcagtg agctaccaca gttgcaggcc ctggacctga gctacaacag ccagcccttt	1680
	agcatgaagg gtataggcca caatttcagt tttgtggccc atctgtccat gctacacagc	1740

- 94 -

	cttagcctgg	cacacaatga	cattcatacc	cgtgtgtcct	cacatctcaa	cagcaactca	1800
	gtgaggtttc	ttgacttcag	cggcaacggg	atgggcccga	tgtgggatga	ggggggcctt	1860
	tatctccatt	tcttccaagg	cctgagtggc	ctgctgaagc	tggacctgtc	tcaaaataac	1920
	ctgcatatcc	tccggcccca	gaaccttgac	aacctcccca	agagcctgaa	gctgctgagc	1980
5	ctccgagaca	actacctatc	tttctttaac	tggaccagtc	tgtccttcct	gccaacctg	2040
	gaagtccatg	acctggcagg	caaccageta	aaggccctga	ccaatggcac	cctgcctaata	2100
	ggcaccctcc	tccagaaact	ggatgtcagc	agcaacagta	tctgtctctgt	gggtcccagcc	2160
	ttcttcgctc	tggcgggtcga	gctgaaagag	gtcaacctca	gccacaacat	tctcaagacg	2220
	gtggatcgct	cctggtttgg	gcccattgtg	atgaacctga	cagttctaga	cgtgagaagc	2280
10	aacctctctgc	actgtgcctg	tggggcagcc	ttcgtagact	tactgttggga	ggtgcagacc	2340
	aagggtgctg	gcctggctaa	tgggtgtgaag	tgtggcagcc	ccggccagct	gcagggccgt	2400
	agcatcttcg	cacaggacct	gcggctgtgc	ctggatgagg	tcctctcttg	ggactgcttt	2460
	ggcctttcac	tcttggetgt	ggccgtgggc	atggtgggtgc	ctatactgca	ccatctctgc	2520
	ggctgggacg	tctgggtactg	ttttcatctg	tgcttggcat	ggctaccttt	gctggccccg	2580
15	agccgacgca	gcgcccagc	tctcccctat	gatgccttcg	tgggtgttcga	taaggcacag	2640
	agcgcagttg	cggactgggt	gtataacgag	ctgcgggtgc	ggctggagga	gcggcgcggt	2700
	cgcgcagccc	tacgcttgtg	tctggaggac	cagatttggc	tgcttggcca	gacgctcttc	2760
	gagaacctct	gggcttccat	ctatgggagc	cgaagactc	tatttgtgct	ggcccacacg	2820
	gaccgcgtca	gtggcctcct	gcgcaccagc	ttcttgcctg	ctcagcagcg	cctgttggaa	2880
20	gaccgcaagg	acgtggtggt	gttgggtgatc	ctgcgtccgg	atgccaccg	ctcccgcctat	2940
	gtgcgactgc	gccagcgtct	ctgccgccag	agtgtgctct	tctggcccca	gcagcccaac	3000
	gggcaggggg	gcttctgggc	ccagctgagt	acagccctga	ctagggacaa	ccgccacttc	3060
	tataaccaqa	acttctqccg	gggacctaca	gcagaa			3096

25 The deduced amino acid sequence for murine TLR9 (SEQ ID NO:3), comprising 1032 amino acid residues, is shown in Table 4 below in the aligned sequence comparison as mtlr932e.pep. The deduced amino acid sequence for human TLR9 (SEQ ID NO:6), comprising 1032 amino acid residues, is shown in Table 4 below in the aligned sequence comparison as htlr9.pro.

30

Table 4. Amino Acid Sequence of Murine and Human TLR9

	.	:	.	:	.	:	.	:	.	:	60
htlr9.pro	MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWFLKSVPHFSMAA										60
mtlr932e.pep	MVLRRRRTLHPLSLLVQAAVLAETLALGTLPAFLPCELKPHGLVDCNWFLKSVPRFSAAA										60
	.	:	.	:	.	:	.	:	.	:	120
htlr9.pro	PRGNVTLSLSSNRIHHLHDSDFAHLP SLRHLNLKWNCPVGLSPMHFPC HMTIEPSTFL										120
mtlr932e.pep	SCSNITRLSLISNRIHHLHNSDFVHLSNLRLQLNLKWNCPPTGLSPLHFSCHMTIEPRTFL										120
	.	:	.	:	.	:	.	:	.	:	180

- 95 -

	htlr9.pro	AVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNIIMLDSASLAGLHALRFLFMDGNCYY	180
	mtlr932e.pep	AMRTLEELNLSYNGITTVPRLPSSLVNLSSLSHTNIIVLDSLAGLYSLRVLFMDGNCYY	180
		. : . : . : . : . : . : . : . : . :	240
5	htlr9.pro	KNPCRQALEVAPGALLGLGNLTHLSLKYNNTVVPRNLPSSEYLLLSYNRIVKLAPEDL	240
	mtlr932e.pep	KNPCTGAVKVTPGALLGLSNLTHLSLKYNNTKVPRQLPPSEYLLVSYNLIVKLGPEDL	240
		. : . : . : . : . : . : . : . : . :	300
	htlr9.pro	ANLTALRVLDVGGNCRRCDHAPNPMCECPRHFPQLHPDTFSHLSRLEGLVLKDSLSWLN	300
10	mtlr932e.pep	ANLTSLRVLDVGGNCRRCDHAPNPCIECGQKSLHLHPETFHHLSHLEGLVLKDSLSLHTLN	300
		. : . : . : . : . : . : . : . : . :	360
	aa197442.pep	LNLSFNRYKKVSFARLHLASSF	22
	htlr9.pro	ASWFRGLGNLRVLDLSENFYKICITKTKAFQGLTQLRKLNLSFNQKRVSPAHLSLAPSF	360
15	mtlr932e.pep	SSWFQGLVNLVLDLSENFYKICITKTKAFQGLTQLRKLNLSFNQKRVSPAHLHLASSF	360
		. : . : . : . : . : . : . : . : . :	420
	mousepep1	C	1
	aa197442.pep	KNLVSLQELNMNGIFFRLLNKYTLRWLADLPKLHTLHLQMNFINQAQLSIFGTFRALRFV	82
20	htlr9.pro	GSLVALKELDMHGIFFRSLDETTLRPLARLPMLOTLRLQMNFINQAQLSIFRAFPGLRYV	420
	mtlr932e.pep	KNLVSLQELNMNGIFFRSLNKYTLRWLADLPKLHTLHLQMNFINQAQLSIFGTFRALRFV	420
		. : . : . : . : . : . : . : . : . :	480
	mousepep1	DLSDNRISGPSTLSEA	17
25	humanpep1	PAPVDTPSSEDFRPNC	16
	aa197442.pep	DLSDNRISGPSTLSEATPEEADDAEQEELLSADPHAPLSTPASKNFMDRCKNFKFNMDL	142
	htlr9.pro	DLSDNRISGASELT-ATMGADGGEKVWLQPGDLAPAPVDTPSSEDFRPNCSTLNFTLDEL	479
	mtlr932e.pep	DLSDNRISGPSTLSEATPEEADDAEQEELLSADPHAPLSTPASKNFMDRCKNFKFTMDL	480
		. : . : . : . : . : . : . : . : . :	540
30	aa197442.pep	SRNNLVITAEFVNLSRLQCLSLSHNSIAQAVNGS	178
	htlr9.pro	SRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSRNKLDLYHEH	539
	mtlr932e.pep	SRNNLVTIKPEMFVNLSRLQCLSLSHNSIAQAVNGSQFLPLTNLQVLDLSHNKLDLYHWK	540
		. : . : . : . : . : . : . : . : . :	600
35	aa162495.pep	YNSQPFSMKGIGHNFSFVTHLSMLQSLSLAHNDIHRVSSHLSNS	46
	htlr9.pro	SFTELPRLEALDLSYNSQPFGMQGVGHNFSPVAHLRTLRLHLSLAHNNIHSQVSQQLCSTS	599
	mtlr932e.pep	SFSELPLQALDLSYNSQPFSMKGIGHNFSFVAHLSMLHLSLAHNDIHRVSSHLSNS	600
		. : . : . : . : . : . : . : . : . :	660
40	aa162495.pep	VRFLDFSGNGMGRMWDEGGLYLHFFQGLSGVLKLDLSQNNLHILRPQNLDNLPKSLKLLS	106
	htlr9.pro	LRALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDSLQNRHLHTLLPQTLRNLPKSLQVLR	659
	mtlr932e.pep	VRFLDFSGNGMGRMWDEGGLYLHFFQGLSGLLKLDLSQNNLHILRPQNLDNLPKSLKLLS	660
		. : . : . : . : . : . : . : . : . :	720
45	aa162495.pep	LRDNYLSFFNWTSLSFLPNLEVLDLAGNQLKALTNGTLPNGTLLQKLDVSSNSIVS	162

- 96 -

	htlr9.pro	LRDNYLAFPKWWSLHFLPKLEVLDLAGNRLKALTNGSLPAGTRLRRLDVSCNSISFVAPG	719
	mtlr932e.pep	LRDNYLSFFNWTSLSFLPNLEVLDDLGNQLKALTNGTLPNGTLLQKLDVSSNSIVSVVPA	720
	.	:	780
5	a1451215.pep	PIVMNLTVLDVRSNPLHCACGAAFVDLLLEVQT	33
	htlr9.pro	FFSKAKZLRREINLSANALKTVDSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQA	779
	mtlr932e.pep	FFALAVELKEVNLSHNILKTVDRSWFGPIVMNLTVLDVRSNPLHCACGAAFVDLLLEVQT	780
	.	:	840
10	a1451215.pep	KVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFGLSLLAVAVGMVVPILHHLC	93
	htlr9.pro	AVPGLPSRVKCGSPGQLQGSLIFAQDLRLCLDEALSWDGFALSLLAVALGLGVPMIHHLC	839
	mtlr932e.pep	KVPGLANGVKCGSPGQLQGRSIFAQDLRLCLDEVLSWDCFGLSLLAVAVGMVVPILHHLC	840
	.	:	900
15	a1451215.pep	GWDVWYCFHLCLAWLP LLAR-SRRSAQTLFYDAFVVFDKAQS AVADWVYNELRVRL EERR	152
	htlr9.pro	GWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTS AVADWVYNELRGQLEE CR	899
	mtlr932e.pep	GWDVWYCFHLCLAWLP LLAR-SRRSAQALPYDAFVVFDKAQS AVADWVYNELRVRL EERR	899
	.	:	960
20	aa273731.pep	AHTDRVSGLLRTSFLLAQORLL	22
	ai463056.pep	EDRDWLPGQTLFENLWASIYGSRKTLFVLAHTDRVSGLLRTSFLLAQORLL	51
	a1451215.pep GR		154
	htlr9.pro	GRWALRLCLEERDWLPCKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQORLL	959
	mtlr932e.pep	GRRALRLCLEERDWLPQGTLFENLWASIYGSRKTLFVLAHTDRVSGLLRTSFLLAQORLL	959
25	.	:	1020
	humanpep2	H	1
	mousepep2	H	1
	aa273731.pep	EDRKDVVVLVILRPDAXPSRYVRLRQLRCRQSVLFWPQPNGQGGFWAQLSTALTRDNRH	82
30	ai463056.pep	EDRKDVVVLVILRPDAHSRYVRLRQLRCRQSVLFWPQPNGQGGFWAQLSTALTRDNRH	111
	htlr9.pro	EDRKDVVVLVILSPDGRRSRYVRLRQLRCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHH	1019
	mtlr932e.pep	EDRKDVVVLVILRPDAHSRYVRLRQLRCRQSVLFWPQPNGQGGFWAQLSTALTRDNRH	1019
	.	:	1080
35	humanpep2	FYNRNFCQGPTAE	14
	mousepep2	FYNQNFCRGPTAE	14
	aa273731.pep	FYNQNFCRGPTAE	95
	ai463056.pep	FYNQNFCRGPTA	123
	htlr9.pro	FYNRNFCQGPTAE	1032
40	mtlr932e.pep	FYNQNFCRGPTAE	1032

The following SEQ ID NOs correspond to the sequences as shown in Table 4:
 htlr9.pro: SEQ ID NO:6; mtlr932e.pep: SEQ ID NO:3; aa197442.pep: SEQ ID NO:8;
 mousepep1: SEQ ID NO:17; humanpep1: SEQ ID NO:19; aa162495.pep: SEQ ID NO:14;

- 97 -

ai451215.pcp: SEQ ID NO:16; aa273731.pcp: SEQ ID NO:10; ai463056.pcp: SEQ ID NO:12; humanpep2: SEQ ID NO:20; and mousepep2: SEQ ID NO:18.

Example 2. Reconstitution of TLR9 signaling in 293 fibroblasts

5 The cloned mouse TLR9 cDNA (see above) and human TLR9 cDNA (gift from B. Beutler, Howard Hughes Medical Institute, Dallas, TX) in pT-Adv vector (from Clontech) were cloned into the expression vector pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

Since NF- κ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al., *Mol Cell* 2:253-258 (1998); Muzio M et al., *J Exp Med* 187:2097-2101 (1998)), cells were transfected with hTLR9 or co-transfected with hTLR9 and a NF- κ B-driven luciferase reporter construct. Human fibroblast 293 cells were transiently transfected with (Figure 1A) hTLR9 and a six-times NF- κ B-luciferase reporter plasmid (NF- κ B-luc, kindly provided by Patrick Baeuerle, Munich, Germany) or (Figure 1B) with hTLR9 alone. After stimulus with CpG-ODN (2006, 2 μ M, TCGTCGTTTGTGCTTTTGTGCTT, SEQ ID NO:112), GpC-ODN (2006-GC, 2 μ M, TGCTGCTTTTGTGCTTTTGTGCTT, SEQ ID NO:118), LPS (100 ng/ml) or media, NF- κ B activation by luciferase readout (8h, Figure 1A) or IL-8 production by ELISA (48h, Figure 1B) were monitored. Results are representative of three independent experiments. Figure 1 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Figure 2 demonstrates the same principle for the transfection of mTLR9. Human fibroblast 293 cells were transiently transfected with mTLR9 and the NF- κ B-luc construct (Figure 2). Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG-DNA stimulation similar to hTLR4 reconstitution of LPS responses.

To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- κ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates (2x10⁶ cells/plate) with 16 μ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH,

- 98 -

Cölbe, Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in **Figure 3**. The clones were also screened for IL-8 production or NF- κ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

- 5 293-hTLR9-luc: expressing human TLR9 and 6-fold NF- κ B-luciferase reporter
- 293-mTLR9-luc: expressing murine TLR9 and 6-fold NF- κ B-luciferase reporter
- 293-hTLR9: expressing human TLR9
- 293-mTLR9: expressing murine TLR9

- 10 **Figure 4** demonstrates the responsiveness of a stable 293-hTLR9-luc clone after stimulation with CpG-ODN (2006, 2 μ M), GpC-ODN (2006-GC, 2 μ M), Me-CpG-ODN (2006 methylated, 2 μ M; TZGTZGTTTTGTZGTTTTGTZGTT, Z = 5-methylcytidine, SEQ ID NO:128), LPS (100 ng/ml) or media, as measured by monitoring NF- κ B activation. Similar results were obtained utilizing IL-8 production with the stable clone 293-hTLR9.
- 15 293-mTLR9-luc were also stimulated with CpG-ODN (1668, 2 μ M; TCCATGACGTTTCCTGATGCT, SEQ ID NO:84), GpC-ODN (1668-GC, 2 μ M; TCCATGAGCTTCCTGATGCT, SEQ ID NO:85), Me-CpG-ODN (1668 methylated, 2 μ M; TCCATGAZGTTTCCTGATGCT, Z = 5-methylcytidine, SEQ ID NO:207), LPS (100 ng/ml) or media, as measured by monitoring NF- κ B activation (**Figure 5**). Similar results were
- 20 obtained utilizing IL-8 production with the stable clone 293-mTLR9. Results are representative of at least two independent experiments. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific manner. These cells can be used for screening of optimal ligands for innate immune responses driven by TLR9 in multiple species.

25

Example 3. Expression of soluble recombinant human TLR9 in yeast cells (*Pichia pastoris*)

- Human TLR9 cDNA coding for amino acids 1 to 811 was amplified by PCR using the primers 5'-ATAGAATTCAATAATGGGTTTCTGCCGAGCGCCCT-3' (SEQ ID NO:194)
- 30 and 5'-ATATCTAGATCCAGGCAGAGGCGCAGGTC-3' (SEQ ID NO:195), digested with EcoRI and XbaI, cloned into the yeast expression vector pPICZB (Invitrogen, Groningen,

- 99 -

Netherlands) and transfected into yeast cells (*Pichia pastoris*). Clones were selected with the antibiotic zeozin and protein production of soluble human TLR9 was induced with methanol (see Figure 6: SDS-PAGE, Coomassie stained, arrow marks hTLR9; lane 1: supernatant of culture induced with methanol; lane 2: supernatant of culture not induced). Thus TLR9 protein can be isolated from transfectants and further utilized for protein studies and vaccination purposes.

Example 4. hTLR9 expression correlates with CpG-DNA responsiveness.

Bacterial DNA has been described as a mitogen for both murine and human B cells. Although LPS is also mitogenic for murine B cells, it is generally accepted that LPS is not a mitogen for human B cells. Figure 7 demonstrates that human B cells proliferate after stimulation with *E. coli* DNA or a CpG-ODN but not DNase-digested *E. coli* DNA or a control GpC-ODN. Purified human B cells were stimulated with 50 µg/ml *E. coli* DNA, a comparable amount of DNase I-digested *E. coli* DNA, 2 µM CpG-ODN (2006), 2 µM GpC-ODN (2006-GC) or 100 ng/ml LPS. B cell proliferation was monitored at day two by ³H-thymidine uptake. These data demonstrate that it was DNA within the *E. coli* DNA preparation that was mitogenic and that a CpG-motif within the ODN was required.

Human dendritic cells (DC) have been claimed to be responsive to CpG-DNA. While analyzing human dendritic cell responses to CpG-DNA, we noted that plasmacytoid DC (CD123+DC) produced IFN-α, TNF, GM-CSF, and IL-8 upon exposure to CpG-DNA but not to LPS (Figure 8 and unpublished data). The converse was true for stimulation of monocyte-derived dendritic cells (MDDC) (Figure 8 and unpublished data). Purified CD123+DC or MDDC were stimulated with 50 µg/ml *E. coli* DNA, a comparable amount of DNase I-digested *E. coli* DNA, 2 µM CpG-ODN (2006), 2 µM GpC-ODN (2006-GC) or 100 ng/ml LPS (Figure 8). IL-8 and TNF concentration was determined by enzyme-linked immunosorbent assay (ELISA). The CD123+DC response was DNA- and CpG-motif restricted. Monocyte-derived dendritic cells (MDDC) however demonstrated the converse response pattern, a response to LPS but not CpG-DNA. Due to this segregated response we analyzed TLR expression.

We have shown that CpG-DNA utilizes the Toll/IL-1R (TIR) signal transduction pathway implying the need for a TIR domain in the CpG-DNA signaling receptor. Häcker H

- 100 -

et al., *J Exp Med* 192:595-600 (2000). It was further demonstrated that TLR9-deficient mice are non-responsive to CpG-ODN. Hemmi H et al., *Nature* 408:740-5. By semi-quantitative RT-PCR both B cells and CD123+ DC yielded positive signals for hTLR9 while MDDC, monocytes and T cells were weak to negative (**Figure 9**). The cDNAs were prepared from

5 monocyte-derived dendritic cells (MDDC), lane 1; purified CD14+ monocytes, lane 2; B cells, lane 3; CD123+ DC, lane 4; CD4+ T cells, lane 5; and CD8+ T cells, lane 6. cDNA amounts were normalized based on GAPDH amount determined by TAG-MAN PCR (Perkin-Elmer). RT-PCR was performed for 30 cycles on normalized cDNA diluted 1:5 for human TLR2, 4 and 9, while GAPDH was diluted 1:125. We also tested for hTLR2 and hTLR4

10 expression. MDDC and monocytes were positive while B cells, T cells and CD123+DC were weak to negative (**Figure 9**). Weak signals delivered by PCR could be explained by contaminating cells, however a strong positive signal implies expression. These data demonstrated a clear correlation between hTLR9 mRNA expression and B cell or CD123+DC responsiveness to CpG-DNA (**Figures 7 and 8**). A correlation could also be

15 shown for hTLR2 and hTLR4 expression and MDDC responsiveness to LPS (**Figure 8**). This data demonstrates that hTLR9 is a relevant receptor for CpG-DNA responses and that its expression determines responsiveness. If TLR9 expression could be modulated, agonism or antagonism of CpG-DNA responses could be achieved.

20 **Example 5. Species specificity of TLR9 signaling**

By iterative examination of the flanking sequences surrounding CG dinucleotides, CpG-motifs have been identified. Paradoxically, or by twist of nature, the human optimal CpG-motif, GTCGTT (SEQ ID NO:66), is different from the murine motif, GACGTT (SEQ ID NO:129). Human peripheral blood mononuclear cells (PBMC) (**Figure 10A**) and murine

25 splenocytes (**Figure 10B**) were stimulated with ODN 2006 (filled circle, TCTGTCGTTTTGTCGTTTGTCTGTT, SEQ ID NO:112), ODN 2006-GC (open circle), ODN 1668 (filled triangle, TCCATGACGTTTCCTGATGCT, SEQ ID NO:84) or ODN 1668-GC (open triangle, TCCATGAGCTTCCTGATGCT, SEQ ID NO:85) at indicated concentrations and IL-12 production was monitored after 8 hours. **Figure 10A** shows that titration of the

30 optimal human ODN, 2006, on PBMC induces IL-12 production. The optimal murine sequence, 1668, however was much less effective in eliciting IL-12 from PBMC. The two

- 101 -

control GpC-ODNs were essentially negative. The converse was true for murine splenocytes (Figure 10B), in that the murine sequence induced optimal IL-12 while the human sequence was much less effective. It should also be noted that the K_{ac} (concentration of half-maximal activation) of murine splenocytes for 1668 was greater than human PBMC for 2006 (compare Fig. 10A to Fig. 10B).

Because stable TLR9 transfectants mirrored primary cell responsiveness to CpG-DNA (Figures 4 and 5), it was hypothesized that stable transfectants could potentially discern species-specific CpG-motifs through TLR9 receptors. Therefore 293-hTLR9-luc (expressing human TLR9 and 6-fold NF- κ B-luc reporter), 293-mTLR9-luc (expressing murine TLR9 and 6-fold NF- κ B-luc reporter), 293-hTLR9 (expressing human TLR9) and 293-mTLR9 (expressing murine TLR9) clones were tested for CpG-DNA motif responsiveness. Figure 11 shows titration curves for 2006 or 1668 and their controls versus either hTLR9 or mTLR9 cells. Depicted are both NF- κ B-driven luciferase and IL-8 production as readout. In both 293 hTLR9-luc and 293-mTLR9-luc cells stimulation with CpG-DNA resulted in NF- κ B activation, as determined by measurement of the induced expression of firefly luciferase under the control of a minimal promotor containing six tandem NF- κ B-binding sites. After lysis of the cells luciferase can be detected photometrically based on an enzymatic reaction by luciferase which creates photons. IL-8 production was monitored using enzyme-linked immunosorbent assay (ELISA). Figure 11 depicts clones stimulated with ODN 2006 (filled circle), ODN 2006-GC (open circle), ODN 1668 (filled triangle) or ODN 1668-GC (open triangle) at indicated concentrations and NF- κ B activation or IL-8 production were measured after 10 and 48 hours, respectively. Results shown in Figure 11 are representative of three independent experiments. Strikingly, CpG-motif sequence specificity was conferred in a species-specific manner by TLR9. Additionally, the half-maximal concentration for either 2006 or 1668 appears nearly the same as those determined on primary cells (compare Figure 10 and Figure 11). These data demonstrate that TLR9 is the CpG-DNA receptor and that exquisite specificity to CpG-DNA sequence is conferred by TLR9.

Example 6. Use of stable TLR9 clones to test responsiveness to substances other than phosphorothioate ODN

As described in the foregoing Examples, the stable TLR9 clones were initially

- 102 -

screened for fidelity of phosphorothioate CpG-ODN reactivity. The 293-hTLR9 cells demonstrated reactivity to CpG-DNA and not LPS in a CpG-motif dependent manner (Figures 4 and 5). In the present example the stable TLR9 transfectants were tested for responsiveness to additional DNAs. NF- κ B activation was monitored after stimulation with *E. coli* DNA (black bars) or *E. coli* DNA digested with DNase I (gray bars) in 293-hTLR9-luc cells. Figure 12 demonstrates an *E. coli* DNA dose-dependent induction of NF- κ B-driven luciferase expression to a level comparable to phosphorothioate CpG-ODN (Figure 11). Activity was destroyed by DNase I digestion, indicating specificity of response to DNA and not contaminant bacterial products. The stable TLR9 transfectants can be used to screen the activity of DNAs from various species or vector DNAs intended for immune system stimulation. In particular, TLR9 transfectants can be used to screen and compare the immunostimulatory activity of DNAs from various species of pathogens, DNA constructs, DNAs intended for use as vaccines, gene replacement therapeutics, and nucleic acid vectors.

293-hTLR9-luc cells also were stimulated with the phosphodiester variants of ODN 2006 (filled circle), ODN 2006-GC (open circle), ODN 1668 (filled triangle) or ODN 1668-GC (open triangle) at indicated concentrations, and NF- κ B activation was monitored after 12 hours (Figure 13A). Likewise, 293-mTLR9-luc cells were stimulated with the phosphodiester variants of ODN 2006 (filled circle), ODN 2006-GC (open circle), ODN 1668 (filled triangle) or ODN 1668-GC (open triangle) at indicated concentrations, and NF- κ B activation was monitored after 12 hours (Figure 13B). These assays show that the stable TLR9 transfectants responded to DNAs other than phosphorothioate-modified ODN. These data demonstrate the utility of stable TLR transfectants for screening for agonists of the TLR9 receptor.

Example 7. TLR9 determines CpG-ODN activity

Although 2006 and 1668 are discussed in terms of CpG-motif differences, they are very different in several aspects (see Table 5 for comparison). The lengths are different, 24 versus 20 nucleotides, and 2006 has four CG dinucleotides compared to one in 1668. Additional differences are the CG position relative to the 5' and 3' ends and also 5' sequence differences. In order to determine if motif specificity is a quality of the motif and not the global sequence environment, for this experiment several sequences were produced holding

these variables constant. As a starting point, the 1668 sequence was modified by converting the central C to T and the distal TG to CG, thereby creating a second CG in the resulting sequence 5000 (SEQ ID NO:130, Table 5). Then point nucleotide changes were made, progressing toward a 2006-like sequence, 5007 (SEQ ID NO:98). The ODN 5002 (SEQ ID NO:132) is most like 1668 with the exception that C's at positions 12 and 19 have been converted to T's. The last 16 nucleotides of ODN 5007 are the same as the last 15 nucleotides of 2006 with the exception of an additional T. The ODN concentration of half-maximal activation (K_{ac}) was determined by producing ODN titration curves using either 293-hTLR9-luc or 293-mTLR9-luc cells and NF- κ B-driven luciferase expression as a readout. Example curves are given in Figure 14. Stable transfectants 293-hTLR9-luc and 293-mTLR9-luc were stimulated with ODN 5002 (filled circle) or ODN 5007 (open circle) at indicated concentrations and NF- κ B activation was monitored after 12 hours. Results shown in Figure 14 are representative of three independent experiments. Values for K_{ac} for multiple ODN are given in Table 5. Similar results were obtained for those ODN tested with 293-hTLR9 and 293-mTLR9 cells utilizing IL-8 as readout.

Table 5. CpG-DNA sequence specificity of human and murine TLR9 signaling activity

CpG-DNA	Sequence	293-hTLR9 K_{ac} (nM)	293-mTLR9 K_{ac} (nM)	SEQ ID NO:
1668	TCCATGACGTTTCCTGATGCT	>10,000	70	84
1668-GC	TCCATGAGCTTCCTGATGCT	>10,000	>10,000	85
2006	TCGTCGTTTTCGTCGTTTTCGTCGTT	400	>10,000	112
2006-GC	TGCTGCTTTTGTGCTTTTGTGCTT	>10,000	>10,000	118
5000	TCCATGACGTTCTTGACGCT	10,000	82	130
5001	TCCATGACGTTCTTGACGTT	7,000	55	131
5002	TCCATGACGTTCTTGATGTT	7,000	30	132
5003	TCCATGACGTTTTTGATGTT	10,000	30	133
5004	TCCATGTCGTTCTTGATGTT	5,000	400	134
5005	TCCATGTCGTTTTTGATGTT	3,000	2,000	135
5006	TCCATGTCGTTTTTGTTGTT	3,000	650	136
5007	TCCATGTCGTTTTTGTCGTT	700	1,000	98
5002	TCCATGACGTTCTTGATGTT	ND	30	132
5008	TCCATGACGTTATTGATGTT	ND	40	137
5009	TCCATGACGTCCTTGATGTT	ND	>10,000	138
5010	TCCATGACGTCATTGATGTT	ND	>10,000	139

- 104 -

In previous unpublished work by the inventors, it had been noted that a CA substitution converting the mouse CpG-motif from GACGTTC to GACGTCA was deleterious. To extend our examination of the motif, three more ODN were created to dissect this effect (5008-5010, SEQ ID NOs:137-139, Table 5).

5 The activity displayed by the 293-hTLR9-luc clone increased with progressive nucleotide substitutions converting the mouse sequence toward the human sequence (Table 5, sequences 5000-5007). The converse was true for the 293-mTLR9-luc clone, which showed highest activity for the mouse sequences. The originally hypothesized CpG-motif was purine-purine-CG-pyrimidine-pyrimidine. Most notable to motif definition as determined by TLR9
10 genetic complementation was the non-conservative pyrimidine for purine change A to T immediately 5' of the CG (Table 5). These changes improved 293-hTLR9-luc responsiveness but diminished 293-mTLR9-luc responsiveness. These results support the notion that the preferred mouse motif contains ACG while the preferred human sequence contains TCG. The conservative pyrimidine for pyrimidine change T to C in the mouse motif, ACGTT
15 versus ACGTC (5002 versus 5009), completely destroyed 293-mTLR9 responsiveness. Although not a complete iterative analysis of the CpG-motif, the data refine our understanding of the motif. More importantly these data strongly support direct CpG-motif engagement by TLR9.

20 **Example 8. Antagonist definition**

It has been demonstrated that DNA uptake and endosomal maturation are required for signal initiation by CpG-DNA. It has been hypothesized that in order for DNA to enter the endosomal/lysosomal compartment a non-CpG dependent uptake receptor may be required. 293 cells were transiently transfected with mTLR9 treated with either medium only or 1.0 µM
25 CpG-ODN 1668 (Figure 15). Additionally the 1668-treated TLR9 transfectants were simultaneously exposed to various doses of a non-CpG ODN (PZ2; 5'-CTCCTAGTGGGGGTGTCCTAT-3', SEQ ID NO:43). IL-8 production was monitored after 48h by ELISA. Figure 15 shows that PZ2, in a dose-dependent manner, was able to antagonize the activation of TLR9-transfected cells stimulated with a CpG ODN.

30 Figure 16 demonstrates that the stable TLR9 transfectants, 293-hTLR9-luc cells, are sensitive to non-CpG-ODN blockade. 293-hTLR9-luc cells were incubated with CpG-ODN

- 105 -

(0.5 μ M) (black bars) or TNF- α (10 ng/ml) (gray bars) and increasing concentrations of a blocking ODN (5'-HHHHHHHHHHHHHHWGGGGG-3', SEQ ID NO:140; H = A, T, C; W = A, T) as indicated. NF- κ B activation was monitored after 12 hours and is presented as percent yields. Thus both mTLR9 and hTLR9 activity can be blocked by non-stimulatory
5 ODN. The blockade is specific to blocking ODN since the TNF-driven NF- κ B signal was not diminished. Antagonism of CpG-DNA responses could thus be defined in stable TLR9 cells and therefore high throughput screening can be done for TLR9 antagonist.

Bafilomycin A poisons the proton pump needed for H⁺ transport into endosomes, which is required for endosomal maturation. Figure 17 shows that blockade of endosomal
10 maturation in 293-hTLR9-luc cells fully blocks CpG-ODN induction of NF- κ B. 293-hTLR9-luc cells were preincubated with 10 nM Bafilomycin A (gray bars) or dimethylsulfoxide (DMSO) control (black bars) for 30 min and stimulated with CpG-ODN (2006, 0.5 μ M), IL-1 (10 ng/ml) or TNF- α (10 ng/ml) as indicated. NF- κ B activation was monitored after 12 hours and is presented as percent yields. The blockade was specific to CpG-DNA generated signal
15 because both IL-1 and TNF induction of NF- κ B was unaffected. These data demonstrate that 293 cells stably complemented with hTLR9 behave in a manner similar to primary CpG-DNA responsive cells, in that cellular uptake and endosomal maturation are required for induction of signal by CpG-DNA. Thus the stable transfectants can be used as indicator for TLR9 drug antagonist.

CpG-DNA signaling appears to occur via a Toll/IL-1R-like pathway. It was shown in the mouse that CpG-DNA signaling is dependent on MyD88, IRAK and TRAF6. Häcker H et al., *J Exp Med* 192:595-600 (2000). Hemmi et al. demonstrated that mTLR9-deficient mice lack activation of IRAK upon CpG-ODN stimulation. Hemmi H et al., *Nature* 408:740-5 (2000). Figure 18 shows that CpG-DNA signaling via human TLR9 was MyD88
20 dependent. hTLR9 (293-hTLR9) was co-transfected with a six-times NF- κ B luciferase reporter plasmid and increasing concentrations of the dominant negative human MyD88 expression vector. Cells were not stimulated (filled circles), stimulated with CpG-ODN (2006, 2 μ M) (open circles) or TNF- α (10 ng/ml) (filled triangles) and NF- κ B activation was monitored after 12 hours. Results are representative of at least two independent experiments.
25 Figure 18 demonstrates that dominant negative MyD88 blocks NF- κ B induction in 293-hTLR9 cells following CpG-DNA stimulation. The blockade of MyD88 did not affect NF-

- 106 -

κB induction via TNF induced signal transduction. In general these data confirm the central role of MyD88 to TLR signaling and specifically the role of MyD88 in CpG-DNA initiation of signal. Thus human cells transfected with TLR9 can be used as indicators to find molecules to antagonize CpG-DNA via genetic mechanisms.

5

Example 9. Antibody production

Peptides for human and mouse TLR9 were designed for coupling to a carrier protein and injected into rabbits to obtain anti-peptide polyclonal antisera. Mouse peptide 1 (mousepep1, see Table 4) can be found in EST aa197442 and peptide 2 (mousepep2, see
10 Table 4) in EST aa273731 and ai463056. Human peptide 1 (humanpcp1, see Table 4) and peptide 2 (humanpep2, see Table 4) were taken from the published human sequence.

Three rabbit antisera were generated by this method: anti-mousepep1, specific for the extracellular domain of murine TLR9; anti-humanpcp1, specific for the extracellular domain of hTLR9; and antisera against a combination of mousepep2 and humanpep2, specific for the
15 cytoplasmic domain of both murine and human TLR9. Immunoprecipitates with anti-FLAG antibody were electrophoresed by PAGE and, using standard Western blotting techniques, transferred to membrane and probed with the various antisera. **Figure 19** shows the response to hTLR9-FLAG and mTLR9-FLAG. The TLR9 in these blots are indicated with arrows, while the lower molecular weight bands represent anti-FLAG antibody.

20

Example 10. Mutation adjacent to the CXXC-domain (hTLR9-CXXCm, mTLR9-CXXCh)

The CXXC motif resembles a zinc finger motif and is found in DNA-binding proteins and in certain specific CpG binding proteins, e.g. methyl-CpG binding protein-1 (MBD-1).
25 Fujita N et al., *Mol Cell Biol* 20:5107-5118 (2000). Human and murine TLR9 contain two CXXC motifs. The CXXC domain is highly conserved between human and murine TLR9 but followed by 6 amino acids (aa) which differ quite substantially in polarity and size. By the use of a site-specific mutagenesis kit (Stratagene, La Jolla, CA, USA) these six amino acid residues (human: PRHFPQ 269-274); mouse: GQKSLH 269-274) were interchanged between
30 human and murine TLR9. These mutations were generated by the use of the primers 5'-CTGCATGGAGTGCGGCCAAAAGTCCCTCCACCTACATCCCGATAC-3' (SEQ ID

- 107 -

NO:141) and

5'-GTATCGGGATGTAGGTGGAGGGACTTTTGGCCGCACTCCATGCAG-3' (SEQ ID NO:142) for human TLR9 and the primers

5'-CTGTATAGAATGTCCTCGTCACTTCCCCCAGCTGCACCCTGAGAC-3' (SEQ ID

5 NO:143) and

5'-GTCTCAGGGTGCAGCTGGGGGAAGTGACGAGGACATTCTATACAG-3' (SEQ ID NO:144) for murine TLR9 according to the manufacturer's protocol.

	CXXC motif:	CXXCXXXXXXXXCXXC		SEQ ID NO:145
10	Wildtype hTLR9:	CRRCDHAPNPCMECPRHFPQ	aa 255-274	SEQ ID NO:146
	hTLR9-CXXCm:	CRRCDHAPNPCMECGQKSLH	aa 255-274	SEQ ID NO:147
	Wildtype mTLR9:	CRRCDHAPNPCMICGQKSLH	aa 255-274	SEQ ID NO:148
	mTLR9-CXXCh:	CRRCDHAPNPCMICPRHFPQ	aa 255-274	SEQ ID NO:149

15 For the stimulation of the hTLR9 variant hTLR9-CXXCm, 293 cells were transiently transfected with hTLR9 or hTLR9-CXXCm and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 20). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. The data show that hTLR9 can be improved by converting the human CXXC domain to the murine CXXC

20 domain. For the stimulation of the mTLR9 variant mTLR9-CXXCh, 293 cells were transiently transfected with mTLR9 or mTLR9-CXXCh and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 21). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. It appears that the human CXXC domain may diminish mTLR9-CXXCh activity relative to the

25 wild type mTLR9.

Example 11. Mutation in the MBD motif (hTLR9-MBDmut, mTLR9-MBDmut)

The MBD motif is a domain recently described for CpG binding in the protein MBD-1. Fujita N et al., *Mol Cell Biol* 20:5107-5118 (2000); Ohki I et al., *EMBO J* 18:6653-6661

30 (1999). Human and murine TLR9 contain this motif at position 524-554 and 525-555, respectively.

- 108 -

MBD-1	R-XXXXXXXX-R-X-D-X-Y-XXXXXXXXXX-R-S-XXXXXX-Y	SEQ ID NO:125
hTLR9	Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXXX-R-L-XXXXXX-Y	SEQ ID NO:126
mTLR9	Q-XXXXXXXX-K-X-D-X-Y-XXXXXXXXXX-Q-L-XXXXXX-Y	SEQ ID NO:127

5

The core of this domain consists of D-L-Y in human TLR9 (aa 534-536) and mouse TLR9 (aa 535-537). Through site-specific mutagenesis D534 and Y536 in human TLR9, and D535 and Y537 in murine TLR9, were mutated to alanines creating the sequence A-L-A for human (aa 534-536) and murine TLR9 (aa 535-537). These mutations were generated by the use of the

10 primers 5'-CACAATAAGCTGGCCCTCGCCACGAGCACTC-3' (SEQ ID NO:150) and 5'-GAGTGCTCGTGGGCGAGGGCCAGCTTATTGTG-3' (SEQ ID NO:151) for human TLR9 and the primers 5'-CATAACAACTGGCCTTGGCCCACTGGAAATC-3' (SEQ ID NO:152) and 5'-GATTTCAGTGGGCCAAGGCCAGTTTGTATG-3' (SEQ ID NO:153) for murine TLR9 according to the manufacturer's protocol.

15 For the stimulation of mTLR9 variant, mTLR9-MBDmut, 293 cells were transiently transfected with mTLR9 or mTLR9-MBD-mut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (**Figure 22**). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. For the stimulation of hTLR9 variant, hTLR9-MBDmut, 293 cells were transiently transfected with hTLR9 or

20 hTLR9-MBD-mut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (**Figure 23**). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. The disruption of the putative CpG binding domain DXY in TLR9 destroyed receptor activity. These data demonstrate that the MBD motif is most likely involved in CpG-DNA binding and can be thus be manipulated to better

25 understand CpG-DNA binding and efficacy.

Example 12. Proline to Histidine mutation in the TIR-domain (hTLR9-PHmut, mTLR9-PHmut)

Toll-like receptors have a cytoplasmic Toll/IL-1 receptor (TIR) homology domain

30 which initiates signaling after binding of the adapter molecule MyD88. Medzhitov R et al., *Mol Cell* 2:253-8 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15-8 (1999). Reports by

- 109 -

others have shown that a single-point mutation in the signaling TIR-domain in murine TLR4 (Pro712 to His) or human TLR2 (Pro681 to His) abolishes host immune response to lipopolysaccharide or gram-positive bacteria, respectively. Poltorak A et al., *Science* 282:2085-8 (1998); Underhill DM et al., *Nature* 401:811-5 (1999). Through site-specific mutagenesis the equivalent Proline at position 915 of human and murine TLR9 were mutated to Histidine (Pro915 to His). These mutations were generated by the use of the primers 5'-GCGACTGGCTGCATGGCAAACCCCTCTTTG-3' (SEQ ID NO:154) and 5'-CAAAGAGGGTTTTGCCATGCAGCCAGTCGC-3' (SEQ ID NO:155) for human TLR9 and the primers 5'-CGAGATTGGCTGCATGGCCAGACGCTCTTC-3' (SEQ ID NO:156) and 5'-GAAGAGCGTCTGGCCATGCAGCCAATCTCG-3' (SEQ ID NO:157) for murine TLR9 according to the manufacturer's protocol.

For the stimulation of mTLR9 variant, mTLR9-PHmut, 293 cells were transiently transfected with mTLR9 or mTLR9-PHmut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 22). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. For the stimulation of hTLR9 variant, hTLR9-PHmut, 293 cells were transiently transfected with hTLR9 or hTLR9-PHmut and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 23). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. These data demonstrate that TLR9 activity can be destroyed by the Pro to His mutation. This mutation has the potential to be used as a dominant negative to block TLR9 activity thus a genetic variant could compete for ligand or signaling partners and disrupt signaling.

Example 13. Exchange of the TIR-domain between murine and human TLR9 (hTLR9-TIR_m, mTLR9-TIR_h)

Toll-like receptors have a cytoplasmic Toll/IL-1 receptor (TIR) homology domain that initiates signaling after binding of the adapter molecule MyD88. Medzhitov R et al., *Mol Cell* 2:253-8 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15-8 (1999). This is also true for TLR9. To generate molecules consisting of human extracellular TLR9 and murine TIR domain (hTLR9-TIR_m) or murine extracellular TLR9 and human TIR domain (mTLR9-TIR_h), the following approach was chosen. Through site-specific mutagenesis a ClaI

- 110 -

restriction site was introduced in human and murine TLR9. For human TLR9 the DNA sequence 5'-GGCCTCAGCATCTTT-3' (3026-3040, SEQ ID NO:158) was mutated to 5'-GGCCTATCGATTTT-3' (SEQ ID NO:159), introducing a ClaI site (underlined in the sequence) but leaving the amino acid sequence (GLSIF, aa 798-802) unchanged. For murine

5 TLR9 the DNA sequence 5'-GGCCGTAGCATCTTC-3' (2434-2447, SEQ ID NO:160) was mutated to 5'-GGCCTATCGATTTT-3' (SEQ ID NO:161), introducing a ClaI site and creating the amino acid sequence (GLSIF, aa 799-803) which differs in one position (aa 800) from the wildtype murine TLR9 sequence (GRSIF, aa 799-803) but is identical to the human sequence.

10 **hTLR9-TIRm.** The primers used for human TLR9 were 5'-CAGCTCCAGGGCCTATCGATTTTGCACAGGACC-3' (SEQ ID NO:162) and 5'-GGTCCTGTGCAAAAATCGATAGGCCCTGGAGCTG-3' (SEQ ID NO:163). For creating an expression vector containing the extracellular portion of human TLR9 connected to the murine TIR domain, the human expression vector was cut with ClaI and limiting amounts of

15 EcoRI and the fragment coding for the murine TIR domain generated by a ClaI and EcoRI digestion of murine TLR9 expression vector was ligated in the vector fragment containing the extracellular portion of hTLR9. Transfection into *E.coli* yielded the expression vector hTLR9-TIRm (human extracellular TLR9-murine TIR-domain).

mTLR9-TIRh. The primers used for murine TLR9 were 5'-CAGCTGCAGGGCCTATCGATTTTCGCACAGGACC-3' (SEQ ID NO:164) and 5'-GGTCCTGTGCGAAAATCGATAGGCCCTGCAGCTG-3' (SEQ ID NO:165). For creating an expression vector containing the extracellular portion of murine TLR9 connected to the human TIR domain, the murine expression vector was cut with ClaI and limiting amounts of

25 EcoRI and the fragment coding for the human TIR domain generated by a ClaI and EcoRI digestion of human TLR9 expression vector was ligated in the vector fragment containing the extracellular portion of mTLR9. Transfection into *E.coli* yielded the expression vector mTLR9-TIRh (murine extracellular TLR9-human TIR-domain).

For the stimulation of the mTLR9 variant, mTLR9-TIRh, 293 cells were transiently transfected with mTLR9 or mTLR9-TIRh and stimulated after 16 hours with ODN 2006 and

30 ODN 1668 at concentrations indicated (Figure 24). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. For the stimulation of the

- 111 -

hTLR9 variant, hTLR9-TIRm, 293 cells were transiently transfected with hTLR9 or hTLR9-TIRm and stimulated after 16 hours with ODN 2006 and ODN 1668 at concentrations indicated (Figure 25). 48 hours after stimulation supernatant was harvested and IL-8 production was measured by ELISA. Replacement of the murine TLR9-TIR domain with human does not significantly affect mTLR9 activity. Replacement of the human TLR9-TIR with murine however appears to have a negative effect on hTLR9. These data demonstrate that manipulations could be made to influence TLR9 activities.

Example 14. TLR9-fusion protein with green-fluorescent-protein (hTLR9-GFP, mTLR9-GFP)

Human and murine TLR9 were individually cloned into the vector pEGFP-N1 (Clontech, Palo Alto, CA, USA) to create expression vectors encoding human and murine fusion proteins consisting of an N-terminal TLR9 protein fused to C-terminal green-fluorescent protein (GFP). These constructs can be used to trace TLR9 localization and expression. Such detections can be used for staining in FACS analysis, confocal microscopy and Western blot, or for purification of polypeptides and subsequent antibody production.

Example 15. TLR9-fusion protein with FLAG-peptide (hTLR9-FLAG, mTLR9-FLAG)

Human and murine TLR9 were individually cloned into the vector pFLAG-CMV-1 (Sigma, St. Louis, MO, USA) to create expression vectors encoding human and murine fusion proteins consisting of an N-terminal leader peptide (preprotrypsin, which is cleaved intracellularly during processing of the protein), FLAG-peptide (DYKDDDDK) and TLR9 protein which does not contain its own signal peptide. These constructs can be used to trace TLR9 localization and expression, e.g., using anti-FLAG antibodies. Such detections can be used for staining in FACS analysis, confocal microscopy and Western blot, or for purification of polypeptides and subsequent antibody production.

Example 16. Method of cloning human TLR7

Two accession numbers in the GenBank database, AF245702 and AF240467, describe the DNA sequence for human TLR7. To create an expression vector for human TLR7, human TLR7 cDNA was amplified from a cDNA made from human peripheral mononuclear

- 112 -

blood cells (PBMC) using the primers 5'-CACCTCTCATGCTCTGCTCTCTTC-3' (SEQ ID NO:166) and 5'-GCTAGACCGTTTCCTTGAACACCTG-3' (SEQ ID NO:167). The fragment was cloned into pGEM-T Easy vector (Promega), cut with the restriction enzyme NotI and ligated into a NotI-digested pCDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence for hTLR7 is SEQ ID NO:168, is presented in Table 6. The open reading frame starts at base 124, ends at base 3273, and codes for a protein of 1049 amino acids. SEQ ID NO:169 (Table 7), corresponding to bases 124-3273 of SEQ ID NO:168 (Table 6), is the coding region for the polypeptide of SEQ ID NO:170 (Table 8).

The protein sequence of the cloned hTLR7 cDNA matches the sequence described under the GenBank accession number AF240467. The sequence deposited under GenBank accession number AF245702 contains two amino acid changes at position 725 (L to H) and 738 (L to P).

Table 6. cDNA Sequence for Human TLR7 (5' to 3'; SEQ ID NO:168)

15	agctggctag cgttttaaacg ggccctctag actcgagcgg ccgcgaattc actagtgtatt	60
	cacctctcat gctctgctct cttcaaccag acctctacat tccatttttg aagaagacta	120
	aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt taacataatc	180
	ctaatttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg tgatgtcact	240
20	ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt	300
	cctggaggta ttcccacgaa caccacgaac ctccacctca ccattaacca cataccagac	360
	atctccccag cgtcctttca cagactggac catctggtag agatcgattt cagatgcaac	420
	tgtgtacctt ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaaa	480
	cccagaagct ttagtggact cacttattta aaatcccttt acctggatgg aaaccagcta	540
25	ctagagatac cgcagggcct ccgccttagc ttacagcttc tcagccttga ggccaacaac	600
	atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat actctacctg	660
	ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc	720
	ttcctaaact tgacaaagt aaaagtgtc tccctgaaag ataacaatgt cacagccgtc	780
	cctactgttt tgccatctac tttaacagaa ctatatctct acaacaacat gattgcaaaa	840
30	atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct aagtggaaat	900
	tgccctcggt gttataatgc ccatttctt tgtgcgccgt gtaaaaataa ttctccccta	960
	cagatccctg taaatgcttt tgatgcgctg acagaattaa aagttttacg tctacacagt	1020
	aactctcttc agcatgtgcc cccaagatgg tttaagaaca tcaacaaact ccagggaactg	1080
	gatctgtccc aaaacttctt ggccaaagaa attggggatg cttaaatttct gcattttctc	1140
35	cccagcctca tccaattgga tctgtctttc aattttgaac ttcaggtcta tcgtgcatct	1200
	atgaatctat cacaagcatt ttcttctactg aaaagcctga aaattctgcg gatcagagga	1260
	tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt	1320

- 113 -

	gaagttcttg	atcttggcac	taactttata	aaaattgcta	acctcagcat	gtttaaacia	1380
	tttaaaagac	tgaaagtcac	agatctttca	gtgaataaaa	tatcaccttc	aggagattca	1440
	agtgaagttg	gcttctgctc	aaatgccaga	acttctgtag	aaagttatga	acccaggttc	1500
	ctggaacaat	tacattatct	cagatatgat	aagtatgcaa	ggagttgcag	attcaaaaac	1560
5	aaagaggctt	ctttcatgtc	tgttaatgaa	agctgctaca	agtatgggca	gaccttggat	1620
	ctaagtaaaa	atagtatatt	ttttgtcaag	tcctctgatt	ttcagcatct	ttctttcttc	1680
	aaatgcctga	atctgtcagg	aaatctcatt	agccaaactc	ttaatggcag	tgaattccaa	1740
	ccttttagcag	agctgagata	tttggacttc	tccaacaacc	ggcttgattt	actccattca	1800
	acagcatttg	aagagcttca	caaactggaa	gttctggata	taagcagtaa	tagccattat	1860
10	tttcaatcag	aaggaattac	tcatatgcta	aactttacca	agaacctaaa	ggttctgcag	1920
	aaactgatga	tgaacgacaa	tgacatctct	tcctccacca	gcaggaccat	ggagagttag	1980
	tctcttagaa	ctctggaatt	cagaggaaat	cacttagatg	ttttatggag	agaagggtgat	2040
	aacagatact	tacaattatt	caagaatctg	ctaaaattag	aggaattaga	catctctaaa	2100
	aattccctaa	gtttcttgcc	ttctggagtt	tttgatggta	tgctccaaa	tctaagaat	2160
15	ctctcttttg	ccaaaaatgg	gctcaaatct	ttcagttgga	agaaaactca	gtgtctaaag	2220
	aacctggaaa	ctttggacct	cagccacaac	caactgacca	ctgtccctga	gagattatcc	2280
	aactgttcca	gaagcctcaa	gaatctgatt	cttaagaata	atcaaatcag	gagtctgacg	2340
	aagtattttc	tacaagatgc	cttcagattg	cgatatctgg	atctcagctc	aaataaaatc	2400
	cagatgatcc	aaaagaccag	cttcccagaa	aatgtcctca	acaatctgaa	gatgttgctt	2460
20	ttgcatcata	atcggtttct	gtgcacctgt	gatgctgtgt	ggtttgtctg	gtgggttaac	2520
	catacggagg	tgactattcc	ttacctggcc	acagatgtga	cttgtgtggg	gccaggagca	2580
	cacaagggcc	aaagtgtgat	ctccctggat	ctgtacacct	gtgagttaga	tctgactaac	2640
	ctgattctgt	tctcactttc	catatctgta	tctctctttc	tcatggtgat	gatgacagca	2700
	agtcacctct	atctctggga	tgtgtggtat	atttaccatt	tctgtaaggc	caagataaag	2760
25	gggtatcagc	gtctaatatc	accagactgt	tgctatgatg	cttttattgt	gtatgacact	2820
	aaagaccag	ctgtgaccga	gtgggttttg	gctgagctgg	tggccaaact	ggaagacca	2880
	agagagaaac	attttaattt	atgtctcgag	gaaagggact	ggttaccagg	gcagccagtt	2940
	ctggaaaacc	tttcccagag	catacagctt	agcaaaaaga	cagtgtttgt	gatgacagac	3000
	aagtatgcaa	agactgaaaa	ttttaagata	gcattttact	tgteccatca	gaggctcatg	3060
30	gatgaaaaag	ttgatgtgat	tatcttgata	tttcttgaga	agccttttca	gaagtccaag	3120
	ttctccagc	tccgaaaaag	gctctgtggg	agttctgtcc	ttgagtggcc	aacaaaccgc	3180
	caagctcacc	catacttctg	gcagtgtcta	aagaacgccc	tggccacaga	caatcatgtg	3240
	gcctatagtc	aggtgttcaa	ggaaacggtc	tagaatcgaa	ttcccgcggc	cgccactgtg	3300
	ctggatatct	gcagaattcc	accacactgg	actagtggat	ccgagctcgg	taccaagctt	3360
35	aagtttaaac	cgc					3373

Table 7. Coding Region for Human TLR7 (5' to 3'; SEQ ID NO:169)

	atggtgtttc	caatgtggac	actgaagaga	caaattctta	tcctttttta	cataatccta	60
	atttccaaac	tccttggggc	tagatgggtt	cctaaaactc	tgccctgtga	tgtoactctg	120
40	gatgttccaa	agaaccatgt	gatcgtggac	tgcacagaca	agcatttgac	agaaattcct	180
	ggagggtattc	ccacgaacac	cacgaacctc	accctcacca	ttaaccacat	accagacatc	240

- 114 -

	tccccagcgt	cctttcacag	actggaccat	ctggtagaga	tcgatttcag	atgcaactgt	300
	gtacctattc	cactggggtc	aaaaaacaac	atgtgcatca	agaggctgca	gattaaaccc	360
	agaagcttta	gtggactcac	ttatttaaaa	tccctttacc	tgatggaaa	ccagctacta	420
	gagataccgc	agggcctccc	gcctagctta	cagcttctca	gccttgaggc	caacaacatc	480
5	ttttccatca	gaaaagagaa	tctaacagaa	ctggccaaca	tagaaatact	ctacctgggc	540
	caaaactgtt	attatcgaaa	tccttggtat	gtttcatatt	caatagagaa	agatgccttc	600
	ctaaacttga	caaagttaaa	agtgtctctc	ctgaaagata	acaatgtcac	agccgtccct	660
	actgttttgc	catctacttt	aacagaacta	tatctctaca	acaacatgat	tgcaaaaatc	720
	caagaagatg	attttaataa	cctcaaccaa	ttacaaattc	ttgacctaa	tggaatttgc	780
10	cctcgttggt	ataatgcccc	atttccttgt	gcgccgtgta	aaaataattc	tcccctacag	840
	atccctgtaa	atgcttttga	tgcgctgaca	gaattaaaag	ttttacgtct	acacagtaac	900
	tctcttcagc	atgtgcccc	aagatggttt	aagaacatca	acaaactcca	ggaactggat	960
	ctgtcccaaa	acttcttggc	caaagaaatt	ggggatgcta	aatttctgca	ttttctcccc	1020
	agcctcatcc	aattggatct	gtctttcaat	tttgaacttc	aggtctatcg	tgcactctatg	1080
15	aatctatcac	aagcattttc	ttcactgaaa	agcctgaaaa	ttctgcggat	cagaggatat	1140
	gtctttaaag	agttgaaaag	ctttaacctc	tcgccattac	ataatcttca	aaatcttgaa	1200
	gttcttgatc	ttggcactaa	ctttataaaa	attgctaacc	tcagcatgtt	taaacaattt	1260
	aaaagactga	aagtcataga	tctttcagtg	aataaaatat	caccttcagg	agattcaagt	1320
	gaagtgggct	tctgctcaaa	tgccagaact	tctgtagaaa	gttatgaacc	ccaggctctg	1380
20	gaacaattac	attatttcag	atatgataag	tatgcaagga	gttgacagatt	caaaaacaaa	1440
	gaggcttctt	tcattgtctgt	taatgaaagc	tgctacaagt	atgggcagac	cttgatctca	1500
	agtaaaaata	gtatattttt	tgtcaagtcc	tctgattttc	agcatctttc	tttcctcaaa	1560
	tgcctgaatc	tgtcaggaaa	tctcattagc	caaactctta	atggcagtg	attccaacct	1620
	ttagcagagc	tgagatattt	ggacttctcc	aacaaccggc	ttgatttact	ccattcaaca	1680
25	gcatttgaag	agcttcacaa	actggaagtt	ctggatataa	gcagtaatat	ccattatttt	1720
	caatcagaag	gaattactca	tatgctaaac	tttaccaaga	acctaaagg	tctgcagaaa	1800
	ctgatgatga	acgacaatga	catctcttcc	tccaccagca	ggaccatgga	gagtgaagtct	1860
	cttagaactc	tggaattcag	aggaaatcac	ttagatgttt	tatggagaga	aggtgataac	1920
	agatacttac	aattattcaa	gaatctgcta	aaattagagg	aattagacat	ctctaaaaat	1980
30	tccctaagtt	tcttgccctc	tggagttttt	gatggatg	ctccaaatct	aaagaatctc	2040
	tctttggcca	aaaatgggct	caaactcttc	agttggaaga	aactccagtg	tctaaagaac	2100
	ctggaaactt	tggacctcag	ccacaaccaa	ctgacctg	tccctgagag	attatccaac	2160
	tgttccagaa	gcctcaagaa	tctgattctt	aagaataatc	aaatcaggag	tctgacgaag	2220
	tattttctac	aagatgcctt	ccagttgcga	tatctggatc	tcagctcaaa	taaaatccag	2280
35	atgatccaaa	agaccagctt	cccagaaaat	gtcctcaaca	atctgaagat	gttgcttttg	2340
	catcataatc	ggtttctgtg	cacctgtgat	gctgtgtggt	ttgtctgggtg	ggttaaccat	2400
	acggagggtga	ctattcctta	cctggccaca	gatgtgactt	gtgtggggcc	aggagcacac	2460
	aagggccaaa	gtgtgatctc	cctggatctg	tacacctgtg	agttagatct	gactaacctg	2520
	attctgttct	cactttccat	atctgtatct	ctctttctca	tggatgat	gacagcaagt	2580
40	cacctctatt	tctgggatgt	gtggtatatt	taccatttct	gtaaggccaa	gataaagggg	2640
	tatcagcgtc	taatattacc	agactgttgc	tatgatgctt	ttattgtgta	tgacactaaa	2700
	gacctcagctg	tgacctgagt	ggttttggct	gagctgggtg	ccaaactgga	agacctcaaga	2760

	gagaaacatt	ttaattttatg	tctcgaggaa	agggactggg	taccagggca	gccagttctg	2820
	gaaaaccttt	cccagagcat	acagcttagc	aaaaagacag	tgtttgat	gacagacaag	2880
	tatgcaaaga	ctgaaaattt	taagatagca	ttttacttgt	cccatcagag	gctcatggat	2940
	gaaaaagttg	atgtgattat	cttgatattt	cttgagaagc	cttttcagaa	gtccaagttc	3000
5	ctccagctcc	ggaaaaggct	ctgtgggagt	tctgtccttg	agtggccaac	aaacccgcaa	3060
	gctcaccat	acttctggca	gtgtctaaag	aacgccctgg	ccacagacaa	tcatgtggcc	3120
	tatagtcagg	tgttcaagga	aacggctc				3147

Table 8. Amino Acid Sequence of Human TLR7

[illegible]

- 116 -

	AF240467.pep	KRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNK	480
	hTLR7.pep	KRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNK	480
	AF245702.pep	KRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNK	480
5		. : . : . : . : . : . : . :	540
	AF240467.pep	EASFMSVNESCYKYGQTLDSLKSNISFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP	540
	hTLR7.pep	EASFMSVNESCYKYGQTLDSLKSNISFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP	540
	AF245702.pep	EASFMSVNESCYKYGQTLDSLKSNISFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQP	540
10		. : . : . : . : . : . : . :	600
	AF240467.pep	LAELRYLDFSNNRDLHLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKVLOK	600
	hTLR7.pep	LAELRYLDFSNNRDLHLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKVLOK	600
	AF245702.pep	LAELRYLDFSNNRDLHLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKVLOK	600
15		. : . : . : . : . : . : . :	660
	AF240467.pep	LMMNDNDISSSTSRTESESLRTEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISK	660
	hTLR7.pep	LMMNDNDISSSTSRTESESLRTEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISK	660
	AF245702.pep	LMMNDNDISSSTSRTESESLRTEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISK	660
20		. : . : . : . : . : . : . :	720
	AF240467.pep	SLSFLPSGVFDGMPNPNLKNLSLAKNGLKSFWSKKLQCLKNLETLDLSHNQLTTVPERLSN	720
	hTLR7.pep	SLSFLPSGVFDGMPNPNLKNLSLAKNGLKSFWSKKLQCLKNLETLDLSHNQLTTVPERLSN	720
	AF245702.pep	SLSFLPSGVFDGMPNPNLKNLSLAKNGLKSFWSKKLQCLKNLETLDLSHNQLTTVPERLSN	720
25		. : . : . : . : . : . : . :	780
	AF240467.pep	CSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLLL	780
	hTLR7.pep	CSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLLL	780
	AF245702.pep	CSRSHKNLILKNNQIRSPTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLLL	780
30		. : . : . : . : . : . : . :	840
	AF240467.pep	HHRFLCTCDAVWFVWVWNHTEVTIPYLATDVTCVGPGAHKQSVISLDLYTCELDLTNL	840
	hTLR7.pep	HHRFLCTCDAVWFVWVWNHTEVTIPYLATDVTCVGPGAHKQSVISLDLYTCELDLTNL	840
	AF245702.pep	HHRFLCTCDAVWFVWVWNHTEVTIPYLATDVTCVGPGAHKQSVISLDLYTCELDLTNL	840
35		. : . : . : . : . : . : . :	900
	AF240467.pep	ILFSLSISVSLFLMVMMTASHLYFNDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK	900
	hTLR7.pep	ILFSLSISVSLFLMVMMTASHLYFNDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK	900
	AF245702.pep	ILFSLSISVSLFLMVMMTASHLYFNDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTK	900
40		. : . : . : . : . : . : . :	960
	AF240467.pep	DPAVTEWVLAELVAKLEDPREKHFNLCEERDWLPGQPVLENLSQSIQLSKKTVFVMTDK	960
	hTLR7.pep	DPAVTEWVLAELVAKLEDPREKHFNLCEERDWLPGQPVLENLSQSIQLSKKTVFVMTDK	960
	AF245702.pep	DPAVTEWVLAELVAKLEDPREKHFNLCEERDWLPGQPVLENLSQSIQLSKKTVFVMTDK	960
45		. : . : . : . : . : . : . :	1020
	AF240467.pep	YAKTENFKIAFYLSHQRLMDEKVDVILIFLEKPFQSKFLQLRKRLCGSSVLEWPTNPQ	1020

- 118 -

	ATTCTCCTCC	ACCAGACCTC	TTGATTCCAT	TTTGAAAGAA	AACTGAAAAT	GGTGTTTTCG	60
	ATGTGGACAC	GGAAGAGACA	AATTTTGATC	TTTTTAAATA	TGCTCTTAGT	TTCTAGAGTC	120
	TTTGGGTTTC	GATGGTTTCC	TAAAACTCTA	CCTTGTGAAG	TTAAAGTAAA	TATCCCAGAG	180
	GCCCATGTGA	TCGTGGACTG	CACAGACAAG	CATTTGACAG	AAATCCCTGA	GGGCATTCCC	240
5	ACTAACACCA	CCAATCTTAC	CCTTACCATC	AACCACATAC	CAAGCATCTC	TCCAGATTCC	300
	TTCCGTAGGC	TGAACCATCT	GGAAGAAATC	GATTTAAGAT	GCAATTGTGT	ACCTGTTCTA	360
	CTGGGGTCCA	AAGCCAATGT	GTGTACCAAG	AGGCTGCAGA	TTAGACCTGG	AAGCTTTAGT	420
	GGACTCTCTG	ACTTAAAAGC	CCTTTACCTG	GATGGAAACC	AACTTCTGGA	GATACCACAG	480
	GATCTGCCAT	CCAGCTTACA	TCTTCTGAGC	CTTGAGGCTA	ACAACATCTT	CTCCATCACG	540
10	AAGGAGAATC	TAACAGAACT	GGTCAACATT	GAAACACTCT	ACCTGGGTCA	AAACTGTTAT	600
	TATCGAAATC	CTTGCAATGT	TTCCTATTCT	ATTGAAAAAG	ATGCTTTCCT	AGTTATGAGA	660
	AATTTGAAGG	TTCTCTCACT	AAAAGATAAC	AATGTCACAG	CTGTCCCCAC	CACTTTGCCA	720
	CCTAATTTAC	TAGAGCTCTA	TCTTTATAAC	AATATCATT	AGAAAATCCA	AGAAAATGAT	780
	TTTAATAACC	TCAATGAGTT	GCAAGTTCCT	GACCTAAGTG	GAAATTCCCC	TCGATGTTAT	840
15	AATGTCCCAT	ATCCGTGTAC	ACCGTGTGAA	AATAATTCCO	CCTTACAGAT	CCATGACAAT	900
	GCTTTCAATT	CATTGACAGA	ATTAAAAGTT	TTACGTTTAC	ACAGTAATTC	TCTTCAGCAT	960
	GTGCCCCCAA	CATGGTTTAA	AAACATGAGA	AACCTCCAGG	AACTAGACCT	CTCCCAAAAC	1020
	TACTTGGCCA	GAGAAATTGA	GGAGGCCAAA	TTTTTGCATT	TTCTTCCCAA	CCTTGTGTGAG	1080
	TTGGATTTTT	CTTTCAATTA	TGAGCTGCAG	GTCTACCATG	CATCTATAAC	TTTACCACAT	1140
20	TCACTCTCTT	CATTGGAAAA	CTTGAAAAAT	CTGCGTGTCA	AGGGGTATGT	CTTTAAAGAG	1200
	CTGAAAAACT	CCAGTCTTTC	TGTATTGCAC	AAGCTTCCCA	GGCTGGAAGT	TCTTGACCTT	1260
	GGCACTAACT	TCATAAAAAT	TGCTGACCTC	AACATATTCA	AACATTTTGA	AAACCTCAAA	1320
	CTCATAGACC	TTTCAGTGAA	TAAGATATCT	CCTTCAGAAG	AGTCAAGAGA	AGTTGGCTTT	1380
	TGTCCTAATG	CTCAAACCTC	TGTAGACCGT	CATGGGCCCC	AGGTCCTTGA	GGCCTTACAC	1440
25	TATTTCCGAT	ACGATGAATA	TGCACGGAGC	TGCAGGTTCA	AAAACAAAGA	GCCACCTTCT	1500
	TTCTTGCCCT	TGAATGCAGA	CTGCCACATA	TATGGGCAGA	CCTTAGACTT	AAGTAGAAAT	1560
	AACATATTTT	TTATTAAACC	TTCTGATTTT	CAGCATCTTT	CATTCTCTCA	ATGCCTCAAC	1620
	TTATCAGGAA	ACACCATTGG	CCAAACTCTT	AATGGCAGTG	AACTCTGGCC	GTGAGAGAG	1680
	TTGCGGTACT	TAGACTTCTC	CAACAACCGG	CTTGATTTAC	TCTACTCAAC	AGCCTTTGAA	1740
30	GAGCTCCAGA	GTCTTGAAGT	TCTGGATCTA	AGTAGTAACA	GCCACTATTT	TCAAGCAGAA	1800
	GGAATTACTC	ACATGCTAAA	CTTTACCAAG	AAATTACGGC	TTCTGGACAA	ACTCATGATG	1860
	AATGATAATG	ACATCTCTAC	TTCGGCCAGC	AGGACCATGG	AAAGTGACTC	TCTTCGAATT	1920
	CTGGAGTTCA	GAGGCAACCA	TTTAGATGTT	CTATGGAGAG	CCGGTGATAA	CAGATACTTG	1980
	GACTTCTTCA	AGAATTTGTT	CAATTTAGAG	GTATTAGATA	TCTCCAGAAA	TTCCCTGAAT	2040
35	TCCTTGCCCT	CTGAGGTTTT	TGAGGGTATG	CCGCCAAATC	TAAAGAATCT	CTCCTTGGCC	2100
	AAAAATGGGC	TCAAATCTTT	CTTTTGGGAC	AGACTCCAGT	TACTGAAGCA	TTTGGAATTT	2160
	TTGGACCTCA	GCCATAACCA	GCTGACAAAA	GTACCTGAGA	GATTGGCCAA	CTGTTCCAAA	2220
	AGTCTCACAA	CACGTATTCT	TAAGCATAAT	CAAATCAGGC	AATTGACAAA	ATATTTTCTA	2280
	GAAGATGCTT	TGCAATTGCG	CTATCTAGAC	ATCAGTTCAA	ATAAAATCCA	GGTCATTGAG	2340
40	AAGACTAGCT	TCCCAGAAAA	TGTCCTCAAC	AATCTGGAGA	TGTTGGTTTT	ACATCACAAAT	2400
	CGCTTTCTTT	GCAACTGTGA	TGCTGTGTGG	TTTGTCTGGT	GGGTTAACCA	TACAGATGTT	2460
	ACTATTCCAT	ACCTGGCCAC	TGATGTGACT	TGTGTAGGTC	CAGGAGCACA	CAAAGGTCAA	2520

- 119 -

	AGTGTCAATAT	CCCTTGATCT	GTATACGTGT	GAGTTAGATC	TCACAAACCT	GATTCTGTTC	2580
	TCAGTTTCCA	TATCATCAGT	CCTCTTCTT	ATGGTAGTTA	TGACAACAAG	TCACCTCTTT	2640
	TTCTGGGATA	TGTGGTACAT	TTATTATTTT	TGGAAAGCAA	AGATAAAGGG	GTATCAGCAT	2700
	CTGCAATCCA	TGGAGTCTTG	TTATGATGCT	TTTATTGTGT	ATGACACTAA	AAACTCAGCT	2760
5	GTGACAGAAT	GGGTTTTGCA	GGAGCTGGTG	GCAAAATTGG	AAGATCCAAG	AGAAAAACAC	2820
	TTCAATTGT	GTCTAGAAGA	AAGAGACTGG	CTACCAGGAC	AGCCAGTTCT	AGAAAAACCTT	2880
	TCCCAGAGCA	TACAGCTCAG	CAAAAAGACA	GTGTTTGTGA	TGACACAGAA	ATATGCTAAG	2940
	ACTGAGAGTT	TTAAGATGGC	ATTTTATTTG	TCTCATCAGA	GGCTCCTGGA	TGAAAAAGTG	3000
	GATGTGATTA	TCTTGATATT	CTTGGAAAAG	CCTCTTCAGA	AGTCTAAGTT	TCTTCAGCTC	3060
10	AGGAAGAGAC	TCTGCAGGAG	CTCTGTCCTT	GAGTGGCCTG	CAAAATCCACA	GGCTCACCCA	3120
	TACTTCTGGC	AGTGCCTGAA	AAATGCCCTG	ACCACAGACA	ATCATGTGGC	TTATAGTCAA	3180
	ATGTTCAAGG	AAACAGTCTA	GCTCTCTGAA	GAATGTCACC	ACCTAGGACA	TGCCTTGAAT	3240
	CGA						3243

15 Table 10. Coding Region for Murine TLR7 (5' to 3'; SEQ ID NO:174)

	ATGGTGT	TTTT	CGATGTGGAC	ACGGAAGAGA	CAAATTTTGA	TCTTTTAA	TATGCTCTTA	60
	GTTTCTAGAG	TCTTTGGGT	TGGATGGTTT	CCTAAACTC	TACCTTGTGA	AGTTAAAGTA		120
	AATATCCCAG	AGGCCCATGT	GATCGTGGAC	TGCACAGACA	AGCATTTGAC	AGAAATCCCT		180
	GAGGGCATT	C	CACTAACAC	CACCAATCTT	ACCCTTACCA	TCAACCACAT	ACCAAGCATC	240
20	TCTCCAGATT	CCTTCCGTAG	GCTGAACCAT	CTGGAAGAAA	TCGATTAAAG	ATGCAATTGT		300
	GTACCTGTT	C	TACTGGGTC	CAAAGCCAAT	GTGTGTACCA	AGAGGCTGCA	GATTAGACCT	360
	GGAAGCTTT	A	GTGGACTCTC	TGACTTAAAA	GCCCTTTACC	TGGATGGAAA	CCAACCTCTG	420
	GAGATACCAC	AGGATCTGCC	ATCCAGCTTA	CATCTTCTGA	GCCTTGAGGC	TAACAACATC		480
	TTCTCCATCA	CGAAGGAGAA	TCTAACAGAA	CTGGTCAACA	TGAAACACT	CTACCTGGGT		540
25	CAAACTGTT	ATTATCGAAA	TCCTTGCAAT	GTTTCTTATT	CTATTGAAAA	AGATGCTTTC		600
	CTAGTTATGA	GAAATTTGAA	GGTTCTCTCA	CTAAAAGATA	ACAATGTCAC	AGCTGTCCCC		660
	ACCACTTTGC	CACCTAATTT	ACTAGAGCTC	TATCTTTATA	ACAATATCAT	TAAGAAAATC		720
	CAAGAAAATG	ATTTTAAATA	CCTCAATGAG	TTGCAAGTTC	TTGACCTAAG	TGGAAATTGC		780
	CCTCGATGTT	ATAATGTCCC	ATATCCGTGT	ACACCGTGTG	AAAATAATTC	CCCCTTACAG		840
30	ATCCATGACA	ATGCTTTCAA	TTCATTGACA	GAATTAAAAG	TTTTACGTTT	ACACAGTAAT		900
	TCTCTTCAGC	ATGTGCCCCC	AACATGGTTT	AAAAACATGA	GAAACCTCCA	GGAAGTAGAC		960
	CTCTCCAAA	ACTACTTGGC	CAGAGAAATT	GAGGAGGCCA	AATTTTGTGA	TTTCTTCCC		1020
	AACCTTGTTG	AGTTGGATTT	TTCTTTCAT	TATGAGCTGC	AGGTCTACCA	TGCATCTATA		1080
	ACTTTACCAC	ATTCACTCTC	TTCATTGGAA	AACCTGAAAA	TTCTGCGTGT	CAAGGGGTAT		1140
35	GTCTTTAAAG	AGCTGAAAAA	CTCCAGTCTT	TCTGTATTGC	ACAAGCTTCC	CAGGCTGGAA		1200
	GTTCTTGACC	TTGGCACTAA	CTTCATAAAA	ATTGCTGACC	TCAACATATT	CAAAACATTTT		1260
	GAAAACCTCA	AACTCATAGA	CCTTTCAGTG	AATAAGATAT	CTCCTTCAGA	AGAGTCAAGA		1320
	GAAGTTGGCT	TTTGTCCCTAA	TGCTCAAAC	TCTGTAGACC	GTCATGGGCC	CCAGGTCCTT		1380
	GAGGCCTTAC	ACTATTTCCG	ATACGATGAA	TATGCACGGA	GCTGCAGGTT	CAAAAACAAA		1440
40	GAGCCACCTT	CTTCTTGCC	TTTGAATGCA	GACTGCCACA	TATATGGGCA	GACCTTAGAC		1500
	TTAAGTAGAA	ATAACATATT	TTTTATTAAA	CCTTCTGATT	TTCAGCATCT	TTCATTCTCTC		1560

5	AAATGCCTCA	ACTTATCAGG	AAACACCATT	GGCCAAACTC	TTAATGGCAG	TGAACCTCTGG	1620	
	CCGTTGAGAG	AGTTGCGGTA	CTTAGACTTC	TCCAACAACC	GGCTTGATTT	ACTCTACTCA	1680	
	ACAGCCTTTG	AAGAGCTCCA	GAGTCTTGAA	GTTCTGGATC	TAAGTAGTAA	CAGCCACTAT	1740	
	TTTCAAGCAG	AAGGAATTAC	TCACATGCTA	AACTTTACCA	AGAAATTACG	GCTTCTGGAC	1800	
	AAACTCATGA	TGAATGATAA	TGACATCTCT	ACTTCGGCCA	GCAGGACCAT	GGAAAGTGAC	1860	
	TCTCTTCGAA	TTCTGGAGTT	CAGAGGCAAC	CATTTAGATG	TTCTATGGAG	AGCCGGTGAT	1920	
	AACAGATACT	TGGACTTCTT	CAAGAATTTG	TTCAATTTAG	AGGTATTAGA	TATCTCCAGA	1980	
	AATTCCCTGA	ATTCCTTGCC	TCCTGAGGTT	TTTGAGGGTA	TGCCGCCAAA	TCTAAAGAAT	2040	
10	CTCTCCTTGG	CCAAAAATGG	GCTCAAATCT	TTCTTTTGGG	ACAGACTCCA	GTTACTGAAG	2100	
	CATTTGGA	TTTGGACCT	CAGCCATAAC	CAGCTGACAA	AAGTACCTGA	GAGATTGGCC	2160	
	AACTGTTCCA	AAAGTCTCAC	AACACTGATT	CTTAAGCATA	ATCAAATCAG	GCAATTGACA	2220	
	AAATATTTTC	TAGAAGATGC	TTTGCAATTG	CGCTATCTAG	ACATCAGTTC	AAATAAAATC	2280	
	CAGGTCATT	AGAAGACTAG	CTTCCCAGAA	AATGTCCTCA	ACAATCTGGA	GATGTTGGTT	2340	
	TTACATCACA	ATCGCTTTCT	TTGCAACTGT	GATGCTGTGT	GGTTTGTCIG	GTGGGTAAAC	2400	
	15	CATACAGATG	TTACTATTCC	ATACCTGGCC	ACTGATGTGA	CTTGTGTAGG	TCCAGGAGCA	2460
		CACAAAGGTC	AAAGTGTCAT	ATCCCTTGAT	CTGTATACGT	GTGAGTTAGA	TCTCACAAAC	2520
CTGATTCTGT		TCTCAGTTTC	CATATCATCA	GTCTCTTTTC	TTATGGTAGT	TATGACAACA	2580	
AGTCACCTCT		TTTTCTGGGA	TATGTGGTAC	ATTTATTATT	TTTGAAAAGC	AAAGATAAAG	2640	
GGGTATCAGC		ATCTGCAATC	CATGGAGTCT	TGTTATGATG	CTTTTATTGT	GTATGACACT	2700	
20		AAAAACTCAG	CTGTGACAGA	ATGGGTTTTG	CAGGAGCTGG	TGGCAAAATT	GGAAGATCCA	2760
		AGAGAAAAAC	ACTTCAATTT	GTGTCTAGAA	GAAAGAGACT	GGCTACCAGG	ACAGCCAGTT	2820
		CTAGAAAACC	TTTCCCAGAG	CATACAGCTC	AGCAAAAAGA	CAGTGTTTGT	GATGACACAG	2880
	AAATATGCTA	AGACTGAGAG	TTTAAAGATG	GCATTTTATT	TGTCTCATCA	GAGGCTCCTG	2940	
	GATGAAAAAG	TGGATGTGAT	TATCTTGATA	TTCTTGAAAA	AGCCTCTTCA	GAAGTCTAAG	3000	
	25	TTTCTTCAGC	TCAGGAAGAG	ACTCTGCAGG	AGCTCTGTCC	TTGAGTGGCC	TGCAAATCCA	3060
		CAGGCTCACC	CATACTTCTG	GCAGTGCCTG	AAAAATGCCC	TGACCACAGA	CAATCATGTG	3120
		GCTTATAGTC	AAATGTTCAA	GGAAACAGTC				3180

30	 :	60
	hTLR7.pep	MVFPMTLKRQILILFNIILISKLLGARWFPKTLPCDVTLDVPKNHVVDCTDKHLTEIP	60
	mTLR7.pep	MVFSMWTRKRQILIFLNMLLVSRVFGFRWFPKTLPCSEVKVNIPEAHVIVDCTDKHLTEIP	60
	 :	120
35	hTLR7.pep	GGIPTNTTNLTLTINHIPDISPASFHRLDHLVEIDFRCNCVPIPLGSKNNMCIXRLQIKP	120
	mTLR7.pep	EGIPTNTTNLTLTINHIPSISPDSEFRRLNHLEEIDLRNCVPLVGLSKANVCTKRLQIRP	120
	 :	180
	hTLR7.pep	RSFSGLTLYKSLYLDGNQLLEIPQGLPSSLQLLSLEANNIFSIRKENLTLANIEILYLGL	180
40	mTLR7.pep	GSFSGLSDLKALYLDGNQLLEIPQDLPSSLHLLSLEANNIFSITKENLTENVNIETLYLGL	180
	 :	240
	hTLR7.pep	QNCYYRNPCVYSYSIEKDAFLNLTCLKVLSLKDNNVTAVPTVLPSTLTLEYLYNNMIAKI	240

		QNCYYRNPNCVNSYSIEKDAFLVMRNKLVLSLKDNNTAVPTTLPNNLLEYLYNNIIKKI	240
		. : . : . : . : . : . : . : . :	300
	hTLR7.pep	QEDDFNNLNQLQIIDLDSGNCPRCYNAPFPCAPCKNNSPLQIPVNAFDALTELKVLRLHSN	300
5	mTLR7.pep	QENDFNNLNELQVLDLSGNCPRCYNVPYPCTPCENNSPLQIHDNAFNSLTELVRLHSN	300
		. : . : . : . : . : . : . : . :	360
	hTLR7.pep	SLQHVPPRWFKNINKLQELDLSONFLAKEIGDAKFLHFLPSLIQLDLSFNFELOQVYRASM	360
10	mTLR7.pep	SLQHVPPTWFKNMRNLQELDLSONYLAREIEEAKFLHFLPNLVELDFSFNYELQVYHASI	360
		. : . : . : . : . : . : . : . :	420
	hTLR7.pep	NLSQAFSSSLKSLKILRIRGYVFKELKSFNLSPLHNLQNLEVLDLGTNFIKIANLSMFKQF	420
	mTLR7.pep	TLPHSLSSLENLKIILRVKGYVFKELKNSSLSVLHKLPRLEVLDLGTNFIKIADLNIFKH	420
15		. : . : . : . : . : . : . : . :	480
	hTLR7.pep	KRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNK	480
	mTLR7.pep	ENLKLIDLSVNKISPSSEESREVGFPCNAQTSVDRHGQVLEALHYFRYDEYARSCRFKNK	480
		. : . : . : . : . : . : . : . :	540
20	hTLR7.pep	EA-SFMSVNESCYKYGTLDLSKNISIFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQ	539
	mTLR7.pep	EPFSFLPLNADCHIYGQTLDSRNNIFFIKPSDFQHLSFLKCLNLSGNTIGQTLNGSELW	540
		. : . : . : . : . : . : . : . :	600
	hTLR7.pep	PLAELRYLDIFSNNRDLHLSTAFEELHKLEVLDISSNSHYFOSEGITHMLNFTKNLKVLO	599
25	mTLR7.pep	PLRELRYLDIFSNNRDLLYSTAFEELQSLEVLDLSSNSHYFQAEGITHMLNFTKKLRLLD	600
		. : . : . : . : . : . : . : . :	660
	hTLR7.pep	KLMNDNDISSSTSRIMESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISK	659
30	mTLR7.pep	KLMNDNDISTASRTMESDSLRILEFRGNHLDVLWRAGDNRYLDFFKNLFNLEVLDISR	660
		. : . : . : . : . : . : . : . :	720
	hTLR7.pep	NSLSFLPSGVFDGMPPNKLNLAKNGLKSFWSKKLQCLKNLETLDLSHNQLTTVPERLS	719
	mTLR7.pep	NSLNSLPPEVFEGMPPNKLNLAKNGLKSFWDRLQLLKHLEILDLSHNQLTKVPERLA	720
35		. : . : . : . : . : . : . : . :	780
	hTLR7.pep	NCSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLL	779
	mTLR7.pep	NCSKSLTTLILKHNQIRQLTKYFLEDALQLRYLDISSNKIQVIQKTSFPENVLNLEMLV	780
		. : . : . : . : . : . : . : . :	840
40	hTLR7.pep	LHNRFLCTCDAVWFVWVWNHTEVTIPYLATDVTCVGPAGHKGQSVISLDLYTCELDLTN	839
	mTLR7.pep	LHNRFLCNCDVWFVWVWNHTDVTIPYLATDVTCVGPAGHKGQSVISLDLYTCELDLTN	840
		. : . : . : . : . : . : . : . :	900
	hTLR7.pep	LILFSLSISVSLFLMVMNTASHLYFNDVWYIYHFKAKIKGYQRLISPDCCYDAFIVYDT	899
45	mTLR7.pep	LILFVSISISVSLFLMVMNTSHLFFNDVWYIYFWKAKIKGYQHLSMESCYDAFIVYDT	900

- 122 -

[illegible]

In Table 11 the sequences are assigned as follows: mTLR7.pep, SEQ ID NO:175; hTLR7.pep, SEQ ID NO:170; bb210788.pcp, SEQ ID NO:176; aa276879.pep, SEQ ID NO:177; aa266744.pep, SEQ ID NO:178; and bb116163.pep, SEQ ID NO:179.

25 **Example 18. Method of cloning human TLR8**

Two accession numbers in the GenBank database, AF245703 and AF246971, describe the DNA sequence for human TLR8. To create an expression vector for human TLR8, human TLR8 cDNA was amplified from a cDNA made from human peripheral mononuclear blood cells (PBMC) using the primers 5'-CTGCGCTGCTGCAAGTTACGGAATG-3' (SEQ ID NO:180) and 5'-GCGCGAAATCATGACTTAACGTCAG-3 (SEQ ID NO:181). The fragment was cloned into pGEM-T Easy vector (Promega), cut with the restriction enzyme NotI and ligated into a NotI-digested pCDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence for hTLR8 is SEQ ID NO:182, is presented in Table 12. The open reading frame starts at base 83, ends at base 3208, and codes for a protein of 1041 amino acids. SEQ ID NO:183 (Table 13), corresponding to bases 83-3205 of SEQ ID NO:182 (Table 12), is the coding region for the polypeptide of SEQ ID NO:184 (Table 14).

The protein sequence of the cloned hTLR8 cDNA matches the sequence described

under the GenBank accession number AF245703. The sequence deposited under GenBank accession number AF246971 contains an insertion at the N-terminus of 15 amino acids (MKESLQNSSCSLGKETKK; SEQ ID NO:185) and three single amino acid changes at positions 217 (P to S), 266 (L to P) and 867 (V to I).

5

Table 12. cDNA Sequence for Human TLR8 (5' to 3'; SEQ ID NO:182)

	gctccccgcc	gccatggcgg	cgcggggaat	tgcattctgc	gctgctgcaa	gttacggaat	60
	gaaaaattag	aacaacagaa	acatggaaaa	catgttcctt	cagtcgtcaa	tgctgacctg	120
	cattttcctg	ctaatactctg	gttcctgtga	gttatgcgcc	gaagaaaatt	tttctagaag	180
10	ctatccttgt	gatgagaaaa	agcaaatga	ctcagttatt	gcagagtga	gcaatcgctg	240
	actacaggaa	gttccccaaa	cgggtgggcaa	atatgtgaca	gaactagacc	tgtctgataa	300
	tttcatcaca	cacataacga	atgaatcatt	tcaagggtctg	caaaatctca	ctaaaataaa	360
	tctaaaccac	aaccccaatg	tacagcacca	gaacggaaat	cccggtatac	aatcaaatgg	420
	cttgaatata	acagacgggg	cattcctcaa	cctaaaaaac	ctaaggaggt	tactgcttga	480
15	agacaaccag	ttaccccaaa	taccctctgg	tttgccagag	tctttgacag	aacttagtct	540
	aattcaaac	aatatataca	acataactaa	agagggcatt	tcaagactta	taaacttgaa	600
	aaatctctat	ttggcctgga	actgctatct	taacaaagtt	tgcgagaaaa	ctaacaataga	660
	agatggagta	tttgaaacgc	tgacaaattt	ggagttgcta	tcactatctt	tcaattctct	720
	ttcacacgtg	ccacccaaac	tgccaagctc	cctacgcaaa	ctttttctga	gcaacaccca	780
20	gatcaaatat	attagtgaag	aagatttcaa	gggattgata	aatttaacat	tactagattt	840
	aagcgggaac	tgtccgaggt	gcttcaatgc	cccatctcca	tgctgcctt	gtgatgggtg	900
	tgcttcaatt	aatatagatc	gttttgcttt	tcaaaacttg	acccaacttc	gatacctaaa	960
	cctctctagc	acttccctca	ggaagattaa	tgctgcctgg	tttaaaaata	tgccctcatct	1020
	gaagggtgctg	gatcttgaat	tcaactatct	agtgggagaa	atagcctctg	gggcattttt	1080
25	aacgatgctg	ccccgcttag	aaataacttg	cttgctcttt	aactatataa	aggggagtta	1140
	tccacagcat	attaatatct	ccagaaactt	ctctaaactt	ttgtctctac	gggcattgca	1200
	tttaagaggt	tatgtgttcc	aggaactcag	agaagatgat	ttccagcccc	tgatgcagct	1260
	tccaaactta	tcgactatca	acttgggtat	taattttatt	aagcaaatcg	atttcaaaact	1320
	tttccaaaat	ttctccaatc	tggaaattat	ttacttgtca	gaaaacagaa	tatcaccgtt	1380
30	ggtaaaaagat	acccggcaga	gttatgcaaa	tagttcctct	tttcaacgtc	atatccggaa	1440
	acgacgtca	acagattttg	agtttgaccc	acattcgaa	ttttatcatt	tcaccgctcc	1500
	tttaataaag	ccacaatgtg	ctgcttatgg	aaaagcctta	gatttaagcc	tcaacagtat	1560
	tttcttcatt	gggcccacc	aatttgaaaa	tcttctctgac	attgcctgtt	taaatctgtc	1620
	tgcaaatagc	aatgctcaag	tgttaagtgg	aactgaattt	tcagccattc	ctcatgtcaa	1680
35	atatttggat	ttgacaaaca	atagactaga	ctttgataat	gctagtgtc	ttactgaatt	1740
	gtccgacttg	gaagttctag	atctcagcta	taattcacac	tatttcagaa	tagcaggcgt	1800
	aacacatcat	ctagaattta	ttcaaaattt	cacaaatcta	aaagttttta	acttgagcca	1860
	caacaacatt	tatacttta	cagataagta	taacctggaa	agcaagtc	tggtagaatt	1920
	agttttcagt	ggcaatcgcc	ttgacatttt	gtggaatgat	gatgacaaca	ggtatatctc	1980
40	cattttcaaa	ggtctcaaga	atctgacacg	tctggattta	tcccttaata	ggctgaagca	2040

- 124 -

	catcccaaat	gaagcattcc	ttaatttgcc	agcgagtctc	actgaactac	atataaatga	2100
	taatatgtta	aagtttttta	actggacatt	actccagcag	tttcctcgtc	tcgagttgct	2160
	tgacttacgt	ggaaacaaac	tactcttttt	aactgatagc	ctatctgact	ttacatcttc	2220
	ccttcggaca	ctgctgctga	gtcataacag	gatttccac	ctaccctctg	gctttctttc	2280
5	tgaagtcagt	agtctgaagc	acctcgattt	aagttccaat	ctgctaaaaa	caatcaacaa	2340
	atccgcactt	gaaactaaga	ccaccaccaa	attatctatg	ttggaactac	acggaaaccc	2400
	ctttgaatgc	acctgtgaca	ttggagattt	ccgaagatgg	atggatgaac	atctgaatgt	2460
	caaaattccc	agactggtag	atgtcatttg	tgccagtcct	ggggatcaaa	gagggaagag	2520
	tattgtgagt	ctggagctaa	caacttggtg	ttcagatgtc	actgcagtga	tattattttt	2580
10	cttcacgttc	tttatcacca	ccatgggtat	gttggtgcc	ctggctcacc	atttgtttta	2640
	ctgggatgtt	tggtttatat	ataatgtgtg	tttagctaag	gtaaaaggct	acaggtctct	2700
	ttccacatcc	caaactttct	atgatgctta	catctcttat	gacaccaaag	acgcctctgt	2760
	tactgactgg	gtgataaatg	agctgcgcta	ccacctgaa	gagagccgag	acaaaaacgt	2820
	tctcctttgt	ctagaggaga	gggattggga	ccgggatttg	gccatcatcg	acaacctcat	2880
15	gcagagcatc	aaccaaagca	agaaaacagt	atttgtttta	acaaaaaat	atgcaaaaag	2940
	ctggaacttt	aaaacagctt	tttacttggt	tttgagagg	ctaattggatg	agaacatgga	3000
	tgtgattata	tttatcctgc	tggagccagt	gttacagcat	tctcagtatt	tgaggctacg	3060
	gcagcggatc	tgtaagagct	ccatcctcca	gtggcctgac	aaccogaagg	cagaaggctt	3120
	gttttgga	actctgagaa	atgtggtctt	gactgaaaat	gattcacggg	ataacaatat	3180
20	gtatgtcgat	tccattaagc	aatactaact	gacgttaagt	catgatttcg	cgcaatcaact	3240
	agtgaattcg	cggccgcctg	caggctgacc	atatgggaga	gctcccaacg	cgttggaatgc	3300
	atagcttgag						3310

Table 13. Coding Region for Human TLR8 (5' to 3'; SEQ ID NO:183)

25	atggaaaaca	tgttccttca	gtcgtaaatg	ctgacctgca	ttttcctgct	aatatctggt	60
	tcctgtgagt	tatgcgccga	agaaaatttt	tctagaagct	atccttgtga	tgagaaaaag	120
	caaaatgact	cagttattgc	agagtgcagc	aatcgctgac	tacaggaagt	tcccaaacg	180
	gtgggcaaat	atgtgacaga	actagacctg	tctgataatt	tcatcacaca	cataacgaat	240
	gaatcatttc	aagggtctga	aaatctcact	aaaataaatc	taaaccacaa	ccccaatgta	300
30	cagcaccaga	acggaaatcc	cggatataca	tcaaattggct	tgaatatcac	agacggggca	360
	ttcctcaacc	taaaaaacct	aagggaagta	ctgcttgaag	acaaccagtt	accccaata	420
	ccctctgggt	tgccagagtc	tttgacagaa	cttagtctaa	ttcaaaacaa	tatatacaac	480
	ataactaaag	agggcatttc	aagacttata	aacttgaaaa	atctctatct	ggcctggaac	540
	tgctatttta	acaaagtctg	cgagaaaact	aacatagaag	atggagtatt	tgaaacgctg	600
35	acaaatttgg	agttgctatc	actatctttc	aattctcttt	cacacgtgcc	acccaaactg	660
	ccaagctccc	tacgcaaaact	ttttctgagc	aacaccaga	tcaaatacat	tagtgaagaa	720
	gatttcaagg	gattgataaa	tttaacatta	ctagatttaa	gcgggaactg	tccgaggtgc	780
	ttcaatgccc	catttccatg	cgtgccttgt	gatgggtgtg	cttcaattaa	tatagatcgt	840
	tttgcttttc	aaaacttgac	ccaacttcga	tacctaaacc	tctctagcac	ttccctcagg	900
40	aagattaatg	ctgcctgggt	taaaaatatg	cctcatctga	aggtgctgga	tcttgaaatc	960
	aactatttag	tgggagaaat	agcctctggg	gcatttttaa	cgatgctgcc	ccgcttagaa	1020

	atacttgaact	tgtcttttaa	ctatataaag	gggagttatc	cacagcatat	taatatattcc	1080
	agaaacttct	ctaaactttt	gtctctacgg	gcattgcatt	taagagggtta	tgtgtttccag	1140
	gaactcagag	aagatgattt	ccagcccctg	atgcagcttc	caaacttata	gactatcaac	1200
	ttgggtatta	attttattaa	gcaaatcgat	ttcaaacttt	tccaaaattt	ctccaatctg	1260
5	gaaattattt	acttgtcaga	aaacagaata	tcaccgttgg	taaaagatac	ccggcagagt	1320
	tatgcaaata	gttcctcttt	tcaacgtcat	atccggaaac	gacgctcaac	agattttgag	1380
	tttgaccac	attcgaactt	ttatcatttc	accogtccct	taataaagcc	acaatgtgct	1440
	gcttatggaa	aagccttaga	tttaagcctc	aacagtattt	tcttcattgg	gccaaaccaa	1500
	tttgaaaatc	ttctgacat	tgccctgtta	aatctgtctg	caaatagcaa	tgctcaagtg	1560
10	ttaagtggaa	ctgaattttc	agccattcct	catgtcaaat	atttggtatt	gacaaacaat	1620
	agactagact	ttgataatgc	tagtgcctct	actgaattgt	ccgacttgga	agttctagat	1680
	ctcagctata	attcacacta	tttcagaata	gcaggcgtaa	cacatcatct	agaatttatt	1740
	caaaatttca	caaatctaaa	agttttaaac	ttgagccaca	acaacattta	tactttaaca	1800
	gataagtata	acctggaaag	caagtcctct	gtagaattag	ttttcagtgg	caatcgccct	1860
15	gacattttgt	ggaatgatga	tgacaacagg	tatatctcca	ttttcaaagg	tctcaagaat	1920
	ctgacacgtc	tggattttat	ccttaatagg	ctgaagcaca	tcccaaata	agcattcctt	1980
	aatttgccag	cgagtctcac	tgaactacat	ataaatgata	atatgttaaa	gttttttaac	2040
	tggacattac	tccagcagtt	tcctcgtctc	gagttgcttg	acttacgtgg	aaacaaacta	2100
	ctctttttta	ctgatagcct	atctgacttt	acatcttccc	ttcggacact	gctgctgagt	2160
20	cataacagga	tttcccacct	acctctgggc	ttcttttctg	aagtccagtag	tctgaagcac	2220
	ctcgatttaa	gttccaatct	gctaaaaaca	atcaacaaat	ccgcacttga	aactaagacc	2280
	accaccaa	tatctatgtt	ggaactacac	ggaaacccct	ttgaatgcac	ctgtgacatt	2340
	ggagatttcc	gaagatggat	ggatgaacat	ctgaatgtca	aaattcccag	actggtagat	2400
	gtcatttgtg	ccagtccttg	ggatcaaaga	gggaagagta	ttgtgagtct	ggagctaaca	2460
25	acttgtgttt	cagatgtcac	tgacgtgata	ttatttttct	tcacgttctt	tatcaccacc	2520
	atggttatgt	tggctgccc	ggctcaccat	ttgttttact	gggatgtttg	gtttatatat	2580
	aatgtgtgtt	tagctaagg	aaaaggctac	aggtctcttt	ccacatccca	aactttctat	2640
	gatgcttaca	tttcttatga	caccaaagac	gcctctgtta	ctgactgggt	gataaatgag	2700
	ctgcgctacc	accttgaaga	gagccgagac	aaaaacgttc	tcctttgtct	agaggagagg	2760
30	gattgggacc	cggtattggc	catcatcgac	aacctcatgc	agagcatcaa	ccaaagcaag	2820
	aaaaacagtat	ttgttttaac	caaaaaatat	gcaaaaagct	ggaactttta	aacagctttt	2880
	tacttggctt	tgacagagg	aatggatgag	aacatggatg	tgattatatt	tatcctgctg	2940
	gagccagtg	tacagcattc	tcagtatttg	aggctacggc	agcggatctg	taagagctcc	3000
	atcctccagt	ggcctgacaa	ccgaaggcca	gaaggcttgt	tttggcaaac	tctgagaaat	3060
35	gtggtcttga	ctgaaaatga	ttcacggtat	aacaatatgt	atgtcgattc	cattaagcaa	3120
	tac						3123

		.	:	.	:	.	:	.	:	.	:	.	:	.	:	60	
40	AF245703.pep															MENMFLOSSMLTICIFLLISGSCELCAEENFSRSYPDEKKQN	42
	hTLR8.pep															MENMFLOSSMLTICIFLLISGSCELCAEENFSRSYPDEKKQN	42
	AF246971.pep															MXESSLQNSSCSLQRETRKKENMFLOSSMLTICIFLLISGSCELCAEENFSRSYPDEKKQN	60

	AF245703.pep	DSVIAECSNRRLQEV	PQT	VGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQH	120					
	hTLR8.pep	DSVIAECSNRRLQEV	PQT	VGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQH	102					
5	AF246971.pep	DSVIAECSNRRLQEV	PQT	VGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQH	120					
		.	:	.	:	.	:	.	:	180
	AF245703.pep	QNGNPGIOSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTEL	SLIQNNIYNIT		162					
	hTLR8.pep	QNGNPGIOSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTEL	SLIQNNIYNIT		162					
10	AF246971.pep	QNGNPGIOSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTEL	SLIQNNIYNIT		180					
		.	:	.	:	.	:	.	:	240
	AF245703.pep	KEGISRLINLNKLYLAWNCYFNKVCBKTNI	EDGVFETLTNLELLSLSFNLSLHVPPKLP		222					
	hTLR8.pep	KEGISRLINLNKLYLAWNCYFNKVCBKTNI	EDGVFETLTNLELLSLSFNLSLHVPPKLP		222					
15	AF246971.pep	KEGISRLINLNKLYLAWNCYFNKVCBKTNI	EDGVFETLTNLELLSLSFNLSLHVSPKLP		240					
		.	:	.	:	.	:	.	:	300
	AF245703.pep	SLRKLFLSNTQIKYI	SEEDFKGLINLTLLDLSGNCPRCFNAPFCVPCDGGASINIDRFA		282					
	hTLR8.pep	SLRKLFLSNTQIKYI	SEEDFKGLINLTLLDLSGNCPRCFNAPFCVPCDGGASINIDRFA		282					
20	AF246971.pep	SLRKLFLSNTQIKYI	SEEDFKGLINLTLLDLSGNCPRCFNAPFCVPCDGGASINIDRFA		300					
		.	:	.	:	.	:	.	:	360
	AF245703.pep	FQNLTQLRYLNL	SSTSLRKINA	AWFKNMPHLKVL	DLEFN	YLVE	ETIASGAFLTMLPRLEIL		342	
	hTLR8.pep	FQNLTQLRYLNL	SSTSLRKINA	AWFKNMPHLKVL	DLEFN	YLVE	ETIASGAFLTMLPRLEIL		342	
25	AF246971.pep	FQNLTQLRYLNL	SSTSLRKINA	AWFKNMPHLKVL	DLEFN	YLVE	ETIASGAFLTMLPRLEIL		360	
		.	:	.	:	.	:	.	:	420
	AF245703.pep	DLSFN	YIKGSYPQHINISRNFSKL	LSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLG		402				
	hTLR8.pep	DLSFN	YIKGSYPQHINISRNFSKL	LSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLG		402				
30	AF246971.pep	DLSFN	YIKGSYPQHINISRNFSKL	LSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLG		420				
		.	:	.	:	.	:	.	:	480
	AF245703.pep	INFIKQIDFKLFQNF	SNLEIIYLS	ENRISPLVKDTRQSYANSSSFQRIKRRSTDFEFD		462				
	hTLR8.pep	INFIKQIDFKLFQNF	SNLEIIYLS	ENRISPLVKDTRQSYANSSSFQRIKRRSTDFEFD		462				
35	AF246971.pep	INFIKQIDFKLFQNF	SNLEIIYLS	ENRISPLVKDTRQSYANSSSFQRIKRRSTDFEFD		480				
		.	:	.	:	.	:	.	:	540
	AF245703.pep	PHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLS			522					
	hTLR8.pep	PHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLS			522					
40	AF246971.pep	PHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLS			540					
		.	:	.	:	.	:	.	:	600
	AF245703.pep	GTEFSAIPHVKYLDLTNNRLDFDNASALTE	SDLEVLDLSYN	SHYFRIAGVTHHLEFIQ		582				
	hTLR8.pep	GTEFSAIPHVKYLDLTNNRLDFDNASALTE	SDLEVLDLSYN	SHYFRIAGVTHHLEFIQ		582				
45	AF246971.pep	GTEFSAIPHVKYLDLTNNRLDFDNASALTE	SDLEVLDLSYN	SHYFRIAGVTHHLEFIQ		600				

[illegible]

Example 19. Method of cloning the murine TLR8

- 128 -

Alignment of human TLR8 protein sequence with mouse EST database using tfasta yielded 1 hit with mouse EST sequence bf135656. Two primers were designed that bind to bf135656 sequence for use in a RACE-PCR to amplify 5' and 3' ends of the murine TLR8 cDNA. The library used for the RACE PCR was a mouse spleen marathon-ready cDNA commercially available from Clontech. A 5' fragment with a length of 2900 bp and a 3' fragment with a length of 2900 bp obtained by this method were cloned into Promega pGEM-T Easy vector. After sequencing of the 5' end and 3' end of each fragment, partial sequences of mTLR8 were obtained and allowed the design of primers for amplification of the complete murine TLR8 cDNA.

Three independent PCR reactions were set up using a spleen murine cDNA from Clontech as a template with the primers 5'-GAGAGAAACAAACGTTTTACCTTC-3' (SEQ ID NO:188) and 5'-GATGGCAGAGTCGTGACTTCCC-3' (SEQ ID NO:189). The resulting amplification products were cloned into pGEM-T Easy vector, fully sequenced, translated into protein, and aligned to the human TLR8 protein sequence (GenBank accession number AF245703). The cDNA sequence for mTLR8 is SEQ ID NO:190, presented in Table 15. The open reading frame of mTLR8 starts at base 59, ends at base 3157, and codes for a protein of 1032 amino acids. SEQ ID NO:191 (Table 16), corresponding to bases 59-3154 of SEQ ID NO:190 (Table 15), is the coding region for the polypeptide of SEQ ID NO:192 (Table 17). To create an expression vector for murine TLR8, cDNA pGEM-T Easy vector with the mTLR8 insert was cut with NotI, the fragment isolated, and ligated into a NotI-digested pCDNA3.1 expression vector (Invitrogen).

Table 15. cDNA Sequence for Murine TLR8 (5' to 3'; SEQ ID NO:190)

	attcagagtt ggatgtaag agagaaacaa acgttttacc ttcctttgtc tatagaacat	60
25	ggaaaacatg cccctcagt catggattct gacgtgcttt tgtctgctgt cctctggaac	120
	cagtgccatc ttccataaag cgaactattc cagaagctat ccttgtagac agataaggca	180
	caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagttc cccaaactat	240
	aggcaagtat gtgacaaaca tagacttgtc agacaatgcc attacacata taacgaaaga	300
	gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaaacaa	360
30	gcacccaaat gaaaataaaa atggtatgaa tattacagaa ggggcacttc tcagcctaag	420
	aatctaaca gttttactgc tggaagacaa ccagttatat actatactg ctgggttgcc	480
	tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa	540
	cacttttggg cttaggaact tggaagact ctatttgggc tggaactgct attttaaatg	600
	taatcaaacc ttttaaggtag aagatggggc atttaaaaat cttatacact tgaaggtag	660

- 129 -

	ctcattatct	ttcaataacc	ttttctatgt	gcccccaaaa	ctaccaagtt	ctctaaggaa	720
	actttttctg	agtaatgcca	aatcatgaa	catcactcag	gaagacttca	aaggactgga	780
	aaatttaaca	ttactagatc	tgagtggaaa	ctgtccaagg	tgttacaatg	ctccatttcc	840
	ttgcacacct	tgcaaggaaa	actcatccat	ccacatacat	cctctggctt	ttcaaagtct	900
5	cacccaactt	ctctatctaa	acctttccag	cacttccctc	aggacgattc	cttctacctg	960
	gtttgaaaat	ctgtcaaata	tgaaggaaat	ccatcttgaa	ttcaactatt	tagttcaaga	1020
	aattgcctcg	ggggcatttt	taacaaaact	accagtttta	caaatecttg	atttgtcctt	1080
	caactttcaa	tataaggaaat	atttacaatt	tattaatatt	tcctcaaatt	tctctaagct	1140
	tcgttctctc	aagaagttgc	acttaagagg	ctatgtgttc	cgagaactta	aaaagaagca	1200
10	tttcgagcat	ctccagagtc	ttccaaactt	ggcaaccatc	aacttgggca	ttaactttat	1260
	tgagaaaatt	gatttcaaag	ctttccagaa	tttttccaaa	ctcgacgtta	tctattttatc	1320
	aggaaatcgc	atagcatctg	tattagatgg	tacagattat	tcctcttggc	gaaatcgtct	1380
	tcggaaaacct	ctctcaacag	acgatgatga	gtttgatcca	cacgtgaatt	tttaccatag	1440
	caccaaacct	ttaataaagc	cacagtgtac	tgcttatggc	aaggccttgg	atttaagttt	1500
15	gaacaatatt	ttcattattg	ggaaaagcca	atltgaaggt	tttcaggata	tcgcctgctt	1560
	aatctgtcc	ttcaatgcca	atactcaagt	gtttaatggc	acagaattct	cctccatgcc	1620
	ccacattaaa	tatttggtat	taaccaacaa	cagactagac	tttgatgata	acaatgcttt	1680
	cagtgtctct	cacgatctag	aagtgtctgga	cctgagccac	aatgcacact	atttcagtat	1740
	agcaggggta	acgcaccgtc	taggatttat	ccagaactta	ataaacctca	gggtgttaaa	1800
20	cctgagccac	aatggcattt	acaccctcac	agaggaaagt	gagctgaaaa	gcatctcact	1860
	gaaagaattg	gttttcagtg	gaaatcgtct	tgaccatttg	tggaatgcaa	atgatggcaa	1920
	atactgggcc	atlttttaaaa	gtctccagaa	tttgatacgc	ctggacttat	catacaataa	1980
	ccttcaacaa	atcccaaatg	gagcatttct	caatttgcct	cagagcctcc	aagagttact	2040
	tatcagtggg	aacaaattac	gtttctttta	ttggacatta	ctccagtatt	ttcctcacct	2100
25	tcacttgctg	gattttatga	gaaatgagct	gtattttcta	cccaattgcc	tatctaagtt	2160
	tgacatttcc	ctggagacac	tgctactgag	ccataatcat	ttctctcacc	tacctcttgg	2220
	cttctctctc	gaagccagga	atctggtgca	cctggatcta	agtttcaaca	caataaagat	2280
	gatcaataaa	tcctccctgc	aaaccaagat	gaaaacgaac	ttgtctattc	tggagctaca	2340
	tgggaactat	tttgactgca	cgtgtgacat	aagtgtattt	cgaagctggc	tagatgaaaa	2400
30	tctgaatata	acaattccta	aattggtaaa	tggtatatgt	tccaatcctg	gggatcaaaa	2460
	atcaaagagt	atcatgagcc	tagatctcac	gacttgtgta	tcggatacca	ctgcagctgt	2520
	cctgtttttc	ctcacattcc	ttaccacctc	catggttatg	ttggctgctc	tggttcacca	2580
	cctgttttac	tgggatgttt	ggtttatcta	tcacatgtgc	tctgctaagt	taaaaggcta	2640
	caggacttca	tcacatccc	aaactttcta	tgatgcttat	atlttcttatg	acaccaaaga	2700
35	tgcatctgtt	actgactggg	taatcaatga	actgcgctac	caccttgaag	agagtgaaga	2760
	caaaaagtgtc	ctcctttgtt	tagaggagag	ggattgggat	ccaggattac	ccatcattga	2820
	taacctcatg	cagagcataa	accagagcaa	gaaaacaatc	tttgttttta	ccaagaaata	2880
	tgccaagagc	tggaaactta	aaacagcttt	ctacttggcc	ttgcagaggc	taatggatga	2940
	gaacatggat	gtgattattt	tcactctcct	ggaaccagtg	ttacagtact	cacagtacct	3000
40	gaggcttcgg	cagaggatct	gtaagagctc	catcctccag	tggccaaca	atcccaaagc	3060
	agaaaacttg	ttttggcaaa	gtctgaaaaa	tgtggtcttg	actgaaaatg	attcacggta	3120
	tgacgatttg	tacattgatt	ccattaggca	atactagtga	tgggaagtca	cgactctgcc	3180

- 130 -

atcataaaaa cacacagctt ctccttataa tgaaccgaat

3220

Table 16. Coding Region for Murine TLR8 (5' to 3'; SEQ ID NO:191)

	atggaaaaaca	tgccccctca	gtcatggatt	ctgacgtgct	tttgtctgct	gtcctctgga	60
5	accagtgcc	tcttcataa	agcgaactat	tccagaagct	atccttgtga	cgagataagg	120
	cacaactccc	ttgtgattgc	agaatgcaac	catcgtcaac	tgcatgaagt	tccccaaact	180
	ataggcaagt	atgtgacaaa	catagacttg	tcagacaatg	ccattacaca	tataacgaaa	240
	gagtcctttc	aaaagctgca	aaacctcact	aaaatcgatc	tgaaccacaa	tgccaaaaca	300
	cagcacccaa	atgaaaataa	aatgggtatg	aatattacag	aaggggcaact	tctcagccta	360
10	agaaatctaa	cagttttact	gctggaagac	aaccagttat	atactatacc	tgctgggttg	420
	cctgagtctt	tgaagaact	tagcctaatt	caaaacaata	tatttcaggt	aactaaaaac	480
	aacacttttg	ggcttaggaa	cttggaaga	ctctatttgg	gctggaactg	ctattttaaa	540
	tgtaatcaaa	cctttaaggt	agaagatggg	gcatttaaaa	atcttataca	cttgaaggta	600
	ctctcattat	ctttcaataa	ccttttctat	gtgcccccca	aactaccaag	ttctctaagg	660
15	aaactttttc	tgagtaatgc	caaaatcatg	aacatcactc	aggaagactt	caaaggactg	720
	gaaaatttaa	cattactaga	tctgagtggg	aactgtccaa	ggtgttacia	tgctccattt	780
	ccttgcacac	cttgcaagga	aaactcatcc	atccacatac	atcctctggc	ttttcaaagt	840
	ctcacccaac	ttctctatct	aaacctttcc	agcacttccc	tcaggacgat	tccttctacc	900
	tggtttgaaa	atctgtcaaa	tctgaaggaa	ctccatcttg	aattcaacta	tttagttcaa	960
20	gaaattgcct	cgggggcatt	tttaacaaaa	ctaccagtt	tacaaatcct	tgattttgtc	1020
	ttcaactttc	aatataagga	atattttacia	tttattaata	tttctctaaa	tttctctaag	1080
	cttcgttctc	tcaagaagtt	gcacttaaga	ggctatgtgt	tccgagaact	taaaaagaag	1140
	catttcgagc	atctccagag	tcttccaaac	ttggcaacca	tcaacttggg	cattaacttt	1200
	attgagaaaa	ttgattttcaa	agctttccag	aattttttcca	aactcgacgt	tatctattta	1260
25	tcaggaaatc	gcatagcata	tgtattagat	ggtagagatt	attcctcttg	gcgaaatcgt	1320
	cttcggaaac	ctctctcaac	agacgatgat	gagtttgatc	cacacgtgaa	ttttttaccat	1380
	agcaccaaac	ctttaataaa	gccacagtgt	actgcttatg	gcaaggcctt	ggattttaagt	1440
	ttgaacaata	ttttcattat	tgggaaaagc	caatttgaag	gttttcagga	tatcgccctgc	1500
	ttaaatctgt	ccttcaatgc	caatactcaa	gtgtttaatg	gcacagaatt	ctcctccatg	1560
30	ccccacatta	aatatttggg	tttaaccaac	aacagactag	actttgatga	taacaatgct	1620
	ttcagtgatc	ttcacgatct	agaagtgtctg	gacctgagcc	acaatgcaca	ctattttcagt	1680
	atagcagggg	taacgcaccg	tctaggattt	atccagaact	taataaacct	caggggtgta	1740
	aacctgagcc	acaatggcat	ttacaccttc	acagaggaaa	gtgagctgaa	aagcatctca	1800
	ctgaaagaat	tggttttcag	tggaaatcgt	cttgaccatt	tgtggaatgc	aatgatggc	1860
35	aaatactggg	ccatttttaa	aagtctccag	aatttgatac	gcctggactt	atcatacaat	1920
	aaccttcaac	aaatcccaaa	tggagcattc	ctcaatttgc	ctcagagcct	ccaagagtta	1980
	cttatcagtg	gtaacaaatt	acgtttcttt	aattggacat	tactccagta	ttttctctac	2040
	cttcacttgc	tggattttatc	gagaaatgag	ctgtattttc	tacccaattg	cctatctaag	2100
	tttgacatt	ccctggagac	actgctactg	agccataatc	atttctctca	cctacctctc	2160
40	ggcttctctc	ccgaagccag	gaatctgggtg	cacctggatc	taagtttcaa	cacaataaag	2220
	atgatcaata	aatcctccct	gcaaaccaag	atgaaaacga	acttgtctat	tctggagcta	2280

5	catgggaact	atcttgactg	cacgtgtgac	ataagtgatt	ttcgaagctg	gctagatgaa	2340
	aatctgaata	tcacaattcc	taaattggta	aatgttatat	gttccaatcc	tggggatcaa	2400
	aaatcaaaga	gtatcatgag	cctagatctc	acgacttggt	tatcggatac	cactgcagct	2460
	gtcctgtttt	tcctcacatt	ccttaccacc	tcctatggta	tggttgctgc	tctggttcac	2520
	cacctgtttt	actgggatgt	ttggtttatc	tatcacatgt	gctctgctaa	gttaaaaggc	2580
10	tacaggactt	catccacatc	ccaaactttc	tatgatgctt	atatttctta	tgacaccaaa	2640
	gatgcatctg	ttactgactg	ggtaatcaat	gaactgcgct	accaccttga	agagagtga	2700
	gacaaaagtg	tcctcctttg	tttagaggag	agggattggg	atccaggatt	acccatcatt	2760
	gataacctca	tgcagagcat	aaaccagagc	aagaaaacaa	tctttgtttt	aaccaagaaa	2820
	tatgccaaaga	gctggaactt	taaaacagct	ttctacttgg	ccttgacagag	gctaattggat	2880
	gagaacatgg	atgtgattat	tttcatcctc	ctggaaccag	tggtacagta	ctcacagtac	2940
	ctgaggcttc	ggcagaggat	ctgtaagagc	tcctatcctc	agtggcccaa	caatcccaaa	3000
	gcagaaaact	tgttttggca	aagtctgaaa	aatgtggctc	tgactgaaaa	tgattcacgg	3060
	tatgacgatt	tgtacattga	ttccattagg	caatac			3096

Table 17. Amino Acid Sequences of Murine TLR8 and Human TLR8

	mTLR8.pep	MENMPPQSWILTCFCLLSSGTS A I F H K A N Y S R S Y P C D E I R H N S L V I A E C N H R Q L H E V P Q T	60
	hTLR8.pep	MENMFLQSSMLT C I F L L I S G S C E L C A E E N F S R S Y P C D E K K Q N D S V I A E C S N R R L Q E V P Q T	60
20		:	120
	mTLR8.pep	I G K Y V T N I D L S D N A I T H I T K E S F Q X L Q N L T K I D L N H N A K Q Q H - - - P N E N K N G M N I T E G A	116
	hTLR8.pep	V G K Y V T E L D L S D N F I T H I T N E S F Q G L Q N L T K I N L N H N P N V Q H Q N G N P G I Q S N G L N I T D G A	120
25		:	180
	mTLR8.pep	L L S L R N L T V L L L E D N Q L Y T I P A G L P E S L K E L S L I Q M N I F Q V T K N N T F G L R N L E R L Y L G W N	176
	hTLR8.pep	F L N L K N L R E L L L E D N Q L P Q I P S G L P E S L T E L S L I Q M N I Y N I T K E G I S R L I N L K N L Y L A W N	180
		:	240
30	mTLR8.pep	C Y F K - - C N Q T F K V E D G A F K N L I H L K V L S L S F N N L F Y V P P K L P S S L R K L F L S N A K I M N I T Q	234
	hTLR8.pep	C Y F N K V C E K T - N I E D G V F E T L T N L E L L S L S F N S L S H V P P K L P S S L R K L F L S N T Q I K Y I S E	239
		:	300
	mTLR8.pep	E D F K G L E N L T L L D L S G N C P R C Y N A P F P C T P C K E N S S I H I H P L A F Q S L T Q L L Y L N L S S T S L	294
35	hTLR8.pep	E D F K G L I N L T L L D L S G N C P R C F N A P F P C V P C D G G A S I N I D R F A F Q N L T Q L R Y L N L S S T S L	299
		:	360
	mTLR8.pep	R T I P S T W F E N L S N L K E L H L E F N Y L V Q E I A S G A F L T K L P S L Q I L D L S F N F Q Y K E Y L Q F I N I	354
	hTLR8.pep	R K I N A A W F K N M P H L K V L D L E F N Y L V G E I A S G A F L T M L P R E I L D L S F N Y I K G S Y P Q H I N I	359
40		:	420
	mTLR8.pep	S S N F S K L R S L K K L H L R G Y V F R E L K K K H F E H L Q S L P N L A T I N L G I N F I E K I D F K A F Q N F S K	414
	hTLR8.pep	S R N F S K L L S L R A L H L R G Y V F Q E L R E D D F Q P L M Q L P N L S T I N L G I N F I K Q I D F K L F Q N F S N	419

- 132 -

			480
	mTLR8.pep	LDVIYLSGNRIASVLDGT--DY--SSWRNRLRKPLSTDDDEFDPHVNFYHSTKPLIKPQ	469
	hTLR8.pep	LEIYLSENRISPLVKDTRQSYANSSSFQRIKRRSTDF-EFDPHSNFYHFTRPLIKPQ	478
5			540
	mTLR8.pep	CTAYGKALDLSLNNIFIIGKSQFZGFQDIACLNLSFNANTQVFNGTBFSSMPHIKYLDLT	529
	hTLR8.pep	CAAYGKALDLSLNSIFFIGPNQFZNLDPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLT	538
			600
10	mTLR8.pep	NNRLDFDNNAFSDLHDLEVLDLSHNAHYFSIAGVTHRLGFIONLINLRVLNLSHNGIYT	589
	hTLR8.pep	NNRLDFDNASALTELSDEVLDSLNSHYFRIAGVTHLEFIQNFTNLKVLNLSHNNIYT	598
			660
	mTLR8.pep	LTESELKSISLKELVFSGNRLDHLWNANDGKYWSIFKSLQNLIRLDLSYNNLQQIPNGA	649
15	hTLR8.pep	LTDKYNLESKSLVELVFSGNRLDILWNDDNRYISIFKGLKNLTRLDLNRLKHIPNEA	658
			720
	mTLR8.pep	FLNLPQSLQELLISGNKLRFFNWTLQYFPHLHLLDLRNELYFLPNCLSKFAHSLETLL	709
	hTLR8.pep	FIINLPASLTEHINDNMLKFFNWTLQQFPRIELLDLRGNKLLFLTDSLSDFTSSLRTLL	718
20			780
	bf135656.pep	NHFSHLPSGFLSEARNLVHLDLSFNTIKMINKSSLQTKMKTNLSILELHGNYFDCTC	57
	mTLR8.pep	LSHNHFSHLPSGFLSEARNLVHLDLSFNTIKMINKSSIQTMMKTNLSILELHGNYFDCTC	769
	hTLR8.pep	LSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGPNPECTC	778
25			840
	bf135656.pep	DISDFRSWLDENLNITIPKLVNVCISNPGDQKSKSIMSLDLTTCVSDTTAAVLFFLTFLT	117
	mTLR8.pep	DISDFRSWLDENLNITIPKLVNVCISNPGDQKSKSIMSLDLTTCVSDTTAAVLFFLTFLT	829
	hTLR8.pep	DIGDFRRWMDHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILPFFTFFI	838
30			900
	bf135656.pep	TSMVMLAALVHHLFYWDVWFIYHMCASAKLKGRTSSTSQTIFYDAYISYDTKDASVTDWVI	177
	mTLR8.pep	TSMVMLAALVHHLFYWDVWFIYHMCASAKLKGRTSSTSQTIFYDAYISYDTKDASVTDWVI	889
	hTLR8.pep	TTMVMLAALAHHLFYWDVWFIYNVCLAKVKGYRSLSTSQTIFYDAYISYDTKDASVTDWVI	898
35			960
	bf135656.pep	NELRYHLE	185
	mTLR8.pep	NELRYHLEESDKSVLLCLEERDWDPLPIIDNMQSINQSKKTI FVLTKKYAKSWNFKT	949
	hTLR8.pep	NELRYHLEESRDKNVLLCLEERDWDPLAIIDNMQSINQSKKTVFVLTKKYAKSWNFKT	958
40			1020
	mTLR8.pep	AFYALQRLMDENMDVIFIILPEVLQYSQYLRLRQRIKSSILQWPNPNKAENLFWQSL	1009
	hTLR8.pep	AFYALQRLMDENMDVIFIILPEVLQHSQYLRLRQRIKSSILQWPDNPKAEGLFWQTL	1018
45			1080
	mTLR8.pep	KNVVLTEENDSRYDDLYIDSIRQY	1032

- 133 -

hTLR8 .pep RNVVLTENDSRYNMYVDSIKQY

1041

In Table 17 the sequences are assigned as follows: mTLR8.pep, SEQ ID NO:192;
hTLR8.pep, SEQ ID NO:184; and bf135656.pep, SEQ ID NO:193.

5

Example 20. Transient transfectants expressing TLR8 and TLR7

The cloned human TLR7 and human TLR8 cDNA (our result) were cloned into the expression vector pCDNA3.1(-) from Invitrogen using the NotI site. Utilizing a "gain of function" assay, hTLR7 and hTLR8 expression vectors were transiently expressed in human
10 293 fibroblasts (ATCC, CRL-1573) using the calcium phosphate method. Activation was monitored by IL-8 production after stimulus with CpG-ODN (2006 or 1668, 2 μ M) or LPS (100 ng/ml). None of the stimuli used activated 293 cells transfected with either hTLR7 or hTLR8.

Example 21. Screening for TLR9, 8 and 7 modulators

Human TLR receptors 9, 8 and 7 are expressed differentially among tissues which may be due to differences in promoter structure. Du X et al., *Eur Cytokine Netw* 11:362-71 (2000); Chuang TH et al., *Eur Cytokine Netw* 11:372-8 (2000). For the human Toll-like receptors 9, 8 and 7 the genomic locus has been defined and sequenced. TLR9 is located on
20 chromosome 3 (GenBank accession numbers NT_005985, AC006252), TLR7 on chromosome X (GenBank accession numbers NT_011774, AC005859, AC003046) and TLR8 close to TLR7 also on chromosome X (GenBank accession numbers NT_011774, AC005859). To verify differences in the promoter regions the putative promoter region of each gene are cloned in reporter vectors like pGL2-Basic (Promega, Madison, WI, USA)
25 which contains the luciferase gene (luc) adjacent to a multiple cloning site. After transient transfection of these constructs in various cell lines, different stimuli can be tested for the activation of the inserted promoter region which is detected by luciferase activity. The promoter regions defined by the cloning of mTLR9, mTLR8 and mTLR7 can be utilized in the same manner. Definition of compounds that agonize or antagonize TLR9, 8, or 7
30 expression can be used to enhance or dampen responses to nucleic acid ligands or to any TLR9, 8 or 7 ligand defined by screening. These constructs can be adapted to high throughput screening after stable transfection similar to the use of TLR9 stable transfectants.

- 134 -

Each of the foregoing patents, patent applications and references is hereby incorporated by reference. While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

Example 22. Method cloning the murine and human extracellular TLR9 domain fused to human IgG1 Fc

Human IgG1 Fc was amplified from human B cell cDNA using the sense and antisense primers 5' TATGGATCCTCTTGTGACAAACTCACACATGC (SEQ ID NO:216) and 5' ATA AAGCTTTCATTTACCCGGAGACAGGGAGAG (SEQ ID NO:217) and ligated into pCDNA3.1(-) (Invitrogen) after digestion with the restriction endonucleases BamHI and HindIII creating the vector pcDNA-IgGFc. The extracellular domain of human TLR9 (amino acids 1 to 815) was amplified with the sense and antisense primers 5' TATGAATTCCCACCATGGGTTTCTGCCGCAG (SEQ ID NO:218) and 5' ATAGGATCCCCGGGGCACCAGGCCGCCGCCGCCGCCGGAGAGGGCCTCATCCAGGC (SEQ ID NO:219). The primers amplify the extracellular domain of human TLR9 and create adjacent to amino acid 815 an additional NotI restriction site, a glycine linker and thrombin protease recognition site. The translated sequence of this region starting at amino acid 812 is DEALSGGRGGGLVPRGS (SEQ ID NO:220). The fragment was cut with EcoRI and BamHI and cloned into pcDNA-IgGFc, creating the vector coding for the fusion protein of the extracellular domain of human TLR9 fused to the Fc part of human IgG1 (pcDNAhTLR9IgGFc). Expressed extracellular TLR9 protein can be separated from the IgG1 Fc fragment by digestion with Thrombin (see figure).

The extracellular part of murine TLR9 (amino acids 1 to 816) was amplified with the sense and antisense primers 5' TATATGCGGCCGCCACCATGGTTCTCCGTCGAAG (SEQ ID NO:221) and 5' TATATGCGGCCGCCAGAGAGGACCTCATCCAGGC (SEQ ID NO:222) and cloned into pcDNAhTLR9IgGFc after NotI digestion of PCR fragment and vector. This procedure exchanged the human extracellular part of TLR9 with the murine counterpart.

Example 23. Method of expression and purification of the extracellular domain of TLR9 fused to human IgG1 Fc

Vector DNA coding for the human or murine TLR9 human IgGFc fusion protein was
 5 transfected by Ca_2PO_4 method into 293 fibroblast cells. Transfected cells were selected with
 0.7 mg/ml G418 and cloned. Expression of fusion protein was monitored by enzyme-linked
 immunosorbent assay (ELISA). Cells were lysed in lysis buffer (PBS, 1% Triton X-100) and
 supernatant was applied to ELISA plates coated with polyclonal antibody against human IgG-
 Fc. Bound fusion protein was detected by incubation with biotinylated polyclonal antibodies
 10 against human IgG-Fc and streptavidin-horseradish peroxidase conjugate.

For purification of the fusion protein cell lysates from 10^9 cells were produced and
 incubated with Protein A sepharose which binds tightly to human IgG-Fc. Incubation with
 the protease thrombin releases the soluble extracellular domain of human TLR9. **Figure 27**
 shows an example of the TLR9 fusion protein visualized by a silver stained SDS-gel. **Figure**
 15 **27** demonstrates that lysates of transfected cells included a strong band travelling between
 100 and 150 kD which was not present either in lysates of mock-transfected cells or in
 supernatants transfected or mock-transfected cells. The apparent molecular weight of the
 band decreased following thrombin treatment, consistent with cleavage at the thrombin
 protease recognition site interposed between the extracellular TLR9 domain and the Fc
 20 fragment.

Example 24. Method of cloning the murine and human extracellular TLR7 and TLR8 domain fused to human IgG1 Fc and its expression in 293 cells

The extracellular domains of murine TLR7 (amino acids 1 to 837), human TLR7
 25 (amino acids 1 to 836), murine TLR8 (amino acids 1 to 816) and human TLR8 (amino acids 1
 to 825) were amplified with the primer pairs

5' TATATGCGGCCGCCCACCATGGTGTTCGATGTGGACACG (SEQ ID NO:223)
 and 5' TATATGCGGCCGCCATCTAACTCACACGTATACAGATC (SEQ ID NO:224);
 5' TATATGCGGCCGCCCACCATGGTGTTCGAATGTGGACACTG (SEQ ID NO:225)
 30 and 5' TATATGCGGCCGCCATCTAACTCACAGGTGTACAGATC (SEQ ID NO:226);
 5' TATATGCGGCCGCCCACCATGGAAAACATGCCCCCTCAG (SEQ ID NO:227) and

- 136 -

5' TATATGCGGCCCGCCATCCGATACACAAGTCGTGAGATC (SEQ ID NO:228); and
5' TATATGCGGCCCGCCACCATGGAAAACATGTTTCCTTCAGTC (SEQ ID NO:229)
and 5' TATATGCGGCCCGCCATCTGAAACACAAGTTGTTAGCTC (SEQ ID NO:230),
respectively. Fragments were cloned into pcDNA-IgGFc after NotI digestion.

5 Vector DNA coding for the extracellular domain of human or murine TLR7 or TLR8
fused to human IgGFc fusion protein was transfected by Ca_2PO_4 method into 293 fibroblast
cells. Transfected cells were selected with 0.7 mg/ml G418 and cloned. Expression of fusion
protein was monitored by ELISA. Cells were lysed in lysis buffer (PBS, 1% Triton X-100)
and supernatant was applied to ELISA plates coated with polyclonal antibody against human
10 IgG-Fc. Bound fusion protein was detected by incubation with biotinylated polyclonal
antibodies against human IgG-Fc and Streptavidin-horseradish peroxidase conjugate.

**Example 25. Method of antibody production against murine and human TLR9 and
characterization of activity**

15 C57/B6 mice were immunized three times by intraperitoneal administration of 20 μg
of the extracellular domain of human TLR9 mixed with 10 nmol of the CpG-ODN 1668.
B cells taken from immunized mice were fused with a non antibody producing B-cell
hybridoma P3XAG8 using standard protocols. Hybridoma supernatants were screened for
reactivity in ELISA using murine and human TLR9 fusion proteins. For identification of
20 positive hybridomas ELISA plates were coated with polyclonal antibody against human IgG-
Fc and incubated with lysate containing murine or human TLR9 IgG-Fc fusion protein.
Plates were then incubated with individual hybridoma supernatants, and bound TLR9-specific
antibodies were detected by incubation with biotinylated polyclonal antibodies against murine
IgG and Streptavidin-horseradish peroxidase conjugate.

25 Ten antibodies have been isolated which are of IgG1, IgG2a and IgG2b isotype. They
have been tested for reactivity against human and murine TLR9 and their performance in
western blotting or intracellular staining. Table 18 shows the names (ID), isotypes, reactivity
and performance in western blotting and intracellular staining.

All isolated antibodies were readily purified using standard protein A affinity
30 chromatography.

Table 18. Monoclonal Antibodies Raised Against Murine and Human TLR9

#	ID	Isotype	Reactivity in ELISA		Western Blotting	Intracellular Staining
			mTLR9	hTLR9		
1	1-3A11	G1	YES	YES	YES	NO
2	1-1B1	G1	YES	YES	YES	NO
3	1-2A9	G2a	NO	YES	YES	YES
4	1-3F2	G1	YES	YES	YES	NO
5	2-1E2	G2a	NO	YES	YES	YES
6	1-5G5	G2a	YES	YES	YES	YES
7	1-2F1	G1	YES	YES	YES	NO
8	1-5F12	G2b	NO	YES	NO	NO
9	1-3C9	G2a	NO	YES	YES	YES
10	1-3F5	G2b	NO	YES	NO	NO

Example 26. Method for Intracellular Staining

Mock transfected 293 cells and human TLR9 transfected 293 cells were seeded on
 5 cover slips and cultured overnight. The following day cells were washed in PBS and fixed
 with 2% formalin for 10 minutes at room temperature. Cells were permeabilized with 0.2%
 saponin in PBS and incubated with 2µg/ml anti human TLR9-specific antibody 2-1E2 for 1h.
 After two wash steps cells were incubated with Alexis488-conjugated goat anti-mouse IgG
 antibody and TLR9 was visualized utilizing confocal microscopy on a Zeiss LSM510
 10 microscope. Results indicated that cytoplasm of human TLR9 transfected 293 cells, but not
 mock transfected 293 cells, stained positive for human TLR9.

Example 27. Method for Western Blotting

Lysates of 293 cells transfected with murine TLR9, human TLR9 or murine TLR2
 15 IgG1-Fc fusion protein were separated by SDS-PAGE. Proteins were transferred to a nylon
 membrane utilizing a BioRad semi dry blotter according to the manufacturer's protocol. The
 membrane was incubated with 2µg/ml of the human TLR9-specific antibody 2-1E2, and
 human TLR9 was detected by polyclonal goat anti-mouse peroxidase conjugate. Peroxidase
 activity was monitored with ECL reagent (Amersham) and incubation of the membrane on
 20 film (see Figure 29).

What is claimed is:

- 138 -

Claims

1. An isolated nucleic acid molecule selected from the group consisting of
 - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:1, and which code for a murine TLR9 having an amino acid sequence set forth as SEQ ID NO:3,
 - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and
 - (c) complements of (a) or (b).
2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule codes for SEQ ID NO:3.
3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:1.
4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:2.
5. An isolated TLR9 polypeptide or fragment thereof comprising at least one amino acid of murine TLR9 selected from the group consisting of amino acids 2, 3, 4, 6, 7, 18, 19, 22, 38, 44, 55, 58, 61, 62, 63, 65, 67, 71, 80, 84, 87, 88, 91, 101, 106, 109, 117, 122, 123, 134, 136, 140, 143, 146, 147, 157, 160, 161, 167, 168, 171, 185, 186, 188, 189, 191, 199, 213, 217, 220, 227, 231, 236, 245, 266, 269, 270, 271, 272, 273, 274, 278, 281, 285, 297, 298, 301, 305, 308, 311, 322, 323, 325, 326, 328, 332, 335, 346, 348, 353, 355, 358, 361, 362, 365, 367, 370, 372, 380, 381, 382, 386, 389, 392, 394, 397, 409, 412, 413, 415, 416, 419, 430, 432, 434, 435, 438, 439, 443, 444, 446, 447, 448, 450, 451, 452, 454, 455, 459, 460, 463, 465, 466, 468, 469, 470, 472, 473, 474, 475, 478, 488, 489, 494, 495, 498, 503, 508, 510, 523, 531, 539, 540, 543, 547, 549, 561, 563, 565, 576, 577, 579, 580, 587, 590, 591, 594, 595, 597, 599, 601, 603, 610, 611, 613, 616, 619, 632, 633, 640, 643, 645, 648, 650, 657, 658, 660, 667, 670, 672, 675, 679, 689, 697, 700, 703, 705, 706, 711, 715, 716, 718, 720, 723, 724, 726, 729, 731, 735, 737, 743, 749, 750, 751, 752, 754, 755, 759, 760,

- 139 -

772, 774, 780, 781, 786, 787, 788, 800, 814, 821, 829, 831, 832, 835, 844, 857, 858, 859, 862, 864, 865, 866, 879, 893, 894, 898, 902, 910, 917, and 927 of SEQ ID NO:3, wherein the TLR9 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR9 polypeptide or fragment thereof except for the at least one amino acid of murine TLR9.

6. The isolated TLR9 polypeptide or fragment thereof of claim 5, further comprising at least one amino acid of murine TLR9 selected from the group consisting of amino acids 949, 972, 975, 976, 994, 997, 1000, 1003, 1004, 1010, 1011, 1018, 1023, and 1027 of SEQ ID NO:3.
7. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the human TLR9 has an amino acid sequence set forth as SEQ ID NO:6.
8. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof has an amino acid sequence selected from the group consisting of SEQ ID NO:3 and fragments of SEQ ID NO:3.
9. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof is an extracytoplasmic domain of TLR9.
10. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof comprises an MBD motif as set forth as SEQ ID NO:126 or SEQ ID NO:127.
11. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof selectively binds to an immunostimulatory nucleic acid (ISNA).
12. The isolated TLR9 polypeptide or fragment thereof of claim 5, wherein the isolated TLR9 polypeptide or fragment thereof selectively binds to a CpG nucleic acid.

- 140 -

13. An isolated nucleic acid molecule which encodes the isolated TLR9 polypeptide or fragment thereof of claim 5.
14. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.
15. A host cell comprising the expression vector of claim 14.
16. The host cell of claim 15, further comprising at least one expression vector selected from the group consisting of:
 - (a) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR7 polypeptide operably linked to a promoter, and
 - (b) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR8 polypeptide operably linked to a promoter.
17. The host cell of claim 15, further comprising a reporter construct capable of interacting with a TIR domain.
18. An expression vector comprising the isolated nucleic acid molecule of claim 13 operably linked to a promoter.
19. A host cell comprising the expression vector of claim 18.
20. The host cell of claim 19, further comprising at least one expression vector selected from the group consisting of:
 - (a) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR7 polypeptide operably linked to a promoter, and
 - (b) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR8 polypeptide operably linked to a promoter.

- 141 -

21. The host cell of claim 19, further comprising a reporter construct capable of interacting with a TIR domain.
22. An isolated nucleic acid molecule selected from the group consisting of
 - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:173, and which code for a murine TLR7 having an amino acid sequence set forth as SEQ ID NO:175,
 - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and
 - (c) complements of (a) or (b).
23. The isolated nucleic acid molecule of claim 22, wherein the isolated nucleic acid molecule codes for SEQ ID NO:175.
24. The isolated nucleic acid molecule of claim 22, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:173.
25. The isolated nucleic acid molecule of claim 22, wherein the isolated nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:174.
26. An isolated TLR7 polypeptide or fragment thereof comprising at least one amino acid of murine TLR7 selected from the group consisting of amino acids 4, 8, 15, 16, 18, 21, 23, 24, 25, 27, 37, 39, 40, 41, 42, 44, 45, 61, 79, 83, 86, 89, 92, 96, 103, 109, 111, 113, 119, 121, 127, 128, 131, 145, 148, 151, 164, 172, 176, 190, 202, 203, 204, 205, 222, 225, 226, 228, 236, 238, 243, 250, 253, 266, 268, 271, 274, 282, 283, 287, 288, 308, 313, 314, 315, 325, 328, 331, 332, 341, 343, 344, 347, 351, 357, 360, 361, 362, 363, 364, 365, 366, 370, 371, 377, 378, 387, 388, 389, 392, 397, 398, 413, 415, 416, 419, 421, 422, 425, 437, 438, 440, 446, 449, 453, 454, 455, 456, 462, 470, 482, 486, 487, 488, 490, 491, 493, 494, 503, 505, 509, 511, 529, 531, 539, 540, 543, 559, 567, 568, 574, 583, 595, 597, 598, 600, 611, 613, 620, 624, 638, 645, 646, 651, 652, 655, 660, 664, 665, 668, 669, 672, 692, 694, 695, 698, 701, 704, 714, 720, 724, 727, 728, 733, 738, 745, 748, 755, 762, 777, 780, 789,

- 142 -

803, 846, 850, 851, 860, 864, 868, 873, 875, 884, 886, 888, 889, 890, 902, 903, 911, 960, 967, 970, 980, 996, 1010, 1018, 1035, and 1045 of SEQ ID NO:175, wherein the TLR7 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR7 polypeptide or fragment thereof except for the at least one amino acid of murine TLR7.

27. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the human TLR7 has an amino acid sequence set forth as SEQ ID NO:170.
28. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof has an amino acid sequence selected from the group consisting of SEQ ID NO:175 and fragments of SEQ ID NO:175.
29. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof is an extracytoplasmic domain of TLR7.
30. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof comprises an MBD motif as set forth as any one of SEQ ID NOs: 203, 204, 212, and 213.
31. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof selectively binds to an ISNA.
32. The isolated TLR7 polypeptide or fragment thereof of claim 26, wherein the isolated TLR7 polypeptide or fragment thereof selectively binds to a CpG nucleic acid.
33. An isolated nucleic acid molecule which encodes the isolated TLR7 polypeptide or fragment thereof of claim 26.
34. An expression vector comprising the isolated nucleic acid molecule of claim 22 operably linked to a promoter.

- 143 -

35. A host cell comprising the expression vector of claim 34.
36. The host cell of claim 35, further comprising a reporter construct capable of interacting with a TIR domain.
37. An expression vector comprising the isolated nucleic acid molecule of claim 33 operably linked to a promoter.
38. A host cell comprising the expression vector of claim 37.
39. The host cell of claim 38, further comprising a reporter construct capable of interacting with a TIR domain.
40. An isolated nucleic acid molecule selected from the group consisting of
 - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:190, and which code for a murine TLR8 having an amino acid sequence set forth as SEQ ID NO:192,
 - (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and
 - (c) complements of (a) or (b).
41. The isolated nucleic acid molecule of claim 40, wherein the isolated nucleic acid molecule codes for SEQ ID NO:192.
42. The isolated nucleic acid molecule of claim 40, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:190.
43. The isolated nucleic acid molecule of claim 40, wherein the isolated nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:191.

- 144 -

44. An isolated TLR8 polypeptide or fragment thereof comprising at least one amino acid of murine TLR8 selected from the group consisting of amino acids 5, 6, 9, 10, 14, 15, 18, 21, 22, 23, 24, 25, 26, 27, 28, 30, 39, 40, 41, 43, 44, 50, 51, 53, 55, 61, 67, 68, 74, 80, 85, 93, 98, 99, 100, 104, 105, 106, 107, 110, 114, 117, 119, 121, 124, 125, 134, 135, 138, 145, 155, 156, 157, 160, 161, 162, 163, 164, 166, 169, 170, 174, 180, 182, 183, 186, 187, 191, 193, 194, 196, 197, 199, 200, 207, 209, 210, 227, 228, 230, 231, 233, 234, 241, 256, 263, 266, 267, 268, 269, 272, 274, 275, 276, 280, 285, 296, 298, 299, 300, 303, 305, 306, 307, 310, 312, 320, 330, 333, 335, 343, 344, 345, 346, 347, 349, 351, 356, 362, 365, 366, 375, 378, 379, 380, 381, 383, 384, 386, 387, 392, 402, 403, 408, 414, 416, 417, 422, 426, 427, 428, 429, 430, 431, 433, 437, 438, 439, 440, 441, 444, 445, 449, 456, 461, 463, 471, 483, 486, 489, 490, 494, 495, 496, 505, 507, 509, 512, 513, 519, 520, 523, 537, 538, 539, 541, 542, 543, 545, 554, 556, 560, 567, 569, 574, 575, 578, 586, 592, 593, 594, 595, 597, 599, 602, 613, 617, 618, 620, 621, 623, 628, 630, 633, 639, 641, 643, 644, 648, 655, 658, 661, 663, 664, 666, 668, 677, 680, 682, 687, 688, 690, 692, 695, 696, 697, 700, 702, 703, 706, 714, 715, 726, 727, 728, 730, 736, 738, 739, 741, 746, 748, 751, 752, 754, 757, 764, 766, 772, 776, 778, 781, 784, 785, 788, 791, 795, 796, 801, 802, 806, 809, 817, 820, 821, 825, 828, 829, 831, 839, 852, 853, 855, 858, 863, 864, 900, 903, 911, 918, 934, 977, 997, 1003, 1008, 1010, 1022, 1023, 1024, 1026, and 1030 of SEQ ID NO:192, wherein the TLR8 polypeptide or fragment thereof has an amino acid sequence which is identical to a human TLR8 polypeptide or fragment thereof except for the at least one amino acid of murine TLR8.
45. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the human TLR8 has an amino acid sequence set forth as SEQ ID NO:184.
46. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof has an amino acid sequence selected from the group consisting of SEQ ID NO:192 and fragments of SEQ ID NO:192.
47. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof is an extracytoplasmic domain of TLR8.

- 145 -

48. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof comprises an MBD motif as set forth as any one of SEQ ID NOs: 205, 206, 214, and 215.
49. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof selectively binds to an ISNA.
50. The isolated TLR8 polypeptide or fragment thereof of claim 44, wherein the isolated TLR8 polypeptide or fragment thereof selectively binds to a CpG nucleic acid.
51. An isolated nucleic acid molecule which encodes the isolated TLR8 polypeptide or fragment thereof of claim 44.
52. An expression vector comprising the isolated nucleic acid molecule of claim 40 operably linked to a promoter.
53. A host cell comprising the expression vector of claim 52.
54. The host cell of claim 53, further comprising a reporter construct capable of interacting with a TIR domain.
55. An expression vector comprising the isolated nucleic acid molecule of claim 51 operably linked to a promoter.
56. A host cell comprising the expression vector of claim 55.
57. The host cell of claim 56, further comprising a reporter construct capable of interacting with a TIR domain.
58. An isolated nucleic acid molecule which hybridizes under stringent conditions to the

- 146 -

isolated nucleic acid molecule of claim 1 or claim 13.

59. A method for inhibiting TLR9 signaling activity in a cell, comprising:
contacting the cell with an isolated nucleic acid molecule of claim 58 in an amount effective to inhibit expression of TLR9 polypeptide in the cell.
60. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the isolated nucleic acid molecule of claim 1 or claim 13.
61. A method for inhibiting TLR9 signaling activity in a cell, comprising:
contacting the cell with an isolated nucleic acid molecule of claim 60 in an amount effective to inhibit expression of TLR9 polypeptide in the cell.
62. A method for identifying nucleic acid molecules which interact with a TLR polypeptide or a fragment thereof, comprising:
contacting a TLR polypeptide selected from the group consisting of TLR7, TLR8, TLR9, and nucleic acid-binding fragments thereof with a test nucleic acid molecule; and
measuring an interaction of the test nucleic acid molecule with the TLR polypeptide or fragment thereof.
63. The method of claim 62, wherein the TLR polypeptide or fragment thereof is expressed in a cell.
64. The method of claim 62, wherein the TLR polypeptide or fragment thereof is an isolated TLR polypeptide or fragment thereof.
65. The method of claim 64, wherein the isolated TLR polypeptide or fragment thereof is immobilized on a solid support.
66. The method of claim 62, wherein the TLR polypeptide or fragment thereof is fused

- 147 -

with an Fc fragment of an antibody.

67. The method of claim 66, wherein the TLR polypeptide or fragment thereof comprises a TLR extracytoplasmic domain.
68. The method of claim 62, wherein the interaction is binding.
69. The method of claim 68, wherein the measuring is accomplished by a method selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), biomolecular interaction assay (BIA), electromobility shift assay (EMSA), radioimmunoassay (RIA), polyacrylamide gel electrophoresis (PAGE), and Western blotting.
70. The method of claim 63, wherein the measuring is accomplished by a method comprising measuring a response mediated by a TLR signal transduction pathway.
71. The method of claim 70, wherein the response mediated by a TLR signal transduction pathway is selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine.
72. The method of claim 71, wherein the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
73. The method of claim 71, wherein the cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.
74. The method of claim 70, further comprising:
comparing (a) the response mediated by a TLR signal transduction pathway as measured in presence of the test nucleic acid molecule with (b) a response mediated by a TLR signal transduction pathway as measured in absence of the test nucleic acid molecule; and

- 148 -

determining the test nucleic acid molecule is an ISNA when (a) exceeds (b).

75. The method of claim 70, further comprising:
comparing the response to a reference response when the TLR polypeptide is independently contacted with a reference nucleic acid molecule; and
determining if the response is stronger or weaker than the reference response.
76. The method of claim 70, further comprising:
comparing the response to a reference response when the TLR polypeptide is concurrently contacted with a reference nucleic acid molecule; and
determining if the response is stronger or weaker than the reference response.
77. The method of claim 62, wherein the TLR polypeptide or fragment thereof is TLR7.
78. The method of claim 62, wherein the TLR polypeptide or fragment thereof is TLR8.
79. The method of claim 62, wherein the TLR polypeptide or fragment thereof is TLR9.
80. A screening method for identifying an ISNA, comprising:
contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test nucleic acid molecule;
detecting presence or absence of a response mediated by a TLR signal transduction pathway in the presence of the test nucleic acid molecule arising as a result of an interaction between the functional TLR and the test nucleic acid molecule; and
determining the test nucleic acid molecule is an ISNA when the presence of a response mediated by the TLR signal transduction pathway is detected.
81. The method of claim 80, further comprising comparing the response mediated by the TLR signal transduction pathway arising as a result of an interaction between the functional TLR and the test nucleic acid molecule with a response arising as a result of an interaction between the functional TLR and a reference ISNA.

- 149 -

82. The method of claim 81, wherein the screening method is performed on a plurality of test nucleic acid molecules.
83. The method of claim 82, wherein the response mediated by the TLR signal transduction pathway is measured quantitatively and wherein the response mediated by the TLR signal transduction pathway associated with each of the plurality of test nucleic acid molecules is compared with a response arising as a result of an interaction between the functional TLR and a reference ISNA.
84. The method of claim 83, wherein a subset of the plurality of test nucleic acid molecules is selected based on ability of the subset to produce a specific response mediated by the TLR signal transduction pathway.
85. The method of claim 80, wherein the functional TLR is expressed in a cell.
86. The method of claim 85, wherein the cell is an isolated mammalian cell that naturally expresses the functional TLR.
87. The method of claim 86, wherein the cell comprises an expression vector comprising an isolated nucleic acid which encodes a reporter construct selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
88. The method of claim 80, wherein the functional TLR is part of a cell-free system.
89. The method of claim 80, wherein the functional TLR is part of a complex with another TLR.
90. The method of claim 89, wherein the complex is a complex of TLR9 and TLR7.
91. The method of claim 89, wherein the complex is a complex of TLR9 and TLR8.

- 150 -

92. The method of claim 80, wherein the functional TLR is part of a complex with a non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B, and functional homologues and derivatives thereof.
93. The method of claim 80, wherein the reference ISNA is a CpG nucleic acid.
94. The method of claim 80, wherein the test nucleic acid molecule is a CpG nucleic acid.
95. The method of claim 80, wherein the response mediated by a TLR signal transduction pathway is selected from the group consisting of induction of a gene under control of NF- κ B promoter and secretion of a cytokine.
96. The method of claim 95, wherein the gene under control of NF- κ B promoter is selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
97. The method of claim 95, wherein the cytokine is selected from the group consisting of IL-8, TNF- α , and IL-12 p40.
98. A screening method for comparing TLR signaling activity of a test compound with an ISNA, comprising:
- contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a reference ISNA and detecting a reference response mediated by a TLR signal transduction pathway;
 - contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 with a test compound and detecting a test response mediated by a TLR signal transduction pathway; and
 - comparing the test response with the reference response to compare the TLR signaling activity of the test compound with the ISNA.

- 151 -

99. The method of claim 98, wherein the functional TLR is contacted with the reference ISNA and the test compound independently.
100. The method of claim 99, wherein the screening method is a method for identifying an ISNA mimic, and wherein when the test response is similar to the reference response the test compound is an ISNA mimic.
101. The method of claim 98, wherein the functional TLR is contacted with the reference ISNA and the test compound concurrently to produce a test-reference response mediated by a TLR signal transduction pathway and wherein the test-reference response may be compared to the reference response.
102. The method of claim 101, wherein the screening method is a method for identifying an ISNA agonist, and wherein when the test-reference response is greater than the reference response the test compound is an ISNA agonist.
103. The method of claim 101, wherein the screening method is a method for identifying an ISNA antagonist, and wherein when the test-reference response is less than the reference response the test compound is an ISNA antagonist.
104. The method of claim 98, wherein the functional TLR is expressed in a cell.
105. The method of claim 104, wherein the cell is an isolated mammalian cell that naturally expresses the functional TLR9.
106. The method of claim 105, wherein the cell comprises an expression vector comprising an isolated nucleic acid which encodes a reporter construct selected from the group consisting of IL-8, IL-12 p40, NF- κ B-luc, IL-12 p40-luc, and TNF-luc.
107. The method of claim 98, wherein the functional TLR is part of a cell-free system.

- 152 -

108. The method of claim 98, wherein the functional TLR is part of a complex with another TLR.
109. The method of claim 98, wherein the functional TLR is part of a complex with a non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B, and functional homologues and derivatives thereof.
110. The method of claim 98, wherein the reference ISNA is a CpG nucleic acid.
111. The method of claim 98, wherein the test compound is not a nucleic acid molecule.
112. The method of claim 98, wherein the test compound is a polypeptide.
113. The method of claim 98, wherein the test compound is a part of a combinatorial library of compounds.
114. A screening method for identifying species specificity of an ISNA, comprising:
 - contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a first species with a test ISNA;
 - contacting a functional TLR selected from the group consisting of TLR7, TLR8, and TLR9 of a second species with the test ISNA;
 - measuring a response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA;
 - measuring a response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA; and
 - comparing (a) the response mediated by a TLR signal transduction pathway associated with the contacting the functional TLR of the first species with the test ISNA with (b) the response mediated by the TLR signal transduction pathway associated with the contacting the functional TLR of the second species with the test ISNA.
115. The method of claim 114, wherein the functional TLR is expressed in a cell.

- 153 -

116. The method of claim 115, wherein the cell is an isolated mammalian cell that naturally expresses the functional TLR.
117. The method of claim 114, wherein the functional TLR is part of a cell-free system.
118. The method of claim 114, wherein the functional TLR is part of a complex with another TLR.
119. The method of claim 114, wherein the functional TLR is part of a complex with a non-TLR protein selected from the group consisting of MyD88, IRAK, TRAF6, I κ B, NF- κ B, and functional homologues and derivatives thereof.
120. A method for identifying lead compounds for a pharmacological agent useful in treatment of disease associated with TLR9 signaling activity, comprising
providing a cell comprising a TLR9 as provided in claim 5;
contacting the cell with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of TLR9 signaling activity; and
determining a second amount of TLR9 signaling activity as a measure of the effect of the pharmacological agent on the TLR9 signaling activity, wherein a second amount of TLR9 signaling activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces TLR9 signaling activity and wherein a second amount of TLR9 signaling activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases TLR9 signaling activity.

1/20




Fig. 1a




Fig. 1b

2/20




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

4/20




Fig. 8

5/20




Fig. 9




Fig. 10a




Fig. 10b

6/20




Fig. 11

7/20




Fig. 12

8/20




Fig. 13a




Fig. 13b

9/20




Fig. 14

10/20




Fig. 15




Fig. 16




Fig. 17




Fig. 18

12/20




Fig. 19

13/20




Fig. 20

14/20




Fig. 21

15/20




Fig. 22

16/20




Fig. 23

17/20




Fig. 24

18/20




Fig. 25




Fig. 26

20/20




Fig. 27

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.